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1Executive summary
Blood transfusion services (BTS) have the responsibility to collect blood only 
from donors who are at low risk for any infection that could be transmitted 
through transfusion and who are unlikely to jeopardize their own health by blood 
donation. A rigorous process to assess the suitability of prospective donors is 
therefore essential to protect the safety and sufficiency of the blood supply, and 
safeguard the health of recipients of transfusion and blood donors themselves, 
while ensuring that suitable donors are not deferred unnecessarily. 
These World Health Organization (WHO) guidelines, Blood donor selection: guidelines 
on assessing donor suitability for blood donation have been developed to assist 
blood transfusion services in countries that are establishing or strengthening 
national systems for the selection of blood donors1. They are designed for use 
by policy makers in national blood programmes in ministries of health, national 
advisory bodies such as national blood commissions or councils, and blood 
transfusion services. 
WHO guidance on criteria for the selection of blood donors was first published in 
the distance learning materials, Safe Blood and Blood Products, Module 1: Safe 
Blood Donation (1) in 1994. These earlier recommendations were developed on 
the basis of international best practice but did not have a clear evidence base. 
In 2009, the WHO Blood Transfusion Safety programme (WHO/BTS) convened a 
guideline development group (GDG) to prepare evidence-based recommendations 
on criteria for assessing the suitability of blood donors. The GDG also recognized 
the need to provide guidance on establishing national systems for blood donor 
selection. Details of the members of the GDG and their areas of expertise are 
provided in the Acknowledgements.
WHO/BTS also established an external review group (ERG) to review and comment 
on the draft guidelines at various stages of the developmental process. The ERG 
comprised members of the WHO Expert Advisory Panel on Blood Transfusion 
Medicine and experts from WHO Collaborating Centres in Transfusion Medicine 
as well as directors of national blood transfusion services and blood programme 
managers from each WHO region (see Acknowledgements). The role of the ERG 
was to review the draft guidelines and advise WHO on the relevance, applicability 
and feasibility of the recommendations. An advanced draft was reviewed by 
participants and facilitators during an inter-regional workshop on blood donor 
selection and donor counselling for priority countries in the African and Eastern 
Mediterranean regions, June 2011, Nairobi, Kenya.
The guidelines are presented in two parts. Part 1 (Sections 2 and 3) addresses 
the requirements for an effective national system for blood donor selection; policy 
recommendations are provided on p. 5. Part 2 provides guidance on specific 
criteria for blood donor selection in relation to general donor assessment, donor 
1 The term “blood donors” includes donors of whole blood, red cells, platelets, plasma and 
other blood components, donated as whole blood and/or through apheresis.
2medical history and risk assessment for transfusion-transmissible infections 
(TTI); technical recommendations on donor selection criteria are summarized 
on pp. 6–15 and elaborated in Sections 4 to 7.
Blood donor selection: guidelines on assessing donor suitability for blood donation 
was developed in accordance with the WHO guidelines development process, 
which requires systematic review of new evidence for key questions and 
recommendations, as well as a consideration of programme feasibility and the 
cost implications of potential new recommendations. A systematic review of the 
published and “grey” literature was conducted covering the period 1995–2011, 
and also in 2012 for selected topics. Particular efforts were made to identify 
systematic literature reviews and evidence related specifically to blood donor 
selection in low- and middle-income countries. Detailed literature search strategies 
and the decision-making process for the formulation of recommendations are 
available in Annex 3. 
High quality evidence on which to base decisions on the suitability of prospective 
donors for blood donation is, however, limited or even lacking in relation to many 
medical conditions and risk behaviours. Where published evidence is lacking, 
recommendations are based on international best practices and the knowledge 
and expertise of members of the guideline development group and external 
review group in the fields of human physiology, pathology and clinical medicine. 
In conditions where emerging evidence suggests that deferral criteria may be 
relaxed, a precautionary approach is recommended until good evidence of safety 
becomes available. It is anticipated that the recommendations in this document 
will remain valid until 2017 when a review of these guidelines will be undertaken 
to explore any new evidence, particularly in relation to controversial issues or 
where changes in practice may be appropriate.
3Acronyms
AIDS Acquired immunodeficiency syndrome
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WHO World Health Organization
4Preface
The safety and availability of blood and blood products for transfusion requires 
the recruitment and selection of voluntary non-remunerated blood donors, the 
quality-assured screening of all donated blood and the safe and rational clinical 
use of blood. The World Health Organization (WHO) recommends the following 
integrated strategy for blood safety and availability (3).
1  Establishment of well-organized blood transfusion services that are 
coordinated at national level and that can provide sufficient and timely 
supplies of safe blood to meet the transfusion needs of the patient 
population. 
2 Collection of blood from voluntary non-remunerated blood donors at 
low-risk of infections that can be transmitted through blood and blood 
products, the phasing out of family/replacement blood donation and the 
elimination of paid donation.
3 Quality-assured screening of all donated blood for transfusion-transmissible 
infections, including HIV, hepatitis B, hepatitis C and syphilis, blood 
grouping and compatibility testing, and preparation of blood components. 
4  Rational use of blood to reduce unnecessary transfusions and minimize the 
risks associated with transfusion, the use of alternatives to transfusion, 
where possible, and safe clinical transfusion procedures.
5  Implementation of effective quality systems, including quality management, 
documentation, training of all staff and assessment. 
Each country should establish a national system for blood donor selection 
for the donation of whole blood, red cells, platelets, plasma and other blood 
components, donated as whole blood or apheresis donations. The assessment 
of donor suitability should be undertaken in accordance with national criteria 
for blood donor selection. These criteria should be consistently applied in every 
blood donation setting on each occasion of donation to all blood donors, including 
voluntary non-remunerated donors and even where systems are still based on 
family/replacement donors and paid donors. 
These guidelines on blood donor selection should be used in conjunction with 
other WHO resources, in particular Towards 100% voluntary blood donation: A 
global framework for action (4), The Melbourne Declaration on 100% voluntary 
non-remunerated donation of blood and blood components (5), Blood donor 
counselling: Implementation guidelines (6) and Screening donated blood for 
transfusion-transmissible infections (7).
Dr Neelam Dhingra 
Coordinator
Blood Transfusion Safety
5Policy recommendations
1 Each country should establish a national system for blood donor selection 
for the donation of blood or blood components.
2 All prospective blood donors, either donating as whole blood donations or 
through apheresis donations, should be assessed, prior to blood collection, 
for their suitability to donate on each occasion of donation, in every blood 
donation setting.
3 National donor selection guidelines and criteria should be based on 
epidemiological and/or scientific evidence or, where evidence is limited or 
lacking, on best practices.
4 Donor acceptance and deferral policies for the prevention of TTI should be 
based on up-to-date information on the local epidemiology of infections, 
the markers screened for, the availability of suitable blood screening and 
confirmatory assays, and the technologies in use. 
5 Blood transfusion services should have mechanisms for surveillance to 
monitor emerging infections and diseases associated with transmission 
through transfusion, and assess the risk of transmission and the possible 
consequences to the blood supply of excluding “at-risk” donors. 
6 National donor selection criteria should define conditions of acceptance 
and deferral for each criterion. 
7 Adequate resources, including a sufficient number of qualified and trained 
staff, should be made available for the consistent and reliable assessment 
of donor suitability for blood donation. 
8 Quality systems should be in place for blood donor selection, including 
selection criteria, staff training and documentation. 
9 Blood transfusion services should have systems for the notification and 
counselling of individuals who have been deferred from blood donation and 
for their referral for further management if any abnormalities are found.
10 Blood transfusion services should establish mechanisms for monitoring 
and evaluation to assess the implementation and effectiveness of donor 
selection criteria.
11 National regulatory mechanisms for the oversight of the functions of blood 
transfusion services should include activities related to blood donor selection.
12 National procurement policy and supply systems should encompass the 
equipment and consumables required for assessing the suitability of blood 
donors.
6Technical recommendations
These technical recommendations provide a summary of recommendations on 
donor selection criteria in Sections 4–7, by condition.
Condition Acceptance or deferral criteria Page 
numbers
Abortion Defer for up to 6 months 46–47
Acne Accept provided venepuncture site is 
unaffected 
Also refer to Section 6.2
60–61, 
64–65
Acupuncture Defer for 12 months following last 
procedure
68, 90
Age limits for blood 
donation
Usually 18 to 65 years
Refer to Section 4.1
39–40
Alcohol intake Accept if no signs of intoxication 40–41, 
89
Allergy Accept if symptom free 
Defer permanently if history of 
anaphylaxis
57
Anaemia Accept if past history of iron deficiency 
anaemia, with a known cause not a 
contraindication to donation, when 
treatment completed and fully recovered
Accept vitamin B12 or folate deficiency 
when fully recovered and on 
maintenance treatment 
Defer if does not meet minimum 
haemoglobin level for blood donation or 
under investigation or on treatment for 
anaemia
Defer permanently if chronic anaemia 
of unknown cause or associated with 
systemic disease 
43–44, 
49–50
Anaphylaxis Defer permanently 57
Antibiotics Accept 14 days after completion of 
treatment
Accept if on long-term antibiotics for 
acne
41, 55, 
60, 65
Ankylosing spondylitis Defer permanently 
Also refer to Section 5.10
60
Arthritis Refer to Sections 5.6 and 5.10 57, 60
7Asthma Accept provided asymptomatic on 
maintenance dose of non-steroid and/or 
inhaled steroid medication
Defer for 14 days after full recovery from 
acute exacerbation
Defer for 14 days after completion of 
course of oral or injected steroid
54–55, 
57
Babesiosis Defer permanently 82
Biopsy Accept when normal activities resumed
Also refer to Section 6.4
67
Blood transfusion Defer recipient of blood and blood 
products for 12 months following 
transfusion
Defer permanently if on regular 
treatment with plasma-derived 
coagulation factors
Also refer to Section 6.3.1
65–66
Bronchitis Defer for 14 days after full recovery 
from acute attack and completion of 
treatment
Also refer to Section 5.3
55
Brucellosis Defer permanently 84
Burns Accept if fully healed 61
Campylobacter Defer for 28 days following full recovery 85
Cardiovascular diseases Accept surgically corrected simple 
congenital cardiac malformation with no 
residual symptoms
Accept asymptomatic disorder: e.g. 
functional murmurs, mitral valve prolapse
Defer permanently all other conditions 
Also refer to Section 5.2
52–53
Central nervous system 
diseases
Accept if history of epilepsy or seizures 
provided off medication and seizure-free 
for 3 years
Defer permanently all other conditions 
58–59
Cerebrovascular diseases Defer permanently
Also refer to Section 5.8.1
58–59
Chagas disease Refer to Section 7.4.2 81–82, 
87
Chickenpox Defer for 14 days following full recovery
Also refer to Section 7.3.6
78
Chikungunya virus Refer to Section 7.3.5 77
Cholecystitis Accept when fully recovered 55
8Coagulation disorders Accept if carrier for haemophilia A or B 
provided normal coagulation factor levels 
and no history of bleeding or treatment 
with blood products
Defer permanently if coagulation factor 
deficiencies
52
Coeliac disease Accept if fully treated 55–56
Colitis Accept irritable bowel syndrome without 
debility 
Defer active inflammatory bowel disease 
unless well, in long-term remission and 
meets minimum haemoglobin levels for 
blood donation
55
Common cold Refer to Section 4.3 41
Cosmetic treatment 
(invasive)
Defer for 12 months following last 
procedure
68, 90
Creutzfeldt-Jakob disease 
(CJD)
Defer permanently sporadic and familial 
CJD and first-degree relatives 
Defer permanently if history of treatment 
with pituitary-derived human growth 
hormone, human gonadotrophin, dura 
mater graft, corneal transplantation, 
neurosurgery
Also refer to Section 7.7.1
58, 65, 
86–87
Crohn’s disease Refer to Section 5.4 55
Dementia Defer permanently
Also refer to Section 5.8.3
58–59
Dengue virus Refer to Section 7.3.5 77
Dental treatment Accept 24 hours after simple procedures 
and 7 days after extraction or endodontic 
procedures
67
Depression Accept if feeling well 61–62
Dermatomyositis Defer permanently 57, 
60–61
Diabetes Accept diabetes mellitus controlled 
by diet or oral medication provided no 
history of orthostatic hypotension and 
no evidence of infection, neuropathy or 
vascular disease
Defer permanently if requires insulin 
treatment or has complications with 
multi-organ involvement
56
Diagnostic procedures Defer following minor diagnostic 
procedure including rigid endoscopy until 
normal activity resumed   
Defer for 12 months following invasive 
diagnostic procedure using flexible 
endoscopy 
67
9Diarrhoea Accept 14 days after full recovery 
and completion of therapy, including 
antibiotics
Accept chronic diarrhoea due to irritable 
bowel syndrome without debility; 
otherwise defer 
Defer for 28 days if symptoms 
suggestive of Yersinia enterocolitica
41, 82, 
83, 
84–85
Diverticular disease Accept if well 55
Drug use Injecting drug use:
Defer permanently individuals with a 
history of injecting drug use
Also refer to Section 7.9.2
88–89
Non-injected drugs and alcohol use:
Accept if no signs of intoxication
Defer if displaying signs and symptoms 
of intoxication
89
Eczema Refer to Section 5.11 57, 61
Epilepsy Accept if off medication and seizure-free 
for 3 years
58–59
Epstein-Barr virus Defer until 28 days after full recovery 
Also refer to Section 7.3.4
76
Erythrocytosis Accept secondary erythrocytosis if 
diagnosis of polycythaemia rubra vera 
excluded
51
Essential 
thrombocythaemia
Defer permanently 60
Fever (non-specific) Defer until 14 days after full recovery
Also refer to Section 4.3
41, 42, 
72, 
79–81, 
82, 83, 
84
Fracture Accept when plaster removed and mobile 60
Frequency of donation For whole blood, minimum of 12 weeks 
for males, 16 weeks for females
Also refer to Section 4.6.2
44–46
Gallstones Accept if well 55
Gastro-oesophageal 
reflux
Accept if mild  55
Gonorrhoea Defer for 12 months following 
completion of treatment and assess for 
high-risk behaviour
Also refer to Section 7.5.1
74, 
83–84
G6PD deficiency Accept if no history of haemolysis
Defer permanently if history of 
haemolysis
50–51
10
Haemochromatosis Accept provided meets other criteria 45, 52
Haemoglobin level for 
blood donation
Not less than 12.0 g/dl for females 
Not less than 13.0 g/dl for males 
Also refer to Sections 4.6 and 4.10
43–44, 
48
Haemoglobinopathies Defer permanently thalassaemia major 
or sickle cell disease
Also refer to Section 5.1.2
50
Haemophilia Refer to Section 5.1.7 52
Hepatitis A, hepatitis E 
and hepatitis of unknown 
origin
Defer for 12 months following full 
recovery
Also refer to Section 7.3.1
73–74
Hepatitis B Refer to Section 7.3.1 72–73, 
87–90
Hepatitis C Refer to Section 7.3.1 73, 
87–90
Herpes Accept cold sores and genital herpes 
provided no active lesions 
Defer symptomatic individuals for at 
least 28 days following full recovery 
Defer permanently individuals with HHV8 
infection and current or former sexual 
contacts
Also refer to Section 7.3.4 
76
Hiatus hernia Accept mild cases, provided well 55
HIV/AIDS Refer to Section 7.3.2 74–75, 
83, 
87–90
HTLV Refer to Section 7.3.3 75
Hypertension Accept stable uncomplicated 
hypertension controlled by medication
Defer if recently started or changed anti-
hypertensive medication until 28 days 
after blood pressure stabilized
Defer permanently if hypertensive heart 
or renal disease
53–54
Hypogammaglobulinaemia Defer permanently 57
Immunization Refer to Section 6.1 63–64
Immunological diseases Refer to Section 5.6 57
Infections (acute 
bacterial)
Accept 14 days after full recovery and 
completion of antibiotic treatment
Defer for 28 days following full 
recovery and completion of treatment if 
symptoms suggestive of infection with 
salmonella, campylobacter, streptococcus 
or staphylococcus
41, 85
11
Influenza Accept asymptomatic individuals with no 
close contact with those having active 
infection 
Defer for 14 days after full recovery and 
cessation of any therapy  
Defer for 48 hours after vaccination
Also refer to Section 7.3.7
78
Inoculation injury Defer for 12 months following exposure 73
Iron deficiency Refer to Section 5.1.1 43–46, 
49
Irritable bowel syndrome Accept, if without debility 55
Leishmaniasis Refer to Section 7.4.4 82–83
Leukaemia Defer permanently 59–60
Lyme disease Defer for 28 days following full recovery 
and completion of treatment, whichever 
is longer
84
Lymphoma Defer permanently 59–60
Malaria Local criteria depending on endemicity
Refer to Section 7.4.1
79–81, 
87
Malabsorption syndromes Defer permanently except treated coeliac 
disease  
55–56
Malignant diseases Accept malignancy “in situ” (e.g. basal 
cell carcinoma, cervical carcinoma in 
situ), if successfully treated, regularly 
monitored and in good health
Defer if current diagnosis of malignancy 
or less than 5 years since completion of 
treatment
Defer permanently if malignant 
melanoma, lymphoproliferative or 
haematological disorders
Also refer to Section 5.9
59–60
Measles Defer for 14 days following full recovery
Also refer to Section 7.3.6
78
Medications Take account of indication for treatment
Accept long-term low-dose antibiotics for 
acne 
Defer for 14 days following antibiotic use 
Retinoids, dutasteride, finasteride, aspirin 
and non-steroidal anti-inflammatory drugs: 
also refer to Section 7.7
64–65
Menstruation Accept 46–47
Minor illnesses Defer for 14 days after full recovery 
from acute infection and completion of 
antibiotic treatment
41
12
Multiple sclerosis Defer permanently
Also refer to Section 5.8.4
58–59
Mumps Defer for 14 days following full recovery
Also refer to Section 7.3.6
78
Musculoskeletal 
disorders
Accept acute or chronic simple disorders 
(e.g. mild rheumatoid arthritis, back pain, 
sciatica, frozen shoulder, osteoarthritis) 
if mobile 
Defer permanently if systemic disease 
affecting joints: e.g. severe rheumatoid 
arthritis, psoriatic arthropathy, ankylosing 
spondylitis
60
Myelodysplastic 
syndrome 
Defer permanently 59–60
Nephritis Refer to Section 5.7 57–58
Peptic ulcer Defer until completion of treatment and 
full recovery
55
Piercing Defer for 12 months following 
last acupuncture, piercing, tattoo, 
scarification or invasive cosmetic 
procedure 
68, 90
Platelet disorders Refer to Section 5.1.4 51
Polycythaemia Accept secondary erythrocytosis
Defer permanently polycythaemia rubra 
vera 
51, 
59–60
Pregnancy and lactation Defer during pregnancy and lactation 
and up to 6 months following delivery or 
termination
46–47 
Prisons and penal 
institutions
Refer to Section 7.9.4 89–90
Psoriasis Refer to Section 5.11 60–61
Psoriatic arthropathy Defer permanently 
Also refer to Section 5.10
60
Psychiatric disorders Accept anxiety disorder or mood disorder 
provided in generally good health, not 
obviously over-anxious, depressed or 
manic on the day of donation, regardless 
of medication
Defer permanently psychotic disorder 
requiring maintenance treatment
61–62
Pulmonary embolus Refer to Section 5.2.2 54
Red cell membrane 
defects
Accept if no history of haemolysis
Defer permanently if history of 
haemolysis
50–51
13
Renal diseases Accept if fully recovered from acute self-
limiting condition (e.g. acute nephritis) 
provided renal function normal 
Defer permanently if chronic renal disease 
causing ill-health or anaemia or associated 
with chronic or recurrent infection
49–50, 
53–54, 
57–58
Respiratory diseases Defer acute respiratory infection 
for 14 days following full recovery 
and completion of therapy, including 
antibiotics
Defer permanently if breathless at rest 
or minimal exertion or if cyanosed, has 
severe obstructive airways disease 
(including if on long-term oral steroid 
therapy), or chronic or recurrent 
respiratory infection 
Also refer to Section 5.3
41, 
54–55, 
57
Rickettsial infection Defer for 6 months following completion 
of treatment or cessation of symptoms 
Defer acute Q fever for 2 years following 
completion of treatment and full 
recovery, whichever is longer
Defer permanently chronic Q fever 
85–86
Rocky Mountain spotted 
fever
Refer to Section 7.6 85–86
Rubella infection Defer for 14 days following full recovery
Also refer to Section 7.3.6
78
Salmonella infection Defer for 28 days following full recovery 85
Scarification Refer to Section 7.9.5 68, 90
Scleroderma Defer permanently 60–61
Sex workers Defer permanently 87–88
Sexual behaviour (high-
risk)
Refer to Section 7.9.1 87–88
Sickle cell disease Accept sickle trait provided haemoglobin 
above required lower limit
Defer permanently sickle cell disease
Also refer to Section 5.1.2
50
14
Skin diseases Accept mild common skin disease (e.g. 
acne, eczema, psoriasis) if lesions not 
infected, venepuncture site is unaffected 
Defer if generalized skin disease and on 
systemic medication
Defer if contagious skin disease
Defer permanently if systemic disease 
affecting skin (e.g. scleroderma, 
systemic lupus erythematosus, 
dermatomyositis, systemic cutaneous 
amyloidosis) 
Also refer to Sections 5.11 and 
6.2 
60–61, 
64–65
Streptococcus infection Defer for 28 days following full recovery
Defer for 14 days following full healing if 
recent superficial but significant wounds
85
Stroke Defer permanently
Also refer to Section 5.8.1 
58–59
Surgery Defer following minor surgery until 
treatment is complete and successful 
and normal activity resumed
Defer for 12 months following major 
surgery
Defer permanently following 
neurosurgical procedure, dura mater 
graft or corneal transplant 
Also refer to Sections 6.4 and 7.7
67, 
86–87
Syphilis Defer permanently if has ever had a 
diagnosis of syphilis
Also refer to Section 7.5.1
83–84
Systemic lupus 
erythematosus
Defer permanently
Also refer to Section 5.11
57, 
60–61
Tattoos Refer to Section 7.9.5 68, 90
Thalassaemia Accept thalassaemia trait provided well 
and haemoglobin above required lower 
limit
Defer permanently thalassaemia major
Also refer to Section 5.1.2
50
Thrombocytopenia Accept past history of acute autoimmune 
thrombocytopenia more than 5 years 
previously, if well and not on treatment, 
except prophylactic antibiotics following 
splenectomy
Defer permanently if thrombocytopenia of 
unknown cause or associated with long-
term haematological or systemic disease
51, 
59–60
Thrombosis Refer to Section 5.2.2 52–53, 
54
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Thyroid disorders Accept if benign disorder and euthyroid 
(with or without treatment)
Defer if under investigation for thyroid 
disease, if hyper- or hypo-thyroid, or with 
a history of malignant thyroid tumours 
(also refer to Section 5.9)
Defer permanently if history of 
thyrotoxicosis due to Graves’ disease
56–57
Transient cerebral 
ischaemic episodes
Defer permanently
Also refer to Section 5.8.1 
58–59
Transplantation Defer for 12 months following 
transplantation of allogeneic tissues
Defer permanently if transplanted with 
allogeneic cells or tissue sourced since 
1980 from a country in which risk of 
vCJD has been identified
Defer permanently following stem cell or 
organ transplantation, dura mater graft, 
corneal transplant or xenograft
65–67
Tuberculosis Defer for 2 years following confirmation 
of cure
Also refer to Section 7.5.6
85
Ulcerative colitis Refer to Section 5.4 55–56
Urinary tract diseases Accept lower urinary tract infections 14 
days after full recovery and completion 
of treatment
Also refer to Section 5.7
57–58
Vaccination Refer to Section 6.1 63–64
Variant Creutzfeldt-Jakob 
disease (vCJD)
Defer permanently variant Creutzfeldt-
Jakob disease (vCJD)
Refer to Section 7.7.2
58, 
86–87
Vitiligo Accept 57
Weight Refer to Section 4.4 41–42
West Nile virus Refer to Section 7.3.5 76–77, 
87
Yersinia enterocolitica 
infection
Defer for 28 days following full 
recovery if recent abdominal symptoms, 
particularly diarrhoea, suggestive of Y. 
enterocolitica infection
84–85
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1 Introduction
1.1 BLOOD DONOR SELECTION 
The primary responsibility of a blood transfusion service is to provide a safe, 
sufficient and timely supply of blood and blood products. In fulfilling this 
responsibility, the BTS should ensure that the act of blood donation is safe and 
causes no harm to the donor (3,5,8). It should build and maintain a pool of safe, 
voluntary non-remunerated blood donors and take all necessary steps to ensure 
that the products derived from donated blood are efficacious for the recipient, 
with a minimal risk of any infection that could be transmitted through transfusion. 
All prospective blood donors should therefore be assessed for their suitability 
to donate blood, on each occasion of donation. The purpose of blood donor 
selection is to:
 Protect donor health and safety by collecting blood only from healthy 
individuals
 Ensure patient safety by collecting blood only from donors whose donations, 
when transfused, will be safe for the recipients
 Identify any factors that might make an individual unsuitable as a donor, 
either temporarily or permanently 
 Reduce the unnecessary deferral of safe and healthy donors
 Ensure the quality of blood products derived from whole blood and 
apheresis donations
 Minimize the wastage of resources resulting from the collection of 
unsuitable donations. 
Information provided by 164 countries to the WHO Global Database on Blood 
Safety indicates that, worldwide, more than 92 million blood donations are 
collected annually. Of these, an estimated 1.6 million units are discarded due 
to the presence of infectious markers for TTI, including HIV, hepatitis B, hepatitis 
C and syphilis. In addition, at least 13 million prospective donors are deferred 
from donating blood due to anaemia, existing medical conditions or the risk of 
infections that could be transmitted through transfusion (9). The scale of these 
discards and deferrals highlights the need for effective blood donor selection 
to minimize the unnecessary deferral of suitable donors, and the donation of 
blood by unsuitable donors that subsequently has to be discarded; this will 
reduce the wastage of resources, including donor and staff time, consumables 
and screening tests, and also avoid needless discomfort to donors.
Significant variations have been observed between countries in the extent to 
which national donor selection criteria are defined, prospective donors are 
assessed and the quality and effectiveness of the donor selection process are 
monitored. In some countries, national systems of blood donor selection are 
not well-developed and donor selection criteria are not clearly defined or applied 
uniformly. This may result in blood being collected from donors who have not 
been properly assessed for their suitability to donate; this may affect their health 
and pose a higher risk of transmission of infections through transfusion. 
In many countries, donor selection criteria are still based on tradition and 
customary practice rather than on evidence (10,11) and criteria from one country 
are often adopted in other countries without due consideration of the profiles 
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of the general and potential donor populations, the prevailing epidemiology of 
infections and diseases, local culture and available resources. Some countries 
take a highly precautionary approach to the selection of donors for the safety 
of blood products, donors and patients. Policies for donor selection should take 
into account the need for a balance between the safety and sufficiency of the 
blood supply and available resources (11,12,13). 
In 2005, World Health Assembly resolution WHA58.13 (14) urged Member States, 
inter alia, to establish or strengthen systems for the recruitment and retention 
of voluntary, non-remunerated blood donors and the implementation of stringent 
criteria for donor selection. World Health Assembly resolution WHA63.12 (15) 
in 2010 also urged Member States to take all necessary steps to update their 
national regulations on donor assessment and deferral. However, there are relatively 
few internationally-recognized guidelines on blood donor selection (Annex 1) and 
all of these have been developed to address the needs of specific regions or 
countries. There is therefore a need for global guidance on the development of 
systems and criteria for blood donor selection that could then be adapted at 
national level. 
1.2 AIM AND OBJECTIVES 
Aim
The aim of Blood donor selection: guidelines on assessing donor suitability for 
blood donation is to guide and support countries in establishing effective national 
systems for blood donor selection, including policies, guidelines and criteria in 
order to ensure the safety of the recipients of blood and blood products and 
protect donor health and safety. 
Objectives
These guidelines are intended for use in countries which have not yet established 
national systems for blood donor selection or which are in the process of developing 
or revising donor selection guidelines and criteria. The specific objectives are to:
1 Provide guidance on the measures needed to develop and implement 
effective systems for assessing the suitability of individuals to donate 
blood. 
2 Review the available evidence base and provide recommendations on 
criteria for blood donor selection.
The donor selection criteria recommended in these guidelines apply to donors of 
whole blood, red cells, platelets, plasma and other blood components, donated 
as whole blood or through apheresis, including plasma for fractionation. These 
include a) criteria that have worldwide applicability and should be applied uniformly, 
and b) criteria that require local adaptation in the light of epidemiological data, 
demography, the health of the population, the screening and confirmatory tests 
performed and the available technology.
Whilst these guidelines are designed to promote best practice in blood transfusion 
services to ensure the collection of donations from the lowest risk donors 
possible, consideration should always be given to the issue of sufficiency, 
balancing any risk of infection against the risk of blood shortages resulting from 
the development of too stringent national guidelines. Infectious risks are not the 
same in all countries, or even within individual countries, and it is crucial that 
selection guidelines are developed according to the circumstances and needs 
of each country. 
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1.3 TARGET AUDIENCE
The target audience includes personnel and representatives from the following 
institutions and organizations:
 National blood programmes in ministries of health 
 National advisory bodies responsible for policy making on blood safety, 
such as national blood commissions or councils
 Blood transfusion services, including directors, medical officers, blood 
donor managers, quality managers, donor care staff responsible for blood 
donor selection, laboratory managers and other staff
 Public health institutions 
 Reference laboratories 
 Regulatory agencies 
 Blood donor organizations and other nongovernmental organizations and 
institutions involved in blood donor education and recruitment 
 Professional societies and patient associations.
These guidelines may also be useful for other relevant stakeholders such as 
education and training institutions, transplantation services, plasma collection 
and fractionation facilities and disease prevention programmes focusing on 
infections such as HIV, hepatitis, malaria and Chagas disease.
1.4 METHODOLOGY
In 2009, the WHO Blood Transfusion Safety programme scoped the guidelines to 
define the content and assess the topics on which recommendations on blood 
donor selection were required. It identified three key questions to be addressed:
1 What are the components of an effective national system for assessing 
the suitability of prospective donors to donate blood?
2 What are the criteria for the acceptance or deferral of prospective blood 
donors to avoid blood donation by unsuitable individuals in order to 
protect the health and safety of recipients of transfusion and ensure 
patient safety?
3 What are the criteria for the acceptance or deferral of prospective blood 
donors to protect donor health and safety while avoiding the unnecessary 
deferral of suitable donors?
WHO/BTS convened a guideline development group (GDG) whose members were 
selected on the basis of their specialist expertise in haematology, transfusion 
medicine and blood donor management (refer to Acknowledgements) (16). The 
role of the GDG, in conjunction with WHO/BTS, included identification of priority 
questions and outcomes; retrieval of the evidence; assessment and synthesis 
of the evidence; identification of issues that are controversial or where change 
of practice is recommended; review of internationally-recognized guidelines and 
current practices worldwide; formulation of recommendations; preparation of the 
text; and planning for the dissemination, implementation, impact evaluation and 
updating of the guidelines. WHO/BTS also established an external review group 
(ERG) comprising members of the WHO Expert Advisory Panel on Blood Transfusion 
Medicine and experts from WHO Collaborating Centres in Transfusion Medicine 
as well as directors of national blood transfusion services and blood programme 
managers from each WHO region (refer to Acknowledgements). The composition 
of the ERG was designed to ensure a wide range of specialist expertise and 
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experience from blood transfusion services in all regions at different stages 
of development. The role of the ERG was to review the draft guidelines and 
advise WHO on their relevance and applicability in their countries in the context 
of epidemiology, risk behaviours and activities, cultural practices and available 
blood screening and confirmatory testing technologies. 
An early draft of the guidelines was pilot-tested in Ethiopia in 2010 and revised 
drafts were circulated electronically to members of the ERG in 2010 and 2011; 
their comments were carefully reviewed by the GDG and incorporated into the 
guidelines. The guidelines were submitted for review and approval to the WHO 
Guidelines Review Committee (GRC), which reviewed and provided guidance on 
the process and methodology for evidence retrieval and the assessment and 
synthesis of evidence to ensure that the evidence collected was unbiased, up-
to-date and relevant. Detailed comments received from the GRC were addressed 
systematically and the guidelines were modified to incorporate these comments.
A further external review of the advanced draft of the guidelines to assess the 
feasibility of their implementation was undertaken by participants in an inter-
regional workshop on blood donor selection and donor counselling for priority 
countries in the African and Eastern Mediterranean regions, June 2011, Nairobi, 
Kenya (17) (refer to Acknowledgements); and, relevant comments were addressed 
by the GDG in developing the final draft.
Evidence base
A systematic literature search was conducted to collect and review the evidence 
(1995–2011, and also in 2012 for selected topics) on defined physiological 
conditions, diseases and risk behaviours in relation to the suitability of individuals 
for blood donation. The literature search covered the more widely consulted 
published literature from peer-reviewed journals, regional journals, book chapters, 
institutional and other knowledge databases, as well as lesser-known published 
literature and unpublished and non-reviewed “grey literature”. 
As these guidelines have been developed particularly for use in countries that 
have not yet established national systems for blood donor selection, the literature 
search strategy was specially designed to collect literature from low and middle-
income countries. 
Searched domains
A systematic search of the following databases was undertaken: PubMed, Cochrane 
Library, WHO Library Database (WHOLIS), Institute for Scientific Information (ISI) 
Web of Knowledge, World Bank eLibrary and WHO regional databases: African 
Index Medicus (AIM), Index Medicus for the Eastern Mediterranean (IMEMR), Index 
Medicus for South-East Asia (IMSEAR), Western Pacific Region Index Medicus 
(WPRIM), Virtual Health Library – Latin American and Caribbean Literature on 
Health Sciences Information (VHL-LILACS), Virtual Health Library – MEDCARIB 
and the Pan American Health Organization.
The “grey literature” was retrieved using the public search engines Google and 
Yahoo mainly to collect literature from low and middle-income countries, focusing 
on a) the existence and availability of national guidelines and criteria for blood 
donor selection, and b) current practice in blood donor selection in countries.
Keywords and medical subject heading (MeSH) terms, and key authors and 
institutions were used to retrieve relevant citations on each topic from various 
databases. Detailed search strategies with the date and time of the search, 
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databases searched, keywords and MeSH terms used and the search strings 
are documented in Annex 3.
A preliminary screen by review of titles was carried out by the searcher to eliminate 
obviously irrelevant and duplicate citations. Citations of possible relevance were 
then forwarded to the chair of the GDG who undertook a further review of the 
titles and the abstracts, where appropriate. Key papers that addressed each of 
the study questions were then selected and the full text of these papers was 
reviewed. 
Quality of evidence
The evaluation of the quality of evidence, the safety profiles of interventions, the 
assessment of current medical and scientific knowledge and practice, and the 
cost-effectiveness of practices was undertaken by the guideline development group 
and WHO/BTS. This formed the basis for the formulation of recommendations 
on criteria for the acceptance and deferral of prospective blood donors. 
It is recognized that there is a paucity of high quality evidence on which to base 
decisions on blood donor selection. While some attempts have been made to 
apply the principles of evidence-based medicine (EBM) to transfusion medicine 
(10,11,18,19), the randomized controlled trial, the major tool of EBM, cannot 
apply to donor selection, and there are few directly relevant published clinical, 
epidemiological and observational studies, systematic reviews and audits on 
criteria for blood donor selection. 
Many long-established donor selection criteria are based on medical knowledge 
of the disease process and human physiology, the haemodynamic effect of 
blood donation and the potential for harm to either the donor or the recipient. 
In general, acceptance criteria specify conditions in which there is no or minimal 
risk to donor or recipient, based either on published evidence of safety from 
observational studies or on general medical principles. Deferral criteria are based 
almost entirely on general principles aimed at minimizing any risk to the donor 
or recipient. Evidence is rarely available because observational studies of blood 
donation in many such conditions would be unethical. 
Given the paucity of the evidence on donor selection criteria, formal assessment 
of the quality of evidence to support the recommendations was undertaken only 
for three topics, because of their controversial nature, discrepancies between 
international guidelines or the potential impact of a change of practice on the 
blood donor base, i.e. individuals with a history of epileptic seizures; men who 
have sex with men (MSM); and injecting drug users. 
Key citations that had important and relevant information on these topics were 
analysed for the quality of evidence, using the GRADE system (http://www.
gradeworkinggroup.org) that considers factors such as study design, quality, 
consistency, directness and precision to assess the quality of the collected 
evidence. Summaries of evidence tables were made to assist in the development 
of recommendations on these topics. 
Where published evidence is lacking, recommendations on donor selection 
criteria are based on international best practice and the medical knowledge and 
expertise of members of the guideline development group and external review 
group. In conditions where emerging evidence suggests that deferral criteria 
may be relaxed, a precautionary approach is recommended until good evidence 
of safety becomes available. 
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Recommendations
The document is presented in two parts. Part 1 (Sections 2 and 3) addresses 
the requirements for an effective national system for blood donor selection; policy 
recommendations are provided on pp. 12. Part 2 provides guidance on specific 
criteria for blood donor selection in relation to general donor assessment, donor 
medical history and TTI risk assessment; technical recommendations on donor 
selection criteria are summarized on pp. 13–22 and elaborated in Sections 4 to 7.
Review and updating of the guidelines
It is anticipated that the guidelines will remain valid until 2017. The WHO 
Blood Transfusion Safety Team will be responsible for initiating a review of the 
document at that time. 
Part 1
National system for blood 
donor selection
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2 Establishing a national 
system for blood donor 
selection
The selection and management of blood donors is an essential part of the blood 
donation process. National health authorities and blood transfusion services 
are responsible for ensuring that a national system is in place for the selection 
of all blood donors through an assessment of their suitability to donate blood. 
The national system for blood donor selection should include: 
 National policy and legislative framework 
 National guidelines and criteria on blood donor selection
 Public information and donor education 
 Suitable infrastructure and facilities
 Adequate financial and human resources
 Quality system, including standard operating procedures, documentation 
and records 
 Donor haemovigilance
 Monitoring and evaluation. 
2.1  NATIONAL POLICY AND LEGISLATIVE FRAMEWORK 
Every country should have a national blood policy that defines the strategies for 
blood donor recruitment, selection, deferral, blood screening for TTI, confirmatory 
testing, donor notification, counselling and referral. The national blood policy 
should be supported and enforced by a legislative and regulatory framework and 
implemented through national guidelines. The legislative framework should define 
the fundamental principles and ethics of blood donation and donor selection. It 
should address the responsibilities of the BTS in:
 Protecting the health and safety of blood donors and ensuring confidentiality, 
privacy, self-determination and non-discrimination 
 Protecting the health of recipients of blood and blood products and 
ensuring the safety, quality and availability of blood and blood products.
Blood donors have a responsibility to self-defer if they are aware of having been 
exposed to any risk of an infection or a known health condition or treatment 
that could influence their suitability to donate blood. Blood donors also have 
the right to withdraw at any stage of the donation process. 
Patients have a right to be protected from avoidable adverse effects of transfusion. 
Thus, while anyone may offer to become a blood donor, no one has the right to 
donate blood (20,21). 
2.2 NATIONAL GUIDELINES AND CRITERIA ON BLOOD DONOR 
SELECTION 
National guidelines on blood donor selection should be developed through a 
full consultative process. A mechanism such as a national expert advisory 
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group should be established with a remit to develop and periodically review 
the guidelines and criteria on blood donor selection, in consultation with key 
stakeholders including:
 National policy makers
 National blood programme managers
 Senior BTS personnel
 Experts in transfusion medicine and science, including clinical users of 
blood, microbiologists and social scientists
 Representatives of the regulatory agency. 
National guidelines on blood donor selection should include the criteria for 
blood donor selection and their implementation in the BTS for assessing donor 
suitability. The formulation and implementation of donor selection criteria will 
protect the health of blood donors and the recipients of transfusion. It will also 
help to maintain and raise standards of donor management and care and minimize 
unnecessary donor deferrals. Guidelines on blood donor selection should be 
comprehensive, relevant to the local situation and simple to apply in practice. 
The BTS should consider the feasibility of their implementation in day-to-day 
routine settings, in both fixed and mobile blood collection sites.
In developing national guidelines, a review of existing international guidelines, 
relevant literature and best practices would help to identify the medical and 
scientific principles underlying donor selection criteria. National guidelines should 
be based on evidence and risk assessment, taking into account national data on 
the epidemiology of medical conditions and transfusion-transmissible infections, 
and risk behaviours (22). It is also important to consider the nutritional and 
health status of the population and cultural practices. 
National guidelines and criteria on blood donor selection should comply with 
national legislative and regulatory requirements and should be reviewed regularly 
and updated in response to changes in epidemiology, advances in technology, the 
latest medical and scientific information and new evidence. Emerging infections and 
other situations that may influence donor and patient safety should be monitored 
and may necessitate the revision and modification of donor selection criteria. 
Donor acceptance and deferral criteria and blood screening procedures have to 
be balanced to provide optimal safety for both donors and recipients while at the 
same time ensuring an adequate supply of blood and blood products (23,24). 
National health authorities should assess whether, and to what extent, any criteria 
for donor selection could be relaxed in order to maintain adequate blood supplies 
in an emergency situation, such as pandemic influenza. However, any deviation 
from national guidelines and criteria on blood donor selection should be limited 
to a defined period in managing the emergency situation (25). 
Donor questionnaire
A donor questionnaire is the key tool in donor selection for assessing donor 
health and safety and for reducing the risk of transmission of infection, in 
particular for infections for which no suitable screening tests are available. A 
standardized donor questionnaire incorporating selection criteria is now widely 
accepted as being necessary for uniformity and consistency in approach and for 
ease of implementation in assessing donor suitability. It ensures that the same 
information is collected systematically about each donor on each occasion of 
donation and forms the basis for a one-to-one confidential interview with a trained 
member of staff. The use of a donor questionnaire prompts donor selection 
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staff to ask important questions and carefully assess the donor’s health. By 
presenting all relevant information in a standard format, a donor questionnaire 
facilitates decisions on the acceptance or deferral of the donor. 
A standard questionnaire that elicits a prospective donor’s demographic, 
medical and risk history should be used throughout the country. The design 
and implementation of the donor questionnaire is the responsibility of the BTS. 
The questionnaire should be simple, unambiguous, culturally acceptable, easy 
to complete and available in local languages where appropriate. Donor selection 
staff should be trained to recognize donors having difficulty in understanding any 
questions, for example, due to low literacy levels, and to explain the questions 
and facilitate the process for donors to provide accurate responses. A donor 
selection questionnaire takes considerable time to develop and should be piloted 
and validated as fit for purpose to ensure that all ambiguity is removed and that 
it yields the expected results. The questionnaire should be reviewed at frequent 
intervals to ensure that it is effective and should be revised in accordance 
with changes in the selection criteria in the national guidelines (26). Revised 
versions should be introduced and used uniformly in all blood donation settings. 
An example of a donor questionnaire is included as Annex 2. 
2.3 PUBLIC INFORMATION AND DONOR EDUCATION 
Effective public information and donor education are the first steps in the process 
of donor selection. The dissemination of information on donor suitability through 
public awareness campaigns and donor information and education materials will 
help to ensure that individuals who volunteer as blood donors are well-informed 
and likely to be accepted. 
Informing potential donors about the health conditions and risk behaviour that 
would make them unsuitable as blood donors and the screening tests that are 
performed on donated blood enables prospective donors to assess their own 
suitability and provides an opportunity for them to self-defer (27,28). It should 
be made clear that there is no discrimination in donor selection on the grounds 
of gender, race or religion, and neither the donor nor the recipient has the right 
to require that any such discrimination be practised (29).
Towards 100% voluntary blood donation: a global framework for action (4) provides 
guidance on strategies to foster a culture of voluntary blood donation, including donor 
information and education, for building a safe, sustainable voluntary donor base.
Information materials on the donor selection process and criteria should be 
developed, including an explanation of their rationale and objectives. These 
materials should be simple and easy to understand, and written in languages 
suitable for the donor population. 
2.4 INFRASTRUCTURE AND FACILITIES
It is essential that suitable infrastructure and facilities are made available 
in which blood donor selection can be performed in a friendly and conducive 
environment. Whether it is carried out in a fixed location or mobile setting, the 
venue for donor selection should provide adequate privacy and confidentiality. 
A pleasant atmosphere for blood donation will encourage donors to relax and help 
to reduce anxiety. Space used for donor selection should be arranged to maximize 
the opportunities for confidential discussion between BTS staff and donors. 
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Sufficient, suitable and well-maintained equipment for donor health assessment 
should be available. This may include equipment for haemoglobin screening, 
sphygmomanometers, weighing scales and essential consumables, such as 
disposable sterile lancets, disinfectants and stationery.
2.5 FINANCIAL AND HUMAN RESOURCES
A system of adequate and sustainable finances is imperative for a stable and 
sufficient supply of safe blood and blood products. The cost of public information 
programmes, donor education and donor selection is an important component of 
the BTS’s operating costs. A dedicated budget should therefore be allocated for 
training of staff, the development of information, education and communication 
materials, and the supply of equipment and consumables required for assessing 
donor suitability. Effective donor education, recruitment and selection contribute 
to minimizing the collection of blood from unsuitable donors, thus reducing the 
wastage of blood, consumables, and donor and staff time. 
The responsibility for donor selection and care lies with a physician or registered 
nurse in attendance at the donation session. An adequate number of staff should 
be employed to ensure proper donor assessment and selection. Staff involved 
in donor selection should be appropriately qualified, well-trained and skilled in 
providing information, advice and counselling in order to assess donor suitability 
for blood donation. 
Staff working in donor selection should have an understanding of the principles 
and basis for donor selection criteria and have the technical and clinical skills 
required to perform the health and risk assessment. The key skills, knowledge 
and competencies required for staff involved in donor selection include:
 Understanding of the donor selection criteria
 Pre-donation information and counselling
 Interview and assessment based on a standardized donor questionnaire
 Ability to explain questions in the donor questionnaire, ensure 
understanding and allay donors’ apprehensions 
 Basic health check, including haemoglobin screening
 Counselling of deferred donors 
 Post-donation advice and care. 
2.6 QUALITY SYSTEM
The implementation of a quality system is a pre-requisite for a consistent 
approach to donor selection. Essential elements of a quality system in the donor 
selection process include: 
 An organizational structure that defines the authority, responsibility and 
reporting channels of all personnel, including written job specifications
 Donor selection criteria, as part of the national guidelines for the BTS, 
to ensure uniform application in every facility in which blood donations 
are collected
 Standard operating procedures (SOPs) that guide every process, procedure 
and task to ensure consistency, accuracy and donor adherence, including 
information on the necessary staff, facilities, forms, worksheets and 
references, such as:
— Donor interview and assessment based on a standardized donor 
questionnaire
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— Basic health check, including haemoglobin screening 
 Staff training and competency assessment, including a training curriculum 
and training records
 Records system (electronic or manual) that ensures traceability and 
confidentiality, including: 
— Donor records associated with each donation, including completed 
donor questionnaires 
— Results of basic health check and haemoglobin screening 
— Donor deferrals and reasons for deferral
— Adverse donor reactions
 Periodic monitoring and evaluation of the donor selection process.
The confidentiality of donor records and the traceability of donations should be 
assured at all times through the use of unique identification numbers for donors 
and donations, and a mechanism linking donors to donations.
All instruments and equipment used in the donor selection process, such as 
weighing scales and devices for the measurement of body temperature, blood 
pressure and haemoglobin, should be maintained and calibrated in accordance 
with quality requirements. The health and safety of staff should be safeguarded, 
including protection from sharps injuries during haemoglobin screening (30,31). 
Special attention should be given to the disposal of sharps, effluent copper 
sulphate and other waste materials (32). 
The education and training of staff and regular quality monitoring are necessary 
for continual quality improvement.
2.7 DONOR HAEMOVIGILANCE
Donor haemovigilance is a continuous process of data collection and analysis 
of adverse donor events and reactions in order to investigate their causes 
and outcomes; haemovigilance data should be utilized for clinical and public 
health decision making. All adverse events and reactions in donors should be 
identified, documented and reported. These data should be regularly analysed in 
order to undertake possible corrective and preventive actions. The goal of donor 
haemovigilance is to reduce the occurrence of adverse events and reactions and 
improve the outcomes both for donors and patients. 
All donors should be advised to inform the BTS of any ill-effects they suffer after 
donating, such as a delayed faint, or if they recall an illness or information that 
should have been declared before donation. Donors should also be asked to 
notify the BTS if they become unwell within 28 days of donation, particularly with 
an illness that they may have been incubating at the time of donation. This is 
especially important with an infection such as hepatitis A where prompt action 
may prevent infection in the recipient (33). 
Donor haemovigilance is a requirement of the quality system (34) and contributes to: 
 Improved donor safety through the implementation of corrective and 
preventive actions to avert the occurrence or recurrence of adverse donor 
events and reactions 
 Tracing of donors and withdrawal of donations that may have or could 
contribute to serious adverse reactions in recipients
 Improved patient safety through better donor selection criteria and 
processes 
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 Epidemiological follow-up of the donor population. 
A rapid response system should be in place to share any relevant information 
related to adverse donor events and reactions for appropriate action to be taken 
for improving donor and patient safety.
Information about any adverse effects in the recipients of transfusion should also 
be fed back into the donor haemovigilance system to improve donor selection. 
Also refer to Section 3.5 on adverse donor reactions and post-donation care.
2.8 MONITORING AND EVALUATION 
The process of donor selection requires on-going monitoring and evaluation 
to ensure that it achieves its objectives of ensuring donor and patient health 
and safety and a sufficient supply of safe blood and blood products. The main 
parameters to be monitored include: 
 Donor demographics and characteristics
 Donor deferrals
 Donor adverse reactions
 Confidentiality, including facilities, procedures and documentation 
 Complaints
 Blood screening results
 Transfusion reactions in recipients of blood and blood products
 Errors and untoward events 
 Staff competency assessment and training needs.
Quantitative and qualitative data collection methods including focus group 
discussions could be considered to assess the effectiveness of blood donor 
selection. 
In order to maintain a balance between sufficiency, safety and emerging risks, 
donor selection criteria and the reasons for donor deferrals should be regularly 
evaluated to identify whether any criteria need to be removed, modified or 
extended to provide improved protection of donors and recipients, and to minimize 
the deferral of suitable donors. The application of the criteria should also be 
monitored to ensure they are being interpreted correctly and to identify any areas 
where additional staff training may be required.
Epidemiological monitoring of infection rates in blood donors, including age and 
gender-specific prevalence rates in new and repeat donors, contributes to a 
better understanding of donor behaviour and assessment of risk. Knowing and 
understanding confirmed infection rates in blood donors helps to ensure that 
donor selection, donor deferral and blood screening strategies are up-to-date 
and effective. 
Post-donation counselling may reveal the probable exposure histories of infected 
donors and can help identify populations at risk of infection. This can provide 
information on the possible routes of infection and the effectiveness of the donor 
education and donor selection, including whether donor education materials give 
sufficient information about TTI risk and why the donor decided to donate. This 
kind of information aids in understanding patterns of infection in “asymptomatic” 
individuals and can be used to improve donor education, the donor selection 
criteria and donor selection process. 
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The following indicators may be used to monitor and evaluate the system of 
donor selection:
 Total number of individuals presenting to donate blood
 Number and percentage of deferrals from donation, by types of deferral:
 Permanent deferral
 Temporary deferral
 Number and percentage of deferrals from donation, by reasons for 
deferral:
— Low haemoglobin
— Other medical conditions
— High-risk behaviour
— Travel 
— Other reasons
 Number and percentage of deferrals from donation, by age and gender 
of donors
 Percentage of donors who self-deferred following donor assessment and 
counselling
 Percentage of incomplete donor questionnaires
 Rate of adverse donor reactions, by types of reaction 
 Prevalence of markers of transfusion-transmissible infection in screened 
donations:
— HIV 
— Hepatitis B (HBV)
— Hepatitis C (HCV)
— Syphilis
— Others
 Number and percentage of confirmed positive donors, by age, gender 
and types of donor.
While the donor questionnaire and interview process is intended to elicit relevant 
information on which to assess donor suitability for blood donation, the process 
sometimes may not be effective (35) and operational research may be required 
to identify mechanisms for improving the process of donor selection and to 
address issues such as: 
 How to improve donor selection criteria 
 How to improve the effectiveness of donor education 
 How to assess the sensitivity and specificity of certain questions in the 
donor questionnaire
 How to ask donors culturally-sensitive questions 
 Whether donors understand the donor questionnaire 
 How to increase donor adherence to selection criteria
 How to reduce blood discard rates 
 How to improve donor retention.
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3 Assessing donor suitability 
Donors should be in good health at the time of donation and free of infections 
transmissible by blood. The BTS should provide clear and unambiguous guidance for 
staff involved in donor selection. Rigorous donor selection should be consistently 
applied to all blood donors either donating whole blood or through apheresis, 
whether first-time or repeat donors. The process should be planned to make 
best use of staff and donor time, and make blood donation as convenient as 
possible for blood donors, without long waiting periods.
Key principles of blood donor selection are as follows: 
 The health and safety of the donor as well as the recipient must be 
safeguarded
 Only individuals in good health should be accepted as donors of whole 
blood and blood components
 The selection of blood donors should be based on regularly reviewed 
selection criteria, without discrimination of any kind including gender, 
race, nationality or religion 
 A prospective donor’s health status and medical history should be 
evaluated for each donation, on the day of donation prior to blood 
collection
 The BTS should provide appropriate donor information and a simple donor 
questionnaire for health and risk assessment and obtain the donor’s 
informed consent to blood donation
 Staff should be suitably qualified and trained in the donor selection 
process
 Good communication should be established between the BTS staff and 
the donor, and donor confidentiality should be assured
 The BTS has a duty of care to provide counselling to all deferred donors 
and referral for their further management. 
3.1 DONOR SELECTION PROCESS
The purpose of donor selection is to assess the suitability of an individual to 
be a blood donor so that blood donation is safe for the donor and the blood 
products derived from this donation are safe for the recipients. The donor 
selection process should be carried out in accordance with written standard 
operating procedures.
The steps involved in the donor selection process, prior to blood collection, are 
shown in Figure 1:
1 Donor registration 
2 Pre-donation information 
3 Completion of donor questionnaire 
4 Donor interview and pre-donation counselling 
5 Donor health and risk assessment
6 Informed consent.
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Figure 1: The blood donor selection process
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Compliance with all donor selection criteria is crucial to ensure a safe blood 
donation process and outcomes. All potential and existing donors should be asked 
to adhere to the blood donor selection criteria by providing accurate information 
and answers to all questions asked, both for the protection of their health and 
that of patients who receive transfusion. 
Donor registration 
All prospective donors who meet the general criteria for blood donation such as 
age and good health should be registered when they attend a blood donation 
session, even if they are subsequently not accepted for donation. 
Essential donor registration information includes the individual’s full name, 
date of birth, gender and contact details. A unique donor number should be 
assigned at first registration. At each occasion of donation, a unique identifier 
using a numeric or alphanumeric system should be allotted to the donation; 
this should be attached to the donor questionnaire, primary blood collection 
bag, its corresponding satellite bags and the blood sample tubes. During donor 
registration, prospective donors should be provided with donor information and 
education materials and the donor questionnaire, which should be completed 
on each occasion of donation. 
Pre-donation information 
Pre-donation information is an important step in the blood donor selection. The 
process of donor selection begins even before donors come to give blood through 
public awareness campaigns and donor education. At the donation session, pre-
donation information should be provided either orally or through printed, graphic, 
audio-visual or online materials, presented in a simple and clear format and in 
appropriate languages. 
Pre-donation information provides an opportunity for the prospective donors 
to know about health conditions or high-risk behaviour that would make them 
unsuitable to donate blood. This information assists the donors in deciding 
whether to self-defer; it may also assist in donor return if they understand the 
reason why they should not donate blood on this occasion (36,37). 
Pre-donation information has the following objectives, to: 
 Increase donor awareness of the donor selection criteria, the process of 
blood donation and the tests that will be performed on donors’ blood
 Encourage prospective donors to inform the BTS of any medical conditions 
or TTI-related risks that may affect their suitability to donate blood
 Encourage individuals to self-defer from blood donation if they recognize 
that they are not suitable to donate blood due to general health or 
medical conditions or risk for TTI. 
Pre-donation information should cover:
 Nature and use of blood and its components; the need for voluntary non-
remunerated blood donors; and the importance of maintaining healthy 
lifestyles 
 The blood donation process, including the donor questionnaire, donor 
medical history, health and risk assessment, venepuncture, blood 
collection as whole blood or apheresis procedure, post-donation care 
and the screening tests performed on donated blood
 Rationale for the donor questionnaire and pre-donation health assessment 
and the importance of donor compliance in the donor selection process; 
and donor’s duties, responsibilities and rights (21) 
33
 Options for the donor to decide about blood donation prior to proceeding 
further, to withdraw or self-defer at any time during or after the donation 
process, without any undue embarrassment or questioning
 Transfusion-transmissible infections, including HIV, HBV, HCV and syphilis, 
routes of their transmission, natural history and prevention; types of 
screening tests performed; and window period of infection and alternative 
testing sites for individuals seeking to ascertain their infection status
 Possible consequences for donors and the donated blood in the case of 
abnormal TTI test results; the mechanism for notification about abnormal 
test results and post-donation counselling, assurance of confidentiality 
and if necessary, referral for further testing, treatment and care 
 The possibility of adverse donor reactions. 
Completion of donor questionnaire 
Each prospective blood donor should complete a donor questionnaire to provide 
information in relation to the donor selection criteria defined in the national 
guidelines. In most situations, the donor questionnaire is given to donors at the 
time of registration for completion before the donor interview and assessment. 
Alternatively, the donor questionnaire may be sent to the donor’s residence 
to be completed before donation. This has the advantage of allowing donors 
time to think about the answers and saves time at a blood donation session. 
However, donors may misunderstand some of the questions and self-defer for 
the wrong reasons.
The donor questionnaire may also be administered electronically as a computer-
based questionnaire. A wide literature is developing around computerized 
questionnaires and computer assisted self-interviews (CASI). CASI is shown to 
elicit more information on risk behaviour than traditional face-to-face interviews 
and may reduce the proportion of donors with a history of high-risk behaviour 
by encouraging personal disclosure and self-deferral (38,39). 
A particular focus is required on first-time donors as they are not familiar with 
the questionnaire and its purpose and may take longer to complete it; however, 
it has been reported that regular donors may take less care in filling in the 
questionnaire (40). 
It is essential that donors are aware of the importance of the questionnaire, the 
significance of the questions and the need for providing accurate information 
(41). The information provided by the donor can then be further elaborated on 
during the interview. 
Donor interview and pre-donation counselling
The completed donor questionnaire should be reviewed prior to donation in a 
one-to-one confidential interview between the donor and a donor selection staff 
member so that an assessment can be made of the donor’s general health, 
medical history and any TTI risks. It also provides an opportunity to check whether 
the donor has understood the questions and has answered them correctly. 
Many people do not understand medical terms and may be so eager to give 
blood that they do not recognize the significance of their answers for their own 
health. Assistance should therefore be provided to anyone who has difficulty in 
understanding the questions. 
Assurance about the confidentiality of the donor’s medical history is essential. 
If donors understand why it is in their own interests to give accurate and 
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complete information about their health, it will reassure them that their welfare 
is important to the BTS and may motivate them to become regular donors. The 
donor’s ability to understand the blood donation process and provide informed 
consent should be assessed.
Whenever possible, the medical history should be further elaborated by a donor 
selection staff member, particularly for new donors. An initial question such 
as “When did you last see a health care professional?” may avoid multiple 
questions and lead to further information about the donor’s medical history. 
Similarly, relevant travel information may be elicited by a simple question such 
as “When did you last travel to another region or country?” 
Pre-donation counselling is an integral part of the donor interview. It enables 
donor selection staff to:
 Check that the donor has understood all questions and responded 
accurately to the questionnaire 
 Answer the donor’s questions and provide reassurance in case of anxiety 
 Explain reasons for any deferral and give advice about further medical 
care, if needed
 Ensure that the donor is able to give informed consent to donate and 
recognizes that his/her signature is an affirmation that responses provided 
to the questionnaire are accurate.
Donor health and risk assessment
The assessment of the donor health and TTI risks requires privacy, a sensitive, 
non-judgemental approach and an assurance of confidentiality. The reason for 
questions aimed at eliciting any health and TTI risks should be explained and 
the donor should be offered an opportunity to self-defer. The assessment of 
donor suitability and deferral, where appropriate, aims to exclude donations 
from individuals at risk of TTI, particularly from those with recently acquired 
infection that cannot or may not be detected by routine screening tests or with 
infections for which no effective blood screening tests are available. An in-depth 
discussion may be needed, particularly with new donors who may not know about 
the “window period” or the signs and symptoms of an infection. Individuals who 
visit the BTS to obtain HIV testing pose a risk to the blood supply (42). 
The donor assessment not only enables the review of the donor’s medical history 
and medications, but also provides an opportunity for a basic health check 
to assess whether the donor is in general good health. Any signs of debility, 
under-nutrition, pallor, jaundice, cyanosis, dyspnoea or intoxication from alcohol 
or drugs should also be noted (also refer to Section 4.2 on donor appearance 
and inspection). 
Physical examination, weighing and/or measurement of vital signs (pulse, blood 
pressure) are part of the basic health check and are carried out at this stage. 
The venepuncture site should be examined to check that the donor’s veins are 
accessible and suitable to enable easy venepuncture. 
The basic health check also enables an assessment to be made of any physical 
disabilities that may impede the donation process, such as:
 Mobility: the donor should be able to easily access the donor bed or 
couch
 Sight or hearing impairment: assistance should be provided by a staff 
member. 
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Issues that require special attention during donor health and risk assessment 
include:
 The prevalent culture and context of the environment for donation; in 
some situations, a donor may simply be overawed by the medical setting 
and procedures
 The provision of sufficient privacy and assurance of confidentiality to make 
the donor comfortable when answering probing and sensitive questions
 Identifying and overcoming language barriers or lack of understanding 
of questions in the donor questionnaire 
 Ensuring good communication by using simple jargon-free language and 
explaining any medical terms. 
Informed consent
Informed consent is a voluntary agreement given by the prospective donor to the 
donation of blood, to the testing of a blood sample for TTI, for the transfusion of 
the donated blood to patients and if required, for the use of the blood for additional 
tests, quality assurance or research purposes. To obtain informed consent, the 
BTS should provide the following minimum information to the potential donor: 
 The donation process and potential adverse donor reactions 
 The tests that will be performed (TTI and others) on the samples taken 
from the donated blood and the reasons for these tests
 Confidentiality of all personal information, including test results.
The donor should sign and provide informed consent to the donation of blood 
or blood components on a voluntary basis. Informed consent signifies that the 
donor has understood the questionnaire, has provided accurate answers and is 
willing to donate blood (43). It also indicates that the donor understands the blood 
donation process, the possibility of adverse reactions to blood donation, the risks 
of the transmission of infections through donated blood and the implications of 
any abnormalities that may be detected during the donation process and blood 
screening, and is providing consent for post-donation notification and counselling, 
if detected to have a positive viral infection marker or any other abnormality. The 
donor’s understanding of the questionnaire and its implications is of particular 
importance in countries where donors may be held legally liable if they give 
incorrect information. 
In countries in which young people under the legal age of majority may be accepted 
as blood donors, written consent to donate blood may be obtained from a parent 
or guardian, prior to donation, in accordance with national requirements. 
3.2  DONOR DEFERRAL 
Donors who do not to meet the selection criteria should be deferred on a 
temporary or permanent basis. All deferred donors should be treated with respect 
and care in a confidential manner and should be given a clear explanation of 
the reason for deferral and an opportunity to ask questions. They should be 
informed whether the deferral is to safeguard their own health and/or that of 
the recipient. It is the responsibility of the BTS to ensure that donors who are 
deferred due to medical conditions are referred for further investigations and 
management, as appropriate. 
Studies have found that deferral has a negative impact on future donor return, 
particularly by first-time donors and those deferred for more than a year (37,44). 
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Temporarily deferred donors should be advised on when they could donate and 
encouraged to return. Donors are less likely to return to donate blood if unclear or 
unsatisfactory information is given about the reason for deferral. Many temporarily 
deferred donors do not spontaneously return to donate blood and may need to 
be recalled after the deferral period is over. Counselling of deferred blood donors 
could enhance the compliance of donors to seek follow-up medical care (45).
A system should be in place for donor counselling and referral if any further 
investigations, treatment and care are indicated. Refer to Blood donor counselling: 
Implementation guidelines (6).
3.3 DONOR RECORDS 
The record of the donor’s general health, medical history and TTI risk assessment 
as part of the donor questionnaire should always be signed by the donor as being 
correct. The questionnaire becomes part of the donor’s records and documents 
the informed consent. 
Records should be kept of each activity associated with blood donation, ideally 
in an electronic database capable of generating reports. In addition to donor 
identification, assessment and selection, records should reflect donor deferrals, 
adverse reactions or unexpected events and any unsuccessful donations. 
Donor records should be confidential, easily retrievable and should allow 
traceability: from the donor to the patient receiving transfusion and vice versa. 
Records should be retained for a period of time defined by local or national 
legislation or guidelines. Donor records should be reviewed regularly and donor 
data (e.g. male: female ratio, donor deferrals, adverse donor events and reactions) 
should be analysed in order to monitor the effectiveness of donor selection so 
that remedial action can be taken, where necessary. 
Key records, including dates, times and signatures, to be maintained and retained 
during the donor selection process include:
 Donor registration information
 Completed donor questionnaires and informed consent
 Outcomes of donor interview and assessment
 Donor deferral records 
 Unique donation number for each donation
 Donor counselling and follow-up records 
 Adverse donor events and reactions 
 Donor deferral registry.
Data on donor deferrals should be collected and regularly reviewed to enable 
the BTS to assess the major causes of deferral, particularly those that result 
in the greatest numbers of donor deferrals and those presenting high risk to 
patients. These vary from country to country; hence there is a need to collect 
local data on which to base relevant decisions. The most common causes of 
donor deferral are of particular interest as these will indicate whether donor 
information and education may need to be improved or donor selection criteria 
should be reviewed. A deferral database will also indicate whether staff are 
interpreting the selection guidelines correctly and where further education and 
training should be focused. 
Donor deferral records also enable the previous deferral status of donors to 
be checked and decisions made on the re-entry of temporarily deferred donors. 
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A donor deferral registry (DDR) is a confidential list of donors who are positive for 
a transfusion-transmissible infection and who have been permanently deferred. 
A DDR is used to monitor the incidence and prevalence of such infections 
in the donor population and may also assist in identifying areas that require 
strengthening in the donor selection process.
3.4 CONFIDENTIAL UNIT EXCLUSION (CUE)
The system of confidential unit exclusion (CUE) offers donors the opportunity to 
inform the BTS immediately after donation or subsequently if they consider that 
their blood may be unsafe for transfusion; this may be particularly useful if donors 
have been persuaded or coerced to donate. Where CUE is used, donors should 
be given information to enable them to contact the BTS and to communicate 
that their blood should not be used for transfusion. 
The CUE system is designed to add an additional level of safety to the donor 
selection and blood screening processes and has been found to be effective in 
some settings (46). However, there is some evidence that it may have limited effect 
on reducing the transmission of infections through window-period donations (47) 
and may lead to the discard of safe donations (48,49). One study suggested that 
its use may have negative consequences by reducing the perceived responsibility 
of staff in eliciting a history of high-risk behaviour (40). 
3.5 ADVERSE DONOR REACTIONS AND POST-DONATION 
CARE 
Donors should be managed in a way that ensures high standards of care and 
assures them of the importance accorded to their health and well-being by the 
BTS. Nevertheless, there are recognized adverse reactions that can occur during 
blood donation; these can generally be minimized or avoided by appropriate 
donor selection and care, and appropriately trained staff (50,51). Donors who 
have suffered an adverse reaction have been shown to be less likely to return 
to donate again (37).
Vasovagal episodes and soft tissue injuries (bruises and haematomas at the 
venepuncture site) are the most common donor reactions. The majority of these 
are minor and donors usually recover quickly; however, these reactions can be 
of concern to donors and reassurance should be provided. In some cases, a 
reaction may prompt the donor to reveal a relevant medical history. A minority 
of adverse reactions may require medical care outside the BTS and may lead 
to prolonged symptoms or incapacity. 
Staff should be trained in the recognition and management of adverse donor 
reactions, including the provision of first aid. The incidence of bruising should 
be monitored so that further venepuncture training may be provided to staff as 
necessary. A system for the reporting and investigation of adverse donor events 
and reactions should be in place as part of the donor haemovigilance system.
Donors should be provided with oral and written advice on the management 
of bruises and delayed vasovagal events and should also be given information 
about how to contact the BTS for further advice, if necessary. 
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4 General donor assessment 
Only individuals in good health should be accepted as blood donors. Good health 
is difficult to define, but certain associated parameters may be established 
from a brief medical history, observation and simple tests. Staff undertaking 
donor health and risk assessment should be well-trained in the observation 
of donor appearance and detection of signs of ill health. Staff should receive 
explicit guidance on what to look for and when to refer a donor to a health-care 
professional for further medical attention.
Donors should feel well on the day of donation and be able to perform their routine 
daily activities. Information about minor illnesses, exposure to communicable 
diseases, travel to disease endemic areas, pregnancy and lactation and medical 
and surgical interventions should be elicited so as to determine suitability for 
blood donation or the need for deferral. The BTS physician may request additional 
information and advice about the health of a prospective donor from the donor’s 
own doctor or specialist.
Sections 4, 5, 6 and 7 contain recommendations on acceptance and deferral of 
donors based on selection criteria which fall into four broad categories:
 Conditions that are acceptable
 Conditions that require temporary deferral for defined periods of time
 Conditions that require permanent deferral
 Conditions that require individual assessment.
4.1 AGE 
4.1.1 Lower age limit
A lower age limit should be set for blood donation, taking into account national 
legal requirements for consent, the increased risk of vasovagal reactions in 
younger donors, and the increased iron requirements of adolescents and young 
menstruating females. 
The lower age limit for blood donation in most countries is 18 years, although 
in some countries national legislation permits 16–17 year-olds to donate 
provided that they fulfil the physical and haematological criteria required and 
that appropriate consent is obtained.
Studies of adverse events in blood donors have shown an increased rate of 
vasovagal reactions in younger donors (50,52); a study conducted in the United 
States of America in 2006 reported a 10.7% risk of a vasovagal reaction in 
donors aged 16–17 years, compared with 8.3% in 18–19 year-olds and 2.8% 
in donors aged 20 years or older (53). The age of 16 should therefore be an 
absolute lower limit for blood donation to ensure donor health and safety.
Adolescents of either gender are at risk of iron deficiency during the pubertal 
growth spurt when the average daily total requirement of absorbed elemental 
iron is 1.50 mg/day for males aged 15–17 years and 1.62 mg/day for females 
(54,55). 
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Recommendations
 The usual lower age limit for blood donation is 18 years 
 Where permitted by national legislation or in setting a lower age limit of 16 
or 17 years for blood donation, the BTS should consider:
— The age of legal consent below which parental permission is required 
and the need to inform parents/guardians about the process, benefits 
and risks of blood donation so that informed consent can be obtained
— The balance between the benefit of an increased blood supply by recruiting 
younger donors against the increased risk of adverse reactions in this 
age group
— The increased iron requirement of adolescents and the possible 
compromise of their iron status by frequent blood donations
4.1.2 Upper age limit 
Upper age limits for blood donation of between 60 and 70 years have been 
implemented in the past because of concerns regarding the increasing incidence 
of cardiovascular disease with age and the potential risk of adverse reactions, 
which are more likely in first-time donors.
There is now extensive published literature on the safety of blood donation in 
older individuals in both the allogeneic and autologous setting, indicating that 
vasovagal and other adverse reactions are infrequent in older donors who fulfil 
normal donor selection criteria (56,57,58,59,60). The upper age limit has been 
safely removed for regular blood donors in countries where healthy life expectancy 
is high (56,61,62,63,64). Nevertheless, many BTS have an upper age limit of 
60 years for first-time donors. 
Recommendations
 In setting an upper age limit for blood donors, the BTS should consider the 
healthy life expectancy of the population
 The usual upper age limit for blood donation is 65 years 
 First-time donors older than 60 years and regular donors over the age of 65 
may be accepted at the discretion of the responsible physician 
 First-time donors over 60 years should make their first donation at a donation 
site where a physician is available
4.2 DONOR APPEARANCE AND INSPECTION
The prospective donor should appear generally well and should not be febrile, 
breathless or suffering from a persistent cough. Donors should be observed 
to rule out malnutrition or any debilitating condition. They should have a sound 
mental status and not be under the influence of alcohol or drugs.
The colour of exposed skin and mucous membranes should be normal, with 
no jaundice, cyanosis, flushing or pallor, and no signs of skin infection, rash or 
obviously enlarged lymph nodes. If body piercings or tattoos are present, the 
risk of transfusion-transmissible infections (TTI) should be assessed (also refer 
to Section 7.9.5 on cosmetic treatments and rituals). 
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The venepuncture site should be clean, free from any skin lesions or scars and 
the arms should be examined for signs of injecting drug use. Antecubital veins 
should be easily visible or palpable to enable proper venepuncture, thus avoiding 
any discomfort to the donor and minimizing the risk of major bruises or other 
soft tissue injury at the venepuncture site.
Donors with sight or hearing impairment may be accepted provided clear and 
confidential communication can be established. If assistance is required, it 
should be provided by a staff member or other independent person and not a 
family member or friend. 
Recommendation 
 Prospective donors should be accepted only if they appear to be in good 
health and comply with donor selection criteria
4.3 MINOR ILLNESSES
Minor non-specific symptoms (e.g. general malaise, pain, fever, headache, 
cough, diarrhoea) may indicate the presence of an acute infection that may 
be transmissible by transfusion. Donors should be asked to confirm that they 
are free from such symptoms on the day of donation and that they have fully 
recovered from any recent infection(s). Individuals suffering from minor illnesses 
and not feeling well should not donate blood.
There is no evidence that minor infections such as common upper respiratory 
infections can be transmitted by transfusion, but it is nevertheless advisable as 
a precautionary measure to defer blood donation until any such infection has 
resolved (65).
Recommendation
Defer 
 Individuals with a history of recent infection: defer for 14 days following full 
recovery and cessation of any therapy, including antibiotics
4.4 WEIGHT
It is important to set weight limits for blood donation to protect donors from 
adverse effects, in particular vasovagal episodes and anaemia. Low body weight 
and low blood volume have been shown to be independent predictors for vasovagal 
reactions (50,66).
It is generally accepted that the volume of whole blood donated should not exceed 
13% of blood volume: e.g. a donor should weigh at least 45 kg to donate 350 ml 
(± 10%) or 50 kg to donate 450 ml ± 10% (67,68). There are no defined upper 
weight limits for blood donation; however, gross obesity may be a reason for 
deferral if veins are inaccessible, or if the donor’s weight exceeds the safe loading 
capacity of the blood collection bed or impairs his/her mobility or the capacity of 
staff to provide care in the event of an adverse reaction. The estimation of blood 
volume is more difficult in obese individuals as fat contains proportionately less 
blood than muscle. Hence, blood volume may be overestimated (69), resulting 
in an increased risk of an adverse reaction. 
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For apheresis procedures, the total volume of donated plasma, platelets and 
red cells collected should not exceed 13% of total blood volume (70) and the 
maximum extracorporeal blood volume should not exceed 15% of the donor’s 
total blood volume at any stage of the procedure. In practice, this requires 
that plateletpheresis and plasmapheresis donors should weigh at least 50 
kg. Prospective donors of double red cell apheresis donations should have an 
estimated blood volume of more than 5 litres; this requirement is generally met 
by non-obese individuals weighing more than 70 kg.
The reasons for any obvious rapid weight loss should be ascertained.
Recommendations
 In determining a lower weight limit for blood donors, the BTS should consider 
norms for the weight of the population; if a significant proportion of the donor 
population weighs less than 45 kg or 50 kg, collection volumes may be reduced 
accordingly, while ensuring that blood collection bags and their anticoagulant 
content are adjusted to be compatible with the volumes collected
 Prospective donors of whole blood donations should weigh at least 45 kg to 
donate 350 ml ± 10% and 50 kg to donate 450 ml ± 10% 
 Prospective donors of apheresis platelet or plasma donations should weigh 
at least 50 kg 
 Prospective donors of double red cell apheresis donations should have an 
estimated blood volume of more than 5 litres; this requirement is generally 
met by non-obese individuals weighing more than 70 kg.
4.5 VITAL SIGNS
4.5.1 Pulse
A normal pulse rate of 60–100 per minute and a regular rhythm are indicators of 
good health; many BTS recommend that these are examined prior to donation. 
The ability to detect significant abnormalities of pulse rate or rhythm depends 
on the skill and experience of staff. The usefulness of this examination in a 
blood donation setting needs to be assessed. 
4.5.2 Body temperature
A prospective donor who is febrile – defined as a core oral temperature more than 
37.6°C (71) – is by definition unwell and should be deferred. Fever can indicate 
any number of medical conditions and infections, but is usually associated with 
other symptoms (also refer to Section 4.3 on minor illnesses). 
4.5.3 Blood pressure (BP)
A normal blood pressure (systolic 120–129 mmHg, diastolic 80–89 mmHg) is 
generally regarded as an indicator of good health (72). 
The measurement of BP is required by many national guidelines on donor selection 
and some BTS set an upper limit of BP for blood donors (70) on the basis 
that uncontrolled hypertension is an independent risk factor for cardiovascular 
disease. However, a systematic review of the literature found no evidence that 
raised baseline blood pressure, treated hypertension or low blood pressure were 
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predictive of increased adverse reactions, although the level of evidence was 
limited (73).
BP may be measured routinely for the purposes of health screening; however, 
the blood collection session is not the ideal setting for this. Donor anxiety may 
result in the temporary elevation of systolic BP. Accurate BP measurement requires 
the availability of calibrated equipment, suitable facilities, adequate time and 
appropriately skilled staff. 
Recommendations 
 In assessing whether pulse, temperature or blood pressure should be measured 
routinely, selectively or not at all at the time of blood donation, the BTS should 
consider:
— Clinical value of these parameters in the blood donation setting
— Availability of adequate equipment (calibrated and sterile, where 
appropriate), space and time. If blood pressure is used as a selection 
criterion for blood donation, arbitrary acceptable limits of systolic BP 
of 100–140 mmHg and arbitrary acceptable limits of diastolic BP of 
60–90 mmHg are suggested 
— Competence and experience of staff and their ability to perform techniques 
correctly
4.6 DONOR IRON STATUS
4.6.1 Haemoglobin screening
There are no rapid, simple and direct bedside methods for determining iron 
status. The pre-donation assessment of donor haemoglobin remains the best 
approach. Normal ranges for haemoglobin and red cell indices differ between 
ethnic populations, and in males and females, and are also affected by age, 
especially in women (74,75). International and national guidelines (Annex 1) 
commonly recommend minimum haemoglobin levels of 12.5 g/dl for females 
and 13.5 g/dl for males but further studies are needed to justify the selection 
of these levels. In some countries, the same haemoglobin level is used for 
males and females (76). Individuals with haemoglobin levels below the normal 
range are, by definition, anaemic (77). The WHO Global Database on Anaemia 
(55) defines haemoglobin thresholds for anaemia as 12.0 g/dl for non-pregnant 
women (≥15.00 years) and 13.0 g/dl for men (≥15.00 years). There are many 
causes of anaemia and anaemia due to iron deficiency is the most prevalent. 
The aim of haemoglobin screening is to ensure that the prospective donor is not 
anaemic. The lower limit of acceptable haemoglobin for blood donation should 
be set at a level that prevents the selection of anaemic individuals as blood 
donors and also minimizes the exclusion of healthy donors.
Haemoglobin screening safeguards anaemic individuals from donating blood 
and also protects returning donors from donation-induced iron deficiency (DIID), 
the depletion of iron stores by repeated donations (78,79). Collecting a unit of 
blood from a donor with a normal haemoglobin level also provides good quality 
blood components, with adequate and consistent haemoglobin content in the 
collected blood. 
Haemoglobin and/or haematocrit are easily estimated by validated, simple, rapid 
and inexpensive methods, but are insensitive in assessing iron deficiency as 
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values start to fall only when iron stores are depleted. Nevertheless, they remain 
the most convenient measurement parameters at blood donation session and 
when recorded at each subsequent attendance, can detect anaemia and DIID. 
Donor haemoglobin and/or haematocrit levels should be measured immediately 
before each donation using a validated technique that is subject to quality control. 
Donors who do not meet the minimum haemoglobin levels for blood donation 
should be referred for further haematological investigation and treatment. 
They should be encouraged to return to donate when the anaemia has been 
successfully treated.
Recommendations 
 In determining the lower limits of haemoglobin for whole blood donation and 
implementing haemoglobin screening, the BTS should consider:
— Normal haemoglobin range among healthy individuals in the local 
population 
— A haemoglobin level of not less than 12.0 g/dl for females and not 
less than 13.0 g/dl for males as the threshold 
— Selection of a validated haemoglobin screening technique that is subject 
to quality control, the feasibility of its implementation, the availability 
of equipment and the training and skills of staff 
 Only sterile disposable lancets should be used for blood sampling
 Donors whose haemoglobin levels are below the nationally-defined threshold 
should be deferred, counselled and referred for medical assessment
4.6.2 Frequency of donation and iron supplementation 
Iron deficiency is common worldwide and donation-induced iron deficiency is of 
particular concern in relation to women of childbearing age and adolescents. 
Adolescents of both sexes are also at risk of iron deficiency during the pubertal 
growth spurt, when the average daily total requirement of dietary elemental iron 
to be absorbed is 1.50 mg/day for males and 1.62 mg/day for female (54,55). 
A donation of 450 ml of blood removes 200–250 mg of haem iron. The average 
amount of stored iron (ferritin and haemosiderin) in a woman of reproductive 
age in the developed world is about 300 mg; hence, the donation of a unit of 
blood requires the subsequent mobilization of much or all of this reserve (80). In 
developing countries, many women have depleted iron stores and will inevitably 
be precipitated into negative iron balance by blood donation (54,55,76).
Across the world, the minimum interval between whole blood donations varies 
between 56 days (8 weeks) and 16 weeks and different donation intervals are 
usually followed for male and female donors; in practice, some female donors 
are unable to give blood more than once or twice per year due to iron deficient 
states. There is a high prevalence of iron depletion in frequent blood donors; 
increasing the inter-donation interval would reduce the prevalence of iron depletion 
and deferral due to low haemoglobin (76,81,82). 
The standard approach for preventing donation-induced iron deficiency is universal 
screening and deferring those whose pre-donation haemoglobin is below a 
certain threshold. It is important to detect and manage the donation-induced iron 
depletion that inevitably accompanies regular blood donation (78). Reducing the 
frequency of blood donation is likely to reduce the prevalence of iron deficiency 
among blood donors, as might implementing routine iron supplementation (83).
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The onset of DIID may be determined using full blood cell counts and red cell 
indices, including red blood cell distribution width (RDW), when measured serially 
in healthy donors from populations with a low prevalence of inherited conditions 
such as thalassaemia trait. The more sophisticated red cell parameters on 
modern cell counters are even better indicators of DIID onset, even possibly in 
the co-presence of thalassaemia trait, but are more expensive and usually not 
available at blood donation sites.
Haemoglobin estimation alone in regular blood donors may not be adequate 
and serum ferritin estimations may need to be done to detect pre-clinical iron 
deficiency state. Regular ferritin measurement is a useful indicator for iron 
depletion in blood donors. (84,85,86,87,88). 
If the BTS has access to facilities for monitoring donor iron stores by measuring 
serum ferritin concentrations, individual donor algorithms for donation frequency and 
iron supplementation may be developed (78,80,81,83,85,89,90,91,92,93). In some 
circumstances, the more expensive but informative determination of serum soluble 
transferrin receptor concentrations (STR) gives an even better indication of DIID.
Iron supplementation of blood donors has been proposed for routine implementation 
and several pilot operational and clinical trials have been conducted (83). Donor 
iron stores may be replenished by giving oral iron supplements and this particularly 
needs to be considered for repeat and regular blood donors. 
Indiscriminate long-term supplementation with iron salts at a high dose is, 
however, not recommended, because of:
 Possible masking of other pathological causes of iron deficiency, such 
as gastro-intestinal bleeding
 Risk of giving iron salts to people with undiagnosed hereditary 
haemochromatosis or other inherited iron-overloading tendencies (78)
 Toxicity if accidentally ingested by children.
Some of these concerns may be avoided by using low-dose iron preparations 
or carbonyl iron. Such preparations are better tolerated, less toxic and can be 
safely used to reduce donation intervals. 
Donors giving platelets or plasma by apheresis may donate more frequently than 
whole blood donors. A minimum inter-donation interval of 4 weeks for platelet 
donors and 2 weeks for plasma donors is generally recommended, provided that 
haematological and biochemical parameters are monitored and remain within 
acceptable limits (94). The interval before an apheresis platelet or plasma donation 
should be at least 4 weeks following a whole blood donation, an apheresis red 
cell donation or a failed return of red cells during apheresis (70). 
The inter-donation interval between double red cell donations should be 6 months. 
If a double red cell donation is given following whole blood donation, the interval 
should be 12 weeks for males and 16 weeks for females.
Recommendations
 The minimum interval between donations of whole blood should be 12 weeks 
for males and 16 weeks for females 
 The minimum interval between donations of platelets should be 4 weeks 
 The minimum interval between donations of plasma should be 2 weeks 
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 The minimum interval before an apheresis platelet or plasma donation should 
be 4 weeks following a whole blood donation, an apheresis red cell donation 
or a failed return of red cells during apheresis
 In determining the frequency of donation and whether iron supplementation 
is given, the BTS should consider:
— The need for longer donation intervals for young donors and female 
donors of childbearing age 
— Assessing the feasibility and affordability of providing iron supplementation 
to donors susceptible to donation-induced iron deficiency, especially 
women, adolescents, and repeat and regular donors
— Exploring access to facilities for monitoring serum ferritin concentration 
and the feasibility of developing and implementing individual donation 
intervals
4.7 FLUID INTAKE AND FOOD
Most BTS guidelines recommend that donors should maintain their usual food 
and fluid intake before donation but should avoid heavy or fatty meals which may 
result in a lipaemic donation that may need to be discarded. The risk of adverse 
events in fasting donors has not been investigated, but there is evidence that 
an intake of 500 ml of drinking water immediately before donation may reduce 
the risk of a vasovagal reaction (95,96,97). Where possible, donors should have 
access to drinking water in the blood centre before donating. Fasting donors 
should have had some fluid intake in the four hours prior to donation. In countries 
where prolonged fasting is practised, blood collection sessions may be scheduled 
after they have taken food and fluid.
Recommendation
 The BTS should consider providing 500 ml drinking water to donors before 
donation to minimize the risk of vasovagal reactions
4.8 GENDER
4.8.1 Pregnancy, lactation and menstruation
The average woman needs about 350–500 mg additional iron to maintain iron 
balance during pregnancy (54,55). Female donors should be deferred during 
pregnancy and for a sufficient time after delivery (or following abortion or 
miscarriage) and during lactation to allow for the recovery of iron stores. 
Menstruation is not a reason for deferral. However, women who report regular 
excessive menstrual bleeding and are found to have low haemoglobin levels 
should not donate blood and should be referred for medical assessment (90). 
Contracting and relaxing the muscles in the legs, arms and abdomen during 
donation may reduce the risk of vasovagal reactions, particularly among female 
donors (98,99,100,101).
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Recommendations
 The BTS should encourage donors to practise applied muscle tension during 
blood donation
Accept
 Female donors during menstruation, provided that they feel well and meet 
the minimum haemoglobin level for blood donation
Defer
 Female donors during pregnancy and up to 6 months after delivery or termination 
of pregnancy
 Female donors during lactation
4.8.2 Reducing the risk of transfusion-associated acute lung 
injury (TRALI)
The gender of the donor may influence the type of blood component prepared 
from the donation. Plasma-rich blood components from multiparous women are 
more likely to cause TRALI and related disorders than those from males, because 
plasma from such women is likely to contain alloimmune-reactive antibodies; these 
include antibodies to human leucocyte antigens (HLA) or to human neutrophil 
antigens (HNA), which are transferred passively during transfusion, to the possible 
detriment of a recipient who possesses the corresponding antigen (102,103,104). 
Recommendations
 The BTS should consider:
— Maximizing the collection and production of plasma and platelet 
concentrates from male donors 
— Screening multiparous female donors for HLA and/or HNA antibodies 
4.9  OCCUPATION AND LEISURE ACTIVITIES
Delayed vasovagal reactions, defined as occurring after the donor leaves the 
blood donation site but within 24 hours of donation, are uncommon (reported as 
46:100 000) (105). However, if the donor is in a hazardous situation, a delayed 
vasovagal reaction may put the donor and others at risk of harm. For this reason, 
most BTS advise donors in hazardous occupations (e.g. emergency services, 
working at heights) not to resume work for at least 24 hours after blood donation. 
Air crew are subject to their own regulations which do not permit blood donation 
within specified time limits (106). Similarly, donors are generally advised not to 
undertake strenuous physical activities for up to 24 hours after blood donation.
Some occupations (e.g. health-care workers, police, military personnel, workers 
with animals) carry an increased risk of exposure to blood-borne infections, 
although confirmed transmission is relatively rare (107,108,109,110,111). While 
such individuals should have been immunized against relevant diseases, where 
possible, donors in these occupations should be questioned about possible 
exposure risk (e.g. needlestick injuries, blood splashes, bites) and a deferral 
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period, usually of 6–12 months applied, based on the incubation period of the 
relevant infection.
Sex workers are at particular risk of transfusion-transmissible infections and 
should not be accepted as blood donors (also refer to Section 7.9.1 on high-
risk sexual behaviours). 
4.10 SPECIAL CONSIDERATIONS FOR DONOR SELECTION FOR 
APHERESIS DONATIONS
Apheresis is the process by which the required component of whole blood is 
separated and collected from the donor using an automated blood cell separation 
device. Components that can be donated by apheresis include platelets 
(plateletpheresis), plasma (plasmapheresis), leucocytes (leucapheresis) and red 
blood cells (erythrocytapheresis). 
Medical criteria for the acceptance of blood donors in respect of the donor’s 
health should be the same for donors of whole blood and of blood components 
obtained by apheresis. Additional donor selection criteria pertaining to apheresis 
donations are recommended in the relevant sections in this document. Detailed 
recommendations regarding the volume and frequency of apheresis donations 
are outside the scope of these guidelines.
In addition to meeting the selection criteria required for whole blood donation, 
donors giving apheresis donations should also meet requirements that are 
specific for the type of apheresis procedure and the component collected 
(70,112,113,114). For apheresis platelet donation the donor’s platelet count 
should be above 150 x 10 9/L. For apheresis plasma donation, the donor’s 
total protein level should be greater than 60 g/L. For double red cell apheresis, 
donors of either gender require a minimum haemoglobin level of 14.0 g/dl (68).
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5 Donor medical history I: 
 Non-communicable diseases 
Having ascertained the potential suitability of the donor on the basis of the general 
criteria outlined in Section 4, a detailed medical history should be taken, using 
a structured donor questionnaire and interview. This is aimed at identifying and 
deferring, either temporarily or permanently, any donor with a medical condition 
that may predispose the donor to immediate or long-term harm, affect the safety 
or quality of the product derived from the blood or compromise patient safety. 
5.1 HAEMATOLOGICAL DISORDERS
Assessment of the suitability of prospective donors with haematological disorders 
is based on the need to avoid any risks of anaemia, bruising and haematoma 
or thrombosis as a result of the venepuncture. 
Chronic anaemia may be associated with ill health and such individuals are not 
suitable to donate blood. Also refer to Sections 5.9 on malignant diseases and 
6.3 on blood transfusion and transplantation.
5.1.1 Anaemia, including haematinic (iron, B12 and folate) 
deficiency
The history of anaemia should be assessed in relation to its cause, current 
status and any treatment that has been received. Individuals who suffer from 
haematinic deficiency anaemia of whatever etiology should not be accepted as 
donors until the cause of the anaemia has been identified and the anaemia has 
been successfully treated. 
Recommendations
Accept
 Individuals who: 
— Have a past history of iron deficiency anaemia, with a known cause 
that is not a contraindication to donation, and who have completed 
treatment and are fully recovered
— Have a past history of B12 or folate deficiency, are fully recovered and 
are taking maintenance treatment with B12 or folic acid 
Defer
 Individuals who:
— Do not meet the minimum haemoglobin level for blood donation
— Are under investigation or on treatment for anaemia
Defer permanently 
 Individuals who have chronic anaemia of unknown cause or associated with 
systemic disease: e.g. renal failure, rheumatoid disease
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5.1.2 Haemoglobinopathies
The prevalence of inherited haematological conditions in different countries 
should be taken into account in defining donor acceptance and deferral criteria. 
Individuals with thalassaemia major and sickle cell disease are not suitable as 
blood donors (70). The sickle cell trait impairs the effective filtration of blood 
for leucodepletion (115,116). Most BTS do not accept donors with sickle cell 
trait for apheresis donations or for whole blood donations if the blood is to be 
leucofiltered. Blood from donors with sickle cell trait is not suitable for intrauterine 
transfusion or neonatal exchange transfusion (64); it is also unsuitable for patients 
with sickle cell disease (67) as it may exacerbate sickling of the red cells. 
Recommendations
Accept
 Individuals with: 
— Thalassaemia traits, provided they are well and meet the minimum 
haemoglobin level for blood donation 
— Sickle cell trait: accept for whole blood donation provided they meet 
the minimum haemoglobin level for blood donation; blood donated by 
sickle cell trait individuals is, however, not suitable for leucodepletion, 
intrauterine transfusion, neonatal exchange transfusion or for patients 
with sickle cell disease 
Defer permanently 
 Individuals with:
— Thalassaemia major or sickle cell disease
— Sickle cell trait for blood donation by apheresis procedure or for whole 
blood donation if the blood is to be leucofiltered
5.1.3 Enzymopathies and inherited red cell membrane 
defects
Glucose-6–phosphate dehydrogenase (G6PD) deficiency is the most common red 
cell enzyme defect, with hundreds of molecular variants. Most variants have only 
slightly subnormal red cell survival; however, others (e.g. the Mediterranean variant) 
render the cells highly susceptible to oxidative stress. Blood from individuals 
with G6PD deficiency (with a history of haemolysis) is therefore unsuitable for 
transfusion as haemolysis may be precipitated if the recipient develops an 
infectious illness or ingests an oxidative drug or fava beans (117). People with 
the next most common inherited enzyme defect, pyruvate kinase deficiency, will 
usually be too anaemic to donate, even if asymptomatic.
Red cell membrane disorders are inherited diseases due to mutations in various 
membrane or skeletal proteins, resulting in decreased red cell deformability, 
reduced life span and premature removal of the erythrocytes from the circulation. 
Red cell membrane disorders include hereditary spherocytosis, hereditary 
elliptocytosis, hereditary ovalocytosis and hereditary stomatocytosis (118). 
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Recommendations
 Policies for the assessment of prospective donors should be developed by 
BTS in regions where there is a high incidence of enzymopathies and inherited 
red cell membrane defects
Accept
 Individuals with G6PD deficiency or other inherited red cell membrane defects, 
without a history of haemolysis; however, their blood is not suitable for 
intrauterine transfusion, neonatal exchange transfusion or for patients with 
G6PD deficiency
Defer permanently 
 Individuals with G6PD deficiency or inherited red cell membrane defects, with 
a history of haemolysis
5.1.4 Thrombocytopenia
Individuals with thrombocytopenia should not be accepted as blood donors 
because of the risk of bleeding at the venepuncture site and because chronic 
thrombocytopenia may be associated with serious underlying haematological or 
other systemic disease. A past history of autoimmune thrombocytopenia is not 
a contraindication to blood donation, even if treated by splenectomy, provided 
that the prospective donor has been well for five years with no evidence of 
relapse (64).
Recommendations
Accept
 Individuals with a past history of acute autoimmune thrombocytopenia more 
than 5 years previously, provided they are well and no longer require treatment, 
other than prophylactic antibiotics following splenectomy
Defer permanently
 Individuals with thrombocytopenia of unknown cause or associated with long-
term haematological or systemic disease
5.1.5 Secondary erythrocytosis
Donors with secondary erythrocytosis due to smoking may be accepted provided 
that polycythaemia rubra vera has been excluded and other donor selection 
criteria are fulfilled. 
Recommendation
Accept
 Individuals with secondary erythrocytosis, provided that a diagnosis of 
polycythaemia rubra vera is excluded 
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5.1.6 Hereditary haemochromatosis
This inherited condition of iron overload through excessive iron absorption of 
dietary iron can be treated by phlebotomy; individuals who are otherwise healthy 
and meet all other donor selection criteria may be accepted as blood donors 
(119) and indeed bled more frequently before donation-induced iron deficiency 
supervenes (67). However, special arrangements are needed if the maintenance 
therapy requires reduction of the inter-donation interval (120,121). 
Recommendation 
Accept
 Individuals with hereditary haemochromatosis who fulfil all other donor selection 
criteria 
5.1.7 Coagulation disorders, including haemophilia A and B
These disorders are usually due to inherited deficiency of coagulation factors. 
Patients with such disorders are not acceptable as blood donors because of 
the risk of excessive bruising at venepuncture sites and because treatment is 
usually with blood products. 
Known carriers of coagulation disorders may be accepted provided they have normal 
or near normal coagulation factor levels and no bleeding or bruising tendency. 
Acquired coagulation disorders are rare and usually associated with serious 
underlying disease.
Recommendations
Accept
 Individuals with carrier states for inherited coagulation disorders including 
haemophilia A or B, provided they have normal or near normal coagulation 
factor levels, do not have a history of abnormal bleeding and have not received 
treatment with blood products
Defer permanently 
 Individuals with coagulation factor deficiencies, whether inherited or acquired
5.2 CARDIOVASCULAR DISEASES 
Assessment of the suitability of individuals with cardiovascular disease should 
be based on the effect of the condition on the individual‘s ability to tolerate 
haemodynamic changes due to blood donation. 
5.2.1 Cardiovascular diseases 
Observational studies from the United States of America suggest that patients 
with cardiovascular disease (122,123,124,125,126) may safely donate blood 
but these studies were of pre-operative autologous blood donation, mostly in a 
hospital setting using isovolaemic techniques; only one study is applicable to 
voluntary blood donors (127). Some blood services in the United States currently 
accept voluntary donors with a history of myocardial infarction more than 6 
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months previously and who are asymptomatic, or with ischaemic heart disease 
that has been successfully treated, e.g. by angioplasty or coronary artery bypass 
grafting (128). Until additional evidence of safety for donors with such conditions 
is available more generally, these donors should not be accepted for donation 
unless the circumstances are exceptional and the donation is well-monitored.
Recommendations
 Asymptomatic individuals with a history of cardiovascular disease should have 
written permission from their cardiologist or physician to donate blood
Accept 
 Individuals with: 
— Surgically corrected simple congenital cardiac malformations who have 
no residual symptoms
— Asymptomatic disorders such as functional murmurs and mitral valve 
prolapse 
Defer permanently 
 Individuals with: 
— Symptomatic ischaemic heart disease
— Symptomatic peripheral vascular disease, including history of arterial 
thrombosis 
— History of myocardial infarction
— Severe cardiac arrhythmia
— Rheumatic fever with evidence of chronic heart disease 
— Acquired valvular disease with stenosis or regurgitation 
— Valve replacement
— Hypertrophic cardiomyopathy 
— Palliated (i.e. uncorrected) congenital heart disease
5.2.2 Hypertension
There is no evidence that raised baseline blood pressure, treated hypertension 
or low blood pressure are predictive of increased adverse reactions to blood 
donation, although the level of evidence is limited (50,73). In addition, there is 
no evidence of harm to recipients of blood from donors taking anti-hypertensive 
medication. Individuals whose blood pressure is well-controlled by medication and 
meet other donor selection criteria can be accepted as blood donors. Donors 
who have recently started taking anti-hypertensive medication or for whom the 
dose of anti-hypertensive medication has been adjusted, should be deferred for 
a period of 28 days after the blood pressure has been stabilized. 
Also refer to Section 4.5.3 on blood pressure.
54
Recommendations
Accept 
 Individuals with stable uncomplicated hypertension controlled by medication
Defer
 Individuals who have recently started taking anti-hypertensive medication, or 
whose dose of anti-hypertensive medication has been adjusted: defer for 28 
days after the blood pressure has been stabilized
Defer permanently 
 Individuals with hypertensive heart or renal disease
5.2.3 Venous thrombosis and thrombophlebitis
Unexplained venous thrombosis may indicate underlying malignancy or 
thrombophilia. Thrombophilia is a condition in which there is an increased tendency 
for blood clots to form, usually due to an inherited deficiency or abnormality of 
a circulating anticoagulant. It may be discovered through family studies; not all 
individuals with a thrombophilic condition will suffer from blood clots. 
Recurrent thrombophlebitis (inflammation of a vein) may be associated with 
occult malignancy.
Recommendations
Accept 
 Individuals who have: 
— Been identified as having a thrombophilic condition, but with no history 
of a thrombotic episode, and are not on anticoagulant treatment 
— Had a single episode of deep vein thrombosis or pulmonary embolus 
with an identifiable cause, provided that they are fully recovered and 
anticoagulant therapy has been stopped for at least 7 days
— Had a single episode of thrombophlebitis in the last 12 months, provided 
they are otherwise well and off treatment for at least 7 days
Defer permanently 
 Individuals who have had: 
— Two or more episodes of venous thrombosis requiring treatment
— Axillary vein thrombosis or thrombophlebitis affecting the upper limb
— Two or more episodes of thrombophlebitis in the last 12 months
5.3 RESPIRATORY DISEASES
Assessment of the suitability of individuals with respiratory disease requires 
consideration of the health of the donor and assessment of the risk of transmission 
of infection to the recipient. 
Also refer to Section 7.5.6 on tuberculosis.
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Recommendations
Accept 
 Individuals with asthma provided they are asymptomatic on a maintenance 
dose of non-steroid and/or inhaled steroid medication
Defer
 Individuals with:
— Asthma during an acute exacerbation: defer for 14 days after full recovery 
— Asthma on a course of oral or injected steroids: defer for 14 days 
following full recovery and cessation of oral or injected steroids 
— Acute respiratory infections such as bronchitis: defer for 14 days following 
full recovery and cessation of any therapy, including antibiotics
Defer permanently
 Individuals with:
— Respiratory disease if they are breathless at rest or on minimal exertion 
or are cyanosed
— Severe obstructive airways disease, including those on long-term oral 
steroid therapy 
— Chronic or recurrent respiratory infections
5.4 GASTROINTESTINAL DISEASES
Assessment of the suitability of individuals with diseases of the gastro-intestinal 
tract should be based on whether the condition is associated with malabsorption 
and/or acute or chronic blood loss, or may be a portal of entry for infection. 
Recommendations
Accept
 Individuals with:
— Irritable bowel syndrome without debility
— Diverticular disease, if well 
— Mild gastro-oesophageal reflux
— Mild hiatus hernia 
— Treated coeliac disease
— Gallstones
— Cholecystitis, when fully recovered
Defer 
 Individuals with: 
— Active peptic ulceration: defer until completion of treatment and full 
recovery
— Active inflammatory bowel disease (ulcerative colitis or Crohn’s disease): 
may be accepted if they are well, in long-term remission and meet the 
minimum haemoglobin levels for blood donation
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Defer permanently
 Individuals with malabsorption syndromes (except treated coeliac disease) 
5.5 METABOLIC AND ENDOCRINE DISEASES
For the purposes of these guidelines, only two commonly occurring conditions, 
diabetes mellitus and thyroid disease, are considered.
5.5.1 Diabetes mellitus  
Consideration should be given to the donor’s general state of health and ability 
to tolerate a blood donation, as well as the possibility of intercurrent infection 
that may affect the safety of the blood. 
There are no reports suggesting increased adverse donor reactions in diabetic 
donors. A systematic literature review found no studies investigating diabetes 
as a possible risk factor for adverse reactions in voluntary blood donors; two 
studies on pre-operative autologous donation and three experimental studies 
found that blood donation was well tolerated (73).
Individuals with diabetes who require insulin should be permanently deferred from 
blood donation (70) because of concerns regarding diabetes-related complications 
and an increased risk of hepatitis and other infections if safe injection practices 
cannot be assured.
Recommendations
Accept 
 Individuals with diabetes mellitus well-controlled by diet or oral hypoglycaemic 
medication, provided they have no history of orthostatic hypotension and no 
evidence of infection, neuropathy or vascular disease, in particular peripheral 
ulceration 
Defer permanently 
 Individuals with:
— Diabetes who require insulin 
— Complications of diabetes with multi-organ involvement
5.5.2 Thyroid disease
There is no published evidence about any adverse effects from blood donation 
to individuals with a history of thyroid disease. Individuals with successfully 
treated benign thyroid disorders who are euthyroid may safely be accepted as 
blood donors (64). 
Recommendations
Accept
 Individuals with benign thyroid disorders (provided they are euthyroid) such as:
— Asymptomatic goitre
— History of viral thyroiditis
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— Autoimmune hypothyroidism
Defer
 Individuals:
— Under investigation for thyroid disease
— If hyper- or hypo-thyroid 
— With a history of malignant thyroid tumours (also refer to Section 5.9 
on malignant diseases)
Defer permanently
 Individuals with thyrotoxicosis due to Graves’ disease
5.6 IMMUNOLOGICAL DISEASES
Individuals with systemic immunological diseases are generally unwell and are 
therefore not suitable to donate blood. Donors should be questioned about severe 
allergy to materials used in blood collection, such as latex or skin disinfectant, so 
that contact with these materials can be avoided. Passive transfer of IgE by blood 
transfusion has been reported but does not alter acceptance criteria (129,130,131). 
While there is no evidence of harm resulting from blood donation by individuals 
with a history of anaphylaxis, the permanent deferral of such individuals is 
recommended as a precautionary measure (70).
Recommendations
Accept
 Individuals with: 
— Mild, localized or inactive conditions, such as vitiligo or mild rheumatoid 
arthritis without systemic symptoms
— History of allergy, provided they are well and free from allergic symptoms 
on the day of donation
— Asthma (also refer to Section 5.3 on respiratory diseases)
— Eczema (also refer to Section 5.11 on skin diseases)
Defer permanently 
 Individuals with: 
— Severe debilitating autoimmune disorders such as systemic lupus 
erythematosus, dermatomyositis or severe rheumatoid disease
— Immunosuppression due to congenital or acquired hypogamma-
globulinaemia or immunosuppressive medication, with the exception 
of individuals with IgA deficiency
— History of anaphylaxis 
5.7 RENAL AND URINARY TRACT DISEASES
Assessment of the suitability of prospective donors with renal and urinary tract 
disorders should take into account the well-being of the donor and the risk of 
bacterial infection which may enter the bloodstream.
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Recommendations 
Defer 
 Individuals with lower urinary tract infections: defer for 14 days after full 
recovery and completion of treatment
 Individuals with acute self-limiting renal diseases such as acute nephritis 
when fully recovered and renal functions are normal; this may require deferral 
for as long as 5 years after full recovery
Defer permanently
 Individuals with chronic renal disease causing ill-health or anaemia, or 
associated with chronic or recurrent infection
5.8 CENTRAL NERVOUS SYSTEM DISEASES
Assessment of the suitability of prospective donors with central nervous system 
conditions should take into account the well-being of the donor and the risk of 
transfusion-transmission of variant Creutzfeldt-Jakob disease (vCJD).
5.8.1 Cerebrovascular disease
The usual and predictable fall in blood pressure associated with blood donation 
(132,133), especially during sleep the night after donation, may be detrimental to 
individuals with a history of transient cerebral ischaemic episodes or completed 
stroke; such individuals should be permanently deferred.
5.8.2 Epilepsy
Donors with a history of epilepsy or seizure disorder are generally deferred 
because of concerns that vasovagal syncope associated with blood donation may 
precipitate an epileptic seizure. This has not been substantiated by observational 
studies (134,135,136), showing no detriment and recommending acceptance of 
donors with epilepsy who are well-controlled: i.e. seizure-free for a defined period, 
with or without medication. 
5.8.3 Dementia and other neurodegenerative disorders 
Individuals with dementia or neurodegenerative disease due to any cause should 
be permanently deferred due to reasons such as inability to give a reliable 
medical history and the possibility of vCJD (137).
While there is no evidence of transmission of sporadic or familial CJD through 
transfusion, individuals with symptoms suggestive of CJD or a family history of 
CJD should be permanently deferred (also refer to Section 7.7 on prion diseases). 
5.8.4 Multiple sclerosis
Individuals with multiple sclerosis should be permanently deferred because of 
the progressive nature of the condition and uncertainty regarding the etiology.
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Recommendations 
Accept 
 Individuals with a history of epilepsy who have been off medication and 
seizure-free for a period of at least 3 years
Defer permanently
 Individuals with:
— Cerebrovascular disease (a history of transient cerebral ischaemic 
episodes or stroke)
— Dementia or neurodegenerative disease due to any cause
— Multiple sclerosis or other demyelinating diseases
5.9 MALIGNANT DISEASES
Acceptance criteria for prospective donors with a past history of treated solid 
tumours vary widely. Some BTS accept donors who are disease-free for a specified 
period (128,138), while others permanently defer on the basis that there is a 
theoretical possibility of transfusion-transmission of tumour cells or of oncogenic 
viruses (139,140), although these policies are currently under review. 
A large retrospective cohort study of cancer incidence among patients who 
received blood from donors deemed to have a subclinical cancer at the time 
of donation (diagnosed with cancer within five years of the donation) showed 
no excess risk of cancer among recipients of blood from pre-cancerous donors 
compared with recipients of blood from non-cancerous donors (141). However, 
the transmission of donor melanoma by organ transplantation has been reported 
(142). Transfusion-transmitted cancers have never been convincingly demonstrated, 
but most BTS continue to take a precautionary approach and do not accept blood 
from people who have had a malignancy as many malignancies spread through 
the blood stream and by invading surrounding tissues (64,70). Blood donations 
should not be taken from people with recently active malignancies, except in 
the case of basal cell carcinoma or cervical carcinoma in situ. 
A recent literature review concluded that that there is now ample evidence to 
consider accepting selected donors with a history of malignant disease (except 
for those where there are specific safety concerns, such as haematological 
malignancy and melanoma) on the basis of a minimum (suggested 5-year) interval 
after the completion of successful curative treatment (143).
Healthy adults with a remote history of treated malignant conditions from which 
they can be regarded as cured may be able to donate under certain well-monitored 
circumstances. Further studies in this field are indicated. 
Recommendations 
 For individuals with a past history of solid malignant tumour, BTS may consider 
acceptance if 5 years or more since completion of successful curative treatment
Accept
 Individuals with a history of “in situ” malignant disease such as basal cell 
carcinoma or cervical carcinoma in situ, if regularly monitored and considered 
successfully treated and in good health 
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Defer
 Individuals with a current diagnosis of malignancy 
 Individuals with past history of solid malignant tumour if less than 5 years 
since completion of treatment
Defer permanently
 Individuals with a history of malignant melanoma
 Individuals with current or past haematological malignancy, including:
— Leukaemia: i.e. lymphoproliferative and myeloproliferative disorders
— Lymphomas
— Clonal haematological disorders such as:
 Polycythaemia rubra vera and essential thrombocythaemia
 Paroxysmal nocturnal haemoglobinuria
— Myelodysplastic syndromes
5.10 MUSCULOSKELETAL DISORDERS
Assessment of the suitability of prospective donors depends on the nature and 
severity of the disorder and the mobility of the donor.
Recommendations 
Accept 
 Individuals with acute or chronic simple musculoskeletal disorders, such as: 
— Back pain
— Sciatica
— Frozen shoulder
— Osteoarthritis
 provided these conditions do not inhibit their daily routine activities and they 
are able to climb on and off a donation couch without assistance
Defer
 Individuals with fractures until plaster or external fixation is removed and they 
are fully mobile
Defer permanently 
 Individuals with systemic diseases affecting joints, such as:
— Rheumatoid disease
— Psoriatic arthropathy 
— Ankylosing spondylitis
5.11 SKIN DISEASES
Assessment of the suitability of prospective donors with skin diseases should 
consider whether:
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 The condition is a manifestation of systemic disease 
 The donor is receiving prescribed medication such as antibiotics, anti-
inflammatory agents, immunosuppressants or vitamin A analogues
 There is a risk of infection entering the bloodstream.
Also refer to Section 6.2 on medications for guidance on deferral following 
immunosuppressive or retinoid treatment. 
Recommendations
Accept
 Individuals with common skin conditions, such as:
— Mild eczema
— Mild acne
— Mild psoriasis
 provided lesions are not infected, there are no systemic symptoms, the 
venepuncture site is unaffected and they have not received immunosuppressive 
or retinoid treatment; long-term low-dose antibiotic treatment for acne is not 
a contraindication to blood donation
 Individuals with burns, when fully healed 
Defer
 Individuals with: 
— Psoriasis with infected lesions, systemic symptoms, affected venepuncture 
site or receiving immunosuppressive or retinoid treatment
— Generalized skin disease(s) on systemic medication
— Contagious skin diseases such as scabies and ringworm until cleared; 
while not a blood safety risk, there is a potential risk to blood collection 
staff
Defer permanently 
 Individuals with systemic diseases affecting the skin, such as:
— Scleroderma
— Systemic lupus erythematosus
— Dermatomyositis 
— Systemic cutaneous amyloidosis
5.12 PSYCHIATRIC DISORDERS
The acceptance of individuals with current or past mental health problems as 
blood donors depends on an assessment of their ability to fully answer the 
donor questionnaire and interview and to give informed consent to the donation 
process, including the testing of their blood.
In general, donors with anxiety disorders and mood (affective) disorders, such 
as depression or bipolar disorder, may be accepted provided they are stable and 
feel well on the day, regardless of medication (64). Individuals with psychotic 
disorders, such as schizophrenia and related conditions, are usually not suitable 
to donate blood.
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Recommendations 
Accept
 Individuals with anxiety disorders or mood (affective) disorders (e.g. depression, 
bipolar disorder), provided they are generally in good health and are not 
obviously over-anxious, depressed or manic when seen on the day of donation, 
regardless of medication 
Defer permanently 
 Individuals with psychotic disorders requiring maintenance treatment
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6 Donor medical history II: 
 Medical and surgical 
interventions 
Assessment of the suitability of individuals to donate following medical and surgical 
interventions, including vaccinations, should take into consideration whether:
 The reason for the intervention is an indication for deferral
 The intervention puts the donor at increased risk of harm by blood donation
 The intervention could affect the quality or safety of the blood and blood 
products and patient safety.
6.1 IMMUNIZATIONS AND VACCINATIONS
6.1.1 Post-exposure prophylaxis
The deferral period is determined by the incubation period and “window period” 
of the infection and the sensitivity of the available screening tests.
Also refer to Section 7.3 on viral infections.
Recommendations 
HEPATITIS B 
Accept
 Individuals who have received hepatitis B post-exposure prophylaxis with 
vaccine and/or immunoglobulin: accept 12 months after exposure if they have 
been tested and found to be negative for HBsAg and negative for anti-HBc 
or, if anti-HBc positive, must have anti-HBs greater than 100 mIU/ml 
Defer
 Individuals who have received hepatitis B post-exposure prophylaxis with 
vaccine and/or immunoglobulin: defer for 12 months after exposure 
RABIES 
Defer
 Individuals who have received rabies post-exposure prophylaxis with vaccine 
and/or immunoglobulin: defer for 12 months after exposure
6.1.2 Live attenuated viral and bacterial vaccines 
Live attenuated viral vaccines include hepatitis A, Japanese encephalitis, influenza, 
measles, mumps, rubella, polio (oral), smallpox and yellow fever. Bacterial vaccines 
include BCG, cholera and typhoid. 
Blood from a recently vaccinated donor may contain an infective agent which, 
although not harmful to the donor, is theoretically a risk if the blood is transfused 
to an immune-suppressed patient. 
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Some vaccines are not listed here as these vaccines are only given before the 
age of 16 years and should not be given after the age of 16; hence, they are 
not of relevance in blood donor selection (144,145).
Recommendation
Defer
 Individuals who have received live attenuated vaccines: defer for 28 days 
following vaccination 
6.1.3 Inactivated vaccines
Non-live vaccines and toxoids include cholera, diphtheria toxoid, hepatitis B, human 
papillomavirus (HPV), influenza, meningococcal meningitis, pertussis, pneumococcal, 
polio (injected), rabies, tetanus toxoid, tick-borne encephalitis and typhoid. 
These vaccines pose no risk to the recipients of blood; donors may be accepted 
provided they are well.
HBV is an exception as vaccination may cause transient HBsAg positivity. A 
14–day deferral is therefore recommended provided the donor has not been 
exposed to infection (also refer to hepatitis B in Section 7.3 on viral infections).
Recommendations
Accept
 Individuals who have received non-live vaccines and toxoids (with the exception 
of HBV vaccine) with no history or known exposure and who feel well
Defer 
 Individuals with no known exposure to hepatitis B who have recently received 
routine vaccination: defer for 14 days 
6.2 MEDICATIONS 
Deferral criteria for medications taken by donors should take into account the 
underlying condition for which the medication is taken, the pharmacokinetic 
properties of the medication and the effect of the medication on the quality 
or safety of the donated blood (146,147,148). Donors should not omit regular 
medication in order to attend a blood donor session. 
There is no published evidence that medications in donated blood have caused 
adverse effects in a patient receiving transfusion, although it is unlikely that 
such events would be recognized. European Union legislation requires temporary 
deferral based on the “nature and mode of action” of the medication (149).
Recommendations
The BTS should consider the following principles in developing deferral criteria 
for medications: 
 A plasma concentration of the medication below 10% of the therapeutic level 
is highly unlikely to be harmful.
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 When blood components containing < 50 ml donor plasma are transfused to 
an adult or older child (12 years of age or more), the plasma concentration 
of any medications taken by the donor will be < 3% and can therefore be 
disregarded.
 If more than 50 ml plasma from a single donor is transfused, or if the 
recipient is a child less than 12 years of age, the plasma concentration of 
any donor medication may be more than 10% of the therapeutic level. There 
is no evidence that this is likely to cause harm; however, BTS may wish to 
consider additional selection criteria for apheresis donations and for paediatric 
components. Further research is needed in this area. 
 Aspirin and non-steroidal anti-inflammatory medications (NSAIDs) irreversibly 
inhibit platelet aggregation; platelet components should not routinely be 
prepared using donations from donors who have taken aspirin within 5 days 
or other NSAIDs within 48 hours.
 Teratogenic and fetotoxic medicines deserve particular consideration as 
there is a theoretical risk of causing a fetal abnormality in the unlikely event 
that the blood is transfused to a pregnant female during the first trimester. 
Retinoids (etretinate, acitretin, isotretinoin) are highly teratogenic. Dutasteride 
and finasteride (prescribed for benign prostatic hypertrophy) have been shown 
to cause genital abnormalities in male fetuses of experimental animals; there 
is no evidence of harm in humans. 
Accept
 Individuals taking long-term low-dose antibiotics for acne 
Defer
 Individuals taking prescribed treatment with injected medications, including 
self-administration, based on the underlying condition for which the medication 
is taken
 Individuals who have taken the following medications (150):
— Aspirin: defer for 5 days
— Other NSAIDs: defer for 48 hours
— Acitretin: defer for 3 years
— Isotretinoin: defer for 28 days
— Dutasteride: defer for 6 months
— Finasteride: defer for 28 days
— Antibiotics for acute infections: defer for 14 days after completion of 
treatment
Defer permanently
 Individuals treated with human pituitary-derived growth hormone because of 
case reports of transmission of iatrogenic Creutzfeldt-Jakob disease
6.3 BLOOD TRANSFUSION AND TRANSPLANTATION
6.3.1 Blood transfusion 
Despite all efforts to assure the safety of blood transfusion, it remains an 
important risk factor for transfusion-transmitted infections. Hence, anyone who 
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has received transfusion of any blood or blood product should not be accepted 
as a blood donor for a period of 12 months.
For precautions against the secondary transmission of vCJD and iatrogenic CJD 
by blood transfusion, also refer to Section 7.7 on prion diseases.
Recommendations
Accept
 Individuals whose sexual partners or close contacts have received blood 
transfusions 
Defer
 Recipients of blood transfusion: defer for 12 months
 Former sexual contacts of individuals on regular treatment with plasma-derived 
coagulation factors: defer for 12 months after last sexual contact
 Current sexual contacts of individuals on regular treatment with plasma-derived 
coagulation factors 
Defer permanently 
 Recipients of blood transfusion or any other human-derived therapeutic products 
since 1980 in a country in which the risk of vCJD has been identified 
 Individuals on regular treatment with plasma-derived coagulation factors (64) 
6.3.2 Organ, stem cell and tissue transplantation 
A requirement for stem cell or organ transplantation indicates serious underlying 
disease and such patients should not be accepted as blood donors.
The same criteria apply to allogeneic tissue grafts as to allogeneic blood 
transfusion. Recipients of tissue grafts performed since 1980 in countries in 
which the risk of vCJD has been identified should be permanently deferred. 
In some countries, recipients of dura mater grafts and corneal transplants are 
permanently deferred as a precaution against possible transmission of iatrogenic 
CJD (64,145) (also refer to Section 7.5 on prion diseases).
Recipients of xenografts and non-human organ perfusion should be permanently 
deferred from blood donation due to the unknown risks of the transmission of 
animal infections.
Recommendations
Defer
 Recipients of allogeneic tissues: defer for 12 months 
Defer permanently
 Recipients of:
— Stem cell or organ transplantation
— Allogeneic cells or tissue sourced since 1980 from countries in which 
the risk of vCJD has been identified 
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— Dura mater graft
— Corneal transplant
— Xenograft 
— Non-human organ perfusion
6.4 DIAGNOSTIC AND SURGICAL PROCEDURES
The indication for the procedure may be a reason for donor deferral. 
Invasive investigations, particularly if associated with tissue biopsy, carry a risk 
of infection. Flexible endoscopes have been associated with the transmission 
of hepatitis C (152), although a more recent study reported that this is not a 
problem provided that good infection control procedures are followed (153).
Individuals awaiting a surgical procedure that is likely to result in blood loss 
should be temporarily deferred so that iron stores are not compromised pre-
operatively. A deferral period of 12 months following major surgery is usually 
sufficient to allow for the individual’s full recovery, restoration of iron stores and 
resolution of any bacterial infection, and for routine donation testing to detect 
any transfusion-transmissible viral infections. For patients who receive blood 
transfusion during surgery, also refer to Section 6.3 on blood transfusion and 
transplantation. 
Deferral criteria for surgical procedures should take into account the underlying 
condition for which the procedure is indicated. Prospective donors undergoing 
minor surgical procedures should be deferred until treatment is complete and 
successful and they have returned to normal activity.
Dental procedures, although minor, are associated with transient bacteraemia 
(154,155,156). 
Recommendations
Defer
 Individuals who have undergone:
— Minor diagnostic procedures including rigid endoscopy: defer until they 
have resumed normal activity 
— Invasive diagnostic procedures using flexible endoscopy: defer for 12 
months 
— Minor surgical procedures: defer until treatment is complete and 
successful and they have resumed normal activity 
— Major surgery: defer for 12 months 
— Dental treatment: defer for 24 hours following simple procedures and 
up to 7 days following endodontic procedures (root canal therapy) or 
extraction 
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6.5 ALTERNATIVE, COMPLEMENTARY AND TRADITIONAL 
MEDICINE 
Any therapy involving skin penetration (e.g. acupuncture or scarification) may 
cause blood-borne infection unless sterile techniques are used. The BTS should 
be aware of any procedures that are in use locally, including ritual practices and 
cosmetic treatments, and develop deferral criteria based on the standards of 
infection control employed and the sensitivity of donation testing (also refer to 
cosmetic treatments and rituals in Section 7.9 on high-risk behaviours).
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7 TTI and donor risk 
assessment
The microbiological safety of blood donations may be affected by donors’ exposure 
to HIV, hepatitis B, hepatitis C and syphilis and other transfusion-transmissible 
infections (TTI) via a number of different routes. These primarily include sexual 
contact and percutaneous exposure through high-risk sexual behaviours, and 
unsafe blood transfusion and injection practices, cosmetic treatments and 
rituals. Current or previous country of residence, and travel history also need 
to be analysed.
The BTS should assess the potential risks of infections present in its donor 
population and establish donor selection criteria aimed at minimizing the risk 
of transmission of infections from donors to recipients. These criteria should 
be based on the prevalence, incidence and epidemiology of TTI, up-to-date 
information on known and emerging infections, including expert advice regarding 
the nature of the disease and mode of transmission; taking into consideration the 
consequences to the blood supply of excluding “at-risk” donors while preserving 
the sufficiency of the blood supply (157):
 When there is a proven risk of transfusion-associated transmission but 
no appropriate screening assays are available, donor selection criteria 
should be developed to identify and defer potentially infected donors for 
an appropriate period of time
 When there is a theoretical risk of transfusion-associated transmission 
and no appropriate screening assays are available, donor selection criteria 
may be developed to identify and defer potentially infected donors for 
an appropriate period of time.
Procedures should be in place for the frequent review and re-evaluation of 
donor selection criteria in case of emerging infectious diseases, identification 
of new risks or changes to known risks, cultural practices and evidence from 
haemovigilance and other surveillance data. 
Coordination and cooperation among key national institutions, agencies and major 
stakeholders, e.g. blood services, public health institutions, hospitals, regulatory 
agencies and professional bodies is essential for the recognition and control 
of known and emerging TTI. This includes knowledge of disease prevalence, 
incidence and epidemiology, active surveillance of emerging infections and 
potential new endemic areas, the implementation of appropriate donor selection 
criteria, quality-assured screening of all donations and the systematic monitoring 
of transfusion recipients (158,159,160,161). Information on the prevalence and 
epidemiology of certain transfusion-transmissible infections can be found in the 
WHO Global Health Atlas (162). 
7.1 TRANSFUSION-TRANSMISSIBLE INFECTIONS 
The microbial agents of importance to a BTS are those that are transmissible 
by blood transfusion and can cause morbidity and mortality in recipients. In 
order to be transmissible through transfusion, the infectious agent usually has 
the following characteristics:
 Presence of the agent in one or more components of blood for long 
periods and in an infectious form
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 Stability at temperatures at which whole blood and blood components 
are stored
 Generally long incubation period before the appearance of clinical signs 
and symptoms
 Asymptomatic phase or only mild symptoms in the blood donor, hence 
not always identifiable during the blood donor selection process.
Many viruses, bacteria and protozoa can be transmitted by transfusion and 
new agents that potentially can be transmitted through transfusion continue to 
emerge (163,164). 
WHO recommends that, at a minimum, screening of all blood donations should 
be mandatory for the following infections and using the following markers (7):
 HIV-1 and HIV-2: screening for either a combination of HIV antigen-antibody 
or HIV antibodies
 Hepatitis B: screening for hepatitis B surface antigen (HBsAg)
 Hepatitis C: screening for either a combination of HCV antigen-antibody 
or HCV antibodies
 Syphilis (Treponema pallidum pallidum): screening for specific treponemal 
antibodies.
The outcomes of the laboratory screening of donations remain the final decision 
point in the release of blood components for clinical use; however, even with the 
high quality assays and systems now available, the screening process cannot 
be considered to be totally effective because: 
 An infection in donated blood may not be detected due to the collection 
of the donation during the window period of infection or failure due to 
assay sensitivity or error
 There are some emerging infections for which screening is not available 
or effective 
 A donor may be infected with an infectious agent for which donations are 
not routinely screened; in such cases, the donor selection process may 
be able to identify and defer such an individual based on the symptoms 
or perceived risk.
Routine screening for generally less clinically significant TTI, such as hepatitis 
A virus or parvovirus B19 is generally neither practical nor cost-effective. The 
screening tests available, if any, may not be appropriate for blood screening, 
often being designed primarily to aid the diagnosis of infection in symptomatic 
individuals. In these situations, the donor selection process is a significant factor 
in the identification and deferral of donors who might harbour these infections 
in order to prevent them from entering the blood supply.
7.2 DONOR RISK ASSESSMENT
Blood donor selection is the first crucial step in the process of ensuring blood 
safety as it helps to significantly reduce risk through the deferral, prior to 
donation, of any individuals or groups of individuals with identified risks that 
may be associated with infection (165,166).
Understanding the timing of infection is important in the donor selection process: 
firstly, the length of the window period i.e. the time between infectivity and the first 
detection of a defined marker of infection; and secondly, the incubation period, 
i.e. the time between exposure to infection and the onset of any symptoms of 
illness. In settings with effective blood screening programmes, donors who donate 
71
during the window period generally pose the greatest threat to blood safety and 
the selection process needs to be able to identify and defer such individuals. 
In cases where infections are more likely to be symptomatic, the shorter the 
period between infection and symptoms, the less likely it is that an infectious 
donation would be collected. 
Prospective donors should be asked relevant questions to assess their general 
health, any history, signs or symptoms indicative of current or past infections, 
specific high-risk behaviours or activities, travel history, contact with infectious 
diseases and possible exposure to infection. Environmental factors and lifestyles 
associated with a high risk of exposure to infection are also discussed in 
Sections 7.8 and 7.9. 
Individuals who have engaged in behaviours that pose a high risk for HIV, HBV 
and/or HCV infection should not be accepted as blood donors (also refer to 
Section 7.9 on high-risk behaviours).
Individual donor risk may be impossible to ascertain; the application of the 
precautionary principle may require that a donor is deferred on the basis of 
knowledge of the risks to which the donor may be exposed. This approach must 
be reconciled with the duty of the BTS to treat donors and prospective donors 
with respect, compassion and dignity, avoiding discrimination of any kind.
However, there are other occasions when a donor may have a known infection 
risk, either due to being infected or exposure through sexual or household contact 
or other close contact (having cared for, lived with or had direct contact with an 
individual with a suspected or diagnosed infection). As a general policy, donors 
should be deferred following any acute infection until they are fully recovered 
and no longer infectious. If a donor has been in close contact with an infectious 
disease, he/she should not donate within the incubation period of the infection, 
even if known to be immune. If the incubation period is unknown, an arbitrary 
deferral of 28 days from last contact may be implemented. Expert microbiology 
advice may be needed regarding the mode of transmission and appropriate 
deferral periods for specific infections, and may be obtained from WHO (http://
www.who.int) and national and international health organizations. 
Some infections are found only in certain parts of the world. Donor selection 
criteria will therefore be different in endemic and non-endemic regions. In non-
endemic regions, deferral criteria may be applied to donors who have travelled 
to or lived in endemic regions. Deferral periods may be extended if donors have 
had any undiagnosed febrile illness during travel or since return (also refer to 
Section 7.3 on viral infections and Section 7.4 on protozoal infections for deferral 
periods for individuals who have travelled to and from regions that are endemic 
for dengue virus, Chikungunya virus, malaria and Chagas disease). 
These guidelines are applicable to the selection of donors of whole blood and 
other labile blood components through whole blood collection and apheresis. 
In the case of plasma donation for large-scale fractionation purposes, there are 
circumstances in which plasma donations may be collected from individuals 
who would not otherwise be eligible to donate whole blood or other labile blood 
components on the basis of infectious disease risk and/or history. 
7.3 VIRAL INFECTIONS
7.3.1 Hepatitis 
Prospective blood donors should be given relevant information on the risk of 
hepatitis transmission in order to provide them with the opportunity to self-defer. 
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Prospective donors should be asked for a history of jaundice or hepatitis and 
whether they were further investigated to determine the cause. Individuals with 
a history of jaundice or hepatitis may, at the discretion of the physician, be 
accepted as donors based on the tests results. 
To exclude donors at risk of transmitting hepatitis, the BTS should ask if the 
donor, currently or in the past, has had a hepatitis infection (HBV, HCV or other 
types), assess any specific risks of exposure through sexual and household 
contacts, and also enquire whether the donor has had an HBV vaccination within 
the last 14 days. 
Individuals with hepatitis infection may be asymptomatic or present with fever, 
nausea, vomiting, loss of appetite, jaundice, abdominal pain or an enlarged and 
tender liver. 
Hepatitis B 
Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B 
virus (HBV). The virus is transmitted from human to human via blood and body 
fluids; consequently it may be transmitted by transfusion and transplantation, 
via needles and other items exposed to blood, and from mother to child in 
utero, at birth or perinatally (167,168,169). 
The incubation period of the hepatitis B virus is 90 days on average, but can 
vary from 30 to 180 days. Most people do not experience any symptoms 
during the acute infection phase. However, some people have acute illness with 
symptoms that last several weeks. The virus may be detected 30 to 60 days 
after infection and persists for variable periods of time. Infection in childhood 
commonly results in chronic infection (more than 6 months) which may be 
life-long or resolve spontaneously at any time, whereas infection later in life 
is usually acute (170). 
For individuals with confirmed HBV infection, a deferral period of 12 months from 
recovery is generally recommended, and suitability to donate blood is assessed 
based on the results of testing for hepatitis B surface antigen (HBsAg), hepatitis 
B core antibody (anti-HBc) and antibody to hepatitis B surface antigen (anti-HBs) 
levels.
All HBsAg positive donors should be considered to be at high risk of transmitting 
HBV. Additionally, some studies indicate that even when HBsAg is not detectable, 
some individuals may have low levels of detectable viral DNA which will be 
transmitted by blood and may cause infection in the recipient (171,172). 
Recommendations
Accept
 The following individuals may be accepted for blood donation provided they 
have been tested and found to be negative for HBsAg, and negative for anti-
HBc; if anti-HBc positive, they must have anti-HBs greater than 100 mIU/ml: 
— Individuals with a past history of HBV if more than 12 months ago 
— Current sexual contacts of individuals with a history of HBV infection 
if more than 12 months ago 
— Current and former household contacts who have been successfully 
immunized against HBV and are anti-HBs positive more than 100 mIU/
ml but anti-HBc negative 
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— Donors with initially reactive results for HBsAg but confirmed to be 
non-reactive: re-entry procedures should be established and followed
Defer 
 Individuals with active HBV infection or a history of infection within the 
last 12 months
 Current sexual and household contacts of individuals with active HBV infection
 Former sexual contacts of individuals with active HBV infection: defer for 
12 months since last sexual contact
 Former household contacts of individuals with active HBV infection: defer 
for 6 months since last contact 
 Health workers who have suffered an inoculation or mucosal injury: defer for 
12 months following the exposure; health workers who have been vaccinated 
against HBV should be assessed individually 
Hepatitis C 
Hepatitis C is a liver disease caused by the hepatitis C virus (HCV). The hepatitis 
C virus is most commonly transmitted through exposure to infectious blood. This 
can occur through contaminated blood transfusions, blood products and organ 
transplants; injections given with contaminated syringes and needlestick injuries 
in health-care settings; injecting drug use; or being born to a hepatitis C-infected 
mother. Hepatitis C may also be transmitted through sex with an infected person 
or sharing of personal items contaminated with infectious blood, but these are 
less common (173,174,175,176,177). 
The incubation period for hepatitis C is 2 weeks to 6 months. Following initial 
infection, approximately 80% of people do not exhibit any symptoms. About 
75–85 % of newly infected persons develop chronic disease (178).
Recommendations
Accept
 Household contacts of individuals with HCV infection
Defer
 Current sexual contacts of individuals with current or past HCV infection
 Former sexual contacts of individuals with HCV infection: defer for 12 months 
since last sexual contact
 Health workers who have suffered an inoculation or mucosal injury: defer for 
12 months following the exposure 
Defer permanently 
 Individuals with current or past HCV infection 
Hepatitis A 
Hepatitis A is a liver disease caused by the hepatitis A virus (HAV). The virus 
is transmitted primarily by the faecal-oral route, but sexual transmission can 
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occur. The virus can also be transmitted through close physical contact with an 
infectious person, although casual contact among people does not spread the 
virus. Cases of transfusion-transmission by blood and blood products have been 
reported (179,180,181,182). 
The incubation period of hepatitis A is usually 14–28 days. Symptoms of hepatitis 
A range from mild to severe. Unlike hepatitis B and C, hepatitis A infection does 
not cause chronic liver disease and is rarely fatal, but it can cause debilitating 
symptoms and fulminant hepatitis (acute liver failure), which is associated with 
high mortality (183).
Hepatitis E 
Hepatitis E virus (HEV) behaves in similar ways to HAV except that chronicity 
cannot be ruled out. Transfusion-transmission by blood and blood products has 
been reported (184). Cases of hepatitis E are not clinically distinguishable from 
other types of acute viral hepatitis (185).
Diagnosis of hepatitis E infection is therefore usually based on the detection 
of specific antibodies to the virus in the blood. Deferral periods are as for HAV.
Hepatitis of unknown origin
Most cases of hepatitis of unknown origin are due either to undiagnosed hepatitis 
A or hepatitis E, or to non-viral causes. Deferral periods are the same as for HAV.
Recommendations
Defer
 Individuals with active HAV, HEV or hepatitis of unknown origin: defer for 12 
months after full recovery 
 Sexual contacts, household and other close contacts of individuals with HAV, 
HEV or hepatitis of unknown origin: defer for 12 months since last contact 
7.3.2 Human immunodeficiency virus/Acquired 
immunodeficiency syndrome (HIV/AIDS)
HIV can be transmitted via unprotected and close contact with a variety of body 
fluids of infected individuals, such as blood, breast milk, semen and vaginal 
secretions. Individuals cannot become infected through ordinary day-to-day 
contact such as kissing, hugging, shaking hands, or sharing personal objects, 
food or water. 
Behaviours and conditions that put individuals at greater risk of contracting 
HIV include having unprotected anal or vaginal sex (186) (also refer to Section 
7.9 on high-risk behaviours); having another sexually transmitted infection 
such as syphilis, herpes, chlamydia, gonorrhoea or bacterial vaginosis; sharing 
contaminated needles, syringes and other infected equipment and drug solutions 
for injecting drug use; receiving unsafe injections, blood transfusions or medical 
procedures that involve unsterile cutting or piercing; experiencing accidental 
needlestick injuries, including among health workers. 
Infectivity estimates in case of transfusion of infected blood products are much 
higher (around 95%) than for other modes of HIV transmission owing to the much 
larger viral load per exposure than for other routes (187). 
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Recommendations
Accept
 Household contacts of individuals with HIV infection
Defer
 Current sexual contacts of individuals with HIV infection 
 Former sexual contacts of individuals with HIV infection: defer for 12 months 
since last sexual contact
Defer permanently
 Individuals with present or past clinical or laboratory evidence of HIV infection
7.3.3 HTLV I and HTLV II 
Human T-cell lymphotropic viruses (HTLV) are present in the bloodstream in 
lymphocytes. Non cell-associated virus is rarely found. The infectivity of blood 
and blood components is reduced but not removed by leucodepletion. HTLV can 
be transmitted from mother to child, primarily through breast-feeding, and it may 
also be transmitted through sexual contact (188,189). As infection is considered 
to persist for life, screening for anti-HTLV identifies donations that may transmit 
HTLV but does not in itself indicate the timescale of an infection. 
Recommendations
Accept
 Household contacts of individuals with HTLV I and/or II infection 
 Individuals whose mother or maternal grandmother has or had HTLV I and/
or II infection, if blood screening for HTLV I and/or II infection is available
 Former sexual contacts of individuals with HTLV I and/or II infection if more 
than 12 months after the last sexual contact, and blood screening for HTLV 
I and/or II infection is available
Defer
 Current sexual contacts of individuals with HTLV I and/or II infection
 Former sexual contacts of individuals with HTLV I and/or II infection: defer 
for 12 months after last sexual contact
Defer permanently
 Individuals with HTLV I and/or II infection
 Individuals whose mother or maternal grandmother has or had HTLV I and/or 
II infection, if blood screening for HTLV I and/or II infection is not available
 Former sexual contacts of individuals with HTLV I and/or II infection, if blood 
screening for HTLV I and/or II infection is not available
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7.3.4 Herpes viruses
Herpes viruses include herpes simplex types I and II, varicella-zoster, Epstein-
Barr virus, cytomegalovirus and Kaposi’s sarcoma-associated human herpes 
virus 8 (HHV8). All these viruses can give rise to latent infection and some are 
transfusion-transmissible (190,191). Symptomatic donors should be deferred until 
fully recovered. Because of the high prevalence of exposure to these viruses in 
donors and recipients, except in the case of HHV8, the exclusion of donors with 
a history of past infection is neither feasible nor useful. 
HHV8 is transmitted by sexual and non-sexual routes and has been reported to 
be also transmitted by transfusion and transplantation (192,193,194).
Recommendations
Accept
 Individuals with cold sores and genital herpes, provided there are no active 
lesions 
Defer
 Individuals who are symptomatic (except HHV8 infection): defer for at least 
28 days following full recovery
 Contacts of individuals who are symptomatic (except HHV8 infection): defer 
for 28 days
Defer permanently 
 Individuals with HHV8 infection 
 Current and former sexual contacts of individuals with HHV8 infection 
7.3.5 Mosquito-borne viruses
West Nile virus 
West Nile Virus (WNV) is a flavivirus primarily transmitted by mosquitoes, but 
also readily transmitted through blood donations from infected individuals (195). 
It is found in Africa, Europe, Western Asia, the Middle East and North America, 
although in many regions it is highly seasonal. It causes a rapid onset, acute 
infection with a relatively brief period of viraemia. Transfusion-transmission 
has been reported. Symptoms are non-specific and viraemic donors may be 
asymptomatic at the time of donation (196,197). In endemic areas with reported 
human cases, blood screening using molecular technology is the only means of 
preventing transfusion-transmission. 
To identify “at-risk” donors for WNV in non-endemic areas, BTS should elicit 
information on travel history during the donor selection process and maintain 
up-to-date knowledge of disease epidemiology. Some countries have implemented 
a 28–day deferral after visiting an endemic area, extended to 6 months from full 
recovery if the donor has had any symptoms suggestive of WNV (198 199,200).
As a result of increasing numbers of cases of WNV in some countries where 
there were previously only sporadic cases, a number of non-endemic countries 
have introduced the identification and deferral of at-risk donors; and the screening 
of donations from these donors using molecular technology. 
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Recommendations
NoN-ENDEMIC AREAS (IF BLooD SCREENING IS NoT PERFoRMED)
 At-risk donors with symptoms appearing within 14 days following donation 
should be advised to report to the BTS
Defer
 Individuals who:
— Have known West Nile virus infection or symptoms suggestive of WNV: 
defer for 6 months from full recovery
— Have visited an area endemic for WNV with human cases, in the WNV 
season within the last month: defer for 28 days following return
Dengue and chikungunya viruses 
Dengue and chikungunya viruses are transfusion-transmissible mosquito-borne 
arboviruses. Both give rise to acute infections with no chronic infection, but 
re-infection with dengue virus can have very serious sequelae. Although both 
are potentially transmissible, there have been no proven cases of transfusion-
transmission of chikungunya and relatively few reports of transmission of dengue 
(201,202). 
Before 1970, only nine countries had experienced severe dengue epidemics. The 
disease is now endemic in more than 100 countries in Africa, the Americas, the 
Eastern Mediterranean, South-east Asia and Western Pacific. South-east Asia 
and the Western Pacific are the most affected (203).
Chikungunya occurs in Africa, Asia and the Indian subcontinent and outbreaks 
have been reported in all the three regions. There was a large number of imported 
cases in Europe and South East Asia during some of the outbreaks (204). 
BTS in non-endemic areas wishing to exclude at-risk donors should include 
questions about travel history during the donor selection process and maintain 
up-to-date knowledge of disease epidemiology. 
Recommendations
ENDEMIC AREAS
Defer
 Individuals with a history of dengue or chikungunya virus: defer for 6 months 
following full recovery from infection
NoN-ENDEMIC AREAS
Defer 
 Individuals who:
— Have visited an area endemic for dengue or chikungunya: defer for 28 
days following return 
— Have suffered a febrile illness during or following return from an endemic 
region: defer for 6 months following full recovery from infection
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7.3.6 “Childhood illnesses”: measles, rubella, mumps and 
chickenpox 
Infections with childhood illnesses such as measles, rubella, mumps and 
chickenpox are known to occur in adults. Individuals suffering from any of these 
childhood illnesses and their close contacts should be identified as ‘at-risk’ 
donors and should be deferred for a defined period of time (205,206). 
Recommendations
Defer 
 Individuals with measles, rubella, mumps or chickenpox: defer for 14 days 
after full recovery
 Individuals in close contact with patients having active measles, rubella, 
mumps or chickenpox and who are asymptomatic: defer for 21 days following 
last day of close contact
7.3.7 Influenza
For sporadic cases, individuals with active infection should be deferred until 14 
days after full recovery; susceptible contacts should be deferred for 7 days after 
the implicated individual has recovered. 
In a pandemic situation the risk of blood shortage far outweighs any theoretical 
risk of transfusion transmission. The usual donor selection criteria for influenza 
and any specific measures relating to donor deferral should be carefully reviewed. 
Following the precautionary principle, selective donor deferral may be considered 
(25,207).
Recommendations
Accept
 Asymptomatic individuals with no close contact with those having active 
infection 
Defer
 Asymptomatic household contacts and other close contacts of symptomatic 
individuals with active infection: defer for 7 days after last day of close contact
 Symptomatic individuals with active infection: defer for 14 days after full 
recovery and cessation of any therapy 
 Individuals who have received vaccination against influenza: defer for 48 
hours after vaccination; the deferral period should be extended as above if 
the donor is in a specific risk category 
7.4 PROTOZOAL INFECTIONS
Protozoa are predominantly intracellular organisms. Prospective donors from 
non-endemic countries who are at risk of any of the following parasitic protozoal 
infections may be considered suitable to donate plasma for large-scale fractionation 
purposes only, until such time as they meet the specific criteria that would 
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allow the collection of whole blood and other labile blood components for direct 
clinical use.
7.4.1 Malaria 
Malaria is caused by Plasmodium species. There are four parasite species 
that cause malaria in humans: P. falciparum, P. vivax, P. malariae and P. ovale, of 
which P. falciparum and P. vivax are the most common. P. falciparum is the most 
deadly. In recent years, some human cases of malaria have also occurred with P. 
knowlesi – a species that causes malaria among monkeys and occurs in certain 
forested areas of South-East Asia. 
Malaria is primarily transmitted to humans through the bite of the female 
Anopheles mosquito. In many places, transmission is seasonal, with the peak 
during and just after the rainy season. Increased malaria prevention and control 
measures are dramatically reducing the malaria burden in many places. Non-
immune travellers from malaria-free areas are very vulnerable to the disease 
when they become infected (208).
Malaria is also readily transmitted by blood transfusion through donations collected 
from asymptomatic, parasitaemic donors. The parasite is released into the 
bloodstream during its lifecycle and will therefore be present in blood donated 
by infected individuals. The parasites are stable in plasma and whole blood for 
at least 18 days when stored at +4oC and for extended periods in a frozen state 
(209). Donor selection criteria to exclude collecting blood from individuals with 
current or past history of malarial infection and at risk of transmitting malaria 
through transfusion, should be based on local epidemiological evidence and 
endemicity of the infection.
Endemic areas 
Donor selection and deferral strategies should be developed to identify individuals 
with evidence of current malarial infection and defer them for a period of 6 
months after symptoms (fever with rigors) or on completion of treatment and full 
recovery, whichever is longer. Alternatively, the BTS should screen all donations 
for parasitaemia using thick blood films or for evidence of malarial antigen using 
a highly sensitive enzyme immunoassay.
Non-endemic areas
Malaria is increasingly a matter of concern to BTS in non-endemic countries 
(210,211,212). Significant numbers of blood donors from non-endemic countries 
travel to malarious areas and there is wide migration from endemic areas to 
non-endemic areas where migrants may then become blood donors. Malaria is 
gradually spreading into non-endemic areas or regions where it had previously 
been eradicated. 
Recommendations
ENDEMIC AREAS
 The BTS should develop:
— Donor selection criteria to identify and collect blood from donors at the 
lowest risk of infection, both during the malaria season and during the 
rest of the year 
— Strategies to maximize the collection of blood from donors from 
geographical areas with low endemicity
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— Screen all donations for parasitaemia using thick blood films (smear 
microscopy) or for evidence of malarial antigen using a highly sensitive 
enzyme immunoassay
Defer
 Individuals with a recent infection with malaria: defer for 6 months after 
completion of treatment and full recovery, whichever is longer
NoN-ENDEMIC AREAS
The BTS should:
 Define the donor population with a risk of exposure to malaria and thus the 
potential for transmission through blood donations 
 Implement donor selection and deferral strategies to identify individuals 
with a recent history of malaria or a specific identifiable exposure risk, such 
as travel to malarious areas; these donors should be deferred for a period 
defined by the country
 Question prospective donors regarding:
— Place of birth
— Previous residence in endemic areas
— Travel during the previous 12 months 
— History of malaria or any undiagnosed febrile illness during or after 
visiting an endemic area
If sensitive and multi-specific antibody screening tests are not available
Defer 
 Individuals who:
— Have travelled to malaria endemic areas and who have had no symptoms: 
defer for 12 months from last return from a malarious area
— Have travelled to malaria endemic areas and who have had febrile 
symptoms, but not diagnosed as malaria: defer for 12 months following 
full recovery or last return from a malarious area, whichever is the longer
— Lived in a malaria endemic area in the first 5 years of life or for a 
continuous period of 6 months or more: defer for 5 years after last 
return from a malarious area
Defer permanently
 Individuals who have ever had a diagnosis of malaria
If sensitive and multi-specific antibody screening tests are available
Accept
 Asymptomatic individuals with identified malaria exposure risk (travel and/
or residence): accept if more than 6 months after their last return from an 
endemic area 
Defer 
 Individuals with: 
— Identified malaria exposure risk (travel and/or residence), but no 
symptoms: defer for 6 months after last return from malarious area 
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— Identified malaria exposure risk (travel and/or residence) who have had 
febrile symptoms, but not diagnosed as malaria: defer for 6 months from 
cessation of symptoms or last return from a malarious area, whichever 
is the longer 
— A current infection or history of malaria: defer for 3 years following 
completion of treatment and full recovery, whichever is the longer 
7.4.2 Chagas disease 
Chagas disease, also known as American trypanosomiasis, is a potentially life-
threatening illness caused by the protozoan parasite, Trypanosoma cruzi (T. cruzi). 
It is found mainly in Latin America, where it is mostly transmitted to humans by 
the faeces of triatomine bugs, known as “kissing bugs”, among other names, 
depending on the geographical area. T. cruzi can also be transmitted by food 
contaminated with T. cruzi through for example the contact with triatomine bug 
faeces, transfusion of blood from infected donors, passage from an infected 
mother to her newborn during pregnancy or childbirth, organ transplants using 
organs from infected donors and laboratory accidents.
Chagas disease is endemic throughout South and Central America, although 
effective vector control procedures have been implemented in recent years 
(213,214,215,216). In the past decades, it has also been increasingly detected in 
the United States of America, Canada, many European and some Western Pacific 
countries. This is due mainly to population mobility between Latin America and the 
rest of the world. Less frequently, it is due to infection through blood transfusion, 
vertical transmission (from infected mother to child) or organ donation (217).
Infection is life long and infected individuals may be asymptomatic; individuals 
with a history of T. cruzi infection should be permanently deferred.
Endemic areas
In endemic areas, donor selection is not feasible; the prevention of transfusion-
transmission depends on the serological testing of all blood donations and 
treatment of the blood with trypanocidal agents (213,218,219).
Non-endemic areas 
In non-endemic countries, individuals are identified as having been exposed to 
risk of infection if they, their mother or maternal grandmother were born in South 
or Central America (including Southern Mexico), have had a blood transfusion in 
these areas or have lived and/or worked in rural communities in these countries 
for a continuous period (arbitrarily 28 days or more). These individuals should 
be permanently deferred from blood donation unless a validated T. cruzi antibody 
test is available, in which case they may be accepted 6 months after the last 
exposure if sero-negative (220,221).
Recommendations
NoN-ENDEMIC AREAS
If sensitive antibody assays for T. cruzi are not available
Defer permanently
 Individuals who have ever had a diagnosis of Chagas disease
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 Individuals with an identified risk of Chagas disease:
— Born in, resided in for 6 months or more, or have mother or maternal 
grandmother born in an endemic area
— Received blood transfusion or organ transplant in an endemic area
— Travel for 28 days or more in a rural community in an endemic area
If sensitive antibody assays for T. cruzi are available (184)
Accept
 Individuals with an identified risk of exposure to Chagas disease: accept if 
more than 6 months after last return from an endemic area
Defer
 Individuals with an identified risk of exposure to Chagas disease: defer for 
6 months after last return from an endemic area
Defer permanently
 Individuals who have ever had a diagnosis of Chagas disease
7.4.3 Babesiosis 
Babesiosis (Babesia sp.) is transmitted by tick-borne intraerythrocytic parasites. 
Most cases of Babesia infection are asymptomatic, but can include mild fever 
and diarrhoea. The symptoms are often unnoticed or unexplained. In more severe 
cases, the symptoms are similar to those of malaria. The infection may also 
have a chronic asymptomatic phase and the parasite can survive blood storage 
conditions. B. microti is endemic in parts of North America; the reservoir of 
infection is small rodents. Transfusion-transmission has been reported (222,223). 
Prevention relies on checking for a history of previous infection among residents 
or visitors to endemic areas (224,225,226).
Recommendations
Defer permanently
 Individuals who have ever had a diagnosis of babesiosis 
7.4.4 Leishmaniasis 
Leishmaniasis is a parasitic disease endemic in the tropics and subtropics, 
transmitted by the bite of infected sand-flies. The parasite (Leishmania sp.) has 
the potential for transfusion-transmission, but this has been only rarely reported, 
possibly because parasitaemia is transient and low level (227). The prevention of 
transfusion-transmission relies on the permanent deferral of infected individuals 
(228). 
Recommendations
Defer
 Individuals who have spent extended periods in endemic areas: defer for at 
least 12 months since their last return 
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Defer permanently
 Individuals who have ever had a diagnosis of leishmaniasis
7.5 BACTERIAL INFECTIONS
Bacterial contamination of blood components with organisms carried by the 
donor may be exogenous, due to skin contaminants entering the donated blood 
at the time of collection, or endogenous, due to bacteria present in the donor’s 
blood (229,230).
The role of donor selection in minimizing exogenous bacterial infection includes 
inspection of the skin at the venepuncture site and deferral of donors with obvious 
skin lesions (also refer to Sections 4.2 on donor appearance and inspection 
and 5.11 on skin diseases). Other techniques for bacterial reduction (231), 
including skin cleansing, venepuncture technique, use of diversion pouches and 
leucoreduction play an important role in preventing the contamination of blood 
components by exogenous bacteria. Guidance on safe phlebotomy techniques can 
be found in WHO Guidelines on drawing blood: best practices in phlebotomy (31).
Most prospective donors with endogenous bacterial infections present with 
symptoms, such as fever, rash, diarrhoea and malaise, and should be deferred 
from blood donation as part of the general health assessment (also refer to 
Section 4.2 on donor appearance and inspection).
Endogenous bacteria that are transfusion-transmissible include Treponema 
pallidum, Borrelia burgdorferi, Brucella melitensis and Yersinia enterocolitica, but 
blood donations are routinely screened only for T. pallidum. 
7.5.1 Syphilis, yaws and gonorrhoea 
Syphilis, yaws and gonorrhoea are common sexually-transmitted diseases; it 
should be noted that a history of sexually transmitted disease is an important 
indicator for sexual behaviours associated with HIV transmission. Controlling 
sexually transmitted infections is important for preventing HIV infection, particularly 
in people with high risk sexual behaviours (232).
The risk of transmission of syphilis (T. pallidum) through the transfusion of 
processed and stored blood is low as the spirochaetae are released into the 
bloodstream only intermittently during the course of infection, and are destroyed 
within 72 hours of storage at +40oC (63); however T. pallidum can be transmitted 
through fresh blood and platelets. It is not transmitted by plasma products 
fractionated from pooled plasma such as Factor VIII. 
Yaws (Treponema pallidum pertenue) is not transmitted through transfusion, but 
is serologically indistinguishable from syphilis. Serological tests for syphilis may 
remain positive for many years after successful treatment. 
The causative agent of gonorrhoea (Neisseria gonorrhoeae) is not transmissible 
by blood transfusion. Nevertheless most BTS defer individuals with gonorrhoea 
for 12 months following completion of treatment. 
Recommendations
Accept
 Household contacts of individuals with syphilis 
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Defer
 Current sexual contacts of individuals with syphilis 
 Former sexual contacts of individuals with syphilis: defer for 12 months since 
last sexual contact
 Individuals with gonorrhoea: defer for 12 months following completion of 
treatment and assess for high-risk behaviour
 Current sexual contacts of individuals with gonorrhoea
 Former sexual contacts of individuals with gonorrhoea: defer for 12 months 
since last sexual contact
Defer permanently
 Individuals who have ever had a diagnosis of syphilis
7.5.2 Lyme disease 
The spirochete Borrelia burgdorferi is carried by insect vectors including ticks, 
horseflies and mosquitoes. It can survive blood storage temperatures. Transfusion-
transmission is possible but has not been reported. Infected individuals usually 
exhibit symptoms of rash, fever, lymphadenopathy, often progressing to chronic 
arthropathy and/or neurological involvement, and are likely to be identified and 
excluded by careful donor selection (222).
Recommendation
Defer 
 Individuals with a current diagnosis of Lyme disease: defer for 28 days 
following completion of treatment and full recovery, whichever is longer
7.5.3 Brucellosis 
Brucellosis (undulant fever) is caused by the bacterium Brucella melitensis. It is 
usually acquired from an infected animal source but is not usually transmitted 
from person to person. Transfusion-transmission has been reported in endemic 
regions. Infection is usually chronic; this may last for many years with bouts of 
sometimes quite serious illness. 
Recommendation
Defer permanently
 Individuals who have ever had a diagnosis of brucellosis 
7.5.4 Yersinia infection 
This gram-negative bacterium (Yersinia enterocolitica) causes enteritis and is of 
particular concern as it can multiply at +4oC; thus a low-grade bacteraemia in 
a donor is capable of causing severe, sometimes fatal post-transfusion sepsis 
and toxic shock in the recipient. The incidence of this complication has been 
estimated at 1:6 million red cell transfusions (233).
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Donors should be asked about any recent abdominal symptoms, particularly 
diarrhoea, and deferred if they have a history suggestive of Y. enterocolitica. 
They should be asked to inform the BTS if they develop such symptoms within 
14 days of donation. As symptoms may be absent or non-specific, potentially 
infected donors cannot reliably be identified.
Recommendation
Defer
 Individuals with recent abdominal symptoms, particularly diarrhoea, suggestive 
of Y. enterocolitica infection: defer for 28 days following full recovery 
7.5.5 Salmonella, campylobacter, streptococcus and 
staphylococcus 
Post-transfusion sepsis may result from donor bacteraemia associated with 
gastrointestinal, urinary or wound infections (also refer to Section 4.3 on minor 
illnesses). 
Recommendations
Defer
 Individuals with:
— Symptoms suggestive of recent infection with salmonella, campylobacter 
or streptococcus: defer for 28 days following full recovery
— Other evidence of potential infection with staphylococcus: e.g. recent 
superficial but significant wounds: defer for 14 days following full wound 
healing
7.5.6 Tuberculosis 
There is no published report of transfusion-transmission of tuberculosis 
(Mycobacterium tuberculosis) even though the organism is blood-borne. 
Recommendations 
Defer 
 Individuals with tuberculosis: defer for 2 years following confirmation of cure 
 Contacts of individuals with tuberculosis: defer household contacts and other 
close contacts until screened and confirmed clear of infection 
7.6 RICKETTSIAL INFECTIONS
Rickettsiae are organisms that are smaller than bacteria and, except for Q fever 
(Coxiella burnetii), require an insect vector. Transfusion-transmissions of Q fever 
and Rocky Mountain spotted fever have rarely been reported. Deferral periods 
implemented for Q fever range from 2 years to permanent deferral (234).
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Recommendations
Defer 
 Individuals with:
— Rickettsial infection: defer for 6 months following completion of treatment 
or cessation of symptoms 
— Acute Q fever: defer for 2 years following completion of treatment and 
full recovery, whichever is the longer
Defer permanently
 Individuals with chronic Q fever 
7.7 PRION DISEASES
7.7.1 Creutzfeldt-Jakob disease 
Creutzfeldt-Jakob disease (CJD) is the human form of transmissible spongiform 
encephalopathy. It exists in four distinct forms: sporadic, genetic (familial), 
iatrogenic and variant (vCJD). 
There is no evidence of transfusion-transmission of sporadic and familial CJD; 
nevertheless, donors with symptoms suggestive of CJD or a family history of 
CJD should be permanently deferred (235). Iatrogenic CJD has been described 
following treatment with pituitary-derived human growth hormone, human 
gonadotrophin, dura mater grafts, corneal transplants and through contaminated 
neurosurgical instruments. There is no evidence of transfusion-transmission of 
iatrogenic CJD; however donors with a history of such interventions should be 
permanently deferred (236). 
7.7.2 Variant Creutzfeldt-Jakob disease 
Variant Creutzfeldt-Jakob disease (vCJD) emerged in the United Kingdom of Great 
Britain and Northern Ireland (UK) in 1996 as a result of oral transmission of 
spongiform encephalopathy from infected cattle. Data on the number of cases 
worldwide are collected and published by the UK National Creutzfeldt-Jakob 
Disease Research & Surveillance Unit (237). The outbreak of cases in the UK 
has declined but a “second wave” cannot be excluded and cases have occurred 
in other European Union countries (70).
Epidemiological evidence from the UK indicates that vCJD can be transmitted 
by blood transfusion, with important implications for public health worldwide 
(238,239,240,241). WHO guidelines on tissue infectivity distribution in transmissible 
spongiform encephalopathies (242) recommend that national authorities should 
prepare plans for measures to minimize the risk of transfusion-transmission of 
vCJD by blood and blood products, whilst not compromising the adequacy of the 
blood supply, and provide guidance on risk assessment. 
To date, many countries have addressed this risk by excluding blood donors 
with a history of travel or residence in the UK and parts of Europe, for defined 
cumulative exposure periods. The United States Food and Drug Administration 
currently requires deferral of individuals who have spent 3 months or more 
cumulatively in the UK between 1980 and the end of 1996, when effective 
measures were implemented to prevent oral transmission, or who have spent 5 
years or more cumulatively in Europe between 1980 and the present (236). In 
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the UK, France and Ireland, recipients of blood transfusion (including fractionated 
blood products) since 1980 are now permanently deferred. Other countries defer 
donors who have received blood transfusions in the UK or France since 1980.
Recommendations
 Countries should conduct a risk assessment and risk-benefit analysis taking 
into account national and international data on the epidemiology of vCJD 
in order to implement appropriate risk-mitigating measures to prevent the 
transmission of vCJD through blood transfusion
 The decision to defer blood donors with a history of travel or residence for 
defined cumulative exposure periods in specified countries or areas, as a 
measure to reduce the risk of transmitting vCJD by blood transfusion, should 
be based on the findings of the risk assessment and risk-benefit analysis 
and the impact on the blood supply
Defer permanently 
 Individuals with sporadic or familial CJD 
 First-degree relatives of individuals with sporadic or familial CJD 
 Individuals with vCJD 
 Individuals who have received a transfusion or any other human-derived 
therapeutic products since 1980 in a country in which the risk of vCJD has 
been identified 
 Individuals with a history of treatment with pituitary-derived human growth 
hormone, human gonadotrophin, dura mater graft, corneal transplant or 
neurosurgery
7.8 COUNTRY OF RESIDENCE AND TRAVEL HISTORY
Donor exposure to TTI is affected by their current and previous country (or region) 
of residence and their travel history. In areas that are non-endemic for specific 
infections, travel history is of particular importance as prospective donors may be 
unaware of the geographical distribution of TTI such as malaria, Chagas disease, 
West Nile virus and vCJD. Donor selection and donation testing strategies should 
be based on up-to-date and readily available information on the epidemiology 
and prevalence of known and emerging TTI in specific geographical areas 
(243,244,245) (also refer to Sections 7.3 to 7.7). The deferral of prospective 
donors who have visited or been resident in disease-endemic areas should be 
balanced against the sufficiency of the blood supply.
7.9 HIGH-RISK BEHAVIOURS
7.9.1 High-risk sexual behaviours
Certain sexual behaviours have been shown by surveillance data to be associated 
with a high risk of transmission of HIV, HBV and HCV (246,247). It is essential 
that BTS identify and defer from blood donation individuals whose sexual behaviour 
puts them at high risk of acquiring infectious diseases that can be transmitted 
through blood. Deferral policies for high-risk behaviours should be supported by 
public education. Deferral criteria should be simple and easily understood by 
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staff and prospective donors and should ideally enable self-deferral, without the 
need for detailed intrusive questioning about an individual’s sexual behaviour 
(248,249); they should be applied with sensitivity, a non-judgemental approach 
and assurance of confidentiality. 
High-risk sexual behaviours include having multiple sex partners, receiving or paying 
money or drugs for sex, including sex workers and their clients, men having sex 
with men (MSM) (250,251) and females having sex with MSM (246,247,252). MSM 
account for the largest subpopulation of HIV-infected people in most developed 
countries (253,254,255,256) and many countries therefore permanently defer 
men who have ever had oral or anal sex with another man (254,257,258). 
The permanent deferral of MSM has been criticized as being selectively 
discriminatory and lacking scientific rigour (253,259,260,261) and has undergone 
review in some countries in the light of increasingly sensitive and reliable 
technologies for donation screening (249,262). Studies using mathematical 
modelling to predict the effect of reducing deferral intervals for MSM to one or five 
years have suggested that the increased risk of an HIV-infected donation entering 
the blood supply is small, but not zero, with little gain in terms of additional 
donations (263,264,265,266). These studies rely on some assumptions, are 
applicable only to the populations studied, and relate to testing methodologies 
that are not available in some countries and have been superseded in others. 
However, no comparable evidence is currently available. The permanent deferral 
of MSM therefore continues to be endorsed as the default position based on 
the principle of risk reduction to “as low as reasonably achievable” (ALARA).
Deferral criteria for high-risk sexual behaviours in a particular country or region 
should be determined and reviewed frequently, based on the residual risk of 
transfusion-transmitted viral infections, taking into account changes in disease 
epidemiology, improvements in available technologies for donation testing and 
on-going research.
Recommendations
Defer
 Current sexual contacts of individuals whose sexual behaviours put them at 
high risk of transfusion-transmissible infections 
 Former sexual contacts of individuals whose sexual behaviour put them at 
high risk of transfusion-transmissible infections: defer until 12 months since 
last sexual contact
Defer permanently
 Individuals whose sexual behaviour put them at high risk of transfusion-
transmissible infections 
7.9.2 Injecting drug use
The use of injected “recreational” drugs and non-prescribed steroids is commonly 
associated with unsafe practices such as the sharing and re-use of needles. It 
carries a high risk of blood-borne infections, most commonly HCV, but also HBV 
and HIV (246,267,268,269,270,271,272,273,274). 
Many injected drugs are highly addictive and their use may be life-long. The 
safest policy is therefore permanent deferral of anyone who has ever injected 
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non-prescribed drugs. Deferral policies should be regularly reviewed as new 
evidence emerges. 
Recommendations
Defer
 Current sexual contacts of injecting drug users 
 Former sexual contacts of injecting drug users: defer for 12 months since 
last sexual contact 
Defer permanently 
 Individuals with a history of injecting drug use 
7.9.3 Non-injected drugs and alcohol use
The use of alcohol and non-injected “recreational” drugs is widespread in most 
cultures, and many local practices exist.
Prospective donors who demonstrate signs and symptoms of intoxication should 
be deferred as their capacity to give informed consent is likely to be impaired. 
A further consideration is whether regular heavy drinking or use of illicit drugs 
and other dependence-producing psychoactive substances is a marker for other 
high-risk behaviours.
The use of intranasal cocaine has been found to be a risk factor for HCV (275).
There is no documented evidence that recent ingestion of a “recreational” drug (e.g. 
kava) or alcohol by a donor has caused harm to the recipient of their blood. As is the 
case for prescribed medication, the dilution factor is such that the blood recipient 
receives a very small residual quantity, which is unlikely to have any adverse effect. 
Considerations regarding possible allergic reactions to non-prescribed drugs in 
recipients are the same as for prescribed medications (also refer to Section 
6.2 on medications).
Recommendations
Accept 
 If no signs of intoxication
Defer
 If displaying signs and symptoms of intoxication
7.9.4 Detention in prisons and penal institutions
Inmates of prisons and penal institutions should not be accepted as blood 
donors as there is evidence of a higher incidence of HIV, HBV and HCV in these 
populations (276,277). In addition, there is a risk that there may be undue 
coercion to donate blood in these settings and that the donation may not be 
voluntary. The acceptance of individuals with a history of previous imprisonment 
requires assessment of their exposure to risk from drug use, injuries or unsafe 
sexual practices with the consequent appropriate deferral period.
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Recommendation
Defer
 Inmates of prisons and penal institutions 
7.9.5 Cosmetic treatments and rituals 
Any procedures involving penetration of the skin carry a risk of bloodborne 
infections, especially HIV, HBV and HCV, unless performed under sterile conditions. 
These include body piercing, tattooing, scarification, injections with collagen or 
botulinum toxoid (botox), electrolysis and semi-permanent make-up (267,268,2
70,271,278,279,280,281,282). 
Individuals who present with a history of any procedures involving penetration 
of the skin should be assessed for the risk of TTI, based on when, where, by 
whom and how the procedure was performed. The BTS should define the deferral 
period, based on the sterility and safety of the procedure. If it is not possible 
to ascertain the sterility and safety of the procedure, the individual should be 
deferred for a period of 12 months.
Recommendation
Defer
 Individuals who have had acupuncture, piercing, tattoos, ritual scarification or 
any other invasive cosmetic procedures: defer for 12 months following the 
last procedure 
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Glossary
Apheresis
Any procedure in which blood is withdrawn from a donor, a portion (such as 
plasma, leukocytes, or platelets) is separated and retained, and the remainder 
is re-transfused into the donor 
Blood donors
 Voluntary non-remunerated blood donor: A person who donates blood (and 
plasma or cellular components) of his/her own free will and receives no 
payment for it, either in the form of cash, or in kind which could be considered 
a substitute for money
 Family/replacement blood donor: A person who gives a replacement unit of 
blood only when a family member or friend requires transfusion
 Paid “donor”: A person who provides blood for money or other form of payment
 Autologous donor: A patient who donates his/her blood to be stored and 
reinfused, if needed, during surgery
Confidential unit exclusion 
The removal and disposal of a unit of blood after donation at the request of 
the donor
Directed donation
A donation that is given specifically for transfusion to a named patient
Donor deferral
The non-acceptance of a potential blood donor to donate blood or blood 
components, either temporarily or permanently, based on general health or 
medical condition, or the risk of exposure to pathogens
Donor haemovigilance
A set of surveillance procedures for the monitoring, reporting and investigation 
of adverse donor reactions and events which are designed to prevent their 
occurrence or recurrence
Donor selection
The process of assessing the suitability of an individual to donate blood or blood 
components against defined selection criteria
Extracorporeal blood volume 
The volume of blood outside the donor’s body during an apheresis procedure 
and the small volume remaining in the cell separator, excluding the anticoagulant
Incidence
The rate of occurrence of new cases of a particular disease in a population 
being studied
Men who have sex with men (MSM) (250) 
Men who have sex with men is an inclusive public health construct used to 
define the sexual behaviours of males who have sex with other males, regardless 
of the motivation for engaging in sex or identification with any or no particular 
“community” (283). The words “man” and “sex” are interpreted differently in 
diverse cultures and societies, as well as by the individuals involved. As a result, 
the term MSM covers a large variety of settings and contexts in which male-
to-male sex takes place. Perhaps the most important distinction to make is 
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one between men who share a non-heterosexual identity (i.e. gay, homosexual, 
bisexual or other culture-specific concepts that equate with attraction to other 
men) and men who view themselves as heterosexual but who engage in sex 
with other males for various reasons (e.g. isolation, economic compensation, 
sexual desire, gender scripts) (284). Settings with forced gender segregation (e.g. 
prisons, military establishments) are important contexts for male-to-male sexual 
activity not linked to homosexual identity. Given the conditions of imprisonment, 
including human rights violations and lack of access to condoms, the risk of HIV 
transmission in prisons is very high (285).
National blood policy
A statement of intent by the ministry of health that defines the organizational, 
financial and legal measures at the national level that will be taken to ensure 
the quality, safety, availability and accessibility of blood and blood products and 
their safe and appropriate use
Precautionary principle
The concept that precautionary action may be justified to mitigate a perceived 
risk to the safety or supply of blood if the best available evidence shows that 
there are reasonable grounds to support this action, even if the probability of 
that risk occurring is small
Prevalence
The proportion of a specific population that is infected with an infectious agent 
at any particular time
Quality system
Organizational structure, processes, procedures and resources needed to 
implement quality requirements
Risk behaviour 
Behaviour that exposes an individual to the risk of acquiring transfusion-
transmissible infection
Self-deferral
The decision by a potential donor to defer himself/herself from donation of blood 
or blood components, either temporarily or permanently, based on general health 
or medical condition, or the risk of exposure to pathogens
Traceability 
The ability to trace each individual unit of blood, or blood component derived from 
it, from the donor to its final destination, whether this is a patient, a manufacturer 
of therapeutic products or disposal, and vice versa
Transfusion-transmissible infection (TTI)
An infection that is potentially capable of being transmitted by blood transfusion
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Annex 2
Example of a blood donor 
questionnaire
BLOOD TRANSFUSION SERVICE
DONOR QUESTIONNAIRE
Please complete this form
Panel name:    Donor no:
Family name:    First name:
Title:      ID No:
Date of birth:    Gender:
Occupation:
Residential address:
Postal address:
Telephone no. Home:         Work:     Mobile:
E-mail address:
1 HEALTH ASSESSMENT
Please tick the appropriate answer to each question
   Yes No
1.1  Are you feeling well and in good health today? r r
1.2  in the last 4 hours, have you had a meal or snack? r r
1.3  Have you already given blood in the last 16 weeks? r r
1.4  Have you got a chesty cough, sore throat or active r r 
cold sore?
1.5  Are you pregnant or breastfeeding? r r
1.6  Do you have or have you ever had:
a Chest pains, heart disease/surgery or a stroke? r r
b Lung disease, tuberculosis or asthma? r r
c Cancer, a blood disease, an abnormal bleeding r r 
disorder, or a bleeding gastric ulcer or duodenal   
ulcer?
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   Yes No
d Diabetes, thyroid disease, kidney disease,  r r 
epilepsy (fits)?  
e Chagas disease, babesiosis, HTLVI/II or any  r r 
other chronic infectious disease?
1.7 In the last 7 days, have you seen a doctor, dentist r r 
or any other healthcare professional or are you    
waiting to see one (except for routine screening   
appointments)?
1.8 In the past 12 months:
a Have you been ill, received any treatment or taken  r r 
any medication?
b Have you been under a doctor’s care, undergone  r r 
surgery, or a diagnostic procedure, suffered a    
major illness, or been involved in a serious   
accident?
1.9 Have you ever had yellow jaundice (excluding  r r 
jaundice at birth), hepatitis or liver disease or a   
positive test for hepatitis?
a In the past 12 months, have you had close r r 
contact with a person with yellow jaundice or   
 viral hepatitis, or have you been given a   
hepatitis B vaccination?
b Have you ever had hepatitis B or hepatitis C or r r 
think you may have hepatitis now?
c In the past 12 months, have you been tattooed,  r r
 had ear or body piercing, acupuncture,   
circumcision or scarification, cosmetic treatment?
1.10 In the past 12 months, have you or your sexual  r r 
partner received a blood transfusion?
1.11 Have you or your sexual partner been treated with  r r 
human or animal blood products or clotting factors?
1.12 Have you ever had injections of human pituitary  r r 
growth hormone, pituitary gonadotrophin (fertility    
medicine) or seen a neurosurgeon or neurologist?
1.13 Have you or close relatives had an unexplained  r r 
neurological condition or been diagnosed with   
Creutzfeldt-Jacob Disease or ‘mad cow disease’?
1.14 Have you:
a Ever had malaria or an unexplained fever  r r 
associated with travel? 
b Visited any malarial area in the last 12 months? r r
1.15 When did you last travel to another region or 
 country (in months / years)? 
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2 RISK ASSESSMENT 
   Yes No
2.1 Is your reason for donating blood to undergo r r
 an HIV test?
2.2 Have you ever been tested for HIV? r r
2.3 If “Yes” what was the reason?  
 r Voluntary r Employment r Insurance r Medical advice
 Other: 
2.4 Have you ever had casual, oral or anal sex with r r
 someone whose background you do not know, 
 with or without a condom?
2.5 Have you ever exchanged money, drugs,  r r 
goods or favours in return for sex?
2.6 Have you suffered from a sexually transmitted  r r 
disease (STD): e.g. syphilis, gonorrhoea, genital    
herpes, genital ulcer, VD, or ‘drop’?
2.7 In the past 12 months:
a Has there been any change in your marital status? r r
b If sexually active, do you think any of the above  r r 
questions (2.1–2.6) may be true for your sexual   
partner?
c Have you been a victim of sexual abuse? r r
2.8 Have you or your sexual partner suffered from r r
 night sweats, unintentional weight loss, diarrhoea
 or swollen glands?
2.9 Have you ever injected yourself or been injected  r r 
with illegal or non-prescribed drugs including   
body-building drugs or cosmetics (even if this was    
only once or a long time ago)?
2.10 Have you been in contact with anyone with an  r r 
infectious disease or in the last 12 months have    
you had any immunizations, vaccinations or jabs?
2.11 Have you ever been refused as a blood donor,  r r 
or told not to donate blood?
3 DECLARATION
Please do not sign until you have answered all the questions and read 
the declaration below.      
a I confirm that, to the best of my knowledge, I have answered all the 
questions accurately and I consider my blood safe for transfusion 
to a patient.
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b I understand that any wilful misrepresentation of facts could endanger 
my health or that of patients receiving my blood and may lead to 
litigation. I am aware that my blood will be screened for, among 
others, HIV, hepatitis B, hepatitis C and syphilis. I understand that 
these screening tests are not diagnostic and may yield false-positive 
results. If any of the tests give a reactive result, I will be contacted 
using the information I have provided, and offered counselling.
c I understand the blood donation process, and I have been counselled 
regarding the importance of safe blood donation.
d I confirm that I am over the age of 18 years.
e I undertake that should there be any reason for my blood to 
be deemed unsafe for use at any stage, I will inform the Blood 
Transfusion Service.      
Donor’s signature: 
Decision: r Accept r Defer
Donor weight:  kg 
Blood pressure:  Haemoglobin/haematocrit: 
Deferral period:
Reason for deferral: 
Interviewed by (name and signature): 
Venepuncture performed by (name and signature): 
Date: 
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Annex 3
Literature search strategies 
and decision-making 
process for formulation of 
recommendations
LITERATURE SEARCH
Approach 
A systematic literature search was conducted to collect the more widely consulted 
published literature from peer-reviewed journals, regional journals, book chapters, 
institutional and other knowledge databases, as well as lesser-known published 
literature and unpublished and non-reviewed “grey literature”. This approach was 
adopted to gain a better understanding of the guiding forces behind certain current 
local practices in the field of blood donor selection, as well as to inform the 
users of these recommendations about proven, safe and cost-effective practices 
that should be considered when developing national guidelines. 
Guidelines Review Committee 
WHO has established an independent committee of experts, the Guidelines 
Review Committee (GRC), whose role is to ensure that WHO guidelines are 
consistent with internationally accepted best practice, including the appropriate 
use of evidence. The GRC has produced detailed instructions and guidelines 
about the process by which recommendations and guidelines are developed 
by WHO. It has also defined clear and stringent criteria on evidence retrieval, 
assessment and synthesis in order to ensure that the evidence collected is 
up-to-date, relevant to users and unbiased. The current recommendations were 
developed in accordance with the guidance provided by the GRC. 
Search criteria
The literature search focused on collecting evidence concerning various 
physiological conditions, diseases and risk activities in relation to criteria for 
blood donor selection. 
As these recommendations have been developed particularly for use in countries 
that have not yet established national donor selection systems, the literature 
search strategy was specially designed to collect literature from developing 
countries. 
Searched domains
A systematic search of the following databases was undertaken for the period 
1995–2011: PubMed, Cochrane Library, WHO Library Database (WHOLIS), Institute 
for Scientific Information (ISI) Web of Knowledge, World Bank eLibrary and WHO 
regional databases: African Index Medicus (AIM), Index Medicus for the Eastern 
Mediterranean (IMEMR), Index Medicus for South-East Asia (IMSEAR), Western 
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Pacific Region Index Medicus (WPRIM), Virtual Health Library–Latin American and 
Caribbean Literature on Health Sciences Information (VHL-LILACS), Virtual Health 
Library–MEDCARIB and the Pan American Health Organization.
The “grey literature” was retrieved using the public search engines Google and 
Yahoo mainly to collect literature from low and middle-income countries, focusing 
on a) the existence and availability of national guidelines and criteria for blood 
donor selection, and b) current practice in blood donor selection in countries.
SEARCH STRATEGY
Keywords and medical subject heading (MeSH) terms, and key authors and 
institutions were used to retrieve relevant citations from various databases. A 
preliminary screen was carried out by the review of titles by the searcher to eliminate 
obviously irrelevant and duplicate citations. Citations of possible relevance were 
forwarded to the chair of the Guideline Development Group who undertook 
a further review of titles and abstracts, where appropriate. Key papers that 
addressed each of the study questions were then selected and the full text of 
these papers was reviewed.
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Part 2: Criteria for blood    
  donor selection 
4 General donor assessment 
4.1 AGE 
4.1.1 Lower age limit
Question
What should be the lower age limit for blood donation?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse events related to 
blood donation by young donors
 Retain suitable blood donors
Key search and MeSH words
(blood donor) OR (blood donation) OR (donating blood) OR (whole blood donation) 
(iron-deficiency anaemia) AND (whole blood donation)
(whole blood donation) AND (adverse reaction) AND (adolescent*)
Search strategy: PUBMED
#23Search whole blood donation AND adverse reaction* Limits: Humans, English, 
published in the last 10 years Field: Title/Abstract 08:30:20 9 
#22 Search whole blood donation AND adolescent* AND adverse reaction* Limits: 
Humans, English, published in the last 10 years Field: Title/Abstract 08:28:51 0
#21 Search whole blood donation AND adverse reaction* AND adolescent* Limits: 
Humans, English, published in the last 10 years Field: Title/Abstract 08:25:44 0 
#20 Search whole blood donation AND adverse reactions AND adolescent* Limits: 
Humans, English, published in the last 10 years Field: Title/Abstract 08:02:15 0 #19 
Search (((blood donor[Title/Abstract]) OR blood donors[Title/Abstract]) OR donating whole 
blood[Title/Abstract] ) AND adolescent*[Title/Abstract] Limits: Humans, English, published 
in the last 10 years Field: Title/Abstract 08:00:12 15 
#18 Search (blood donor) OR (whole blood donor) OR (donating blood) AND adolescent* 
Limits: Humans, English, published in the last 10 years Field: Title/Abstract 07:57:12 30 
#17 Search (blood donor) OR (blood donors) OR (donating blood) AND adolescent* 
Limits: Humans, English, published in the last 10 years Field: Title/Abstract 07:55:16 51 
#16 Search (blood donor) OR (blood donation) (donating blood) AND (iron-deficiency 
anemia) AND (age limit) Limits: Humans, English, published in the last 10 years Field: 
Title/Abstract 07:05:36 0 
#15 Search (blood donor) OR (blood donation) (donating blood) AND (iron-deficiency 
anemia) ND (age limit) Limits: Humans, English, published in the last 10 years Field: 
Title/Abstract 07:05:23 0
#14 Search (blood donor) OR (blood donation) (donating blood) AND (age limit) AND 
(iron-deficiency anemia) Limits: Humans, English, published in the last 10 years Field: 
Title/Abstract 07:04:25 0 
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#13 Search (blood donor) OR (blood donation) (donating blood) AND (iron deficiency anemia) 
Limits: Humans, English, published in the last 10 years Field: Title/Abstract 07:04:46 1
#12 Search (blood donor) OR (blood donation) (donating blood) AND (iron-deficiency anemia) 
Limits: Humans, English, published in the last 10 years Field: Title/Abstract 07:04:46 0 
#11 Search (blood donor) OR (blood donation) (donating blood) AND (lower age limit) 
AND (iron-deficiency anemia) Limits: Humans, English, published in the last 10 years 
Field: Title/Abstract 07:00:45 0 
#10 Search (blood donor) OR (blood donation) (donating blood) AND (lower age limit) 
AND (adverse reactions) Limits: Humans, English, published in the last 10 years Field: 
Title/Abstract 06:55:05 0
#9 Search (blood donor) OR (blood donation) (donating blood) AND (adverse reactions) 
AND (lower age limit) Limits: Humans, English, published in the last 10 years Field: Title/
Abstract 06:54:22 0 
#8 Search (blood donor) OR (blood donation) (donating blood) AND (adverse reactions) 
Limits: Humans, English, published in the last 10 years Field: Title/Abstract 06:51:48 1 
#7 Search (blood donor) OR (blood donation) (donating blood) AND (donor age) Limits: 
Humans, English, published in the last 10 years Field: Title/Abstract 06:46:47 21 
#6 Search (blood donor) OR (blood donation) (donating blood) AND (age limit) Limits: 
Humans, English, published in the last 10 years Field: Title/Abstract 06:46:18 0 
#5 Search (blood donor) OR (blood donation) (donating blood) AND (lower age limit) 
Limits: Humans, English, published in the last 10 years Field: Title/Abstract 06:45:52 0 
#4 Search (voluntary blood donor) OR (voluntary blood donation) AND (lower age limit) 
Limits: Humans, English, published in the last 10 years Field: Title/Abstract 06:42:32 0 
#3 Search (voluntary blood donor) OR (voluntary blood donation) AND (lower age limit)) 
Limits: Humans, English, published in the last 10 years Field: Title/Abstract 06:42:08 0 
#2 Search (voluntary blood donor) OR (voluntary blood donation) AND (donor age) Limits: 
Humans, English, published in the last 10 years Field: Title/Abstract 06:39:06 15
#1 Search (blood donor) OR (blood donors) OR (blood donation) AND (donor age) Limits: 
Humans, English, published in the last 10 years Field: Title/Abstract 06:37:32 1286
Number of citations screened 143
Number of papers that address the study question 3
Key references
1 Trouern-Trend J et al. A case-controlled multi-centre study of vasovagal reactions in 
blood donors: influence of sex, age, weight, blood pressure and pulse. Transfusion, 
1999, 39:316–320.
2 Newman BH et al. Donor reactions in high-school donors: the effects of sex, weight 
and collection volume. Transfusion, 2006, 46:284–288.
3 Eder AF et al. Adverse reactions to allogeneic whole blood donation by 16- and 17-year-
olds. Journal of the American Medical Association, 2008, 299(19):2279–2286.
Decision-making process
The Guideline Development Group agreed on the following recommendations 
based on data from the above studies, their knowledge of the haemodynamic 
effects of blood donation and experience from best practice. 
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Recommendations
 The usual lower age limit for blood donation is 18 years 
 Where permitted by national legislation or in setting a lower age limit of 16 
or 17 years for blood donation, the BTS should consider:
 The age of legal consent below which parental permission is required and 
the need to inform parents/guardians about the process, benefits and risks 
of blood donation so that informed consent can be obtained
 The balance between the benefit of an increased blood supply by recruiting 
younger donors against the increased risk of adverse reactions in this age 
group
 The increased iron requirement of adolescents and the possible compromise 
of their iron status by regular blood donation
4.1.2 Upper age limit 
Question
What should be the upper age limit for?
 First-time blood donation
 Regular blood donation
Are any additional precautions required for elderly donors?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse events related to 
blood donation by elderly donors
 Retain suitable, healthy blood donors
Key search and MeSH words
(blood donor) OR (blood donation) OR (donating blood) OR (whole blood donation) 
adverse reaction, risk factor, hemovigilance, donor age, elderly donor, homologous 
whole blood donation, autologous whole blood donation
Search strategy: PUBMED
#48 Search (voluntary blood donor) OR (voluntary blood donation) AND (upper age limit) 
Limits: Humans, English, published in the last 10 years Field: Title/Abstract 16:51:04 0
 #2 Search (voluntary blood donor) OR (voluntary blood donation) AND (donor age) Limits: 
Humans, English, published in the last 10 years Field: Title/Abstract 16:47:18 15
#46 Search ((elderly blood donors)) AND (adverse reaction*) Limits: Humans, English, 
published in the last 10 years Field: Title/Abstract 16:36:28 0 
#45 Search ((elderly blood donor)) AND (adverse reaction*) Limits: Humans, English, 
published in the last 10 years Field: Title/Abstract 16:36:28 0 
#44 Search ((elderly blood donor)) AND (donor risk) Limits: Humans, English, published 
in the last 10 years Field: Title/Abstract 16:31:44 26 
#43 Search (((elderly blood donor)) AND (adverse reaction)) OR (donor risk) Limits: 
Humans, English, published in the last 10 years Field: Title/Abstract 16:27:53 5923 
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#42 Search (((blood donor) OR (blood donors) OR (blood donation) ) AND (elderly)) AND 
(adverse reaction) Limits: Humans, English, published in the last 10 years Field: Title/
Abstract 16:26:36 1 
#41 Search ((blood donor) OR (blood donors) OR (blood donation) ) AND (elderly donor) 
Limits: Humans, English, published in the last 10 years Field: Title/Abstract 16:15:06 71 
#40 Search (((blood donor)) AND (elderly donor)) AND (adverse reaction) Limits: Humans, 
English, published in the last 10 years Field: Title/Abstract 16:13:35 0 
#38 Search ((homologous blood donation)) AND (adverse reaction) Limits: Humans, 
English, published in the last 10 years Field: Title/Abstract 16:10:29 1 
#37 Search ((autologous blood donor)) AND (adverse reaction) Limits: Humans, English, 
published in the last 10 years Field: Title/Abstract 16:00:10 1
 #35 Search ((blood donation)) AND (elderly donor) Limits: Humans, English, published 
in the last 10 years Field: Title/Abstract 15:47:44 6 
#34 Search ((voluntary blood donation)) AND (elderly donor) Limits: Humans, English, 
published in the last 10 years Field: Title/Abstract 15:47:00 0 
#33 Search (((voluntary blood donor*)) AND (elderly donor*)) AND (donor risk*) Limits: 
Humans, English, published in the last 10 years Field: Title/Abstract 15:44:30 0 
#32 Search (((voluntary blood donor*) ) AND (elderly donor*)) AND (adverse reaction*) 
Limits: Humans, English, published in the last 10 years Field: Title/Abstract 15:40:57 0
 #31 Search (((voluntary blood donor*)) AND (elderly blood donor)) AND (adverse reaction*) 
Limits: Humans, English, published in the last 10 years Field: Title/Abstract 15:39:04 0 
#30 Search (#2) AND (adverse reaction*) Limits: Humans, English, published in the last 
10 years Field: Title/Abstract 15:20:30 0 
#29 Search (#1) AND (donor safety) Limits: Humans, English, published in the last 10 
years Field: Title/Abstract 15:17:15 93 
#28 Search (#1) AND complication* Limits: Humans, English, published in the last 10 
years Field: Title/Abstract 15:14:15 228 
#24 Search (#1) AND (adverse reaction*) Limits: Humans, English, published in the last 
10 years Field: Title/Abstract 15:02:20 8
Number of citations screened 450
Number of papers that address the study question 8
Key references
1 Eder A et al. The American Red Cross donor vigilance programme: complications of 
blood donations reported in 2006. Transfusion, 2008, 48:1809–1819.
2 Janetko K et al. Effects of blood donation on the physical fitness and hemorheology 
of healthy elderly donors. Vox Sanguinis, 1998, 75:7–11.
3 McVay P et al. Donation reactions among autologous donors. Transfusion, 1990, 
30(3):249–252.
4 Pindyck J, Avoron J, Kuryan M. Blood donation by the elderly. Clinical and policy 
considerations. Journal of the American Medical Association, 1987, 257: 1186–1188.
5 Simon T et al. Characteristics of elderly blood donors. Transfusion, 1991, 31:693–697.
6 Goldman M et al. Effect of changing the age criteria for blood donors. Vox Sanguinis, 
2007, 92(4):368–372.
7 Zeiler T et al. The safety of blood donation by elderly blood donors. Vox Sanguinis, 
2011, 101(4):313–319.
8 Müller-Steinhardt M et al. Safety and frequency of whole blood donations from elderly 
donors. Vox Sanguinis, 2012, 102(2):134–139.
125
Decision-making process
The Guideline Development Group agreed on the following recommendations 
based on data from the above studies, their knowledge of the haemodynamic 
effects of blood donation and experience from best practice. 
Recommendations
 In setting an upper age limit for blood donors, the BTS should consider the 
healthy life expectancy of the population
 The usual upper age limit for blood donation is 65 years
 First-time donors older than 60 years and regular donors over the age of 65 
may be accepted at the discretion of the responsible physician 
 First-time donors over 60 years should make their first donation at a donation 
site where a physician is available
4.3 MINOR ILLNESSES
Question
What selection criteria should be applied to prospective blood donors with a 
history of current or recent minor illness?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse events related to 
blood donation 
 Avoid unnecessary deferral of 
suitable blood donors 
 Minimize risk of transfusion-
transmitted infections or other 
adverse reactions in recipients of 
blood
Key search and MeSH words
blood donor, donor suitability, recipient risk, recipient safety, well-being, evidence, 
hemovigilance
minor infections, cold sores, genital herpes, upper respiratory infections, 
transfusion-transmitted infections
Search strategy: PUBMED
#18Search  ((blood donor) OR (blood donation) AND (donor deferral)) AND (transfusion 
transmitted infections) Limits: Humans, English, published in the last 10 years17:33:58 20
#17Search ((blood donor) OR (blood donation) AND (donor deferral)) AND (upper respiratory 
infections) Limits: Humans, English, published in the last 10 years17:32:07 1
#16Search  ((blood donor) OR (blood donation) AND (donor deferral)) AND (genital 
herpes) Limits: Humans, English, published in the last 10 years17:27:13 1
#15Search  ((blood donor) OR (blood donation) AND (donor deferral) ) AND (cold 
sores) Limits: Humans, English, published in the last 10 years17:25:57 0
#14Search  ((blood donor) OR (blood donation) AND (donor deferral) ) AND (minor 
infections) Limits: Humans, English, published in the last 10 years17:24:41 0
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#13Search (blood donor) AND (donor deferral) AND (cold sores) Limits: Humans, English, 
published in the last 10 years17:23:14 0
#12Search  (blood donor) AND (donor deferral) AND (minor infections) Limits: Humans, 
English, published in the last 10 years17:19:34 0
#11Search (#1) AND #4 Limits: Humans, English, published in the last 10 years17:17:30 3
#10Search  (#3) AND (upper respiratory infections) Limits: Humans, English, published 
in the last 10 years17:16:04 2
#9Search  (#3) AND (genital herpes) Limits: Humans, English, published in the last 10 
years17:15:15 1
#8Search  (#3) AND (cold sores)  Limits:  Humans, English, published in the last 10 
years17:14:29 0
#7Search (#3) AND (minor infection*) Limits: Humans, English, published in the last 10 
years17:13:41 0
#6Search (#3) AND #4 Limits: Humans, English, published in the last 10 years17:12:13 3
#5Search  (minor infection*) OR (cold sores) OR (genital herpes) OR (upper respiratory 
infections) [Title/Abstract] Limits: Humans, English, published in the last 10 years17:11:24 0
#4Search  (minor infection*) OR (cold sores) OR (genital herpes) OR (upper respiratory 
infections) Limits: Humans, English, published in the last 10 years17:10:45 57779
#3Search (#1) AND #2 Limits: Humans, English, published in the last 10 years17:05:33 84
#2Search  (recipient risk) OR (recipient safety) OR (well-being) OR evidence OR 
hemovigilance Limits: Humans, English, published in the last 10 years17:05:06 725802
#1Search (blood donor) OR (blood donation) OR (donating blood) OR (whole blood donation) 
OR (voluntary blood donor) AND (donor suitability) OR (donor deferral) Limits: Humans, 
English, published in the last 10 years17:00:15 193
Number of citations screened 31
Relevant publication 1
Key reference
1 Kitchen A, Barbara J. Transfusion-transmitted infections. In: Murphy M, Pamphilon D 
(eds). Practical transfusion medicine: 221–224. Blackwell Publishing Ltd, Oxford, UK, 
2005.
Decision-making process
The Guideline Development Group agreed on the following recommendations 
based on the above reference and on their medical knowledge and experience 
from best practice. 
Recommendation
Defer 
 Individuals with a history of recent infection: defer for 14 days following full 
recovery and cessation of any therapy, including antibiotics
4.4 WEIGHT
Question
What should be the weight limits for acceptance for blood donation?
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Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse events related to 
blood donation 
Key search and MeSH words
(blood donor) OR (blood donation) OR (donating blood) OR (whole blood donation) 
adverse reaction, body weight, syncope, vasovagal reaction, blood pressure, 
dizziness
Search strategy: PUBMED
#24 Search ((blood donor) [Title/Abstract]) AND obese OR (over weight) OR (fat)[Title/
Abstract] Limits: Humans, English, Publication Date from 1999/01/01 to 2011/05/15 
Field: Title/Abstract 10:47:27 0
#23 Search ((blood donor) ) AND obese Limits: Humans, English, Publication Date from 
1999/01/01 to 2011/05/15 Field: Title/Abstract 10:48:42 38
#22 Search ((vasovagal reaction)) AND weight Limits: Humans, English, Publication Date 
from 1999/01/01 to 2011/05/15 Field: Title/Abstract 10:38:28 9
#21 Search ((vasovagal reaction)[Title/Abstract]) AND weight[Title/Abstract] Limits: 
Humans, English, Publication Date from 1999/01/01 to 2011/05/15 Field: Title/
Abstract 10:37:05 0 
#20 Search (blood donor) AND (vasovagal reaction)[Title/Abstract] Limits: Humans, English, 
Publication Date from 1999/01/01 to 2011/05/15 Field: Title/Abstract 10:35:59 0 
#19 Search ((blood donor) AND (vasovagal reaction)[Title/Abstract]) AND weight[Title/
Abstract] Limits: Humans, English, Publication Date from 1999/01/01 to 2011/05/15 
Field: Title/Abstract 10:35:08 0
#18 Search ((whole blood donor*) OR (donating blood) AND (vasovagal reaction)[Title/
Abstract]) AND weight[Title/Abstract] Limits: Humans, English, Publication Date from 
1999/01/01 to 2011/05/15 Field: Title/Abstract 10:31:31 0
#16 Search ((blood donor) OR (blood donation) OR (donating blood) OR (whole blood 
donation) ) AND faint OR (prefaint reactions) Limits: Humans, English, Publication Date 
from 1999/01/01 to 2011/05/15 Field: Title/Abstract 10:15:52 10
#15 Search ((blood donor) OR (blood donation) OR (donating blood) OR (whole blood 
donation) AND (adverse reaction)) AND weight Limits: Humans, English, Publication Date 
from 1999/01/01 to 2011/05/15 Field: Title/Abstract 10:09:30 4 
#14 Search ((blood donor) OR (blood donation) OR (donating blood) OR (whole blood 
donation) AND (adverse reaction)) AND (body weight) Limits: Humans, English, Publication 
Date from 1999/01/01 to 2011/05/15 Field: Title/Abstract 10:08:12 1
#13 Search ((blood donor) OR (blood donation) OR (donating blood) OR (whole blood 
donation) NOT (cord blood)[Title/Abstract]) AND (adverse reaction)[Title/Abstract] Limits: 
Humans, English, Publication Date from 1999/01/01 to 2011/05/15 Field: Title/Abstract 
10:06:40 0
#12 Search ((whole blood donation) AND (adverse reaction) ) AND (body weight) Limits: 
Humans, English, Publication Date from 1999/01/01 to 2011/05/15 Field: Title/
Abstract 10:04:14 0 
#11 Search ((whole blood donation) AND (adverse reaction) ) AND weight Limits: Humans, 
English, Publication Date from 1999/01/01 to 2011/05/15 Field: Title/Abstract 10:03:51 1 
#7 Search (((blood donor) OR (blood donation) OR (donating blood) OR (whole blood 
donation)) AND (adverse reaction)) AND weight Limits: Humans, English, Publication Date 
from 1999/01/01 to 2011/05/15 Field: Title/Abstract 09:56:16 4 
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#5 Search (((blood donor) OR (blood donation) OR (donating blood) OR (whole blood 
donation)) NOT (cord blood)) AND (body weight) Limits: Humans, English, Publication Date 
from 1999/01/01 to 2011/05/15 Field: Title/Abstract 09:53:52 155
#4 Search ((blood donor) OR (blood donation) OR (donating blood) OR (whole blood 
donation)) AND (body weight) Limits: Humans, English, Publication Date from 1999/01/01 
to 2011/05/15 Field: Title/Abstract 09:51:32 179
Number of citations screened 401
Number of papers that address the study question 2
Key references
1 Trouern-Trend J et al. A case-controlled multi-centre study of vasovagal reactions in 
blood donors: influence of sex, age, weight, blood pressure and pulse. Transfusion, 
1999, 39:316–320.
2 Wiltbank TB et al. Faint and prefaint reactions in whole-blood donors: an analysis of 
predonation measurements and their predictive value. Transfusion, 48(9):1799–1808.
Decision-making process
The Guideline Development Group agreed on the following recommendations 
based on data from the above studies, their knowledge of the haemodynamic 
effects of blood donation and experience from best practice. 
Recommendations
 In determining a lower weight limit for blood donors, the BTS should consider 
norms for the weight of the population; if a significant proportion of the donor 
population weighs less than 45 kg or 50 kg, collection volumes may be reduced 
accordingly, while ensuring that blood collection bags and their anticoagulant 
content are adjusted to be compatible with the volumes collected
 Prospective donors of whole blood donations should weigh at least 45 kg to 
donate 350 ml ± 10% and 50 kg to donate 450 ml ± 10%
 Prospective donors of apheresis platelet or plasma donations should weigh 
at least 50 kg 
 Prospective donors of double red cell apheresis donations should have an 
estimated blood volume of more than 5 litres; this requirement is generally 
met by non-obese individuals weighing more than 70 kg
4.6 DONOR IRON STATUS
Question
What steps should be implemented to safeguard whole blood donors from 
donation-induced iron deficiency? This includes estimation of donor iron status, 
minimum haemoglobin thresholds for whole blood donation, interval between 
donations and iron supplementation.
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Reduce risk of donation-induced iron 
deficiency (DIID)
 Minimize deferral of suitable donors
 Provide a safe and sufficient supply 
of blood and blood components
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Key search and MeSH words
(blood donor) OR (blood donation) OR (donating blood) OR (whole blood donation) 
donor suitability, donor risk, donor safety, donation effect, well-being, hemovigilance, 
evidence, iron-deficiency anaemia, donation-induced iron depletion, donation-
induced iron-deficiency, anaemic, pre-donation haemoglobin, haematocrit, ferritin. 
Not cord blood OR transplantation OR (organ donation) OR stem cell
Search strategy: PUBMED
#4Search (#1) AND (donation-induced iron deficiency)08:46:38 1
#3Search (#2) AND (donation-induced iron deficiency)08:39:13 0
#2Search ((blood donor) OR (blood donation) OR (donating blood) OR (whole blood donation) 
OR (voluntary blood donor)[Title/Abstract]) AND (donor suitability) OR (donor deferral) OR 
(donor risk) OR (donor safety) OR hemovigilance OR (well-being)[Title/Abstract]08:37:38 3
#1Search  ((blood donor) OR (blood donation) OR (donating blood) OR (whole blood 
donation) OR (voluntary blood donor)) AND (donor suitability) OR (donor deferral) OR 
(donor risk) OR (donor safety)08:33:13 19786
#14Search #4 AND (hemoglobin screening)  Limits: Humans, English, published in the 
last 10 years10:09:22 1390
#13Search Blood AND (frequent donor) AND (donor risk) [Title/Abstract] Limits: Humans, 
English, published in the last 10 years10:06:43 0
#12Search Blood AND (frequent donor) AND (donor safety)[Title/Abstract] Limits: Humans, 
English, published in the last 10 years10:04:48 0
#11Search #5 AND (serum ferritin)  Limits: Humans, English, published in the last 10 
years10:01:41 291 
#10Search #5 AND ferritin Limits: Humans, English, published in the last 10 years09:59:47 
422
#9Search #5 AND (pre-donation) hemoglobin Limits: Humans, English, published in the 
last 10 years09:56:50 9
#8Search  #5 AND (iron-deficiency anemia)  Limits:  Humans, English, published in the 
last 10 years09:54:13 499
#7Search #5 AND (donation-induced iron depletion) Limits: Humans, English, published 
in the last 10 years09:40:58 1
#6Search  iron deficiency anemia, anemia OR anaemia OR (donation-induced iron 
depletion) OR haemoglobin OR (pre-donation haemoglobin) OR haematocrit OR ferritin 
[MeSH Terms] Limits:Humans, English, published in the last 10 years09:26:02 66023
#5Search (#3) AND#4 Limits: Humans, English, published in the last 10 years09:24:17 
9703
#4Search  (donor deferral) OR (donor risk) OR (donor safety) OR (donation effect) OR 
(well-being) OR hemovigilance,[Title/Abstract] Limits: Humans, English, published in the 
last 10 years09:23:03 460605
#3Search iron deficiency anemia, anemia OR anaemia OR (donation-induced iron depletion) 
OR haemoglobin OR (pre-donation haemoglobin) OR haematocrit OR ferritin Limits: [Title/
Abstract]Limits: Humans, English, published in the last 10 years09:18:50 64290
#2Search iron deficiency anemia, anemia OR anaemia OR (donation-induced iron depletion) 
OR haemoglobin OR (pre-donation haemoglobin) OR haematocrit OR ferritin Limits: Humans, 
English, published in the last 10 years09:17:14 66973
#3Search anaemia OR haemoglobin OR (pre-donation haemoglobin) OR (haematocrit) OR 
ferritin. Limits: Humans, English, published in the last 10 years08:47:0366972
#2Search  donor safety) OR (donor risk) OR (wellbeing) OR hemovigilance[Title/
Abstract] Limits: Humans, English, published in the last 10 years05:24:03460284
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#1Search  ((donor safety) OR (donor risk) OR (wellbeing)[MeSH Terms]) AND anaemia 
OR (iron-deficiency anemia) OR (donation-induced iron depletion) OR (wellbeing)[MeSH 
Terms] Limits:Humans, English, published in the last 10 years Field: MeSH Terms05:21:510
#33Search (#8) AND#3 Limits: Humans, English, published in the last 10 years19:37:23 0
#32Search #8 AND ferritin Limits: Humans, English, published in the last 10 years19:32:44 0
#31Search  #9 AND hematocrit  Limits:  Humans, English, published in the last 10 
years19:29:24 871
#30Search  #8 AND hematocrit  Limits:  Humans, English, published in the last 10 
years19:28:22 0
#29Search  #8 AND (pre-donation haemoglobin)  Limits:  Humans, English, published in 
the last 10 years19:26:59 0
#28Search #8 AND (donation-induced iron depletion) Limits: Humans, English, published 
in the last 10 years19:26:01 0
#27Search #9 AND (donation-induced iron depletion) Limits: Humans, English, published 
in the last 10 years19:24:53 0
#25Search  #9 AND haematocrit  Limits:  Humans, English, published in the last 10 
years19:22:29 871
#22Search  #21 AND (donor risk)  Limits:  Humans, English, published in the last 10 
years19:09:27 15
#21Search #9 AND (iron-deficiency anemia)  Limits: Humans, English, published in the 
last 10 years19:07:56 493
#20Search #9 AND (pre-donation hemoglobin) Limits: Humans, English, published in the 
last 10 years19:06:44 6
#19Search (#8) AND#9 Limits: Humans, English, published in the last 10 years19:05:44 0
#18Search (#8) AND#9 AND (pre-donation hemoglobin) Limits: Humans, English, published 
in the last 10 years19:05:18 0
#11Search #10 NOT (cord blood) NOT (stem cell) NOT transplantation NOT (organ donation) 
NOT (organ transplantation) NOT liver NOT kidney Limits: Humans, English, published in 
the last 10 years18:55:09 7374
#10Search (#9) AND#3 Limits: Humans, English, published in the last 10 years18:54:05 9983
#9Search  (donor risk) OR (donor safety) OR (well-being) OR hemovigilance[Title/
Abstract] Limits: Humans, English, published in the last 10 years18:51:59 460153
#8Search  (donor selection) OR (donor recruitment) OR (donor deferral)[Title/
Abstract] Limits: Humans, English, published in the last 10 years18:51:11 0
#6Search #4 NOT (cord blood) NOT (stem cell) NOT transplantation NOT (organ donation) 
NOT (organ transplantation) NOT liver NOT kidney Limits: Humans, English, published in 
the last 10 years18:45:50 790
#5Search (#2) AND#3 Limits: Humans, English, published in the last 10 years18:42:00 
10030
#4Search (#1) AND#3 Limits: Humans, English, published in the last 10 years18:41:13 1701
#3Search  anemia OR anaemic OR (iron-deficiency anemia) OR haemoglobin OR (pre-
donation haemoglobin) OR (haematocrit) OR ferritin [Title/Abstract]  Limits:  Humans, 
English, published in the last 10 years18:53:24 66638
#2Search donor selection) OR (donor recruitment) OR (donor deferral) OR (donor risk) OR 
(donor safety) OR (well-being) OR hemovigilance[Title/Abstract] Limits: Humans, English, 
published in the last 10 years18:48:40 461848
#1Search  (blood donor) OR (blood donation) OR (donating blood) OR (whole blood 
donation) OR (voluntary blood donor) Limits: Humans, English, published in the last 10 
years18:36:28 22988
Number of citations screened 5632 
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Key search and MeSH words
donor selection, blood donor suitability, donor risk, donor safety, donation effect, 
well-being, hemovigilance, evidence
iron-deficiency anaemia, donation-induced iron depletion, anaemic, haemoglobin, 
pre-donation haemoglobin, haematocrit, ferritin, iron balance, iron status, iron 
reserve, iron supplementation, oral iron supplements, intravenous-iron supplement
Search strategy: PUBMED
#11 Search ((iron deficiency anaemia, anaemia OR anaemia OR (donation-induced iron 
depletion) OR haemoglobin OR (pre-donation haemoglobin) OR haematocrit OR ferritin 
Limits) AND (frequency of donation) 09:11:32 154
#10 Search ((iron deficiency anaemia, anaemia OR anaemia OR (donation-induced iron 
depletion) OR haemoglobin OR (pre-donation haemoglobin) OR haematocrit OR ferritin 
Limits[Title/Abstract]) AND (frequency of donation)[Title/Abstract] 09:10:23 0
#9 Search (#8) AND (frequency of donation) 09:08:53 996
#8 Search  (iron deficiency anaemia, anemia OR anaemia OR (donation-induced iron 
depletion) OR haemoglobin OR (pre-donation haemoglobin) OR haematocrit OR ferritin 
Limits[Title/Abstract]) AND (donor deferral) OR (donor risk) OR (donor safety) OR (donation 
effect) OR (well-being) OR hemovigilance[Title/Abstract] 09:08:00 1623531
#7 Search ((#1) AND (frequency of donation)[Title/Abstract]) AND (donation-induced iron 
deficiency)[Title/Abstract] 09:02:51 0
#6 Search  ((#1) AND (frequency of donation) [Title/Abstract]) AND (donation-induced 
iron-depletion)[Title/Abstract] 09:00:55 0
#5 Select 1 document(s) 08:46:38 1
#4 Search (#1) AND (donation-induced iron deficiency) 08:46:38 1
#3 Search (#2) AND (donation-induced iron deficiency) 08:39:13 0
#2 Search  ((blood donor) OR (blood donation) OR (donating blood) OR (whole blood 
donation) OR (voluntary blood donor)[Title/Abstract]) AND (donor suitability) OR (donor 
deferral) OR (donor risk) OR (donor safety) OR hemovigilance OR (well-being)[Title/
Abstract] 08:37:38 3
#1 Search  ((blood donor) OR (blood donation) OR (donating blood) OR (whole blood 
donation) OR (voluntary blood donor)) AND (donor suitability) OR (donor deferral) OR 
(donor risk) OR (donor safety) 08:33:13 19786
#30 Search  (#3) AND (iron supplement) OR (iron supplementation) OR (oral iron) OR 
(intravenous-iron) [Title/Abstract] Limits: Humans, English, published in the last 10 years 
11:48:44 0
#29 Search  (#4) AND (iron supplement) OR (iron supplementation) OR (oral iron) OR 
(intravenous-iron) [Title/Abstract] Limits: Humans, English, published in the last 10 years 
11:47:38 0
#28 Search  #3 AND (iron supplement) OR (iron supplementation) OR (oral iron) OR 
(intravenous-iron) Limits: Humans, English, published in the last 10 years 14:03:09 3011
#25Search  (iron balance) OR (iron reserve) OR (iron status) OR (iron deficiency) AND 
(frequency of donation) Limits: Humans, English, published in the last 10 years11:27:34 37
#24Search  (iron balance) OR (iron reserve) OR (iron status) OR (iron deficiency) AND 
(frequency of donation)[Title/Abstract] Limits: Humans, English, published in the last 10 
years11:23:30 0
#23Search  #4 AND (iron balance) OR (iron reserve) OR (iron status) OR (iron 
deficiency) Limits: Humans, English, published in the last 10 years11:22:05 7013
#15Search #3 AND (frequency of donation)  Limits: Humans, English, published in the 
last 10 years11:17:50 74
#20Select 1 document(s)11:04:03 1
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#14Search #4 AND (hemoglobin screening)  Limits: Humans, English, published in the 
last 10 years10:09:22 1390
#13Search Blood AND (frequent donor) AND (donor risk) [Title/Abstract] Limits: Humans, 
English, published in the last 10 years10:06:43 0
#12Search Blood AND (frequent donor) AND (donor safety)[Title/Abstract] Limits: Humans, 
English, published in the last 10 years10:04:48 0
#11Search #5 AND (serum ferritin)  Limits: Humans, English, published in the last 10 
years10:01:41 291#10Search #5 AND ferritin Limits: Humans, English, published in the 
last 10 years09:59:47 422
#9Search #5 AND (pre-donation) hemoglobin Limits: Humans, English, published in the 
last 10 years09:56:50 9
#8Search  #5 AND (iron-deficiency anemia)  Limits:  Humans, English, published in the 
last 10 years09:54:13 499
#5Search (#3) AND#4 Limits: Humans, English, published in the last 10 years09:24:17 9703
#4Search  (donor deferral) OR (donor risk) OR (donor safety) OR (donation effect) OR 
(well-being) OR hemovigilance,[Title/Abstract] Limits: Humans, English, published in the 
last 10 years09:23:03 460605
#3Search iron deficiency anemia, anemia OR anaemia OR (donation-induced iron depletion) 
OR haemoglobin OR (pre-donation haemoglobin) OR haematocrit OR ferritin Limits: [Title/
Abstract]Limits: Humans, English, published in the last 10 years09:18:50 64290
Number of citations screened 1150
Total citations screened 6782
Number of papers that address the study question     20, of which 8 excluded
Selected as key references 12
4.6.1 Haemoglobin screening
Key references 
1 Beutler E, West C. Haematolologic differences between African-Americans and whites: 
the roles of iron deficiency and alpha-thalassemia and haemoglobin levels and mean 
corpuscular volume. Blood, 2005, 106:740–745.
2 Mast AE et al. NHLBI Retrovirus Epidemiology Donor Study-II. (2010) Demographic 
correlates of low haemoglobin deferral among prospective whole blood donors. 
Transfusion, 50(8):1794–1802.
3 Beutler E, Waalen J. The definition of anaemia: what is the lower limit of normal of 
the blood haemoglobin concentration? Blood, 2006, 107:1747–1750.
4 Brittenham GM. Editorial. Iron deficiency in whole blood donors. Transfusion, 2011, 
51(3):458–461.
4.6.2 Frequency of donation and iron supplementation
Key references 
1 Boulton F. Evidence-based criteria for the care and selection of blood donors, with 
some comments on the relationship to blood supply and emphasis on the management 
of donation-induced iron depletion. Transfusion Medicine, 2008, 18:13–27.
2 Eder A. Evidence-based selection criteria to protect blood donors. Journal of Clinical 
Apheresis, 2010, 25:331–337.
3 Bianco C et al. Maintaining iron balance in women blood donors of childbearing age; 
summary of a workshop. Transfusion, 2002, 42:798–805.
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4 Røsvik AS et al. The effect of blood donation frequency on iron status. Transfusion 
and Apheresis Science, 2009, 41:165–169.
5 Cable RG et al. NHLBI Retrovirus Epidemiology Donor Study-II. Iron deficiency in blood 
donors: analysis of enrolment data from the REDS-II Donor Iron Status Evaluation 
(RISE) study. Transfusion, 2011, 51(3): 511–522.
6 Alvarez-Ossorio L et al. Low ferritin levels indicate the need for iron supplementation: 
strategy to minimise iron-depletion in regular blood donors. Transfusion Medicine, 
2000, 10(2):107–112.
7 O’Meara A et al. The value of routine serum ferritin measurement in blood donors. 
Transfusion, 2011, 51(10):2183–2138.
8 Milman N, Kirchhoff M. The influence of blood donation on iron stores assessed by 
serum ferritin and haemoglobin in a population survey of 1359 Danish women. Annals 
of Hematology, 1991, 63(1):27–32.
Decision-making process
The Guideline Development Group agreed on the following recommendations 
based on data from the above studies and review articles, their expert knowledge 
and experience from best practice.
4.6.1 Haemoglobin screening
Recommendations 
 In determining the lower limits of haemoglobin for whole blood donation and 
implementing haemoglobin screening, the BTS should consider:
— Normal haemoglobin range among healthy individuals in the local 
population 
— A haemoglobin level of not less than 12.0 g/dl for females and not 
less than 13.0 g/dl for males as the threshold
— Selection of a validated haemoglobin screening technique that is subject 
to quality control, the feasibility of its implementation, the availability 
of equipment and the training and skills of staff 
— Only sterile disposable lancets should be used for blood sampling
— Donors whose haemoglobin levels are below the nationally-defined 
threshold should be deferred, counselled and referred for medical 
assessment
4.6.2 Frequency of donation and iron supplementation
Recommendations 
 The minimum interval between donations of whole blood should be 12 weeks 
for males and 16 weeks for females 
 The minimum interval between donations of platelets should be 4 weeks 
 The minimum interval between donations of plasma should be 2 weeks 
 The minimum interval before an apheresis platelet or plasma donation should 
be 4 weeks following a whole blood donation, an apheresis red cell donation 
or a failed return of red cells during apheresis
 In determining the frequency of donation and whether iron supplementation 
is given, the BTS should consider:
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— The need for longer donation intervals for young donors and female 
donors of childbearing age 
— Assessing the feasibility and affordability of providing iron supplementation 
to donors susceptible to donation-induced iron deficiency, especially 
women and adolescents, and repeat and regular donors
— Exploring access to facilities for monitoring serum ferritin concentration 
and the feasibility of developing and implementing individual donation 
intervals
4.7 FLUID INTAKE AND FOOD 
Question
What should be the requirements for food and/or fluid intake prior to blood 
donation?
Population Intervention outcome
Prospective blood 
donors
 Acceptance or 
deferral for blood 
donation
 Provision of fluids 
and/or food to 
blood donors
 Minimize adverse events related to 
blood donation 
Key search and MeSH words
(blood donor) OR (blood donation) OR (donating blood) OR (whole blood donation) 
AND (adverse reaction)
water intake, fluid, fast, fasting, Ramadan, food, vasovagal reaction
Search strategy: PUBMED
#45 Search (voluntary blood donation) AND ramadan[Title/Abstract] Limits: Humans, 
English, Publication Date from 1999/01/01 to 2011/05/15 Field: Title/Abstract 
12:32:10 0 
#44 Search (whole blood donation) AND Ramadan [Title/Abstract] Limits: Humans, English, 
Publication Date from 1999/01/01 to 2011/05/15 Field: Title/Abstract 12:30:37 0 
#43 Search (whole blood donation) AND fasting[Title/Abstract] Limits: Humans, English, 
Publication Date from 1999/01/01 to 2011/05/15 Field: Title/Abstract 12:25:16 1
#41 Search (voluntary blood donation) AND fasting[Title/Abstract] Limits: Humans, English, 
Publication Date from 1999/01/01 to 2011/05/15 Field: Title/Abstract 12:16:18 2 
#40 Search (blood donation) AND fasting[Title/Abstract] Limits: Humans, English, 
Publication Date from 1999/01/01 to 2011/05/15 Field: Title/Abstract 12:12:50 17
#39 Search (blood donation) AND fast Limits: Humans, English, Publication Date from 
1999/01/01 to 2011/05/15 Field: Title/Abstract 12:11:33 8 
#38 Search (blood donation) AND (food) Limits: Humans, English, Publication Date from 
1999/01/01 to 2011/05/15 Field: Title/Abstract 12:10:16 35
#37 Search (blood donation) AND (adverse reaction)[Title/Abstract] Limits: Humans, English, 
Publication Date from 1999/01/01 to 2011/05/15 Field: Title/Abstract 12:09:22 0 
#35 Search (blood donation) AND fluid[Title/Abstract] Limits: Humans, English, Publication 
Date from 1999/01/01 to 2011/05/15 Field: Title/Abstract 11:53:36 27
#34 Search (blood donation) AND water[Title/Abstract] Limits: Humans, English, Publication 
Date from 1999/01/01 to 2011/05/15 Field: Title/Abstract 11:43:16 14 
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#31 Search ((blood donation)[Title/Abstract]) AND water OR fluid [Title/Abstract] Limits: 
Humans, English, Publication Date from 1999/01/01 to 2011/05/15 Field: Title/Abstract 
11:15:05 63141
#28 Search ((blood donor)[Title/Abstract]) AND (adverse reaction)[Title/Abstract] Limits: 
Humans, English, Publication Date from 1999/01/01 to 2011/05/15 Field: Title/
Abstract 11:10:28 0 
#27 Search ((blood donor) OR (blood donation) OR (donating blood) OR (whole blood 
donation)[Title/Abstract]) AND (adverse reaction) OR (adverse event) [Title/Abstract] 
Limits: Humans, English, Publication Date from 1999/01/01 to 2011/05/15 Field: 
Title/Abstract 11:09:32 0
Number of citations screened 401
Number of papers that address the study question 3
Key references
1 Hanson SA, France CR. Predonation water ingestion attenuates negative reactions to 
blood donation. Transfusion, 2004, 44(6):924–928.
2 Newman B et al. The effect of a 473-mL (16-oz) water drink on vasovagal donor 
reaction rates in high-school students. Transfusion, 2007, 47:1524–1533.
3 Wieling W et al. Physiologic strategies to prevent fainting responses during or after 
whole blood donation. Transfusion, 2011, 51(12):2727–2738.
Decision-making process
The Guideline Development Group agreed on the following recommendation 
based on data from the above studies and their experience from best practice. 
 Recommendation
 The BTS should consider providing 500 ml drinking water to donors before 
donation to minimize the risk of vasovagal reactions
4.8 GENDER
4.8.1 Pregnancy, lactation and menstruation
Question
What should be the acceptance and deferral criteria for blood donation for females?
 During menstruation
 During and after pregnancy (including miscarriage, abortion)
 During lactation
Population Intervention outcome
Prospective female 
blood donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse events related 
to blood donation, in particular 
donation-induced iron deficiency 
(DIID) 
Key search and MeSH words
(blood donor) OR (blood donation) OR (donating blood) OR (whole blood donation) 
AND 
136
iron-deficiency anaemia, female donors, donor deferral, pregnancy, abortion, 
miscarriage, lactation or breast-feeding
Search strategy: PUBMED
#14Search  (blood donor) OR (blood donation) OR (donating blood) OR (whole blood 
donation) AND (donor deferral) AND breast-feeding[Title/Abstract] Limits: Humans, English, 
published in the last 10 years17:26:19 1
#13Search  (blood donor) OR (blood donation) OR (donating blood) OR (whole blood 
donation) AND (breast feeding) [Title/Abstract]  Limits:  Humans, English, published in 
the last 10 years17:25:34 0
#12Search  (blood donor) OR (blood donation) OR (donating blood) OR (whole blood 
donation) AND (donor deferral) AND menstruation [Title/Abstract] Limits: Humans, English, 
published in the last 10 years17:24:46 0
#11Search  (blood donor) OR (blood donation) OR (donating blood) OR (whole blood 
donation) AND (donor safety) AND menstruation [Title/Abstract] Limits: Humans, English, 
published in the last 10 years17:23:08 0
#9Search (blood donor) OR (blood donation) OR (donating blood) OR (whole blood donation) 
AND (donor deferral) AND lactation [Title/Abstract]  Limits: Humans, English, published 
in the last 10 years17:21:52 1
#8Search (blood donor) OR (blood donation) OR (donating blood) OR (whole blood donation) 
AND (donor safety) AND lactation [Title/Abstract] Limits: Humans, English, published in 
the last 10 years17:21:23 0 
#7Search (blood donor) OR (blood donation) OR (donating blood) OR (whole blood donation) 
AND (donor safety) AND abortion [Title/Abstract] Limits: Humans, English, published in 
the last 10 years17:20:42 0
#6Search (blood donor) OR (blood donation) OR (donating blood) OR (whole blood donation) 
AND (donor deferral) AND abortion [Title/Abstract] Limits: Humans, English, published in 
the last 10 years17:19:51 0
#5Search  (blood donor) OR (blood donation) OR (donating blood) OR (whole blood 
donation) AND abortion [Title/Abstract]  Limits: Humans, English, published in the last 
10 years17:17:28 22
#4Search (blood donor) OR (blood donation) OR (donating blood) OR (whole blood donation) 
AND (donor deferral) AND pregnancy[Title/Abstract] Limits: Humans, English, published 
in the last 10 years17:15:33 4 
#3Search (blood donor) OR (blood donation) OR (donating blood) OR (whole blood donation) 
AND (donor safety) AND pregnancy[Title/Abstract] Limits: Humans, English, published in 
the last 10 years17:14:08 7
#2Search (blood donor) OR (blood donation) OR (donating blood) OR (whole blood donation) 
AND (adverse reaction) AND pregnancy[Title/Abstract] Limits: Humans, English, published 
in the last 10 years17:12:41 5
#1Search  (blood donor) OR (blood donation) OR (donating blood) OR (whole blood 
donation) AND pregnancy[Title/Abstract] Limits: Humans, English, published in the last 
10 years17:11:43 299
Number of citations screened 339
Number of papers that address the study questions 3
Key references
1 WHO/UNICEF/UNU: Iron deficiency anaemia: assessment, prevention and control. A 
guide for programme managers. Geneva, World Health Organization, 2001. 
2 WHO/CDC. Worldwide prevalence of anaemia 1993–2005. WHO Global Database on 
Anaemia. Geneva, World Health Organization, 2008.
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3 Newman B. Iron depletion by whole-blood donation harms menstruating females: the 
current whole-blood-collection paradigm needs to be changed. Transfusion, 2006, 
46(10):1667–1681.
Decision-making process
The Guideline Development Group agreed on the following recommendations 
based on epidemiological studies of iron deficiency, their medical knowledge 
and experience from best practice. 
Recommendations
 The BTS should encourage donors to practise applied muscle tension during 
blood donation
Accept
 Female donors during menstruation, provided that they feel well and meet 
the minimum haemoglobin level for blood donation
Defer
 Female donors during pregnancy and up to 6 months after delivery or termination 
of pregnancy
 Female donors during lactation
4.8.2 Reducing the risk of transfusion-associated acute lung 
injury (TRALI)
Question
What donor selection criteria should be applied to reduce the risk of transfusion-
associated acute lung injury in recipients of blood transfusion?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Reduce the risk of transfusion-
associated acute lung injury in 
recipients of blood transfusion
 Provide a safe and sufficient supply 
of blood and blood components
Key search and MeSH words
(blood donor) OR (blood donation) OR (donating blood) OR (whole blood donation) 
AND 
transfusion-associated acute lung injury (TRALI), Serious Hazards of 
Transfusion (SHOT) donor deferral, donor safety, recipient safety, hemovigilance, 
evidence-based practice/trends, gender
Search strategy: PUBMED
#26 Search  (blood donor) OR (blood donation) OR (donating blood) OR (whole blood 
donation) AND (Serious Hazards of Transfusion)  Limits: Humans, English, published in 
the last 10 years 19:04:40 12
#23Search (transfusion-associated acute lung injury) AND hemovigilance Limits: Humans, 
English, published in the last 10 years18:58:56 8
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#25Search  “Stainsby D”[Author]  Limits:  Humans, English, published in the last 10 
years18:58:03 18
#22Search (blood donor deferral) AND (recipient safety) Limits: Humans, English, published 
in the last 10 years18:54:02 8
#21Search  #10 AND (recipient safety)  Limits:  Humans, English, published in the last 
10 years18:53:04 0
#20Search #10 AND (transfusion-associated acute lung injury) Limits: Humans, English, 
published in the last 10 years18:51:21 0
#19Search  (plasma transfusion) AND (transfusion-associated acute lung injury) Limits: 
Humans, English, published in the last 10 years18:48:17 21
#17Search  “Eder A”[Author]  Limits:  Humans, English, published in the last 10 
years18:43:35 18
#16Select 1 document(s)18:39:57 1
#13Search  (blood donor) OR (blood donation) OR (donating blood) OR (whole blood 
donation) AND (donor deferral) AND (recipient safety) Limits: Humans, English, published 
in the last 10 years18:35:09 8
#10Search (blood donor deferral) AND gender Limits: Humans, English, published in the 
last 10 years18:29:53 10
#9Search (transfusion-associated acute lung injury) AND gender Limits: Humans, English, 
published in the last 10 years18:28:38 1
#8Search (transfusion-associated acute lung injury) AND (recipient safety) Limits: Humans, 
English, published in the last 10 years18:26:13 0
#7Search #5 AND (recipient safety) Limits: Humans, English, published in the last 10 
years18:24:29 0
#6Search #1 AND (recipient safety) Limits: Humans, English, published in the last 10 
years18:23:37 0
#5Search (transfusion-associated acute lung injury) Limits: Humans, English, published 
in the last 10 years18:21:41 61
#4Search  (transfusion-associated acute lung injury)[Title/Abstract]  Limits:  Humans, 
English, published in the last 10 years18:07:24 0
#3Search  (blood donor) AND (transfusion-associated acute lung injury)[Title/
Abstract] Limits: Humans, English, published in the last 10 years18:06:21 0
#2Search (blood donor) OR (blood donation) OR (donating blood) OR (whole blood donation) 
AND (transfusion-associated acute lung injury)[Title/Abstract]  Limits: Humans, English, 
published in the last 10 years18:05:06 0 
#1Search (blood donor) OR (blood donation) OR (donating blood) OR (whole blood donation) 
AND (transfusion-associated acute lung injury) Limits: Humans, English, published in the 
last 10 years18:04:15 31
Number of citations screened 197
Number of papers that address the study question 3
Key references
1 Eder AF et al. Transfusion-related acute lung injury surveillance (2003–2005) and the 
potential impact of the selective use of plasma from male donors in the American 
Red Cross. Transfusion, 2007, 47(4):599–607.
2 Chapman C et al. Ten years of hemovigilance reports of transfusion-related acute 
lung injury in the United Kingdom and the impact of preferential use of male donor 
plasma. Transfusion, 2009, 49(3):440–452.
3 Reil A et al. Specificities of leucocyte alloantibodies in transfusion-related acute lung 
injury and results of leucocyte antibody screening of blood donors. Vox Sanguinis, 
2008, 95(4):313–317.
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Decision-making process
The Guideline Development Group agreed on the following recommendation based 
on data from the above studies considered in the context of blood transfusion 
services in developing countries.
Recommendations
 The BTS should consider:
— Maximizing the collection and production of plasma and platelet 
concentrates from male donors 
— Screening multiparous female donors for HLA and/or HNA antibodies
5 Donor medical history I: 
 Non-communicable diseases 
5.1 HAEMATOLOGICAL DISORDERS
5.1.1 Anaemia, including haematinic (iron, B12 and folate) 
deficiency
Question
What selection criteria should be applied to prospective blood donors with a 
current or past history of anaemia?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse events related to 
blood donation 
 Avoid unnecessary deferral of 
suitable blood donors
Key search and MeSH words
blood donor suitability, donor risk, donor safety, donor deferral
pre-donation haemoglobin, haemoglobin screening, haematocrit, ferritin, iron-
deficiency anaemia, megaloblastic anaemia OR macrocytic anaemia OR pernicious 
anaemia OR hypochromic anaemia, B12 deficiency, folate deficiency
Search strategy: PUBMED
#30Search (#5) AND#8 Limits: Humans, English, published in the last 10 years08:59:33 12
#25Search (#5) AND#6 Limits: Humans, English, published in the last 10 years08:46:06 69 
#22Search (#5) AND#9 Limits: Humans, English, published in the last 10 years08:19:30 11
#19Search (#6) AND#17 Limits: Humans, English, published in the last 10 years08:11:52 
224
#18Search (#5) AND#17 Limits: Humans, English, published in the last 10 years08:09:58 3
#17Search B12 deficiency OR folate deficiency Limits: Humans, English, published in the 
last 10 years08:09:00 2442
#14Search (#6) AND#8 Limits: Humans, English, published in the last 10 years08:02:19 
1769
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#11Search (#10) AND iron-deficiency anemia Limits: Humans, English, published in the 
last 10 years07:55:38 1420
#10Search (#6) AND#9 Limits: Humans, English, published in the last 10 years07:52:43 
1558
#9Search (#7) AND#8 Limits: Humans, English, published in the last 10 years07:48:14 
4736
#8Search  iron-deficiency OR megaloblastic OR macrocytic OR pernicious OR 
hypochromic Limits: Humans, English, published in the last 10 years07:47:48 5443
#7Search  anaemia OR anemia  Limits:  Humans, English, published in the last 10 
years07:46:28 36056
#6Search  pre-donation haemoglobin OR haemoglobin screening OR haematocrit OR 
ferritin Limits: Humans, English, published in the last 10 years07:44:25 19317
#5Search (#3) NOT#4 Limits: Humans, English, published in the last 10 years07:43:02 
1635
#4Search  cord blood OR stem cell OR transplantation OR organ donation OR organ 
transplantation OR organ transplant OR liver OR kidney OR renal transplant OR (twin-twin 
transfusion) OR allogeneic transplant Limits: Humans, English, published in the last 10 
years07:42:07 374406
#3Search (#2) AND#1 Limits: Humans, English, published in the last 10 years07:37:25 
4857
#2Search blood Limits: Humans, English, published in the last 10 years07:37:00 648600
#1Search  (donor suitability) OR (donor deferral) OR (donor risk) OR (donor 
safety) Limits: Humans, English, published in the last 10 years07:36:24 9964
Number of citations screened  95
Number of papers that address the study question 0
Decision-making process
The Guideline Development Group agreed on the following recommendations 
based on their medical knowledge and experience from best practice. 
Recommendations
Accept
 Individuals who: 
— Have a past history of iron deficiency anaemia, with a known cause 
that is not a contraindication to donation, and who have completed 
treatment and are fully recovered
— Have a past history of B12 or folate deficiency, are fully recovered and 
are taking maintenance treatment with B12 or folic acid 
Defer
 Individuals who:
— Do not meet the minimum haemoglobin level for blood donation
—  Are under investigation or on treatment for anaemia 
— Defer permanently
— Individuals who have chronic anaemia of unknown cause or associated 
with systemic disease: e.g. renal failure, rheumatoid disease
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5.1.2 Haemoglobinopathies
Question
What selection criteria should be applied to prospective blood donors with 
inherited red cell disorders such as sickle cell disease, sickle trait, thalassaemia 
and thalassaemia trait?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse events related to 
blood donation 
 Avoid unnecessary deferral of 
suitable blood donors 
 Minimize risk of adverse reactions in 
recipients of blood transfusion
Key search and MeSH words
anaemia haemolytic congenital OR sickle cell disease OR sickle cell trait OR 
haemoglobin C disease OR thalassaemia
donor suitability OR donor deferral OR recipient risk or recipient safety 
Search strategy: PUBMED
#54Search (#53) AND#37 Limits: Humans, English, published in the last 10 years16:29:45 
21
#53Search  donor suitability OR donor deferral OR recipient risk or recipient 
safety Limits: Humans, English, published in the last 10 years16:28:59 3848
#38Search (#3) AND#37 Limits: Humans, English, published in the last 10 years16:03:38 
66
#44Search (#5) AND#37 Limits: Humans, English, published in the last 10 years15:50:03 
16
#37Search  sickle cell disease OR sickle cell trait OR haemoglobin C disease OR 
thalassaemia Limits: Humans, English, published in the last 10 years14:34:00 9248
#36Search  (#3) AND hemolytic congenital anemia  Limits: Humans, English, published 
in the last 10 years14:32:10 0
#35Search (#3) AND#30 Limits: Humans, English, published in the last 10 years14:28:28 0
#34Search (#5) AND#30 Limits: Humans, English, published in the last 10 years14:22:30 0
#30Search  (#7) AND haemolytic congenital  Limits: Humans, English, published in the 
last 10 years13:55:06 64
#7Search  anaemia OR anemia  Limits:  Humans, English, published in the last 10 
years07:46:28 36056
#6Search  pre-donation haemoglobin OR haemoglobin screening OR haematocrit OR 
ferritin Limits: Humans, English, published in the last 10 years07:44:25 19317
#5Search (#3) NOT#4 Limits: Humans, English, published in the last 10 years07:43:02 
1635
#4Search  cord blood OR stem cell OR transplantation OR organ donation OR organ 
transplantation OR organ transplant OR liver OR kidney OR renal transplant OR (twin-twin 
transfusion) OR allogeneic transplant Limits: Humans, English, published in the last 10 
years07:42:07 374406
142
#3Search (#2) AND#1 Limits: Humans, English, published in the last 10 years07:37:25 
4857
#2Search blood Limits: Humans, English, published in the last 10 years07:37:00 648600
#1Search  (donor suitability) OR (donor deferral) OR (donor risk) OR (donor 
safety) Limits: Humans, English, published in the last 10 years07:36:24 9964
Number of citations screened  37
Relevant papers selected 2
Key references
1 Stroncek DF et al. Sickle Hb polymerization in RBC components from donors with sickle 
trait prevents effective WBC reduction by filtration. Transfusion, 2002, 42(11):1466–
1472.
2 Ould Amar AK. Red blood cells from donors with sickle cell trait: a safety issue for 
transfusion? Transfusion Medicine, 2006, 16(4):248–253.
Decision-making process
The Guideline Development Group agreed on the following recommendations 
based on data from the above studies, their medical knowledge and experience 
from best practice. 
Recommendations
Accept
 Individuals with: 
— Thalassaemia traits, provided they are well and meet the minimum 
haemoglobin level for blood donation 
— Sickle cell trait: accept for whole blood donation provided they meet 
the minimum haemoglobin level for blood donation; blood donated by 
sickle cell trait individuals is, however, not suitable for leucodepletion, 
intrauterine transfusion, neonatal exchange transfusion or for patients 
with sickle cell disease 
Defer permanently 
 Individuals with:
— Thalassaemia major or sickle cell disease
— Sickle cell trait for blood donation by apheresis procedure or for whole 
blood donation if the blood is to be leucofiltered
5.1.3 Enzymopathies and inherited red cell membrane 
defects
Question
What selection criteria should be applied to prospective blood donors with 
inherited red cell enzymopathies and membrane defects such as G-6-PD deficiency, 
hereditary spherocytosis?
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Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse effects related to 
blood donation 
 Avoid unnecessary deferral of 
suitable blood donors 
 Minimize risk of adverse reactions in 
recipients of blood transfusion
Key search and MeSH words
anaemia, glucose phosphate dehydrogenase deficiency (G-6-PD) OR favism OR 
pyruvate kinase deficiency OR spherocytosis hereditary
donor suitability OR donor deferral OR recipient risk or recipient safety 
Search strategy: PUBMED
#32Search (pyruvate kinase deficiency OR (PK) deficiency[Title/Abstract]) AND#2309:01:19 
0
#30Search (#21) AND donor suitability OR donor risk08:58:07 17315
#29Search  (donor suitability OR donor risk) AND pyruvate kinase deficiency OR (PK) 
deficiency)08:57:29 4390
#28Search (pyruvate kinase deficiency OR (PK) deficiency) AND#2308:54:29 0
#26Search (pyruvate kinase deficiency) AND#23 Limits: Humans, English, published in 
the last 10 years08:49:32 0
#25Search  (favism OR pyruvate kinase deficiency OR hereditary spherocytosis) 
AND#23 Limits: Humans, English, published in the last 10 years08:48:48 0
#24Search (#5) AND#23 Limits: Humans, English, published in the last 10 years07:36:45 0
#23Search (#21) AND#22 Limits: Humans, English, published in the last 10 years07:35:12 
1275
#22Search recipient risk OR recipient safety07:34:49 6626
#21Search blood Limits: Humans, English, published in the last 10 years07:34:15 648828
#20Search (#7) AND recipient risk OR recipient safety Limits: Humans, English, published 
in the last 10 years07:33:23 488
#19Search (#5) AND recipient risk OR recipient safety Limits: Humans, English, published 
in the last 10 years07:32:41 488
#15Search  (glucose phosphate dehydrogenase deficiency OR (G-6-PD) OR favism OR 
pyruvate kinase deficiency OR hereditary spherocytosis[Title/Abstract]) AND donor 
suitability OR donor deferral[Title/Abstract]  Limits:  Humans, English, published in the 
last 10 years06:57:55 50
#14Search (donor suitability OR donor deferral) AND glucose phosphate dehydrogenase 
deficiency OR (G-6-PD) OR favism OR pyruvate kinase deficiency OR hereditary 
spherocytosis Limits:Humans, English, published in the last 10 years06:38:23 524
#13Search (#5) AND donor suitability Limits: Humans, English, published in the last 10 
years06:37:25 0
#12Search (#10) AND#5 Limits: Humans, English, published in the last 10 years06:36:21 0
#11Search (#10) AND#7 Limits: Humans, English, published in the last 10 years06:35:54 0
#10Search donor suitability OR donor deferral Limits: Humans, English, published in the 
last 10 years06:35:09 322
#9Search (#1) AND#5 Limits: Humans, English, published in the last 10 years06:34:10 0
#8Search (#1) AND#7 Limits: Humans, English, published in the last 10 years06:33:27 0
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#7Search (#6) AND#5 Limits: Humans, English, published in the last 10 years06:32:17 817
#6Search  anaemia OR anemia  Limits:  Humans, English, published in the last 10 
years06:31:55 36064
#5Search glucose phosphate dehydrogenase deficiency OR (G-6-PD) OR favism OR pyruvate 
kinase deficiency OR hereditary spherocytosis06:30:40 8023
#1Search  donor suitability OR donor deferral OR recipient risk or recipient 
safety Limits: Humans, English, published in the last 10 years06:25:44 3849
Number of citations screened  538
Relevant papers selected 1
Background paper
1 Beutler E. G6PD deficiency. Blood, 1994, 84:3613–3636.
Decision-making process
The Guideline Development Group agreed on the following recommendations 
based on data from the background paper above, their medical knowledge and 
experience from best practice. 
Recommendations
 Policies for the assessment of prospective donors should be developed by 
BTS in regions where there is a high incidence of enzymopathies and inherited 
membrane defects.
Accept
 Individuals with G6PD deficiency or other inherited red cell membrane defects, 
without a history of haemolysis; however, their blood is not suitable for 
intrauterine transfusion, neonatal exchange transfusion or for patients with 
G6PD deficiency
Defer permanently
 Individuals with G6PD deficiency or inherited red cell membrane defects, with 
a history of haemolysis
5.1.4 Thrombocytopenia
Question
What selection criteria should be applied to prospective blood donors with current 
or past thrombocytopenia?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse effects related to 
blood donation 
 Avoid unnecessary deferral of 
suitable blood donors 
 Minimize risk of adverse reactions in 
recipients of blood transfusion
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Key search and MeSH words
bruising OR haematoma
blood platelet disorders OR haemorrhagic disorders
thrombocytopenia OR purpura idiopathic thrombocytopenic OR splenectomy
Search strategy: PUBMED
#29Search (#6) AND#28 Limits: Humans, English, published in the last 10 years15:16:09 9
#28Search bruising OR haematoma Limits: Humans, English, published in the last 10 
years15:15:02 11499
#27Search ((blood donor) AND recipient safety) AND thrombocytopenia Limits: Humans, 
English, published in the last 10 years14:02:27 4
#26Search ((blood donor ) AND donor safety ) AND thrombocytopenia Limits: Humans, 
English, published in the last 10 years13:38:05 17
#25Search (#7) AND#23 Limits: Humans, English, published in the last 10 years13:35:40 0
#24Search (#6) AND#23 Limits: Humans, English, published in the last 10 years13:35:05 0
#23Search  thrombocytopenia AND splenectomy  Limits: Humans, English, published in 
the last 10 years13:34:02 697
#22Search (#7) AND#16 Limits: Humans, English, published in the last 10 years13:30:58 12
#17Search (#6) AND#16 Limits: Humans, English, published in the last 10 years12:48:27 34
#16Search  platelet disorders OR haemorrhagic disorders  Limits:  Humans, English, 
published in the last 10 years12:47:37 32958
#13Search (#7) AND#8 Limits: Humans, English, published in the last 10 years12:35:13 14
#12Search (#6) AND#8 Limits: Humans, English, published in the last 10 years12:33:36 19
#9Search (#5) AND#8 Limits: Humans, English, published in the last 10 years12:16:14 29
#8Search  Thrombocytopenia OR purpura idiopathic thrombocytopenia  Limits: Humans, 
English, published in the last 10 years12:12:49 14114
#7Search (#1) AND#4 Limits: Humans, English, published in the last 10 years12:03:39 
1276
#6Search (#1) AND#3 Limits: Humans, English, published in the last 10 years12:03:11 
1217
#5Search (#1) AND#2 Limits: Humans, English, published in the last 10 years12:02:39 
2334
#4Search  recipient risk OR recipient safety  Limits: Humans, English, published in the 
last 10 years12:01:42 3553
#3Search  donor suitability OR donor safety  Limits: Humans, English, published in the 
last 10 years12:01:18 2068 
#2Search  donor suitability OR donor safety OR recipient risk OR recipient 
safety Limits: Humans, English, published in the last 10 years12:00:52 5319
#1Search blood Limits: Humans, English, published in the last 10 years12:00:10 649489 
Number of citations screened  105
Relevant paper selected 1
Key reference
1 Guidelines for the blood transfusion services in the United Kingdom: donor selection 
guidelines, 7th edition. London, UK Blood Transfusion & Tissue Transplantation Services, 
2005
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Decision-making process
The Guideline Development Group agreed on the following recommendations 
based on the above reference and on their medical knowledge and experience 
from best practice. 
Recommendations
Accept
 Individuals with a past history of acute autoimmune thrombocytopenia more 
than 5 years previously, provided they are well and no longer require treatment, 
other than prophylactic antibiotics following splenectomy
Defer permanently
 Individuals with thrombocytopenia of unknown cause or associated with long-
term haematological or systemic disease 
5.1.7 Coagulation disorders, including haemophilia A and B
Question
What selection criteria should be applied to prospective blood donors with 
inherited or acquired coagulation disorders, including familial carriers?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse effects related to 
blood donation 
 Avoid unnecessary deferral of 
suitable blood donors 
 Minimize risk of adverse reactions in 
recipients of blood transfusion
Key search and MeSH words
bruising OR haematoma
blood coagulation disorders OR haemorrhagic disorders OR haemostatic disorders 
OR haemophilia
Search strategy: PUBMED
#29Search (#16) AND#2817:56:02 2
#28Search bruising OR haematoma17:55:13 46667
#27Search ((voluntary) AND#21) NOT#2317:53:02 11
#26Search (#21) NOT#2317:50:27 82
#23Search variant Creutzfeldt-Jakob disease OR Variant CJD OR Hepatitis C virus17:49:47 
39510
#21Search (blood donation) AND haemophilia[Title/Abstract]17:45:39 99
#20Search (blood donation) AND haemorrhagic disorders [Title/Abstract]17:41:36 3
#19Search (blood donation) AND coagulation disorders[Title/Abstract]17:39:34 17
#18Search (blood donation) AND coagulation disorders17:38:34 906
#17Search (#16) NOT#1117:37:26 222
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#16Search (blood donation) AND#417:36:53 447
#15Search (#3) AND haemophilia17:36:00 42
#14Search (#13) NOT#1117:23:52 37
#13Search (#3) AND haemostatic disorder17:22:19 81
#12Search (#10) NOT#1117:20:49 26
#11Search cord blood OR autologous transplant OR hepatic OR liver OR stem cell OR 
cancer OR myeloma OR Creutzfeldt-Jakob disease OR vCJD  Limits:  Humans, English, 
published in the last 10 years17:18:06 861926
#10Search (#3) AND haemorrhagic disorders Limits: Humans, English, published in the 
last 10 years17:14:58 98
#9Search (#6) NOT#8 Limits: Humans, English, published in the last 10 years17:06:49 60
#8Search liver OR kidney transplant OR kidney graft OR vCJD Limits: Humans, English, 
published in the last 10 years16:56:29 148228
#6Search  (#3) AND blood coagulation disorders Limits: Humans, English, published in 
the last 10 years16:53:12 81
#7Search (#3) AND blood coagulation disorders[Title/Abstract] Limits: Humans, English, 
published in the last 10 years16:52:38 0
#5Search (#3) AND#4 Limits: Humans, English, published in the last 10 years16:50:17 158
#4Search blood coagulation disorders OR haemorrhagic disorders OR haemostatic disorders 
OR haemophilia Limits: Humans, English, published in the last 10 years16:49:51 34396
#3Search (#1) AND#2 Limits: Humans, English, published in the last 10 years16:48:28 
6583
#2Search donor safety OR donor suitability OR donor risk OR donor well-being Limits: Humans, 
English, published in the last 10 years16:48:02 14482
#1Search blood Limits: Humans, English, published in the last 10 years16:46:44 649489
Number of citations screened  104
Number of papers that address the study question 0
Decision-making process
In the absence of relevant published evidence, the Guideline Development Group 
agreed on the following recommendations based on their medical knowledge and 
experience from best practice. 
Recommendations
Accept
 Individuals with carrier states for inherited coagulation disorders including 
haemophilia A or B, provided they have normal or near normal coagulation 
factor levels, do not have a history of abnormal bleeding and have not received 
treatment with blood products
Defer permanently
 Individuals with coagulation factor deficiencies, whether inherited or acquired
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5.2 CARDIOVASCULAR DISEASES
5.2.1 Cardiovascular disease
Question
What selection criteria should be applied to prospective blood donors with 
cardiovascular diseases including hypertension?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse effects related to 
blood donation 
 Avoid unnecessary deferral of 
suitable blood donors 
 Minimize risk of adverse reactions in 
recipients of blood
Key search and MeSH words
cardiovascular diseases OR cardiovascular abnormalities OR heart diseases OR 
myocardial ischaemia 
symptomatic ischaemic heart disease OR myocardial infarction OR stenosis OR 
cardiomyopathy OR arterial thrombosis OR angioplasty OR symptomatic peripheral 
vascular disease OR cardiac arrhythmia
Search strategy: PUBMED
#23 Search (#19) AND#12 Limits: Humans, English, published in the last 10 years 
09:51:10 4 
#22 Search (#19) AND#10 Limits: Humans, English, published in the last 10 years 
09:49:06 20 
#21 Search (#19) AND#8 Limits: Humans, English, published in the last 10 years 
09:47:57 3 
#20 Search (#19) AND#4 Limits: Humans, English, published in the last 10 years 
09:47:15 0 
#19 Search (#1) AND#18 Limits: Humans, English, published in the last 10 years 
09:46:15 667 
#18 Search recipient risk OR recipient safety OR recipient well-being[Title/Abstract] Limits: 
Humans, English, published in the last 10 years 09:45:31 3554 
#17 Select 3 document(s) 09:32:03 3 
#16 Search (#3) AND cardiac arrhythmia Limits: Humans, English, published in the last 
10 years 09:30:01 5 
#15 Search ((#3) ) AND “symptomatic vascular disease” Limits: Humans, English, 
published in the last 10 years 09:29:00 0 
#14 Search (#3) AND angioplasty Limits: Humans, English, published in the last 10 
years 09:27:00 4 
#13 Search (#3) AND#12 Limits: Humans, English, published in the last 10 years 
09:25:18 9 
#12 Search angioplasty OR “symptomatic peripheral vascular disease” OR cardiac 
arrhythmia Limits: Humans, English, published in the last 10 years 09:24:36 62845 
#9 Search (#3) AND#8 Limits: Humans, English, published in the last 10 years 09:23:14 18 
#11 Search (#3) AND#10 Limits: Humans, English, published in the last 10 years 
09:20:08 44 
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#10 Search stenosis OR cardiomyopathy OR arterial thrombosis Limits: Humans, English, 
published in the last 10 years 09:16:38 64322 
#8 Search “symptomatic ischaemic heart disease” OR myocardial infarction Limits: 
Humans, English, published in the last 10 years 09:11:28 45775 
#5 Search (#3) AND#4 Limits: Humans, English, published in the last 10 years 08:36:24 0 
#4 Search symptomatic AND ischaemic heart disease [Title/Abstract] Limits: Humans, 
English, published in the last 10 years 08:29:44 37 
#3 Search (#1) AND#2 Limits: Humans, English, published in the last 10 years 08:25:45 
3066
#2 Search donor safety OR donor suitability OR donor risk OR donor well-being[Title/
Abstract] Limits: Humans, English, published in the last 10 years 08:25:15 9936 
#1 Search blood[Title/Abstract] Limits: Humans, English, published in the last 10 years 
08:24:22 274126
#13Search (#12) AND#8 Limits: Humans, English, published in the last 10 years17:50:23 
248#23Search (#12) AND#8 NOT#21 Limits: Humans, English, published in the last 10 
years17:02:13 0
#22Search  ((#11) AND#9) NOT#21 Limits: Humans, English, published in the last 10 
years16:58:32 1442
#21Search kidney OR renal OR transplant OR nephrectomy OR liver OR Twin-twin transfusion 
[Title/Abstract] Limits: Humans, English, published in the last 10 years16:52:28 360618
#20Select 1 document(s)16:32:32 1
#18Search  (#12) AND myocardial ischaemia[Title/Abstract]  Limits:  Humans, English, 
published in the last 10 years16:20:11 0
#17Search (#12) AND heart diseases[Title/Abstract] Limits: Humans, English, published 
in the last 10 years16:18:28 0
#16Search (#12) AND heart disease[Title/Abstract] Limits: Humans, English, published 
in the last 10 years16:15:38 22
#15Search  (#12) AND cardiovascular abnormalities[Title/Abstract]  Limits:  Humans, 
English, published in the last 10 years16:12:48 0
#14Search ((#11) AND#9) AND cardiovascular diseases[Title/Abstract] Limits: Humans, 
English, published in the last 10 years16:07:35 7
#12Search (#11) AND#9 Limits: Humans, English, published in the last 10 years16:05:45 
3066
#11Search  blood[Title/Abstract]  Limits:  Humans, English, published in the last 10 
years16:05:19 274129
#10Search  recipient risk OR recipient safety OR recipient well-being[Title/
Abstract] Limits: Humans, English, published in the last 10 years16:05:00 3554
#9Search  donor safety OR donor suitability OR donor risk OR donor well-being[Title/
Abstract] Limits: Humans, English, published in the last 10 years16:04:02 9936
#8Search cardiovascular diseases OR cardiovascular abnormalities OR heart diseases 
OR myocardial ischaemia[Title/Abstract] Limits: Humans, English, published in the last 
10 years16:02:08 451383
#7Search (#5) AND#4 Limits: Humans, English, published in the last 10 years16:01:25 562
#6Search (#1) AND#3 Limits: Humans, English, published in the last 10 years16:00:58 1752
#5Search (#1) AND#2 Limits: Humans, English, published in the last 10 years16:00:37 6586
#4Search cardiovascular diseases OR cardiovascular abnormalities OR heart diseases OR 
myocardial ischaemia Limits: Humans, English, published in the last 10 years16:00:08 
451935
#3Search  recipient risk OR recipient safety OR recipient well-being  Limits:  Humans, 
English, published in the last 10 years15:58:11 4877
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#2Search donor safety OR donor suitability OR donor risk OR donor well-being Limits: Humans, 
English, published in the last 10 years15:55:08 14488
#1Search blood Limits: Humans, English, published in the last 10 years15:54:13 649624
#0pubmed clipboard17:52:516
Number of citations screened  251
Relevant papers selected 6
Background literature related to autologous predeposit 
donation
1 Hillyer C et al. Comparable safety of blood donation in high-risk autologous donors 
versus non-high risk donors and directed donors in a hospital setting. American Journal 
of Clinical Pathology, 1994, 102 (3):275–277.
2 Klapper E et al. Confirmation of the safety of autologous blood donation by patients 
awaiting heart or lung transplantation. A controlled study using hemodynamic monitoring. 
The Journal of Thoracic and Cardiovascular Surgery. 1995, 110(6):1594–1599. 
3 Mann M, Sacks HJ, Goldfinger D. Safety of autologous blood donation prior to elective 
surgery for a variety of potentially high-risk patients. Transfusion, 1983, 21(3):229–232.
4 Owings DV et al. Autologous blood donations prior to elective cardiac surgery. Safety 
and effect on subsequent blood use. Journal of the American Medical Association, 
1989, 262(14):1963–1968.
5 Speiss BD et al. Autologous blood donation: hemodynamics in a high-risk patient 
population. Transfusion, 1992, 32(1):17–22.
6 Aubuchon JP, Popovsky MA. The safety of preoperative autologous blood donation in 
the nonhospital setting. Transfusion, 1991, 31(6):513–517.
Decision-making process
The Guideline Development Group agreed on the following recommendations 
based on the above studies, their medical knowledge and experience from best 
practice, and applying a precautionary approach.
Recommendations
 Asymptomatic individuals with a history of cardiovascular disease should have 
written permission from their cardiologist or physician to donate blood
Accept 
 Prospective donors with: 
— Surgically corrected simple congenital cardiac malformations who have 
no residual symptoms
— Asymptomatic disorders such as functional murmurs and mitral valve 
prolapse 
Defer permanently 
 Individuals with: 
— Symptomatic ischaemic heart disease
— Symptomatic peripheral vascular disease, including history of arterial 
thrombosis 
— History of myocardial infarction
— Severe cardiac arrhythmia
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— Rheumatic fever with evidence of chronic heart disease 
— Acquired valvular disease with stenosis or regurgitation 
— Valve replacement
— Hypertrophic cardiomyopathy 
— Palliated (i.e. uncorrected) congenital heart disease
5.2.2 Hypertension
Question
What selection criteria should be applied to prospective blood donors with 
hypertension?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse effects related to 
blood donation 
 Avoid unnecessary deferral of 
suitable blood donors 
 Minimize risk of adverse reactions in 
recipients of blood
Systematic review of safety of blood donation from 
individuals with treated hypertension
1 Stainsby D et al. Safety of blood donation from individuals with treated hypertension 
or non-insulin dependent type 2 diabetes – a systematic review. Vox Sanguinis, 2010, 
98(3):431–440.
Decision-making process
With regard to prospective donors with treated hypertension, the Guideline 
Development Group reviewed the evidence from the systematic review and agreed 
on the following recommendations.
Recommendations
Accept 
 Individuals with stable uncomplicated hypertension controlled by medication
Defer
 Individuals who have recently started taking anti-hypertensive medication, or 
whose dose of anti-hypertensive medication has been adjusted: defer for 28 
days after the blood pressure has been stabilized
Defer permanently 
 Individuals with hypertensive heart or renal disease
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5.2.3 Venous thrombosis and thrombophlebitis
Question
What selection criteria should be applied to prospective blood donors with a 
history of venous thrombosis, thrombophlebitis or inherited thrombophilia?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse effects related to 
blood donation 
 Avoid unnecessary deferral of 
suitable blood donors 
 Minimize risk of adverse reactions in 
recipients of blood
Key search and MeSH words
thrombosis OR thrombophlebitis OR upper extremity deep vein thrombosis (DVT) 
OR pulmonary embolus (PE)
Search strategy: PUBMED
#14 Search (blood recipient ) AND deep vein thrombosis Limits: Humans, English, 
published in the last 10 years 17:18:42 60 
#13 Search (blood donor ) AND deep vein thrombosis Limits: Humans, English, published 
in the last 10 years 17:02:50 150 
#11 Search (blood transfusion) AND thrombophlebitis Limits: Humans, English, published 
in the last 10 years 16:41:27 11 
#10 Search (blood recipient) AND thrombophlebitis Limits: Humans, English, published 
in the last 10 years 16:40:16 0 
#9 Search (blood donor) AND thrombophlebitis Limits: Humans, English, published in 
the last 10 years 16:38:35 5 
#8 Search (#5) AND#6 Limits: Humans, English, published in the last 10 years 16:35:31 8 
#7 Search (#4) AND#6 Limits: Humans, English, published in the last 10 years 16:34:22 27
#6 Search thrombosis OR thrombophlebitis OR deep vein thrombosis (DVT) OR pulmonary 
embolus OR (PE) Limits: Humans, English, published in the last 10 years 16:30:05 15610 
#5 Search (#1) AND#3 Limits: Humans, English, published in the last 10 years 16:28:48 
1753 
#4 Search (#1) AND#2 Limits: Humans, English, published in the last 10 years 16:28:24 
6610
#3 Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years 16:27:54 4895 
#2 Search donor safety OR donor suitability OR donor risk OR donor well-being Limits: 
Humans, English, published in the last 10 years 16:26:35 14553 
#1 Search blood Limits: Humans, English, published in the last 10 years 16:24:42 651959
Number of citations screened  113
Number of papers that address the study question 0
Decision-making process
The Guideline Development Group agreed on the following recommendations 
based on their medical knowledge and experience from best practice. 
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Recommendations
Accept 
 Individuals who have: 
— Been identified as having a thrombophilic condition, but with no history 
of a thrombotic episode, and are not on anticoagulant treatment
— Had a single episode of deep vein thrombosis or pulmonary embolus 
with an identifiable cause, provided that they are fully recovered and 
anticoagulant therapy has been stopped for at least 7 days
— Had a single episode of thrombophlebitis in the last 12 months, provided 
they are otherwise well and off treatment for at least 7 days
Defer permanently 
 Individuals who have had: 
— Two or more episodes of venous thrombosis requiring treatment
— Axillary vein thrombosis or thrombophlebitis affecting the upper limb
— Two or more episodes of thrombophlebitis in the last 12 months
5.3 RESPIRATORY DISEASES
Question
What selection criteria should be applied to prospective blood donors with 
respiratory disease?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse effects related to 
blood donation 
 Avoid unnecessary deferral of 
suitable blood donors 
 Minimize risk of adverse reactions in 
recipients of blood
Key search and MeSH words
asthma, breathless
respiratory disease, severe obstructive airways disease
acute respiratory infections, chronic or recurrent respiratory infections
Search strategy: PUBMED
#45 Search ((#10) AND#9) AND#42 Limits: Humans, English, published in the last 10 
years 08:52:43 0 
#43 Search ((#10) AND#8) AND#42 Limits: Humans, English, published in the last 10 
years 08:48:47 5 
#42 Search ((acute OR chronic OR recurrent ) AND respiratory) AND infection Limits: 
Humans, English, published in the last 10 years 08:47:14 8598 
#41 Search (#12) AND#17 Limits: Humans, English, published in the last 10 years 
08:45:17 7 
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#18 Search (#11) AND#17 Limits: Humans, English, published in the last 10 years 
07:36:35 82 
#17 Search respiratory disease OR severe obstructive airways Limits: Humans, English, 
published in the last 10 years 07:12:28 237470 
#16 Search respiratory disease OR ‘severe obstructive airways’ Limits: Humans, English, 
published in the last 10 years 07:12:16 237458 
#15 Search (#12) AND#13 Limits: Humans, English, published in the last 10 years 
07:09:14 1 
#14 Search (#11) AND#13 Limits: Humans, English, published in the last 10 years 
07:07:49 5 
#13 Search asthma OR breathless Limits: Humans, English, published in the last 10 
years 07:07:08 45198 
#12 Search (#10) AND#9 Limits: Humans, English, published in the last 10 years 
07:06:15 111 
#11 Search (#10) AND#8 Limits: Humans, English, published in the last 10 years 
07:05:51 1793 
#10 Search blood donor* OR blood donat* OR donating blood Limits: Humans, English, 
published in the last 10 years 07:04:14 6808 
#9 Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years 07:03:51 4899 
#8 Search donor safety OR donor suitability OR donor risk OR donor well-being Limits: 
Humans, English, published in the last 10 years 07:03:11 14565
Number of citations screened  100
Number of papers that address the study question 0
Decision-making process
The Guideline Development Group agreed on the following recommendations 
based on their medical knowledge and experience from best practice. 
Recommendations
Accept 
 Individuals with asthma provided they are asymptomatic on a maintenance 
dose of non-steroid and/or inhaled steroid medication
Defer
 Individuals with:
— Asthma during an acute exacerbation: defer for 14 days following full 
recovery 
— Asthma on a course of oral or injected steroids: defer for 14 days 
following full recovery and cessation of oral or injected steroids 
— Acute respiratory infections such as bronchitis: defer for 14 days following 
full recovery and cessation of any therapy, including antibiotics
Defer permanently
 Individuals with:
— Respiratory disease if they are breathless at rest or on minimal exertion 
or are cyanosed
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— Severe obstructive airways disease, including those on long-term oral 
steroid therapy 
— Chronic or recurrent respiratory infections
5.4 GASTROINTESTINAL DISEASES
Question
What selection criteria should be applied to prospective blood donors with 
diseases of the gastrointestinal tract?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse effects related to 
blood donation 
 Avoid unnecessary deferral of 
suitable blood donors 
 Minimize risk of adverse reactions in 
recipients of blood
Key search and MeSH words
active inflammatory bowel disease OR ulcerative colitis OR Crohn’s disease
malabsorbtion syndromes OR treated coeliac disease OR Active peptic ulceration
irritable bowel syndrome OR gastro-oesophageal reflux OR hiatus hernia
Search strategy: PUBMED 
#21 Search (#7) AND#19 Limits: Humans, English, published in the last 10 years 
08:54:40 0 
#20 Search (#3) AND#19 Limits: Humans, English, published in the last 10 years 
08:53:54 0 
#19 Search irritable bowel syndrome OR gastro oesophageal reflux OR hiatus hernia 
Limits: Humans, English, published in the last 10 years 08:53:20 12916 
#18 Search ‘irritable bowel syndrome’ OR ‘gastro-oesophageal reflux’ OR hiatus hernia 
Limits: Humans, English, published in the last 10 years 08:53:02 1228 
#12 Search (#7) AND#10 Limits: Humans, English, published in the last 10 years 
08:40:52 28 
#11 Search (#3) AND#10 Limits: Humans, English, published in the last 10 years 
08:34:29 4 
#10 Search malabsorption syndrome OR treated coeliac disease OR active peptic ulcer 
Limits: Humans, English, published in the last 10 years 08:33:36 8395 
#9 Search malabsorption syndrome OR ‘treated coeliac disease’ OR ‘active peptic ulcer’ 
Limits: Humans, English, published in the last 10 years 08:32:57 7907 
#8 Search (#7) AND#4 Limits: Humans, English, published in the last 10 years 08:22:31 7
#7 Search (#1) AND#6 Limits: Humans, English, published in the last 10 years 08:19:16 
6612
#6 Search donor safety OR donor suitability OR donor risk OR donor well-being Limits: 
Humans, English, published in the last 10 years 08:18:18 14559 
#5 Search (#3) AND#4 Limits: Humans, English, published in the last 10 years 08:17:16 4 
#4 Search ‘active inflammatory bowel disease’ OR ulcerative colitis OR Crohn’s disease 
Limits: Humans, English, published in the last 10 years 08:16:30 15124 
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#3 Search (#1) AND#2 Limits: Humans, English, published in the last 10 years 08:14:06 
1753 
#2 Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years 08:13:32 4897 
#1 Search blood Limits: Humans, English, published in the last 10 years 08:12:58 652460
#25  Search (#5) AND#16 Limits: Humans, English, published in the last 10 years 
18:34:56 34 
#24  Select 1 document(s) 18:32:21 1 
#17  Search (#4) AND#16 Limits: Humans, English, published in the last 10 years 
17:54:03 112 
#16  Search gastrointestinal disease Limits: Humans, English, published in the last 10 
years 17:51:41 171971 
#14  Search (blood recipient ) AND deep vein thrombosis Limits: Humans, English, 
published in the last 10 years 17:18:42 60 
#13  Search (blood donor ) AND deep vein thrombosis Limits: Humans, English, published 
in the last 10 years 17:02:50 150 
#11  Search (blood transfusion) AND thrombophlebitis Limits: Humans, English, published 
in the last 10 years 16:41:27 11 
#10  Search (blood recipient) AND thrombophlebitis Limits: Humans, English, published 
in the last 10 years 16:40:16 0 
#9  Search (blood donor) AND thrombophlebitis Limits: Humans, English, published in 
the last 10 years 16:38:35 5 
#8  Search (#5) AND#6 Limits: Humans, English, published in the last 10 years 16:35:31 8 
#7  Search (#4) AND#6 Limits: Humans, English, published in the last 10 years 16:34:22 27 
#6  Search thrombosis OR thrombophlebitis OR deep vein thrombosis (DVT) OR pulmonary 
embolus OR (PE) Limits: Humans, English, published in the last 10 years 16:30:05 15610 
#5  Search (#1) AND#3 Limits: Humans, English, published in the last 10 years 16:28:48 
1753 
#4  Search (#1) AND#2 Limits: Humans, English, published in the last 10 years 16:28:24 
6610 
#3  Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years 16:27:54 4895 
#2  Search donor safety OR donor suitability OR donor risk OR donor well-being Limits: 
Humans, English, published in the last 10 years 16:26:35 14553 
#1  Search blood Limits: Humans, English, published in the last 10 years 16:24:42 
651959
Number of citations screened  39
Number of papers that address the study question 0
Decision-making process
The Guideline Development Group agreed on the following recommendations 
based on their medical knowledge and their experience from best practice. 
Recommendations
Accept
 Individuals with:
— Irritable bowel syndrome without debility
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— Diverticular disease, if well 
— Mild gastro-oesophageal reflux
— Mild hiatus hernia 
— Treated coeliac disease
— Gallstones
— Cholecystitis, when fully recovered
Defer
 Individuals with: 
— Active peptic ulceration: defer until completion of treatment and full 
recovery 
— Active inflammatory bowel disease (ulcerative colitis or Crohn’s disease): 
may be accepted if they are well, in long-term remission and meet the 
minimum haemoglobin levels for blood donation
Defer permanently
 Individuals with malabsorption syndromes (except treated coeliac disease) 
5.5 METABOLIC AND ENDOCRINE DISEASES
5.5.1 Diabetes mellitus
Question
What selection criteria should be applied to prospective blood donors with 
diabetes?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse effects related to 
blood donation 
 Avoid unnecessary deferral of 
suitable blood donors 
 Minimize risk of adverse reactions in 
recipients of blood
Systematic review of safety of blood donation from 
individuals with diabetes
1 Stainsby D et al. Safety of blood donation from individuals with treated hypertension 
or non-insulin dependent type 2 diabetes – a systematic review. Vox Sanguinis, 2010, 
98(3):431–440.
Decision-making process
The Guideline Development Group reviewed the evidence from this systematic 
review and agreed on the following recommendations.
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Recommendations
Accept 
 Individuals with diabetes mellitus well-controlled by diet or oral hypoglycaemic 
medication, provided they have no history of orthostatic hypotension and no 
evidence of infection, neuropathy or vascular disease, in particular peripheral 
ulceration 
Defer permanently
 Individuals with:
— Diabetes who require insulin 
— Complications of diabetes with multi-organ involvement
5.5.2 Thyroid disease
Question
What selection criteria should be applied to prospective blood donors with 
disorders of the thyroid?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse effects related to 
blood donation 
 Avoid unnecessary deferral of 
suitable blood donors 
 Minimize risk of adverse reactions in 
recipients of blood
Key search and MeSH words
malignant thyroid tumours, hyper- or hypo-thyroid
thyrotoxicosis, Graves’ disease
thyroid disease, benign thyroid disorders, asymptomatic goitre, viral thyroiditis, 
autoimmune hypothyroidism
Search strategy: PUBMED
#21 Search ((#1) AND#8) AND#3 Limits: Humans, English, published in the last 10 years 
06:42:09 0#20 Search ((#1) AND#12) AND#3 Limits: Humans, English, published in the 
last 10 years 06:41:17 0 
#19 Search ((#1) AND#16) AND#3 Limits: Humans, English, published in the last 10 
years 06:40:22 0
#18 Search (#5) AND#16 Limits: Humans, English, published in the last 10 years 
06:39:06 0 
#17 Search (#4) AND#16 Limits: Humans, English, published in the last 10 years 
06:38:37 3 
#16 Search thyroid disease OR benign thyroid disorders OR asymptomatic goitre OR viral 
thyroiditis OR autoimmune hypothyroidism Limits: Humans, English, published in the last 
10 years 06:38:09 24809 
#15 Search thyroid disease OR ‘benign thyroid disorders’ OR asymptomatic goitre OR 
viral thyroiditis OR autoimmune hypothyroidism Limits: Humans, English, published in the 
last 10 years 06:37:56 24798 
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#14 Search (#5) AND#12 Limits: Humans, English, published in the last 10 years 
06:35:54 0 
#13 Search (#4) AND#12 Limits: Humans, English, published in the last 10 years 
06:35:24 0 
#12 Search thyrotoxicosis OR Grave’s disease Limits: Humans, English, published in the 
last 10 years 06:34:47 4385 
#11 Search (#5) AND#8 Limits: Humans, English, published in the last 10 years 06:23:21 0 
#9 Search (#4) AND#8 Limits: Humans, English, published in the last 10 years 06:22:21 
3#8 Search thyroid disease OR thyroid tumours OR hyperthyroidism OR hypothyroidism 
Limits: Humans, English, published in the last 10 years 06:17:54 27621#6 Search 
thyroid disease OR thyroid tumours OR hyperthyroidsm OR hypothyroidism Limits: Humans, 
English, published in the last 10 years 06:16:08 30933 
#5 Search (#1) AND#3 Limits: Humans, English, published in the last 10 years 06:13:35 111 
#4 Search (#1) AND#2 Limits: Humans, English, published in the last 10 years 06:13:02 
1793 
#3 Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years 06:12:24 4899 
#2 Search donor safety OR donor suitability OR donor risk OR donor well-being Limits: 
Humans, English, published in the last 10 years 06:11:40 14565 
#1 Search blood donor* OR blood donat* OR donating blood Limits: Humans, English, 
published in the last 10 years 06:11:01 6808
Number of citations screened  3
Relevant papers selected 1
Key reference
1 Guidelines for the blood transfusion services in the United Kingdom: donor selection 
guidelines, 7th edition. London, UK Blood Transfusion & Tissue Transplantation Services, 
2005.
Decision-making process
The Guideline Development Group agreed on the following recommendations based 
the above reference, on their medical knowledge and experience from best practice. 
Recommendations
Accept
 Individuals with benign thyroid disorders (provided they are euthyroid) such 
as:
— Asymptomatic goitre
— History of viral thyroiditis
— Autoimmune hypothyroidism
Defer
 Individuals:
— Under investigation for thyroid disease
— If hyper- or hypo-thyroid
— With a history of malignant thyroid tumours (also refer to Section 5.9 
on malignant diseases)
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Defer permanently
 Individuals with thyrotoxicosis due to Graves’ disease
5.6 IMMUNOLOGICAL DISEASES
Question
What selection criteria should be applied to prospective blood donors with 
immunological disorders?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse effects related to 
blood donation 
 Avoid unnecessary deferral of 
suitable blood donors 
 Minimize risk of adverse reactions in 
recipients of blood
Key search and MeSH words
systemic lupus erythematosus, dermatomyositis, severe rheumatoid disease
hypogammaglobulinaemia, anaphylaxis
vitiligo, mild rheumatoid arthritis, allergy, asthma, eczema, IgA, IgE
Search strategy: PUBMED
#34 Search (#8) AND#33 Limits: Humans, English, published in the last 10 years 
15:36:53 31 
#45 Search (#9) AND#33 Limits: Humans, English, published in the last 10 years 
15:31:54 1 
#33 Search IgA OR IgE Limits: Humans, English, published in the last 10 years 14:20:08 
16717 
#32 Search (#9) AND#26 Limits: Humans, English, published in the last 10 years 
14:19:19 2 
#27 Search (#8) AND#26 Limits: Humans, English, published in the last 10 years 
13:57:18 24 
#26 Search vitiligo OR mild rheumatoid arthritis OR allergy OR asthma OR eczema Limits: 
Humans, English, published in the last 10 years 13:53:14 83302 
#23 Search vitiligo OR ‘mild rheumatoid arthritis’ OR allergy OR asthma OR eczema 
Limits: Humans, English, published in the last 10 years 13:53:03 77095 
#17 Search (#8) AND#11 Limits: Humans, English, published in the last 10 years 
12:26:10 18 
#12 Search (#9) AND#11 Limits: Humans, English, published in the last 10 years 
12:19:36 2 
#11 Search systemic lupus erythematosus OR dermatomyositis OR severe rheumatoid 
disease OR hypogammaglobulinaemia OR anaphylaxis Limits: Humans, English, published 
in the last 10 years 10:19:46 20194 
#10 Search ‘systemic lupus erythematosus’ OR dermatomyositis OR ‘severe rheumatoid 
disease’ OR ‘hypogammaglobulinaemia’ OR anaphylaxis Limits: Humans, English, published 
in the last 10 years 10:19:17 20384 
#9 Search (#7) AND#4 Limits: Humans, English, published in the last 10 years 10:17:16 111 
161
#8 Search (#7) AND#2 Limits: Humans, English, published in the last 10 years 10:16:34 1791 
#7 Search blood donor* OR blood donat* OR donating blood Limits: Humans, English, 
published in the last 10 years 10:15:57 6805 
#6 Search blood donor* OR donating blood Limits: Humans, English, published in the 
last 10 years 10:15:09 6409 
#5 Search (#1) AND#4 Limits: Humans, English, published in the last 10 years 10:13:10 1753 
#4 Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years 10:12:37 4897 
#3 Search (#1) AND#2 Limits: Humans, English, published in the last 10 years 10:12:18 6612 
#2 Search donor safety OR donor suitability OR donor risk OR donor well-being Limits: 
Humans, English, published in the last 10 years 10:11:46 14559 
#1 Search blood Limits: Humans, English, published in the last 10 years 10:11:19 652460
Number of citations screened  78
Relevant papers selected 3
Key references
1 Johansson SG et al. Passive IgE-sensitization by blood transfusion. Allergy, 2005, 
60(9):1192–1199. 
2 Johansson SG et al. High prevalence of IgE antibodies among blood donors in Sweden 
and Norway. Allergy, 2005, 60(10):1312–1315.
3 Stern A et al. Is allergy screening of blood donors necessary? A comparison 
between Questionnaire answers and the presence of circulating IgE antibodies. Vox 
Sanguinis, 1995, 69(2):114–119.
Decision-making process
The Guideline Development Group agreed on the following recommendations 
with reference to the above background literature and based on their medical 
knowledge and experience from best practice. 
Recommendations
Accept
 Individuals with: 
— Mild, localized or inactive conditions, such as vitiligo or mild rheumatoid 
arthritis without systemic symptoms
— History of allergy, provided they are well and free from allergic symptoms 
on the day of donation
— Asthma (also refer to Section 5.3 on respiratory diseases)
— Eczema (also refer to Section 5.11 on skin diseases)
Defer permanently
 Individuals with: 
— Severe debilitating autoimmune disorders such as systemic lupus 
erythematosus, dermatomyositis or severe rheumatoid disease
— Immunosuppression due to congenital or acquired hypogamma-
globulinaemia or immunosuppressive medication, with the exception 
of individuals with IgA deficiency
— History of anaphylaxis 
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5.7 RENAL AND URINARY TRACT DISEASES
Question
What selection criteria should be applied to prospective blood donors with renal 
disorders?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse effects related to 
blood donation 
 Avoid unnecessary deferral of 
suitable blood donors 
 Minimize risk of adverse reactions in 
recipients of blood
Key search and MeSH words
acute nephritis, chronic renal bacterial infection, severe chronic renal disease, 
chronic or recurrent infection
Search strategy: PUBMED
#15 Search (#4) AND#7 Limits: Humans, English, published in the last 10 years 10:55:46 6
#14 Search (#5) AND#7 Limits: Humans, English, published in the last 10 years 10:51:45 0
#13 Search (#5) AND#6 Limits: Humans, English, published in the last 10 years 10:50:33 4
#12 Search (#3) AND#6 Limits: Humans, English, published in the last 10 years 10:45:26 
860
#8 Search (#4) AND#6 Limits: Humans, English, published in the last 10 years 10:37:57 29
#7 Search acute nephritis OR chronic renal infection Limits: Humans, English, published 
in the last 10 years 10:21:48 4706
#6 Search (((renal bacterial infection) OR renal disease) OR recurrent renal infection 
Limits: Humans, English, published in the last 10 years 10:20:49 108359
#5 Search (#1) AND#3 Limits: Humans, English, published in the last 10 years 10:07:23 
120
#4 Search (#1) AND#2 Limits: Humans, English, published in the last 10 years 10:06:53 
1840
#3 Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years 10:06:07 4957
#2 Search donor safety OR donor suitability OR donor risk OR donor well-being Limits: 
Humans, English, published in the last 10 years 10:04:43 14706
#1 Search blood donor* OR blood donat* OR donating Limits: Humans, English, published 
in the last 10 years 10:02:37 7283
Number of citations screened  70
Number of papers that address the study question 0
Decision-making process
The Guideline Development Group agreed on the following recommendations 
based on their medical knowledge and experience from best practice. 
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Recommendations 
Defer
 Individuals with lower urinary tract infections: defer for 14 days after full 
recovery and completion of treatment
 Individuals with acute self-limiting renal diseases such as acute nephritis 
when fully recovered and renal functions are normal; this may require deferral 
for as long as 5 years after full recovery
Defer permanently
 Individuals with severe chronic renal disease causing ill-health or anaemia, 
or associated with chronic or recurrent infection
5.8 CENTRAL NERVOUS SYSTEM DISEASES
5.8.1 Cerebrovascular disease
Question
What selection criteria should be applied to prospective blood donors with 
disorders of the central nervous system including cerebrovascular disease, 
epilepsy and other seizure disorders, dementia and other neurodegenerative 
disorders, multiple sclerosis and other demyelinating disorders?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse effects related to 
blood donation 
 Avoid unnecessary deferral of 
suitable blood donors 
 Minimize risk of adverse reactions in 
recipients of blood
 Prevention of transfusion-
transmission of vCJD
Key search and MeSH words
central nervous system diseases, demyelinating diseases, neurodegenerative 
diseases, transfusion-transmission of vCJD, dementia, cerebrovascular disorders, 
transient ischaemic attack, stroke
Search strategy: PUBMED
#19Search (#18) AND#3 Limits: Humans, English, published in the last 10 years15:29:51 5
#18Search (#17) AND#4 Limits: Humans, English, published in the last 10 years15:28:21 
34
#17Search (transfusion transmission) AND vCJD OR variant Creutzfeld Jacob Disease 
Limits: Humans, English, published in the last 10 years15:25:59 164
#16Search ((#15) AND blood transfusion) AND#3 Limits: Humans, English, published in 
the last 10 years15:16:38 0
#15Search (#4) AND#14 Limits: Humans, English, published in the last 10 years15:15:11 3
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#14Search transient ischaemic attack OR stroke Limits: Humans, English, published in 
the last 10 years15:13:21 69803
#13Search ((#10) AND blood transfusion) AND#3 Limits: Humans, English, published in 
the last 10 years15:12:35 4
#12Search ((#10 ) AND blood transfusion) AND#3 Limits: Humans, English, published 
in the last 10 years15:09:42 4
#11Search (#10) AND#3 Limits: Humans, English, published in the last 10 years15:07:26 5
#10Search (#4) AND#9 Limits: Humans, English, published in the last 10 years15:03:28 45
#9Search dementia OR cerebrovascular disorders Limits: Humans, English, published in 
the last 10 years14:51:39 117355
#8Search (#7) AND#3 Limits: Humans, English, published in the last 10 years14:48:33 7
#7Search (#4) AND#6 Limits: Humans, English, published in the last 10 years14:44:48 103
#6Search central nervous system diseases OR demyelinating diseases OR neurodegenerative 
diseases Limits: Humans, English, published in the last 10 years14:41:38 308059
#5Search (#1) AND#3 Limits: Humans, English, published in the last 10 years14:40:04 112
#4Search (#1) AND#2 Limits: Humans, English, published in the last 10 years14:39:35 
1906
#3Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years14:38:31 5000
#2Search donor safety OR donor suitability OR donor risk OR donor well-being OR donor 
defer* OR donor eligible* OR donor selection OR donor accept* Limits: Humans, English, 
published in the last 10 years14:37:26 16323
#1Search blood donor* OR blood donat* OR donating blood Limits: Humans, English, 
published in the last 10 years14:36:10 6808
Number of citations screened 374
Number of papers that addressed the study question 0
5.8.2 Epilepsy
Key search and MeSH words
Epilepsy OR seizures OR febrile seizures
Search:
#3 Search (“safety”[Title/Abstract] OR “risk”[Title/Abstract]) AND ((“1995”[Publication 
Date] : “2009”[Publication Date]) AND (((blood donor*) OR (blood donat*)) AND ((epilepsy 
OR seizure* OR (febrile seizure*)))) Limits: Humans, English 06:48:35 5 
#2 Search (“1995”[Publication Date] : “2009”[Publication Date]) AND (((blood donor*) 
OR (blood donat*)) AND ((epilepsy OR seizure* OR (febrile seizure*))) Limits: Humans, 
English 06:36:13 15
#1 Search ((blood donor*) OR (blood donat*)) AND ((epilepsy OR seizure* OR (febrile 
seizure*)) Limits: Humans, English 05:41:23 26
Number of citations screened 46
Number of papers that address the study Question 1
Key reference
1 Krumholz A et al. Adverse reactions in blood donors with a history of epilepsy or 
seizures. Transfusion, 1995, 35(6):470–474.
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A single study (Krumholz et al, 1995) investigated the safety of accepting blood 
donations from individuals with epilepsy or seizure disorders. Over a 2-year 
period from 1987, 613 donors with a history of seizures donated blood a total 
of 723 times; of these, 186 (35.7%) were taking anti-epileptic medication and 
61 (8.4%) reported one or more seizures in the preceding year. The total number 
of successful donations during this period was 329 143. Total adverse reactions 
were slightly but not significantly higher in donors with seizure disorders (3.34% 
vs 2.24%); however, syncopal reactions with or without convulsions were lower 
in donors with seizure disorders than in the entire donor population (0.21% vs 
0.28%). The authors concluded that individuals with seizures or epilepsy are 
not at greater risk of adverse reactions after blood donation and restrictions on 
their participation as blood donors are not warranted. 
Critical evaluation of study
This multicentric observational study was carried out twenty years ago and has not 
been repeated since. Clinical practice in donor care has not altered significantly 
in the interim so the findings remain relevant and are applicable worldwide. The 
incidence of adverse reactions in the study group was compared to the overall 
incidence in all blood donors. Matched controls were not identified and there 
was no allowance for confounding factors such as age and donor status (whether 
first-time or repeat donor) that are known to be significant factors in predicting 
the incidence of adverse reactions.
The quality of evidence was therefore assessed as low/very low.
Additional background literature
1 Weisbach V et al. A pilot study of continuous ambulatory monitoring of blood pressure 
in repeated preoperative autologous transfusion. Transfusion, 2006, 46:934–941.
2 Krumholz A et al. Regulations prohibiting blood donation by individuals with seizures 
or epilepsy are not necessary. Medical Law, 1997, 16 (2):339–347.
3 Thomas SHL et al. The haemodynamic responses to venesection and the effects of 
cardiovascular disease. Clinical and Laboratory Haematology, 1992, 14:201–208.
4 van der Linden GJ, Siegenbeek van Heukelom LH, Meinardi H. Blood donation, a risk 
for epileptic patients? Vox Sanguinis, 1986, 51(2):148–151.
5 Ludlam C, Turner M. Managing the risk of transmission of variant Creutzfeld-Jakob 
disease by blood products. British Journal of Haematology, 2005, 132:13–24.
Decision-making process
The Guideline Development Group reviewed the evidence on prospective 
donors with epilepsy and concluded that, until further evidence is available, a 
precautionary approach should continue to be recommended. In the absence of 
relevant published evidence on other central nervous system disorders, the group 
agreed on the following recommendations based on their medical knowledge 
and experience from best practice.
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GRADE table
Study 
design
Limitations Consistency Directness 
(applicability)
Precision 
(confidence 
intervals)
other 
considerations 
Quality
Multicentre 
observational 
study
 Matched 
controls not 
identified
 No 
allowance for 
confounding 
factors (age, 
donor status)
N/A  Applicable 
to current 
practice
 Addresses 
study 
question
N/A Single study 
over 20 years 
ago, not 
repeated
Low
Recommendations 
Accept 
 Individuals with a history of epilepsy who have been off medication and 
seizure-free for a period of at least 3 years
Defer permanently
 Individuals with:
— Cerebrovascular disease (a history of transient cerebral ischaemic 
episodes or stroke)
— Dementia or neurodegenerative disease due to any cause
— Multiple sclerosis or other demyelinating diseases
5.9 MALIGNANT DISEASES
Question
What selection criteria should be applied to prospective blood donors with current 
or past malignant disease?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse effects related to 
blood donation 
 Avoid unnecessary deferral of 
suitable blood donors 
 Minimize risk of adverse reactions in 
recipients of blood
Key search and MeSH words
chronic lympho-proliferative disorders
clonal haematological disorders, polycythaemia rubra vera, essential 
thrombocythaemia, paroxysmal nocturnal haemoglobinuria
melanoma, active malignancies OR cancer*, subclinical cancer 
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Search strategy: PUBMED
#27Search subclinical cancer* Limits: Humans, English, published in the last 10 
years17:49:15 9
#29Search (#4) AND#27 Limits: Humans, English, published in the last 10 years17:48:05 0
#28Search (#5) AND#27 Limits: Humans, English, published in the last 10 years17:47:25 0
#24Search Chronic lympho-proliferative disorders Limits: Humans, English, published in 
the last 10 years17:45:05 3
#23Search (#5) AND#21 Limits: Humans, English, published in the last 10 years17:41:34 0
#22Search (#4) AND#21 Limits: Humans, English, published in the last 10 years17:40:420
#21Search Paroxysmal nocturnal haemoglobinuria Limits: Humans, English, published in 
the last 10 years17:40:06 567
#20Search (#5) AND#18 Limits: Humans, English, published in the last 10 years17:39:06 0
#19Search (#4) AND#18 Limits: Humans, English, published in the last 10 years17:38:29 0
#18Search essential thrombocythaemia Limits: Humans, English, published in the last 
10 years17:37:49 1093
#17Search (#5) AND#15 Limits: Humans, English, published in the last 10 years17:37:08 0
#16Search (#4) AND#15 Limits: Humans, English, published in the last 10 years17:36:32 0
#15Search Polycythaemia rubra vera Limits: Humans, English, published in the last 10 
years17:35:41 1241
#14Search (Clonal haematological disorder*) AND#5 Limits: Humans, English, published 
in the last 10 years17:34:00 0
#13Search (Clonal haematological disorder* ) AND#4 Limits: Humans, English, published 
in the last 10 years17:32:56 0
#12Search (#5) AND#10 Limits: Humans, English, published in the last 10 years17:28:17 0
#11Search (#4) AND#10 Limits: Humans, English, published in the last 10 years17:27:40 0
#10Search Clonal haematological disorders OR Polycythaemia rubra vera OR essential 
thrombocythaemia OR Paroxysmal nocturnal haemoglobinuria Limits: Humans, English, 
published in the last 10 years17:26:56 3663
#9Search donor melanoma AND organ transplantation Limits: Humans, English, published 
in the last 10 years17:22:30 22
#8Search (#5) AND#6 Limits: Humans, English, published in the last 10 years16:45:09 9
#7Search (#4) AND#6 Limits: Humans, English, published in the last 10 years16:42:57 80
#6Search active malignancies OR cancer* Limits: Humans, English, published in the last 
10 years16:40:35 419339
#5Search (#1) AND#3 Limits: Humans, English, published in the last 10 years16:39:49 120
#4Search (#1) AND#2 Limits: Humans, English, published in the last 10 years16:39:20 
1840
#3Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years16:38:20 4957
#2Search donor safety OR donor suitability OR donor risk OR donor well-being Limits: 
Humans, English, published in the last 10 years16:37:58 14706
#1Search blood donor* OR blood donat* OR donating Limits: Humans, English, published 
in the last 10 years16:37:11 7302
Number of citations screened  126
Number of papers that address the study question 2
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Key references
1 Edgren G et al. Risk of cancer after blood transfusion from donors with subclinical 
cancer: a retrospective cohort study. The Lancet, 2007, 369(9574):1724–1730.
2 Yang H et al. Can blood transfusion transmit cancer? A literature review. Transfusion 
Medicine Reviews, 24 (3):235–243.
Edgren et al report a landmark large retrospective cohort study of cancer incidence 
among patients who received blood from donors deemed retrospectively to have 
a subclinical cancer at the time of donation (diagnosed with cancer within five 
years of the donation). There was no excess risk of cancer among recipients of 
blood from pre-cancerous donors compared with recipients of blood from non-
cancerous donors.
GRADE table
Study design Limitations Consistency Directness 
(applicability)
Precision 
(confidence 
intervals)
other 
considerations 
Quality
 Large 
retrospective 
cohort study
 (354 094 blood 
recipients 
of whom 3% 
were exposed 
to blood from 
“precancerous” 
donors)
None Consistent 
across all 
subgroups
 Applicable 
to current 
practice
 Addresses 
study 
question
Adjusted 
relative risk 
1∙00, 95% 
CI 0∙94–
1∙07
None High
The comprehensive literature review by Yang et al concluded that “there is now 
ample evidence to consider accepting selected blood donors with a history of 
cancer”.
Additional background papers
1 Dzik WH, Okayama A. Can blood transfusion transmit disease-producing genes? 
Transfusion, 1999, 39:795–800. 
2 Memon A, Doll R. A search for unknown blood-borne oncogenic viruses. International 
Journal of Cancer, 1994, 58:366–368.
3 Strauss DC, Thomas JM. Transmission of donor melanoma by organ transplantation. 
The Lancet Oncology, 2010, 11(8):790–796.
Decision-making process
Based on the available evidence summarized above, and their medical knowledge 
and expertise, the Guideline Development Group agreed on the following 
recommendations.
Recommendations 
 For individuals with a past history of solid malignant tumour, BTS may consider 
acceptance if 5 years or more since completion of successful curative treatment
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Accept
 Individuals with a history of “in situ” malignant disease such as basal cell 
carcinoma or cervical carcinoma in situ, if regularly monitored and considered 
successfully treated and in good health 
Defer
 Prospective donors with a current diagnosis of malignancy 
 Individuals with past history of solid malignant tumour if less than 5 years 
since completion of treatment
Defer permanently
 Individuals with a history of malignant melanoma
 Individuals with current or past haematological malignancy, including:
— Leukaemia: i.e. lymphoproliferative and myeloproliferative disorders
— Lymphomas
— Clonal haematological disorders such as:
 Polycythaemia rubra vera and essential thrombocythaemia
 Paroxysmal nocturnal haemoglobinuria
— Myelodysplastic syndromes
5.11 SKIN DISEASES
Question
What selection criteria should be applied to prospective blood donors with skin 
diseases?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse effects related to 
blood donation 
 Avoid unnecessary deferral of 
suitable blood donors 
 Minimize risk of adverse reactions in 
recipients of blood
Key search and MeSH words
retinoid treatment, eczema, acne, psoriasis
antibiotics, anti-inflammatory drugs, immunosuppressants or vitamin A analogues
scabies, ringworm
Search strategy: PUBMED
#21 Search (#5) AND skin disease* Limits: Humans, English, published in the last 10 
years 18:56:26 0 
#20 Search (#4) AND skin disease* Limits: Humans, English, published in the last 10 
years 18:55:34 2 
#19 Search (#5) AND#16 Limits: Humans, English, published in the last 10 years 
18:53:59 3 
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#17 Search (#4) AND#16 Limits: Humans, English, published in the last 10 years 
18:52:13 35 
#16 Search antibiotics OR anti-inflammatories OR immunosuppressants OR vitamin a 
analogues Limits: Humans, English, published in the last 10 years 18:33:55 221828 
#15 Search antibiotics OR anti-inflammatories OR immunosuppressants OR ‘vitamin A 
analogues’ Limits: Humans, English, published in the last 10 years 18:33:39 221795 
#14 Search (#5) AND#12 Limits: Humans, English, published in the last 10 years 
18:32:09 0 
#13 Search (#4) AND#12 Limits: Humans, English, published in the last 10 years 
18:29:09 1 
#12 Search retinoid treatment OR eczema OR acne OR psoriasis Limits: Humans, English, 
published in the last 10 years 18:28:35 20345 
#11 Search (#5) AND#7 Limits: Humans, English, published in the last 10 years 18:26:07 1 
#8 Search (#4) AND#7 Limits: Humans, English, published in the last 10 years 18:13:33 29 
#9 Select 1 document(s) 17:54:09 1 
#7 Search skin diseases OR scabies OR ringworm Limits: Humans, English, published 
in the last 10 years 17:50:44 207590 
#6 Search skin diseases OR scabies OR ringworm Limits: Humans, English, published 
in the last 10 years 17:50:31 1117500 
#5 Search (#1) AND#3 Limits: Humans, English, published in the last 10 years 17:46:19 
111 
#4 Search (#1) AND#2 Limits: Humans, English, published in the last 10 years 17:45:49 
1794 
#3 Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years 17:45:17 4899 
#2 Search donor safety OR donor suitability OR donor risk OR donor well-being Limits: 
Humans, English, published in the last 10 years 17:44:46 14568 
#1 Search blood donor* OR blood donat* OR donating blood Limits: Humans, English, 
published in the last 10 years 17:44:09 6811
Number of citations screened  183
Number of papers that address the study question 0
Decision-making process
The Guideline Development Group agreed on the following recommendations 
based on their medical knowledge and experience from best practice. 
Recommendations regarding the use of medication by prospective blood donors 
are addressed in Section 6.2.
Recommendations
Accept
 Individuals with common skin conditions, such as:
— Mild eczema
— Mild acne
— Mild psoriasis 
 provided lesions are not infected, there are no systemic symptoms, the 
venepuncture site is unaffected and they have not received immunosuppressive 
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or retinoid treatment; long-term low-dose antibiotic treatment for acne is not 
a contraindication to blood donation
 Individuals with burns, when fully healed 
Defer
 Individuals with: 
— Psoriasis with infected lesions, systemic symptoms, affected venepuncture 
site or receiving immunosuppressive or retinoid treatment
— Generalized skin disease(s) on systemic medication
— Contagious skin diseases such as scabies and ringworm until cleared; 
while not a blood safety risk, there is a potential risk to blood collection 
staff
Defer permanently 
 Individuals with systemic diseases affecting the skin, such as:
— Scleroderma
— Systemic lupus erythematosus
— Dermatomyositis 
— Systemic cutaneous amyloidosis
5.12 PSYCHIATRIC DISORDERS
Question
What selection criteria should be applied to prospective blood donors with current 
or past psychiatric or mental health disorders?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse effects related to 
blood donation 
 Avoid unnecessary deferral of 
suitable blood donors 
 Minimize risk of adverse reactions in 
recipients of blood
Key search and MeSH words
psychotic disorders OR schizophrenia 
affective disorders OR depression OR bipolar disorder
Search strategy: PUBMED
#13 Search (#5) AND#10 Limits: Humans, English, published in the last 10 years 
04:31:24 0
#11 Search (#4) AND#10 Limits: Humans, English, published in the last 10 years 
04:30:54 3
#10 Search psychotic disorders OR schizophrenia Limits: Humans, English, published in 
the last 10 years 04:29:33 34244
#9 Search (#5) AND#6 Limits: Humans, English, published in the last 10 years 04:28:12 0
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#7 Search (#4) AND#6 Limits: Humans, English, published in the last 10 years 04:27:37 5
#6 Search affective disorders OR depression OR bipolar disorder Limits: Humans, English, 
published in the last 10 years 04:25:58 93871
#5 Search (#1) AND#3 Limits: Humans, English, published in the last 10 years 04:25:11 
120
#4 Search (#1) AND#2 Limits: Humans, English, published in the last 10 years 04:24:44 
1840
#3 Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years 04:24:19 4957
#2 Search donor safety OR donor suitability OR donor risk OR donor well-being Limits: 
Humans, English, published in the last 10 years 04:23:37 14706
#1 Search blood donor* OR blood donat* OR donating Limits: Humans, English, published 
in the last 10 years  
Number of citations screened  8
Relevant papers selected 1
Key references
1 Guidelines for the blood transfusion services in the United Kingdom: donor selection 
guidelines, 7th edition. London, UK Blood Transfusion & Tissue Transplantation Services, 
2005
Decision-making process
The Guideline Development Group agreed on the following recommendations 
based on their medical knowledge and experience from best practice. 
Recommendations 
Accept
 Individuals with anxiety disorders or mood (affective) disorders (e.g. depression, 
bipolar disorder), provided they are generally in good health and are not 
obviously over-anxious, depressed or manic when seen on the day of donation, 
regardless of medication 
Defer permanently
 Individuals with psychotic disorders requiring maintenance treatment
6 Donor medical history II: 
 Medical and surgical interventions 
6.1 IMMUNIZATIONS AND VACCINATIONS
6.1.1 Post-exposure prophylaxis
6.1.2 Live attenuated viral and bacterial vaccines 
Question
What deferral period should be applied to prospective blood donors who have 
recently received immunization with live attenuated bacteria or viruses?
173
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse events related to 
blood donation 
 Avoid unnecessary deferral of 
suitable blood donors 
 Minimize risk of transfusion-
transmitted infection or other 
adverse reaction in recipient of blood
Key search and MeSH words
live attenuated bacterial and viral vaccines include BCG, yellow fever, measles, 
mumps, rubella, polio (oral), live attenuated typhoid, live attenuated cholera and 
smallpox.
immunization with live vaccines, smallpox vaccination, transfusion-transmission 
of vaccinia
Search strategy: PUBMED
#26Search (#5) AND#24 Limits: Humans, English, published in the last 10 years11:55:19 0
#25Select 1 document(s)11:53:49 1
#24Search live attenuated smallpox vaccine* Limits: Humans, English, published in the 
last 10 years11:53:49 1
#23Search (#4) AND#21 Limits: Humans, English, published in the last 10 years11:21:51 0
#22Search (#5) AND#21 Limits: Humans, English, published in the last 10 years11:21:03 0 
#21Search live attenuated typhoid OR live attenuated cholera Limits: Humans, English, 
published in the last 10 years11:20:23 59
#20Search (#5) AND#19 Limits: Humans, English, published in the last 10 years11:18:55 0
#19Search live attenuated viruses OR BCG OR yellow fever OR measles OR mumps OR 
rubella OR polio Limits: Humans, English, published in the last 10 years11:18:07 11834
#17Search (#5) AND#16 Limits: Humans, English, published in the last 10 years11:14:52 0
#16Search live attenuated bacteria Limits: Humans, English, published in the last 10 
years11:14:03 718
#15Search ((#1) AND detectable viraemia) AND#3 Limits: Humans, English, published 
in the last 10 years11:06:23 1
#14Search ((#1) AND transfusion-transmission of vaccinia ) AND#3 Limits: Humans, 
English, published in the last 10 years11:05:26 0
#13Search ((#1) AND smallpox vaccination) AND#3 Limits: Humans, English, published 
in the last 10 years11:04:10 0
#12Select 1 document(s)11:02:13 1
#11Search (#5) AND#10 Limits: Humans, English, published in the last 10 years11:02:13 1
#10Search smallpox vaccination OR detectable viraemia OR transfusion-transmission of 
vaccinia Limits: Humans, English, published in the last 10 years10:59:52 1383
#9Select 1 document(s)10:53:50 1
#8Search (#4) AND#6 Limits: Humans, English, published in the last 10 years10:53:50 1
#7Search (#5) AND#6 Limits: Humans, English, published in the last 10 years10:51:27 0
#6Search immunization with live vaccines Limits: Humans, English, published in the last 
10 years10:50:38 1663
#5Search (#1) AND#3 Limits: Humans, English, published in the last 10 years10:48:52 120
174
#4Search (#1) AND#2 Limits: Humans, English, published in the last 10 years10:48:16 1840
#3Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years10:47:41 4957
#2Search donor safety OR donor suitability OR donor risk OR donor well-being Limits: 
Humans, English, published in the last 10 years10:47:10 14706
#1Search blood donor* OR blood donat* OR donating Limits: Humans, English, published 
in the last 10 years10:46:28 7302
Number of citations screened  5
Relevant papers selected 2
Key references
1 Table 1: Summary of WHO position papers – Recommendations for routine immunization. 
World Health Organization (updated 31 May 2012). 
2 Table 3: Summary of WHO position papers – Recommendations for interrupted or 
delayed routine immunization. World Health Organization (updated 31 May 2012). 
Decision-making process
The Guideline Development Group agreed on the following recommendations 
based on the above references, and on their medical knowledge and experience 
from best practice. 
6.1.1 Post-exposure prophylaxis
Recommendations
HEPATITIS B PoST-ExPoSURE PRoPHYLAxIS 
Accept
 Individuals who have received hepatitis B post-exposure prophylaxis with 
vaccine and/or immunoglobulin: accept 12 months after exposure if they have 
been tested and found to be negative for HBsAg and negative for anti-HBc 
or, if anti-HBc positive, must have anti-HBs greater than 100 mIU/ml 
Defer
 Individuals who have received hepatitis B post-exposure prophylaxis with 
vaccine and/or immunoglobulin: defer for 12 months after exposure 
RABIES 
Defer
 Individuals who have received rabies post-exposure prophylaxis with vaccine 
and/or immunoglobulin: defer for 12 months after exposure
6.1.2 Live attenuated viral and bacterial vaccines
Recommendation
Defer
 Individuals who have received live attenuated vaccines: defer for 28 days 
following vaccination 
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6.1.3 Inactivated vaccines
Question
What deferral period, if any, should be applied to prospective blood donors who 
have recently received routine immunization with non-live vaccines or toxoids?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse events related to 
blood donation 
 Avoid unnecessary deferral of 
suitable blood donors 
 Minimize risk of transfusion-
transmitted infections or other 
adverse reactions in recipients of 
blood transfusion
Key search and MeSH words
non-live vaccines, toxoids, cholera, typhoid, rabies, tick-borne encephalitis, polio 
(injected), influenza, tetanus (vaccine and toxoid), diphtheria toxoid, HAV and HBV 
Search strategy: PUBMED
#18Search (#5) AND#15 Limits: Humans, English, published in the last 10 years17:36:00 
11
#16Search (#4) AND#15 Limits: Humans, English, published in the last 10 years17:34:12 
233
#17Select 200 document(s)17:32:44 200
#15Search HAV OR hepatitis A virus OR HBV or hepatitis B virus Limits: Humans, English, 
published in the last 10 years17:30:37 13389
#14Search (#5) AND#12 Limits: Humans, English, published in the last 10 years17:29:06 0
#13Search (#4) AND#12 Limits: Humans, English, published in the last 10 years17:27:30 14
#12Search polio injected OR influenza OR tetanus vaccine OR tetanus toxoid OR diphtheria 
toxoid Limits: Humans, English, published in the last 10 years17:25:50 21263
#11Search (#5) AND#9 Limits: Humans, English, published in the last 10 years17:22:50 0
#10Search (#4) AND#9 Limits: Humans, English, published in the last 10 years17:22:01 3
#9Search cholera OR typhoid OR rabies OR tick-borne encephalitis Limits: Humans, 
English, published in the last 10 years17:20:40 5275
#8Search (#4) AND#6 Limits: Humans, English, published in the last 10 years17:17:01 1
#7Search (#5) AND#6 Limits: Humans, English, published in the last 10 years17:14:01 0
#6Search Non-live vaccines OR toxoids Limits: Humans, English, published in the last 
10 years17:09:33 1830
#5Search (#1) AND#3 Limits: Humans, English, published in the last 10 years17:02:51 120
#4Search (#1) AND#2 Limits: Humans, English, published in the last 10 years17:02:23 
1844
#3Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years17:01:55 4969
#2Search donor safety OR donor suitability OR donor risk OR donor well-being Limits: 
Humans, English, published in the last 10 years17:01:30 14733
#1Search blood donor* OR blood donat* OR donating Limits: Humans, English, published 
in the last 10 years17:00:46 7314
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Number of citations screened  262
Relevant papers selected 2
Key references
1 Table 1: Summary of WHO position papers – Recommendations for routine immunization. 
World Health Organization (updated 31 May 2012). 
2 Table 3: Summary of WHO position papers – Recommendations for interrupted or 
delayed routine immunization. World Health Organization (updated 31 May 2012). 
Decision-making process
The Guideline Development Group therefore recommended endorsement of 
currently accepted recommendations based on published literature, medical 
principles and experience from best practice.
Recommendations
Accept
 Individuals who have received non-live vaccines and toxoids (with the exception 
of HBV vaccine) with no history or known exposure and who feel well
Defer 
 Individuals with no known exposure to hepatitis B who have recently received 
routine vaccination: defer for 14 days 
6.2 MEDICATIONS 
Question
What deferral period, if any, should be applied to prospective blood donors who 
are taking or have previously taken prescribed medications?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse events related to 
blood donation 
 Avoid unnecessary deferral of 
suitable blood donors 
 Minimize risk of adverse reactions in 
recipients of blood transfusion
Key search and MeSH words
medications, plasma concentration, teratogenic OR fetotoxic drugs, etretinate, 
actitretin, isotretinoin, dutasteride, finasteride, aspirin and non-steroidal anti-
inflammatory drugs (NSAIDs)
Search strategy: PUBMED
#29Search ((#1) AND#9) AND#1919:35:41 0
#28Select 9 document(s)19:33:58 9
#27Search ((#1) AND#6) AND#1719:33:58 9
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#26Search ((#1) AND#6) AND#1519:32:09 0
#25Search ((#1) AND#6) AND#319:30:36 1
#24Select 7 document(s)19:29:07 7
#23Search (#17) AND#419:29:07 7
#22Search ((#19) AND medication*) AND#419:25:54 5
#21Search ((#19) AND medication*) AND#519:23:15 1
#20Search ((#19) AND#9) AND#519:21:42 0
#19Search donor deferral Limits: Humans, English, published in the last 10 years19:20:17 
136
#18Search (#5) AND#17 Limits: Humans, English, published in the last 10 years19:18:12 0
#17Search Aspirin OR non-steroidal anti-inflammatory drugs OR NSAIDs Limits: Humans, 
English, published in the last 10 years19:17:36 41555
#16Search (#5) AND#15 Limits: Humans, English, published in the last 10 years19:16:39 0
#15Search retinoids OR teratogenic drugs OR Etretinate OR Actitretin OR Isotretinoin 
Limits: Humans, English, published in the last 10 years19:16:05 8808
#14Search (#4) AND#12 Limits: Humans, English, published in the last 10 years19:09:00 1
#13Search (#5) AND#12 Limits: Humans, English, published in the last 10 years19:07:38 0
#12Search Teratogenic OR fetotoxic drugs OR Etretinate OR Actitretin OR Isotretinoin 
OR Dutasteride OR Finasteride Limits: Humans, English, published in the last 10 
years19:07:06 2936
#11Search (#4) AND#9 Limits: Humans, English, published in the last 10 years19:05:24 0
#10Search (#5) AND#9 Limits: Humans, English, published in the last 10 years19:04:44 0
#9Search medication* AND plasma concentration* Limits: Humans, English, published 
in the last 10 years19:04:13 456
#8Search (#5) AND#6 Limits: Humans, English, published in the last 10 years19:02:12 1
#7Search (#4) AND#6 Limits: Humans, English, published in the last 10 years19:00:49 15
#6Search Medications Limits: Humans, English, published in the last 10 years18:59:33 
126927
#5Search (#1) AND#3 Limits: Humans, English, published in the last 10 years18:31:03 120
#4Search (#1) AND#2 Limits: Humans, English, published in the last 10 years18:30:41 
1844#3Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years18:30:18 4969
#2Search donor safety OR donor suitability OR donor risk OR donor well-being Limits: 
Humans, English, published in the last 10 years18:29:43 14733
#1Search blood donor* OR blood donat* OR donating Limits: Humans, English, published 
in the last 10 years18:29:127 314
Number of citations screened  39
Number of papers that address the study question 3
Key references
1 Becker C et al. Blood donors on medication – an approach to minimize drug burden 
for recipients of blood products and to limit deferral of donors. Transfusion Medicine 
and Hemotherapy, 2009, 36:107–113.
2 Stichtenoth D, Deicher H, Frolich J. Blood donors on medication. Are deferral periods 
necessary? European Journal of Clinical Pharmacology, 2001, 57 (4–7):433–440.
3 Park HD et al. Evaluation of the transfusion safety of blood products and determination 
of plasma concentrations of acitretin and etretinate in patients receiving transfusions. 
Transfusion. 2008, 48(11):2395–2400. 
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Decision-making process
There is no published evidence that medications in donated blood have caused 
adverse effects in a recipient, although it is unlikely that such events would be 
recognized. In the absence of any such evidence, the Guideline Development 
Group based their recommendations on their medical knowledge and experience 
from best practice. The papers of Becker and Stichtenoth provide information 
on pharmacokinetics and support the current recommendations of the US Food 
and Drug Administration with regard to deferral periods in respect of teratogenic 
and fetotoxic drugs. These recommendations are endorsed, although the work 
of Park et al suggests that they may be overly precautionary.
Recommendations regarding the use of aspirin and related drugs are based on 
well-documented knowledge of the effects of these drugs on platelet function. 
The recommendation of permanent deferral for recipients of human pituitary-derived 
growth hormone is based on the documented occurrence of CJD in such individuals.
Recommendations
 The BTS should consider the following principles in developing deferral criteria 
for medications: 
— A plasma concentration of the medication below 10% of the therapeutic 
level is highly unlikely to be harmful.
— When blood components containing < 50 ml donor plasma are 
transfused to an adult or older child (12 years of age or more), the 
plasma concentration of any medications taken by the donor will be < 
3% and can therefore be disregarded.
— If more than 50 ml plasma from a single donor is transfused, or if the 
recipient is a child less than 12 years of age, the plasma concentration 
of any donor medication may be more than 10% of the therapeutic 
level. There is no evidence that this is likely to cause harm; however, 
BTS may wish to consider additional selection criteria for apheresis 
donations and for paediatric components. Further research is needed 
in this area. 
— Aspirin and non-steroidal anti-inflammatory medications (NSAIDs) 
irreversibly inhibit platelet aggregation; platelet components should 
not routinely be prepared using donations from donors who have taken 
aspirin within 5 days or other NSAIDs within 48 hours.
— Teratogenic and fetotoxic medicines deserve particular consideration as 
there is a theoretical risk of causing a fetal abnormality in the unlikely 
event that the blood is transfused to a pregnant female during the first 
trimester. Retinoids (etretinate, acitretin, isotretinoin) are highly teratogenic. 
Dutasteride and finasteride (prescribed for benign prostatic hypertrophy) 
have been shown to cause genital abnormalities in male fetuses of 
experimental animals; there is no evidence of harm in humans. 
Accept
 Individuals taking long-term low-dose antibiotics for acne 
Defer
 Individuals taking prescribed treatment with injected medications, including 
self-administration, based on the underlying condition for which the medication 
is taken
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 Individuals who have taken the following medications: 
— Aspirin: defer for 5 days
— Other NSAIDs: defer for 48 hours
— Acitretin: defer for 3 years
— Isotretinoin: defer for 28 days
— Dutasteride: defer for 6 months
— Finasteride: defer for 28 days
— Antibiotics for acute infections: defer for 14 days after completion of 
treatment
Defer permanently
 Individuals treated with human pituitary-derived growth hormone because of 
case reports of transmission of iatrogenic Creutzfeldt-Jakob disease
6.3 BLOOD TRANSFUSION AND TRANSPLANTATION
6.3.1  Blood transfusion 
Question
What deferral period, if any, should be applied to prospective blood donors who 
have themselves received a blood transfusion?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse events related to 
blood donation 
 Avoid unnecessary deferral of 
suitable blood donors 
 Minimize risk of transfusion-
transmitted infections in recipients 
of blood transfusion
Key search and MeSH words
blood component transfusion, blood and blood products, plasma-derived clotting 
factor, pre-operative autologous donation.
Search strategy: PUBMED
#22Search (blood component transfusion recipient*) AND#5 Limits: Humans, English, 
published in the last 10 years17:44:13 4
#23Search (plasma-derived clotting factor recipient*) AND#5 Limits: Humans, English, 
published in the last 10 years17:40:31 0
#21Search (plasma-derived clotting factor recipient*) AND donor deferral Limits: Humans, 
English, published in the last 10 years17:23:54 0
#20Search (blood component transfusion recipient) AND donor deferral Limits: Humans, 
English, published in the last 10 years17:21:00 1
#19Search (#6) AND donor deferral Limits: Humans, English, published in the last 10 
years17:18:05 1
#18Search (donor deferral) AND blood component transfusion Limits: Humans, English, 
published in the last 10 years17:16:10 11
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#17Search (#5) AND pre-operative autologous donation Limits: Humans, English, published 
in the last 10 years17:11:40 0
#16Search (#4) AND pre-operative autologous donation, Limits: Humans, English, published 
in the last 10 years17:09:56 2
#15Search (blood donor* AND plasma-derived clotting factor) AND#3 Limits: Humans, 
English, published in the last 10 years17:07:41 0
#14Search (#5) AND#12 Limits: Humans, English, published in the last 10 years17:06:09 0
#13Search (#4) AND#12 Limits: Humans, English, published in the last 10 years17:05:07 3
#12Search plasma-derived clotting factor Limits: Humans, English, published in the last 
10 years17:03:56 354
#11Search (blood donor* AND blood and blood products) AND#3 Limits: Humans, English, 
published in the last 10 years17:02:22 13
#8Search (#5) AND#6 Limits: Humans, English, published in the last 10 years16:58:40 27
#10Search (#5) AND#9 Limits: Humans, English, published in the last 10 years16:39:49 27
#9Search Blood component transfusion Limits: Humans, English, published in the last 
10 years16:38:50 5407
#7Search (#4) AND#6 Limits: Humans, English, published in the last 10 years16:34:23 27
#6Search blood component transfusion AND recipient Limits: Humans, English, published 
in the last 10 years16:31:59 224
#5Search (#1) AND#3 Limits: Humans, English, published in the last 10 years16:30:49 112
#4Search (#1) AND#2 Limits: Humans, English, published in the last 10 years16:30:24 1795
#3Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years16:28:56 4964
#2Search donor safety OR donor suitability OR donor risk OR donor well-being Limits: 
Humans, English, published in the last 10 years16:28:32 14726
#1Search blood donor* OR blood donat* OR donating blood Limits: Humans, English, 
published in the last 10 years16:26:22 6834
Number of citations screened  116
Number of papers that address the study question 0
Key references
None identified
Decision-making process
Blood transfusion is a known risk factor for HIV, hepatitis B and hepatitis C. 
Recommendations for the deferral of prospective donors following transfusion 
are therefore consistent with other risk factors for infection. The Guideline 
Development Group agreed on the following recommendations based on their 
medical and scientific knowledge and experience from best practice.
Recommendations
Accept
 Individuals whose sexual partners or close contacts have received blood 
transfusions 
Defer
 Recipients of blood transfusion: defer for 12 months
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 Former sexual contacts of individuals on regular treatment with plasma-derived 
coagulation factors: defer for 12 months after last sexual contact
 Current sexual contacts of individuals on regular treatment with plasma-derived 
coagulation factors 
Defer permanently 
 Recipients of blood transfusion or any other human-derived therapeutic products 
since 1980 in a country in which the risk of vCJD has been identified 
 Individuals on regular treatment with plasma-derived coagulation factors 
6.3.2 Organ, stem cell and tissue transplantation 
Question
What deferral period should be applied to prospective blood donors who have 
themselves received an organ or tissue transplant?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse events related to 
blood donation 
 Avoid unnecessary deferral of 
suitable blood donors 
 Minimize risk of transfusion-
transmitted infections in recipients 
of blood transfusion
Key search and MeSH words
organ transplantation, allogeneic blood transfusion, allogeneic tissue grafts, 
tissue grafts, dura mater grafts, xenografts, corneal transplants, non-human 
organ perfusion
Search strategy: PUBMED
#29Search non-human AND organ perfusion Limits: Humans, English, published in the 
last 10 years13:49:06 0
#28Search non-human organ perfusion Limits: Humans, English, published in the last 
10 years13:47:54 0
#27Search (#17) AND#25 Limits: Humans, English, published in the last 10 years13:41:27 4
#26Search (#16) AND#25 Limits: Humans, English, published in the last 10 years13:39:18 
21
#25Search allogeneic tissue grafts OR tissue grafts OR dura mater grafts OR xenograft 
Limits: Humans, English, published in the last 10 years13:34:45 30318
#24Search allogeneic tissue grafts OR tissue grafts OR dura mater grafts OR xenografts, 
Limits: Humans, English, published in the last 10 years13:34:17 25462
#23Search (#17) AND organ transplantation* recipient* OR corneal transplant* recipient* 
Limits: Humans, English, published in the last 10 years13:31:30 237
#22Search (#17) AND allogeneic blood transfusion Limits: Humans, English, published 
in the last 10 years13:26:15 5
#21Search (#16) AND allogeneic blood transfusion Limits: Humans, English, published 
in the last 10 years13:22:34 68
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#18Search (#16) AND organ transplantation* recipient* OR corneal transplant* recipient* 
Limits: Humans, English, published in the last 10 years13:18:24 239 
#17Search (#2) AND#4 Limits: Humans, English, published in the last 10 years13:09:16 
112
#16Search (#2) AND#3 Limits: Humans, English, published in the last 10 years13:08:36 
1795
#15Search ((#2) AND#14) AND#4 Limits: Humans, English, published in the last 10 
years13:04:21 5
#14Search allogeneic blood transfusion OR corneal transplants Limits: Humans, English, 
published in the last 10 years13:01:38 4926
#13Search (organ transplantation recipient*) AND donor suitability Limits: Humans, 
English, published in the last 10 years12:55:33 0
#11Select 2 document(s)12:54:17 2
#10Search (organ transplantation recipient*) AND#3 Limits: Humans, English, published 
in the last 10 years12:48:04 2
#9Search (organ transplantation recipient*) AND#2 Limits: Humans, English, published 
in the last 10 years12:46:12 0
#4Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years12:40:52 4964
#3Search donor safety OR donor suitability OR donor risk OR donor well-being Limits: 
Humans, English, published in the last 10 years12:40:26 14726
#2Search blood donor* OR blood donat* OR donating blood Limits: Humans, English, 
published in the last 10 years12:39:48 6834
#1Search blood donor* OR blood donat* OR donating blood12:39:17 26528
Number of citations screened  574
Relevant papers selected 2
Key references
1 Guidelines for the blood transfusion services in the United Kingdom: donor selection 
guidelines, 7th edition. London, UK Blood Transfusion & Tissue Transplantation Services, 
2005
2 Becker C et al. Blood donors on medication – an approach to minimize drug burden 
for recipients of blood products and to limit deferral of donors. Transfusion Medicine 
and Hemotherapy, 2009, 36:107–113.
Decision-making process
There is no published evidence of transfusion-transmitted infection from a donor 
who was the recipient of a tissue transplant. In view of the theoretical risk, the 
Guideline Development Group agreed that the same recommendations should 
be applied as for recipients of labile blood components. 
Recommendations
Defer
 Recipients of allogeneic tissues: defer for 12months 
Defer permanently
 Recipients of:
— Stem cell or organ transplantation
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— Allogeneic cells or tissue sourced since 1980 from countries in which 
the risk of vCJD has been identified 
— Dura mater graft
— Corneal transplant
— Xenograft 
— Non-human organ perfusion
6.4 DIAGOSTIC AND SURGICAL PROCEDURES,
Question
What deferral period, if any, should be applied to prospective blood donors who 
have undergone a recent diagnostic procedure?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse events related to 
blood donation 
 Avoid unnecessary deferral of 
suitable blood donors 
 Minimize risk of transfusion-
transmitted infections in recipients 
of blood transfusion
Key search and MeSH words
biopsy, endoscopy, endoscope
blood transfusion, blood donor, blood donation, donor selection, suitab-, eligib-, 
defer, accept
Search strategy: PUBMED
#15Search ((#2) AND#6) AND#7 Limits: Humans, English, published in the last 10 
years11:23:22 19
#14Search ((#1) AND#6) AND#7 Limits: Humans, English, published in the last 10 
years11:22:21 52
#13Search (#5) AND#6 Limits: Humans, English, published in the last 10 years11:19:12 67
#12Search (#5) AND#8 Limits: Humans, English, published in the last 10 years11:17:56 0
#11Search (#4) AND#8 Limits: Humans, English, published in the last 10 years11:17:11 13
#10Search (#9) AND#3 Limits: Humans, English, published in the last 10 years11:14:45 54
#9Search (#4) AND#6 Limits: Humans, English, published in the last 10 years11:13:59 305
#8Search (#6) AND#7 Limits: Humans, English, published in the last 10 years11:13:07 166
#7Search HCV transmission Limits: Humans, English, published in the last 10 
years11:12:33 1839
#6Search biopsy OR endoscopy OR endoscope OR invasive investigation Limits: Humans, 
English, published in the last 10 years11:08:17 731927
#5Search (#1) AND#3 Limits: Humans, English, published in the last 10 years11:05:36 353
#4Search (#1) AND#2 Limits: Humans, English, published in the last 10 years11:05:01 
2739
#3Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years11:04:30 5021
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#2Search donor safety OR donor suitability OR donor risk OR donor well-being OR donor 
defer* OR donor eligibility OR donor selection OR donor accept* Limits: Humans, English, 
published in the last 10 years11:04:01 16409
#1Search blood donor* OR blood donat* OR donating blood OR blood transfusion Limits: 
Humans, English, published in the last 10 years11:03:26 28992
Number of citations screened  676
Number of papers that address the study question 2
Key references
1 Bronowicki J-P et al. Patient-to-patient transmission of hepatitis C virus during 
colonoscopy. New England Journal of Medicine, 1997, 337 (4):237–240.
2 Ciancio A et al. Digestive endoscopy is not a major risk factor for transmitting hepatitis 
C virus. Annals of Internal Medicine, 2005, 142(11):903–909.
Decision-making process 
Patient-to-patient transmission of HCV has been reported, following flexible 
endoscopy with biopsy. The Guideline Development Group agreed on the following 
recommendations based on a precautionary deferral period of 12 months. 
Recommendations
Defer
 Individuals who have undergone:
— Minor diagnostic procedures including rigid endoscopy: defer until they 
have resumed normal activity 
— Invasive diagnostic procedures using flexible endoscopy: defer for 12 
months 
Question
What deferral period should be applied to prospective blood donors who have 
undergone a recent surgical procedure, including dental treatment?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Minimize adverse events related to 
blood donation 
 Avoid unnecessary deferral of 
suitable blood donors 
 Minimize risk of transfusion-
transmitted infections in recipients 
of blood transfusion
Key search and MeSH words
blood transfusion, blood donor, blood donation, donor selection, suitab-, eligib-, 
defer, accept
adverse event, risk, surgery, surgical, neurosurgery, duramater graft, corneal 
transplant
dental surgery, dental treatment, endodontic treatment, tooth extraction
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Search strategy: PUBMED
#16 Search (dura mater graft OR corneal transplant ) AND#5 Limits: Humans, English, 
published in the last 10 years 10:06:44 2
#15 Search ((#1) AND dura mater graft OR corneal transplant ) AND#3 Limits: Humans, 
English, published in the last 10 years 09:59:14 90
#14 Search (dura mater graft OR corneal transplant ) AND#4 Limits: Humans, English, 
published in the last 10 years 09:57:45 6
#13 Search ((#7) AND blood transfusion) AND#3 Limits: Humans, English, published in 
the last 10 years 09:55:19 0
#12 Search (#5) AND#7 Limits: Humans, English, published in the last 10 years 09:54:05 0
#11 Search (#4) AND#7 Limits: Humans, English, published in the last 10 years 09:53:16 15
#10 Search (#5) AND#6 Limits: Humans, English, published in the last 10 years 08:50:02 
307
#9 Search (#8) AND#3 Limits: Humans, English, published in the last 10 years 08:45:06 
245
#8 Search (#4) AND#6 Limits: Humans, English, published in the last 10 years 08:25:21 
2072
#7 Search dental surgery OR dental treatment OR endodontic treatment OR tooth extraction 
Limits: Humans, English, published in the last 10 years 08:18:51 44455
#6 Search surgery OR elective surgery OR surgical OR neurosurgery OR neurosurgical 
procedure OR dura mater graft OR corneal transplant OR risk OR adverse event Limits: 
Humans, English, published in the last 10 years 08:17:13 1308650
#5 Search (#1) AND#3 Limits: Humans, English, published in the last 10 years 08:08:22 
353
#4 Search (#1) AND#2 Limits: Humans, English, published in the last 10 years 08:07:48 
2739
#3 Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years 08:07:14 5021
#2 Search donor safety OR donor suitability OR donor risk OR donor well-being OR donor 
defer* OR donor eligibility OR donor selection OR donor accept* Limits: Humans, English, 
published in the last 10 years 08:06:15 16409
#1 Search blood donor* OR blood donat* OR donating blood OR blood transfusion Limits: 
Humans, English, published in the last 10 years 08:02:32 28992
Number of citations screened  665
Number of papers that address the study question 3
Key references
1 Kinane D et al. Bacteraemia following periodontal procedures. Journal of Clinical 
Periodontology, 2005, 32:708–713.
2 Rajasuo A et al. Bacteremia following surgical dental extraction with an emphasis on 
anaerobic strains. Journal of Dental Research, 2004, 83 (2):170–174.
3 Olsen I. Update on bacteraemia related to dental procedures. Transfusion and Apheresis 
Science, 2008, 39(2):173–178.
Decision-making process
There is no published evidence to guide recommendations regarding recent 
minor or major surgical procedures. The Guideline Development Group therefore 
agreed on the following recommendations based on the above studies and on 
their medical knowledge and experience from best practice.
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With regard to dental procedures, the above studies provide evidence for transient 
bacteraemia following dental treatment and the study by Olsen supports the 
widely implemented and agreed recommendation for 24-hour deferral.
The recommendations made by the Guideline Development Group regarding 
neurosurgery, dura mater grafts and corneal transplant are consistent with 
precautions against the possible transfusion-transmission of iatrogenic CJD.
Recommendations
Defer
 Individuals who have undergone:
— Minor surgical procedures: defer until treatment is complete and 
successful and they have resumed normal activity 
— Major surgery: defer for 12 months 
— Dental treatment: defer for 24 hours following simple procedures and up 
to 7 days following endodontic procedures (root canal therapy) or extraction 
7 TTI and donor risk assessment
7.3 VIRAL INFECTIONS
7.3.1 Hepatitis 
Hepatitis B 
Question
What should be the criteria for the acceptance or deferral of prospective blood 
donors with HBV infection or at specific risk of exposure to HBV infection, including:
 Individuals with HBV infection or a past history of HBV infection
 Current and former sexual contacts of individuals with HBV infection 
 Current and former close household contacts of individuals with HBV 
infection 
 Health workers at risk of exposure to HBV
 Individuals who have had acupuncture, piercing or tattoos, or any other 
invasive cosmetic or cultural procedures 
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Prevent transmission of HBV 
infection to recipients of blood 
transfusion 
 Avoid unnecessary deferrals of 
suitable blood donors
 Provide safe and sufficient blood 
supply
Key search and MeSH words
hepatitis B, HBV, blood transfusion, blood donor, blood donation, HBV vaccination 
donor selection, suitab*, eligib*, defer, accept, sexual partner, sexual contact, 
household contact, immune*, tattoo, acupuncture, piercing, cosmetic, scarification
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Search strategy: PUBMED
#15Search (tattoo OR acupuncture OR piercing OR cosmetic OR scarification) AND#6 
Limits: Humans, English, published in the last 10 years08:10:53 6
#14Search ((donor suitab* OR donor eligib* OR donor defer OR donor accept*) AND 
sexual partner OR sexual contact OR household contact) AND#5 Limits: Humans, English, 
published in the last 10 years08:05:24 93
#13Search (#12) AND#3 Limits: Humans, English, published in the last 10 years07:44:57 84
#12Search (blood transfusion OR blood donor OR blood donation) AND Hepatitis B OR HBV 
OR HBV vaccination Limits: Humans, English, published in the last 10 years07:37:49 9872
#10Search (sexual partner, sexual contact, household contact, ) AND#6 Limits: Humans, 
English, published in the last 10 years07:33:38 0
#7Search (#6) AND#3 Limits: Humans, English, published in the last 10 years07:08:56 11
#6Search (#4) AND#5 Limits: Humans, English, published in the last 10 years07:04:22 301
#5Search Hepatitis B OR HBV OR HBV vaccination Limits: Humans, English, published 
in the last 10 years07:00:04 18233
#4Search (#1) AND#2 Limits: Humans, English, published in the last 10 years06:45:37 
1903#3Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years06:43:24 4995
#2Search donor safety OR donor suitability OR donor risk OR donor well-being OR donor 
defer* OR donor eligibl* OR donor selection Limits: Humans, English, published in the 
last 10 years06:40:51 16192
#1Search blood donor* OR blood donat* OR donating blood Limits: Humans, English, 
published in the last 10 years06:38:15 6801
Number of citations screened  495
Number of papers that address the study question 3
Key references 
1 Weinbaum CM et al. Recommendations for identification and public health management 
of persons with chronic hepatitis B virus infection. Morbidity and Mortality Weekly 
Report (MMWR), Recommendations and Reports, 2008, 57(RR08):1–20.
2 Pereira A et al. Do patient-related blood donors represent a threat to the safety of 
the blood supply? Haematologica, 2002, 87(4):427–433. 
3 Goldman M et al. Reassessment of deferrals for tattooing and piercing. Transfusion, 
2009, 49(4):648–654. 
Decision-making process
The transmission of HBV through close (household) contact is relatively 
commonplace, but mainly in children. However, sexual contact is one of the main 
routes of infection among adolescents and adults in areas of low endemicity. 
Weinbaum et al have determined that 14%–60% of persons living in households 
with individuals with chronic HBV infection have serologic evidence indicating 
resolved HBV infection, and 3%–20% have evidence indicating chronic infection. 
The risk for infection is highest among unvaccinated children living with a person 
with chronic HBV infection in a household or in an extended family setting and 
among sex partners of chronically infected persons.
No increased risks of transfusion-transmission of HBV have been identified in 
donors with close relatives who have received blood. 
The reduction of the deferral period from 12 months to 4 months following tattooing 
or piercing did not increase the prevalence of markers of HBV or HCV infection.
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Based on the available evidence and their expert knowledge and experience 
from best practice, the Guideline Development Group agreed on the following 
recommendations.
Recommendations
Accept
 The following individuals may be accepted for blood donation provided they 
have been tested and found to be negative for HBsAg, and negative for anti-
HBc; if anti-HBc positive, they must have anti-HBs greater than 100 mIU/ml: 
— Individuals with a past history of HBV if more than 12 months 
ago 
— Current sexual contacts of individuals with a history of HBV infection 
if more than 12 months ago 
— Current and former household contacts who have been successfully 
immunized against HBV and are anti-HBs positive more than 100 mIU/
ml but anti-HBc negative 
— Donors with initially reactive results for HBsAg but confirmed to be 
non-reactive: re-entry procedures should be established and followed
Defer 
 Individuals with active HBV infection or a history of infection within the last 
12 months
 Current sexual and household contacts of individuals with active HBV infection
 Former sexual contacts of individuals with active HBV infection: defer for 12 
months since last sexual contact
 Former household contacts of individuals with active HBV infection: defer for 
6 months since last contact 
 Health workers who have suffered an inoculation or mucosal injury: defer for 
12 months following the exposure; health workers who have been vaccinated 
against HBV should be assessed individually 
Hepatitis C
Question
What should be the criteria for acceptance or deferral of prospective blood donors 
with HCV infection or at specific risk of exposure to HCV infection, including:
 Individuals with HCV infection or a past history of HCV infection
 Current and former sexual contacts of individuals with HCV infection 
 Current and former close household contacts of individuals with HCV 
infection 
 Health workers at risk of exposure to HCV
 Individuals who have had acupuncture, piercing or tattoos, or any other 
invasive cosmetic or cultural procedures 
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Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Prevent transmission of HCV 
infection to recipients of blood 
transfusion 
 Avoid unnecessary deferrals of 
suitable blood donors
 Provide safe and sufficient blood 
supply
Key search and MeSH words
hepatitis C, HCV, blood transfusion, blood donor, blood donation 
donor selection, suitab-, eligib-, defer, accept, sexual partner, sexual contact, 
household contact, tattoo, acupuncture, piercing, cosmetic, scarification
Search strategy: PUBMED
#20Search (tattoo OR acupuncture OR piercing OR cosmetic OR scarification) AND#6 
Limits: Humans, English, published in the last 10 years08:11:42 7
#19Search (#18) AND#3 Limits: Humans, English, published in the last 10 years08:07:08 0
#18Search ((donor suitab* OR donor eligib* OR donor defer OR donor accept*) AND 
sexual partner OR sexual contact OR household contact) AND#5 Limits: Humans, English, 
published in the last 10 years08:03:29 78
#17Search (#15) NOT#16 Limits: Humans, English, published in the last 10 years08:01:02 24
#16Search organ transplantation OR kidney transplantation OR liver transplantation Limits: 
Humans, English, published in the last 10 years07:58:07 70972
#15Search (#14) AND#3 Limits: Humans, English, published in the last 10 years08:17:06 160
#14Search (blood transfusion OR blood donor OR blood donation) AND Hepatitis C OR 
HCV Limits: Humans, English, published in the last 10 years07:51:53 16012
#13Search (#11) AND#3 Limits: Humans, English, published in the last 10 years07:41:56 0
#12Search (#11) AND#2 Limits: Humans, English, published in the last 10 years07:41:02 0
#11Search (sexual partner, sexual contact, household contact) AND#5 Limits: Humans, 
English, published in the last 10 years07:39:19 4
#7Search (#6) AND#3 Limits: Humans, English, published in the last 10 years07:33:42 14
#6Search (#4) AND#5 Limits: Humans, English, published in the last 10 years07:30:24 385
#5Search Hepatitis C OR HCV Limits: Humans, English, published in the last 10 
years07:29:11 25824
#4Search (#1) AND#2 Limits: Humans, English, published in the last 10 years07:27:28 
1904
#3Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years07:25:10 4996
#2Search donor safety OR donor suitability OR donor risk OR donor well-being OR donor 
defer* 
OR donor eligibl* OR donor selection Limits: Humans, English, published in the last 10 
years07:24:38 16198
#1Search blood donor* OR blood donat* OR donating blood Limits: Humans, English, 
published in the last 10 years07:24:00 6805
Number of citations screened  280
Number of papers that address the study question 17
Selected key articles  5
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Key references
1 Cavalheiro Nde P. Sexual transmission of hepatitis C. Revista do Instituto de Medicina 
Tropical de São Paulo. 2007, 49(5):271–277.
2 Cavalheiro Nde P et al. Hepatitis C virus: molecular and epidemiological evidence 
of male-to-female transmission. Brazilian Journal of Infectious Diseases, 2010, 
14(5):427–432.
3 Nguyen O et al. Acute hepatitis C infection with evidence of heterosexual transmission. 
Journal of Clinical Virology, 2010, 49(1):65–68. 
4 Orlando R, Lirussi F. Hepatitis C virus infection: sexual or non-sexual transmission 
between spouses? A case report and review of the literature. Infection, 2007, 
35(6):465–468. 
5 Lock G et al. Hepatitis C – contamination of toothbrushes: myth or reality? Journal 
of Viral Hepatitis, 2006, 13(9):571–573. 
Decision-making process
Although a controversial issue, it can be concluded that there is evidence of 
sexual transmission of hepatitis C, although the efficiency is lower than that 
seen for HBV and HIV. Co-infection with HIV increases the probability of HCV 
transmission through sexual contact, but this is not relevant in this context. In 
addition, direct blood contact in the household environment, from needlestick 
injuries and sharing of items, has resulted in transmission between partners 
and other household contacts.
Based on the available evidence, and their medical and scientific knowledge 
and expertise, the Guideline Development Group agreed on the following 
recommendations.
Recommendations
Accept
 Household contacts of individuals with HCV infection
Defer
 Current sexual contacts of individuals with current or past HCV infection
 Former sexual contacts of individuals with HCV infection: defer for 12 months 
since last sexual contact
 Health workers who have suffered an inoculation or mucosal injury: defer for 
12 months following the exposure 
Defer permanently 
 Individuals with current or past HCV infection 
Hepatitis A, hepatitis E and hepatitis of unknown origin 
Question
What should be the criteria for the acceptance or deferral of prospective blood 
donors with hepatitis A or hepatitis E infection or hepatitis of unknown origin 
or at specific risk of exposure to HAV or HEV infection or hepatitis of unknown 
origin infection, including:
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 Individuals with hepatitis A or hepatitis E infection or hepatitis of unknown 
origin or a past history of hepatitis A or hepatitis E infection or hepatitis 
of unknown origin 
 Current and former sexual contacts of Individuals with hepatitis A or 
hepatitis E infection or hepatitis of unknown origin
 Current and former close household contacts of individuals with hepatitis 
A or hepatitis E infection or hepatitis of unknown origin
 Health workers at risk of exposure to hepatitis A or hepatitis E infection 
or hepatitis of unknown origin
 Individuals who have had acupuncture, piercing or tattoos, or any other 
invasive cosmetic or cultural procedures 
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Prevent transmission of hepatitis A 
or hepatitis E infection or hepatitis of 
unknown origin to recipients of blood 
transfusion 
 Avoid unnecessary deferrals of 
suitable blood donors
 Provide safe and sufficient blood 
supply
Key search and MeSH words
hepatitis A, HAV, hepatitis E, HEV, unknown origin, blood transfusion, blood donor, 
blood donation, HAV vaccination
donor selection, suitab-, eligib-, defer, accept, sexual partner, sexual contact, 
household contact, health workers
Search strategy: PUBMED
#30Search (#28) AND#22 Limits: Humans, English, published in the last 10 years13:33:57 
1
#29Search (#28) AND#3 Limits: Humans, English, published in the last 10 years13:31:49 0
#28Search ((health workers AND at risk) ) AND#21 Limits: Humans, English, published 
in the last 10 years13:30:25 12
#27Search (#25) AND#3 Limits: Humans, English, published in the last 10 years13:16:14 0
#26Search (#23) AND#25 Limits: Humans, English, published in the last 10 years12:56:47 
0
#25Search (sexual partner OR sexual contact OR household contact) AND#21 Limits: 
Humans, English, published in the last 10 years12:44:15 1
#24Search (#23) AND#3 Limits: Humans, English, published in the last 10 years11:21:39 2
#23Search (#22) AND#21 Limits: Humans, English, published in the last 10 years11:19:50 
38
#22Search (blood transfusion OR blood donor OR blood donation ) AND donor safety OR 
donor suitability OR donor risk OR donor well-being OR donor defer* OR donor OR donor 
eligibl* OR donor selection OR donor accept Limits: Humans, English, published in the 
last 10 years11:17:19 43898
#21Search hepatitis E OR HEV OR (hepatitis of unknown origin) Limits: Humans, English, 
published in the last 10 years10:54:09 1280
#20Search blood transfusion OR blood donor OR blood donation AND HAV vaccination 
Limits: Humans, English, published in the last 10 years10:48:10 8
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#19Search (#16) AND#3 Limits: Humans, English, published in the last 10 years10:39:11 0
#18Search (#16) AND#2 Limits: Humans, English, published in the last 10 years10:32:29 2
#17Search (#16) AND#1 Limits: Humans, English, published in the last 10 years10:30:02 3
#16Search (health workers AND at risk) AND#5 Limits: Humans, English, published in 
the last 10 years10:25:19 29
#15Search (#11) AND#1 Limits: Humans, English, published in the last 10 years09:57:13 0
#14Search (#11) AND#2 Limits: Humans, English, published in the last 10 years09:53:06 0
#13Search (#11) AND#3 Limits: Humans, English, published in the last 10 years09:50:58 0
#11Search (sexual partner OR sexual contact OR household contact ) AND#5 Limits: 
Humans, English, published in the last 10 years09:49:04 40
#10Search (#9) AND blood transfusion Limits: Humans, English, published in the last 
10 years09:44:55 1
#9Search (#5) AND#3 Limits: Humans, English, published in the last 10 years09:38:30 9
#8Search ((#1) AND#5) AND#3 Limits: Humans, English, published in the last 10 
years09:26:07 0
#7Search (#6) AND#3 Limits: Humans, English, published in the last 10 years09:25:06 0
#6Search (#4) AND#5 Limits: Humans, English, published in the last 10 years09:22:51 12
#5Search Hepatitis A OR HAV Limits: Humans, English, published in the last 10 
years09:20:53 2461
#4Search (#1) AND#2 Limits: Humans, English, published in the last 10 years09:19:17 
1906
#3Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years09:18:17 5000
#2Search donor safety OR donor suitability OR donor risk OR donor well-being OR donor 
defer* OR donor eligibl* OR donor selection Limits: Humans, English, published in the 
last 10 years09:16:25 16211
#1Search blood donor* OR blood donat* OR donating blood Limits: Humans, English, 
published in the last 10 years09:11:01 6809
Number of citations screened  106
Selected key articles 5
Key reference
1 Sherertz RJ, Russell BA, Reuman PD. Transmission of hepatitis A by transfusion of 
blood products. Archives of Internal Medicine, 1984, 144(8):1579–1580.
2 Noble RC et al. Posttransfusion Hepatitis A in a neonatal intensive care unit. Journal 
of the American Medical Association, 1984, 252(19):2711–2715.
3 Hollinger FB. Posttransfusion hepatitis type A. Journal of the American Medical 
Association, 1983, 250(17):2313–2317.
4 Azimi PH et al. Transfusion-acquired hepatitis A in a premature infant with secondary 
nosocomial spread in an intensive care nursery. American Journal of Diseases of 
Children, 1986, 40(1):23–27.
5 Lee CK et al. Prevention of transfusion-transmitted hepatitis E by donor-initiated self 
exclusion. Transfusion Medicine, 2005, 15(2):133–135. 
Decision-making process
HAV and HEV are both enteroviruses that, although normally transmitted via 
the faeco-oral route, may be transmitted by transfusion if virus is present at a 
sufficiently high level. 
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Both HAV and HEV infections may be asymptomatic and therefore individuals who 
are infected and viraemic may present to donate. Donor selection is therefore 
not an effective means of identifying HAV or HEV infected donors. However, the 
retrospective reporting of diagnosed infections in the month following donation 
may prevent the issue of products that may transmit infection and/or enable 
the monitoring of treatment of recipients of such donations. 
The Guideline Development Group agreed on the following recommendations, 
based on the above papers, their medical and scientific knowledge, and experience 
from best practice.
Recommendations
Defer
 Individuals with HAV, HEV and hepatitis of unknown origin: defer for 12 months 
after full recovery 
 Sexual contacts, household and other close contacts of individuals with HAV, 
HEV or hepatitis of unknown origin: defer for 12 months since last contact
7.3.2 Human immunodeficiency virus/Acquired 
immunodeficiency syndrome (HIV/AIDS)
Question
What should be the criteria for acceptance or deferral of prospective blood donors 
with HIV infection or at specific risk of exposure to HIV infection, including:
 Individuals with HIV infection or a past history of HIV infection
 Current and former sexual partners of individuals with HIV infection 
 Current and former close household contacts of individuals with HIV infection 
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Prevent transmission of HIV infection 
to recipients of blood transfusion 
 Avoid unnecessary deferrals of 
suitable blood donors
 Provide safe and sufficient blood 
supply
Key search and MeSH words
human immunodeficiency virus, HIV, blood transfusion, blood donor, blood donation 
donor selection, suitab-, eligib-, defer, accept, sexual partner, sexual contact, 
household contact, tattoo, acupuncture, piercing, cosmetic, scarification
Search strategy: PUBMED
#18Search ((#2) AND tattoo OR acupuncture OR piercing OR cosmetic OR scarification) 
AND#8 Limits: Humans, English, published in the last 10 years14:51:37 1
#17Search (tattoo OR acupuncture OR piercing OR cosmetic OR scarification) AND#14 
Limits: Humans, English, published in the last 10 years14:36:47 0
#16Search (tattoo OR acupuncture OR piercing OR cosmetic OR scarification) AND#7 
Limits: Humans, English, published in the last 10 years14:35:10 4
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#15Search ((#2) AND#11) AND#3 Limits: Humans, English, published in the last 10 
years14:31:18 1
#14Search (#5) AND#6 Limits: Humans, English, published in the last 10 years14:12:03 25
#13Search (#11) AND#3 Limits: Humans, English, published in the last 10 years14:08:27 3
#12Search (#11) AND#2 Limits: Humans, English, published in the last 10 years14:26:18 33
#11Search (#9) AND#6 Limits: Humans, English, published in the last 10 years14:02:59 
4684#9Search sexual partner OR sexual contact OR household contact Limits: Humans, 
English, published in the last 10 years14:00:56 11624
#8Search (#3) AND#6 Limits: Humans, English, published in the last 10 years13:55:07 106
#7Search (#4) AND#6 Limits: Humans, English, published in the last 10 years13:48:26 435
#6Search Human immunodeficiency virus OR HIV Limits: Humans, English, published in 
the last 10 years13:36:24 95462
#5Search (#1) AND#3 Limits: Humans, English, published in the last 10 years13:28:41 354
#4Search (#1) AND#2 Limits: Humans, English, published in the last 10 years13:28:02 
2733
#3Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years13:27:33 5026
#2Search donor safety OR donor suitability OR donor risk OR donor well-being OR donor 
defer* OR donor eligibil* OR donor selection Limits: Humans, English, published in the 
last 10 years13:27:08 16268
#1Search blood donor* OR blood donat* OR donating blood OR blood transfusion Limits: 
Humans, English, published in the last 10 years13:22:25 29045
Number of citations screened  962
Relevant papers identified 2
Key references
1 HIV/AIDS. Fact sheet N° 360, July 2012. Geneva, World Health Organization, 2012 
(http://www.who.int/mediacentre/factsheets/fs360/en/index.html accessed on 11 
August 2012).
2 Baggaley RF et al. Risk of HIV-1 transmission for parenteral exposure and blood 
transfusion: a systematic review and meta-analysis. AIDS, 2006, 20:805–812.
Decision-making process
No publications were identified that directly address the specific questions as 
sexual partners of HIV-infected individuals have always been excluded from blood 
donation. There is no evidence of infection from household contact. 
The Guideline Development Group agreed on the following recommendations 
based on the above mentioned papers, their medical and scientific knowledge 
and experience from best practice.
Recommendations
Accept
 Household contacts of individuals with HIV infection
Defer
 Current sexual contacts of individuals with HIV infection 
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 Former sexual contacts of individuals with HIV infection: defer for 12 months 
since last sexual contact
Defer permanently
 Individuals with present or past clinical or laboratory evidence of HIV infection
7.3.3 HTLV I and HTLV II
Question
What should be the criteria for acceptance or deferral of prospective blood 
donors with HTLV I and/or II infection or at specific risk of exposure to HTLV I 
and/or II infection, including:
 Individuals with HTLV I and/or II infection or a past history of HTLV I 
and/or II infection 
 Individuals whose mother or maternal grandmother has/had HTLV I and/
or II infection
 Current and former sexual partners of Individuals with HTLV I and/or II 
infection 
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Prevent transmission of HTLV 
infection to recipients of blood 
transfusion 
 Avoid unnecessary deferrals of 
suitable blood donors
 Provide safe and sufficient blood 
supply
Key search and MeSH words
human T-lymphotropic virus, HTLV, blood transfusion, blood donor, blood donation 
donor selection, suitab-, eligib-, defer, accept, mother-to-child, vertical transmission, 
sexual partner, sexual contact 
Search strategy: PUBMED
#15Search (#13) AND#3 Limits: Humans, English, published in the last 10 years08:39:07 0
#13Search ((donor suitab* OR donor eligib* OR donor defer OR donor accept*) AND 
sexual partner OR sexual contact ) AND#5 Limits: Humans, English, published in the 
last 10 years08:37:18 12
#12Search (#9) AND#3 Limits: Humans, English, published in the last 10 years07:29:31 0
#11Search (#9) AND#10 Limits: Humans, English, published in the last 10 years07:27:12 0
#10Search (#1) AND#3 Limits: Humans, English, published in the last 10 years07:26:18 
351
#9Search (#8) AND#5 Limits: Humans, English, published in the last 10 years07:22:34 63
#8Search mother-to-child OR vertical transmission Limits: Humans, English, published 
in the last 10 years07:04:09 5634
#7Search ((#1) AND#5) AND#3 Limits: Humans, English, published in the last 10 
years07:02:12 3
#6Search (#4) AND#5 Limits: Humans, English, published in the last 10 years06:58:30 70
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#5Search Human T-lymphotropic virus OR HTLV Limits: Humans, English, published in 
the last 10 years06:55:47 2346
#4Search (#1) AND#2 Limits: Humans, English, published in the last 10 years06:53:56 
2720
#3Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years06:51:58 5000
#2Search donor safety OR donor suitability OR donor risk OR donor well-being OR donor 
defer* OR donor eligibl* OR donor selection OR donor accept* Limits: Humans, English, 
published in the last 10 years06:51:10 16322
#1Search blood donor* OR blood donat* OR donating blood OR blood transfusion Limits: 
Humans, English, published in the last 10 years06:50:23 28925
Number of citations screened  148
Number of papers that address the study question 2
Key references
1 Lefrère JJ. Human T-lymphotropic virus type I (HTLV-I): risk of transmission with 
transfusion. La Presse Médicale, 2000, 29(20):1134–1138.
2 Eshima N et al. Analysis of the infection system of human T-cell leukaemia virus 
type I based on a mathematical epidemic model. Statistics in Medicine, 2001, 
20(24):3891–3900. 
Decision-making process
HTLV infection is a relatively slow infection with a relatively low level viraemia 
which is almost always totally cell-associated. The appearance of circulating virus 
also coincides with that of circulating antibody. 
The Guideline Development Group agreed on the following recommendations 
based the above mentioned studies, on their medical and scientific knowledge 
and experience from best practice.
Recommendations
Accept
 Household contacts of individuals with HTLV I and/or II infection 
 Individuals whose mother or maternal grandmother has or had HTLV I and/
or II infection, if blood screening for HTLV I and/or II infection is available
 Former sexual contacts of individuals with HTLV I and/or II infection if more 
than 12 months after the last sexual contact, and blood screening for HTLV 
I and/or II infection is available
Defer
 Current sexual contacts of individuals with HTLV I and/or II infection
 Former sexual contacts of individuals with HTLV I and/or II infection: defer 
for 12 months after last sexual contact
Defer permanently
 Individuals with HTLV I and/or II infection
 Individuals whose mother or maternal grandmother has or had HTLV I and/or 
II infection, if blood screening for HTLV I and/or II infection is not available
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 Former sexual contacts of individuals with HTLV I and/or II infection, if blood 
screening for HTLV I and/or II infection is not available
7.3.4 Herpes viruses
Question
What should be the criteria for the acceptance or deferral of prospective blood 
donors with infection with herpes viruses or at specific risk of exposure to herpes 
viruses, including:
 Individuals with herpes viruses infection or a past history of infection 
with herpes viruses 
 Contacts of individuals with herpes virus infection
 Individuals with Kaposi’s sarcoma-associated herpesvirus (HHV8 infection)
 Current and former sexual partners of individuals with Kaposi’s sarcoma-
associated herpesvirus (HHV8 infection)
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Prevent transmission of herpes 
viruses to recipients of blood 
transfusion 
 Avoid unnecessary deferrals of 
suitable blood donors
 Provide safe and sufficient blood 
supply
Key search and MeSH words
herpes virus, herpes simplex virus, HSV, varicella-zoster, VZV, infectious mono-
nucleosis, IM, cytomegalovirus, CMV, Epstein-Barr virus, EBV, HHV8 infection, Kaposi’s 
sarcoma-associated herpes virus, blood transfusion, blood donor, blood donation 
donor selection, suitab-, eligib-, defer, accept, sexual partner, contact 
Search strategy: PUBMED
#15Search (#1) AND#11 Limits: Humans, English, published in the last 10 years08:52:09 14
#14Search ((#1) AND#11) AND#3 Limits: Humans, English, published in the last 10 
years08:49:46 0
#13Search (#12) AND#3 Limits: Humans, English, published in the last 10 years08:49:11 0
#12Search (#4) AND#11 Limits: Humans, English, published in the last 10 years08:48:26 2
#11Search HHV8 infection OR Kaposi’s sarcoma-associated herpes virus Limits: Humans, 
English, published in the last 10 years08:42:53 902
#10Search (#9) AND#3 Limits: Humans, English, published in the last 10 years08:41:31 92
#9Search (#4) AND#8 Limits: Humans, English, published in the last 10 years08:33:15 752
#8Search varicella-zoster OR VZV OR infectious mononucleosis OR IM Limits: Humans, 
English, published in the last 10 years08:25:26 263632
#7Search (#6) AND#3 Limits: Humans, English, published in the last 10 years08:06:30 20
#6Search (#4) AND#5 Limits: Humans, English, published in the last 10 years08:02:18 120
#5Search herpes virus OR herpes simplex virus OR HSV OR cytomegalovirus OR 
CMV OR epstein-barr virus OR EBV Limits: Humans, English, published in the last 10 
years07:58:47 29429
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#4Search (#1) AND#2 Limits: Humans, English, published in the last 10 years07:50:27 
2725
#3Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years07:49:53 5014
#2Search donor safety OR donor suitability OR donor risk OR donor well-being OR donor 
defer* OR donor eligibl* OR donor selection OR donor accept* Limits: Humans, English, 
published in the last 10 years07:48:50 16344
#1Search blood donor* OR blood donat* OR donating blood OR blood transfusion Limits: 
Humans, English, published in the last 10 years07:47:11 28959
Number of citations screened   248
Number of papers that address the study question  3 
Key references
1 Juhl D et al. Detection of herpes simplex virus DNA in plasma of patients with primary 
but not with recurrent infection: implications for transfusion medicine? Transfusion 
Medicine, 2010, 20(1):38–47. 
2 Drew WL et al. Frequency and duration of plasma CMV viraemia in seroconverting 
blood donors and recipients. Transfusion, 2003, 43(3):309–313. 
3 Cannon MJ et al. Lack of evidence for human herpesvirus-8 transmission via 
blood transfusion in a historical US cohort. Journal of Infectious Diseases, 2009, 
199(11):1592–1598. 
Decision-making process
Human cytomegalovirus and to a lesser degree Kaposi’s sarcoma-associated 
human herpes virus 8 (HHV8) are known to be transfusion-transmitted. The 
transmission of other herpes viruses is not unknown, but not commonly reported.
No publications were identified that directly address the specific questions. Although 
donors may have evidence of a range of herpesvirus infections, not all of these 
are likely to be relevant to transfusion. Only those herpes viruses with a proven 
viraemia in asymptomatic individuals are likely to be transmitted, but even then 
identified transmission rates are not as high as might be expected. Transmission 
to immunocompetent individuals is unlikely to result in serious sequelae, if 
indeed a productive infection results. However, immunocompromised individuals 
are highly susceptible and infections are likely to have serious consequences. 
The Guideline Development Group agreed on the following recommendations 
based the above studies, on their medical and scientific knowledge and experience 
from best practice.
Recommendations
Accept
 Individuals with cold sores and genital herpes, provided there are no active 
lesions 
Defer
 Individuals who are symptomatic (except HHV8 infection): defer for at least 
28 days following full recovery
199
 Contacts of individuals who are symptomatic (except HHV8 infection): defer 
for 28 days
Defer permanently
 Individuals with HHV8 infection
 Current and former sexual contacts of individuals with HHV8 infection 
7.3.5 Mosquito-borne viruses
West Nile Virus 
Question
What should be the criteria for the acceptance or deferral of prospective blood 
donors with infection with West Nile virus, at specific risk of exposure to WNV 
or symptoms suggestive of WNV 
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Prevent transmission of WNV to 
recipients of blood transfusion 
 Avoid unnecessary deferrals of 
suitable blood donors
 Provide safe and sufficient blood 
supply
Key search and MeSH words
West Nile virus, WNV, blood transfusion, blood donor, blood donation 
donor selection, suitab-, eligib-, defer, accept, travel, endemic, non-endemic
Search strategy: PUBMED
#8Search ((blood transfusion) AND#5) AND#3 Limits: Humans, English, published in the 
last 10 years15:48:19 6
#7Search (#6) AND#3 Limits: Humans, English, published in the last 10 years15:44:06 4
#6Search (#4) AND#5 Limits: Humans, English, published in the last 10 years15:42:26 61
#5Search West Nile virus OR WNV Limits: Humans, English, published in the last 10 
years15:40:22 1771
#4Search (#1) AND#2 Limits: Humans, English, published in the last 10 years15:39:12 
2725
#3Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years15:37:55 5014
#2Search donor safety OR donor suitability OR donor risk OR donor well-being OR donor 
defer* OR donor eligibl* OR donor selection OR donor accept* Limits: Humans, English, 
published in the last 10 years15:37:14 16344
#1Search blood donor* OR blood donat* OR donating blood OR blood transfusion Limits: 
Humans, English, published in the last 10 years15:36:38 28959
Number of citations screened  71
Number of papers that address the study question 3
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Key references
1 Brown JA et al. West Nile viremic blood donors and risk factors for subsequent West 
Nile fever. Vector-Borne and Zoonotic Diseases, 2007, 7(4):479–488. 
2 Stramer SL. Reacting to an emerging safety threat: West Nile virus in North America. 
Developments in Biologicals (Basel), 2007, 127:43–58. 
3 Vamvakas EC. The development of West Nile virus safety policies by Canadian blood 
services: guiding principles and a comparison between Canada and the United States. 
Transfusion Medicine Reviews, 2006, 20(2):97–109. 
Decision-making process
WNV is an emerging threat to transfusion and one that is spreading into areas 
previously not at risk. Infection is acute and rapid, but infected individuals would 
normally be asymptomatic whilst infectious. Infection is generally seasonal with 
cases occurring during the season when mosquitoes are most active. In non-
endemic countries, donor selection can be based upon travel history only. In 
endemic areas, all donors may require specific screening if cases of transfusion-
transmission are to be avoided.
The Guideline Development Group agreed on the following recommendations 
based on the above studies, their medical and scientific knowledge and experience 
from best practice.
Recommendations
NoN-ENDEMIC AREAS (IF BLooD SCREENING IS NoT PERFoRMED)
 At-risk donors with symptoms appearing within 14 days following donation 
should be advised to report to the BTS
Defer
 Individuals who:
— Have known West Nile virus infection or symptoms suggestive of WNV: 
defer for 6 months from full recovery
— Have visited an area endemic for WNV with human cases, in the WNV 
season within the last month: defer for 28 days following return
Dengue and chikungunya viruses 
Question
What should be the criteria for acceptance or deferral of prospective blood 
donors with infection with dengue or chikungunya viruses, or at specific risk of 
exposure or with symptoms suggestive of dengue or chikungunya? 
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Prevent transmission of dengue and 
chikungunya viruses to recipients of 
blood transfusion 
 Avoid unnecessary deferrals of 
suitable blood donors
 Provide safe and sufficient blood 
supply
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Key search and MeSH words
dengue, chikungunya virus, blood transfusion, blood donor, blood donation
donor selection, suitab-, eligib-, defer, accept, travel, endemic, non-endemic 
Search strategy: PUBMED
#10Search (#2) AND#5 Limits: Humans, English, published in the last 10 years16:40:34 17
#9Search (#1) AND#5 Limits: Humans, English, published in the last 10 years16:42:39 80
#8Search ((#1) AND#5) AND#3 Limits: Humans, English, published in the last 10 
years16:37:30 2
#7Search (#6) AND#3 Limits: Humans, English, published in the last 10 years16:28:08 0
#6Search (#4) AND#5 Limits: Humans, English, published in the last 10 years16:26:59 15
#5Search Dengue OR Chikungunya virus Limits: Humans, English, published in the last 
10 years16:25:06 3707
#4Search (#1) AND#2 Limits: Humans, English, published in the last 10 years16:24:25 
2725
#3Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years16:23:56 5014
#2Search donor safety OR donor suitability OR donor risk OR donor well-being OR donor 
defer* OR donor eligibl* OR donor selection OR donor accept* Limits: Humans, English, 
published in the last 10 years16:23:20 16344
#1Search blood donor* OR blood donat* OR donating blood OR blood transfusion Limits: 
Humans, English, published in the last 10 years16:21:5628959
Number of citations screened  19
Number of papers that address the study question 2 
Key references
1 Teo D et al. Is dengue a threat to the blood supply? Transfusion Medicine, 2009, 
19(2):66–77.
2 Liumbruno GM et al. The Chikungunya epidemic in Italy and its repercussion on the 
blood system. Blood Transfusion, 2008, 6(4):199–210.
Decision-making process
Dengue and chikungunya are infectious agents which have been present for some 
time, but more recently have increased in significance in relation to transfusion-
transmission.
Transfusion-transmissions of dengue and chikungunya have been reported, but 
are relatively low in number considering the number of infected individuals. In 
non-endemic countries, risk may often be mediated through existing malarial 
deferral policies; where this is not the case, individuals who have visited endemic 
areas should be deferred for a minimum of 28 days following their return. 
The Guideline Development Group agreed on the following recommendations 
based on the above studies, their medical and scientific knowledge and experience 
from best practice.
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Recommendations
ENDEMIC AREAS
Defer
 Individuals with a history of dengue or chikungunya virus: defer for 6 months 
following full recovery from infection
NoN-ENDEMIC AREAS 
Defer
 Individuals who:
— Have visited an area endemic for dengue or chikungunya: defer for 28 
days following return 
— Have suffered a febrile illness during or following return from an endemic 
region: defer for 6 months following full recovery from infection
7.4 PROTOZOAL INFECTIONS
7.4.1 Malaria 
Question
What should be the criteria in endemic and non-endemic areas for the acceptance 
or deferral of prospective blood donors with a diagnosis or symptoms suggestive 
of malaria?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Prevent transmission of malaria to 
recipients of blood transfusion 
 Avoid unnecessary deferrals of 
suitable blood donors
 Provide safe and sufficient blood 
supply
Key search and MeSH words
malaria, plasmodium falciparum, vivax, malariae, ovale, knowlsei, blood transfusion, 
blood donor, blood donation
donor selection, suitab-, eligib-, defer, accept, endemic, non-endemic, anopheles 
mosquito, zoono-
Search strategy: PUBMED
#17Search ((#1) AND#6) AND#318:03:22 2
#16Search (#2) AND#617:59:08 46
#14Search (#12) AND#817:53:31 30
#13Search (#12) AND#317:13:10 2
#12Search (#6) AND#717:10:11 92
#11Search ((#1) AND#4) AND#317:07:49 9
#10Search (#9) AND#317:06:06 7
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#9Search (#8) AND#417:03:05 126
#8Search (#1) AND#216:59:32 7384 
#7Search transfusion-transmitted OR transfusion transmission OR transfusion-
associated16:58:44 9441
#6Search (#4) AND#517:09:18 10861
#5Search endemic OR non-endemic OR anopheles mosquito OR zoono*16:56:41 72229 
#4Search malaria OR plasmodium RO falciparum OR vivax OR malariae OR ovale OR 
knowlsei16:54:57 65509 
#3Search recipient risk OR recipient safety OR recipient well-being16:53:28 11824
#2Search donor safety OR donor suitability OR donor risk OR donor well-being OR donor 
defer* OR donor eligibl* OR donor selection OR donor accept*16:43:16 44186
#1Search blood donor* OR blood donat* OR donating blood OR blood transfusion16:40:23 
122970
Number of citations screened   314
Number of papers that address the study question 9 
Papers selected for full evaluation 4
Key references
1 Kitchen AD, Chiodini PL. Malaria and blood transfusion. Vox Sanguinis, 2006, 
90(2):77–84.
2 Garraud O. Measures to prevent transfusion-associated protozoal infections in non-
endemic countries. Travel Medicine and Infectious Disease, 2007, 5(2):110–112. 
3 Kitchen AD et al. Documented cases of post-transfusion malaria occurring in England: 
a review in relation to current and proposed donor-selection guidelines. Vox Sanguinis, 
2005 89(2):77–80.
4 Reesink HW. European strategies against the parasite transfusion risk. Transfusion 
clinique et biologique, 2005, 12(1):1–4.
Decision-making process
The Guideline Development Group agreed on the following recommendations 
based on data from the above studies, their expert knowledge and experience 
from best practice.
Recommendations
ENDEMIC AREAS
The BTS should develop:
 Donor selection criteria to identify and collect blood from donors at the lowest 
risk of infection, both during the malaria season and during the rest of the 
year 
 Strategies to maximize the collection of blood from donors from geographical 
areas with low endemicity
 Screen all donations for parasitaemia using thick blood films (smear microscopy) 
or for evidence of malarial antigen using a highly sensitive enzyme immunoassay
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Defer
 Individuals with a recent infection with malaria: defer for 6 months after 
completion of treatment and full recovery, whichever is longer
NoN-ENDEMIC AREAS
The BTS should:
 Define the donor population with a risk of exposure to malaria and thus the 
potential for transmission through blood donations 
 Implement donor selection and deferral strategies to identify individuals 
with a recent history of malaria or a specific identifiable exposure risk, such 
as travel to malarious areas; these donors should be deferred for a period 
defined by the country
 Question prospective donors regarding:
— Place of birth
— Previous residence in endemic areas
— Travel during the previous 12 months 
— History of malaria or any undiagnosed febrile illness during or after 
visiting an endemic area
If sensitive and multi-specific antibody screening tests are not available
Defer 
 Individuals who:
— Have travelled to malaria endemic areas and who have had no symptoms: 
defer for 12 months from last return from a malarious area
— Have travelled to malaria endemic areas and who have had febrile 
symptoms, but not diagnosed as malaria: defer for 12 months following 
full recovery or last return from a malarious area, whichever is the longer
— Lived in a malaria endemic area in the first 5 years of life or for a 
continuous period of 6 months or more: defer for 5 years after last 
return from a malarious area
Defer permanently
 Individuals who have ever had a diagnosis of malaria
If sensitive and multi-specific antibody screening tests are available
Accept
 Asymptomatic individuals with identified malaria exposure risk (travel and/
or residence): accept if more than 6 months after their last return from an 
endemic area 
Defer 
 Individuals with: 
— Identified malaria exposure risk (travel and/or residence), but no 
symptoms: defer for 6 months after last return from malarious area 
— Identified malaria exposure risk (travel and/or residence) who have had 
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febrile symptoms, but not diagnosed as malaria: defer for 6 months from 
cessation of symptoms or last return from a malarious area, whichever 
is the longer 
— A current infection or history of malaria: defer for 3 years following 
completion of treatment and full recovery, whichever is the longer 
7.4.2 Chagas disease / American trypanosomiasis 
Question
What should be the criteria in endemic and non-endemic areas for the acceptance 
or deferral of prospective blood donors with a diagnosis or symptoms suggestive 
of Chagas disease?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Prevent transmission of Chagas 
disease to recipients of blood 
transfusion 
 Avoid unnecessary deferrals of 
suitable blood donors
 Provide safe and sufficient blood 
supply
Key search and MeSH words
Chagas disease, trypanosomiasis, blood transfusion, blood donor, blood donation 
donor selection, suitab-, eligib-, defer, accept, endemic, non-endemic, zoono-
Search strategy: PUBMED
#13Search ((blood transfusion) AND#8) AND#3 Limits: Humans, English, published in 
the last 10 years06:24:10 2
#12Search (#2) AND#8 Limits: Humans, English, published in the last 10 years06:22:01 15
#11Search ((#2) AND#8) AND#3 Limits: Humans, English, published in the last 10 
years06:20:28 1
#10Search ((#1) AND#8) AND#3 Limits: Humans, English, published in the last 10 
years06:20:01 2
#9Search (#4) AND#8 Limits: Humans, English, published in the last 10 years06:15:12 12
#8Search (#6) AND#7 Limits: Humans, English, published in the last 10 years06:13:18 455
#7Search endemic OR non-endemic OR zoono* Limits: Humans, English, published in 
the last 10 years06:11:55 19580
#6Search Chagas disease OR trypanosomiasis Limits: Humans, English, published in 
the last 10 years06:11:04 3076
#5Search (#1) AND#3 Limits: Humans, English, published in the last 10 years06:10:21 353
#4Search (#1) AND#2 Limits: Humans, English, published in the last 10 years06:09:44 2729
#3Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years06:09:20 5020
#2Search donor safety OR donor suitability OR donor risk OR donor well-being OR donor 
defer* OR donor eligibl* OR donor selection OR donor accept* Limits: Humans, English, 
published in the last 10 years06:08:39 16363
#1Search blood donor* OR blood donat* OR donating blood OR blood transfusion Limits: 
Humans, English, published in the last 10 years06:05:47 28987
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Number of citations screened  32
Number of papers that address the study question 2
Key references
1 Castro E. Chagas’ disease: lessons from routine donation testing. Transfusion Medicine, 
2009, 19(1):16–23.
2 O’Brien SF et al. Assessment of a travel Question to identify donors with risk 
of Trypanosoma cruzi: operational validity and field testing. Transfusion, 2008, 
48(4):755–761. 
Decision-making process
In non-endemic countries, individuals with potential exposure to T. cruzi can be 
identified from previous residency of themselves, their mother and maternal 
grandmother, and from travel history. Deferral for a period of 4–6 months followed 
by screening for specific antibody can be used to re-instate donors with T. cruzi 
risk. In endemic countries infected individuals can be identified through antibody 
screening, but the possibility of recent infection where antibody has not yet 
become detectable must be considered.
The Guideline Development Group agreed on the following recommendations 
based on data from the above studies, their expert knowledge and experience 
from best practice.
Recommendations
NoN-ENDEMIC AREAS
If sensitive antibody assays for T. cruzi are not available
Defer permanently
 Individuals who have ever had a diagnosis of Chagas disease
 Individuals with an identified risk of Chagas disease:
— Born in, resided in for 6 months or more, or have mother or maternal 
grandmother born in an endemic area
— Received blood transfusion or organ transplant in endemic area
— Travel for 28 days or more in rural community in endemic area
If sensitive antibody assays for T. cruzi are available
Accept
 Individuals with an identified risk of exposure to Chagas disease: accept if 
more than 6 months after last return from an endemic area
Defer
 Individuals with an identified risk of exposure to Chagas disease: defer for 
6 months after last return from an endemic area
Defer permanently
 Individuals who have ever had a diagnosis of Chagas disease
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7.4.3 Babesiosis
Question
What should be the criteria in endemic and non-endemic areas for the acceptance 
or deferral of prospective blood donors with a diagnosis or symptoms suggestive 
of babesiosis?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Prevent transmission of babesiosis 
to recipients of blood transfusion 
 Avoid unnecessary deferrals of 
suitable blood donors
 Provide safe and sufficient blood 
supply
Key search and MeSH words
B microti, babesiosis, blood transfusion, blood donor, blood donation 
donor selection, suitab-, eligib-, defer, accept, zoono-
Search strategy: PUBMED
#18Search ((blood transfusion) AND#11) AND#3 Limits: Humans, English, published in 
the last 10 years09:04:49 0
#17Search (#5) AND#6 Limits: Humans, English, published in the last 10 years09:02:31 3
#16Search (#4) AND#6 Limits: Humans, English, published in the last 10 years08:59:39 15
#15Search (#5) AND#11 Limits: Humans, English, published in the last 10 years08:55:40 0
#14Search (#4) AND#11 Limits: Humans, English, published in the last 10 years08:53:36 0
#13Search (#1) AND#11 Limits: Humans, English, published in the last 10 years08:51:22 8
#12Search (#2) AND#11 Limits: Humans, English, published in the last 10 years08:49:21 0
#11Search (#6) AND#7 Limits: Humans, English, published in the last 10 years07:52:09 64
#10Search ((#6) AND#9) AND blood transfusion Limits: Humans, English, published in 
the last 10 years07:48:39 7
#9Search zoono* Limits: Humans, English, published in the last 10 years07:45:55 6083
#8Search ((blood transfusion) AND#6) AND#7 Limits: Humans, English, published in the 
last 10 years07:44:27 8
#7Search defer OR accept OR zoono* Limits: Humans, English, published in the last 
10 years07:41:34 10399
#6Search B. microti OR babesiosis Limits: Humans, English, published in the last 10 
years07:39:49 276
#5Search (#1) AND#3 Limits: Humans, English, published in the last 10 years07:38:59 353
#4Search (#1) AND#2 Limits: Humans, English, published in the last 10 years07:38:12 
2729 
#3Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years07:37:41 5020 
#2Search donor safety OR donor suitability OR donor risk OR donor well-being OR donor 
defer* OR donor eligibl* OR donor selection OR donor accept* Limits: Humans, English, 
published in the last 10 years07:37:10 16363
#1Search blood donor* OR blood donat* OR donating blood OR blood transfusion Limits: 
Humans, English, published in the last 10 years07:36:46 28987
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Number of citations screened 105
Number of papers that address the study question 5
Key references
1 Cable RG, Leiby DA. Risk and prevention of transfusion-transmitted babesiosis and 
other tick-borne diseases. Current Opinion in Hematology, 2003, 10:405–11.
2 Leiby D. Babesiosis and blood transfusion: flying under the radar. Vox Sanguinis, 2006, 
90:157–165.
3 Leiby DA. Transfusion-transmitted Babesia spp.: bull’s-eye on Babesia microti. Clinical 
Microbiology Reviews, 2011, 24(1):14–28.
4 Gubernot DM et al. Transfusion-transmitted babesiosis in the United States: summary 
of a workshop. Transfusion, 2009, 49(12):2759–2771. 
5 Tonnetti L et al. Transfusion-transmitted Babesia microti identified through hemovigilance. 
Transfusion, 2009, 49(12):2557–2563. 
Decision-making process
Transmission of Babesia spp. is ongoing in endemic areas. Individuals presenting 
as potential donors are likely to be asymptomatic and only those who have 
previously been diagnosed with babesiosis can be identified and deferred.
The Guideline Development Group agreed on the following recommendations 
based on data from the above studies, their expert knowledge and experience 
from best practice.
Recommendation
Defer permanently
 Individuals who have ever had a diagnosis of babesiosis 
7.4.4 Leishmaniasis 
Question
What should be the criteria in endemic and non-endemic areas for the acceptance 
or deferral of prospective blood donors with a diagnosis or symptoms suggestive 
of leishmaniasis?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Prevent transmission of 
leishmaniasis to recipients of blood 
transfusion 
 Avoid unnecessary deferrals of 
suitable blood donors
 Provide safe and sufficient blood 
supply
Key search and MeSH words
leishmaniasis, blood transfusion, blood donor, blood donation
donor selection, suitab-, eligib-, defer, accept, endemic, non-endemic, zoono-
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Search strategy: PUBMED
#19Search ((blood transfusion) AND#6) AND#314:32:30 1
#18Search ((blood transfusion) AND#8) AND#314:31:12 0
#17Search (#2) AND#814:28:20 6
#16Search (#1) AND#814:26:02 14
#15Search (blood donor AND donor deferral) AND#614:24:08 2
#14Search (blood donor AND donor deferral) AND#814:22:34 1
#13Search (#4) AND#614:19:57 10
#12Search ((#1) AND#6) AND#314:16:43 1
#11Search ((#1) AND#8) AND#314:11:49 0
#10Search (#5) AND#8 Limits: Humans, English, published in the last 10 years14:10:07 0
#9Search (#4) AND#8 Limits: Humans, English, published in the last 10 years14:08:05 5
#8Search (#6) AND#7 Limits: Humans, English, published in the last 10 years14:05:19 874
#7Search endemic OR non-endemic OR zoono* Limits: Humans, English, published in 
the last 10 years14:04:44 19580
#6Search Leishmaniasis Limits: Humans, English, published in the last 10 years14:03:40 
3718
#5Search (#1) AND#3 Limits: Humans, English, published in the last 10 years14:03:08 353
#4Search (#1) AND#2 Limits: Humans, English, published in the last 10 years14:02:47 
2729#3Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years14:01:54 5020
#2Search donor safety OR donor suitability OR donor risk OR donor well-being OR donor 
defer* OR donor eligibl* OR donor selection OR donor accept* Limits: Humans, English, 
published in the last 10 years14:01:05 16363
#1Search blood donor* OR blood donat* OR donating blood OR blood transfusion Limits: 
Humans, English, published in the last 10 years14:00:38 28987
Number of citations screened   40
Number of papers that address the study question 1
Key reference
1 Cardo LJ. Leishmania: risk to the blood supply. Transfusion, 2006, 46(9):1641–1645.
Decision-making process
The identification of individuals at risk of leishmaniasis is not straightforward. 
Although travel to an endemic area is a clear risk, sand flies are not present all 
year round in many endemic areas. Those spending significant amounts of time 
in such areas may have been exposed, but are likely to remain asymptomatic for 
long periods of time, in some cases for longer than a year. Treated individuals 
may still harbour the parasite for extended periods.
The Guideline Development Group agreed on the following recommendations 
based on their expert knowledge and experience from best practice.
Recommendations 
Defer
 Individuals who have spent extended periods in endemic areas: defer for at 
least 12 months since their last return
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Defer permanently
 Individuals who have ever had a diagnosis of leishmaniasis
7.5 BACTERIAL INFECTIONS
7.5.1 Syphilis, yaws and gonorrhoea 
Question
What should be the criteria for acceptance or deferral of prospective blood 
donors with a current or past diagnosis of syphilis or at specific risk of exposure 
to syphilis?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Prevent transmission of syphilis to 
recipients of blood transfusion 
 Avoid unnecessary deferrals of 
suitable blood donors
 Provision of a safe and sufficient 
blood supply
Key search and MeSH words
T. pallidum, treponema, syphilis, blood transfusion, blood donor, blood donation
donor selection, suitab-, eligib-, defer, accept, sexual partner, sexual contact
Search strategy: PUBMED
#14Search (#13) AND#3 Limits: Humans, English, published in the last 10 years16:31:28 5
#13Search (#7) AND sexual partner OR sexual contact Limits: Humans, English, published 
in the last 10 years16:28:44 1572
#12Search (#11) AND#3 Limits: Humans, English, published in the last 10 years16:20:56 5
#11Search ((#2) AND#6 ) AND sexual partner OR sexual contact Limits: Humans, English, 
published in the last 10 years16:18:53 1572
#9Search ((#2) AND sexual partner OR sexual contact) AND#6 Limits: Humans, English, 
published in the last 10 years16:24:28 102
#8Search (#5) AND#6 Limits: Humans, English, published in the last 10 years16:10:51 4
#7Search (#4) AND#6 Limits: Humans, English, published in the last 10 years16:08:40 47
#6Search T. pallidum OR treponema pallidum OR syphilis Limits: Humans, English, 
published in the last 10 years16:06:09 3498
#5Search (#1) AND#3 Limits: Humans, English, published in the last 10 years16:04:47 353
#4Search (#1) AND#2 Limits: Humans, English, published in the last 10 years16:04:02 
2725
#3Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years16:03:13 5014
#2Search donor safety OR donor suitability OR donor risk OR donor well-being OR donor 
defer* OR donor eligibl* OR donor selection OR donor accept* Limits: Humans, English, 
published in the last 10 years16:02:21 16344
#1Search blood donor* OR blood donat* OR donating blood OR blood transfusion Limits: 
Humans, English, published in the last 10 years16:01:18 28959
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Number of citations screened  163
Relevant papers selected 1
Key references
1 Sexually transmitted infections. Fact sheet N° 110, August 2011. Geneva, World Health 
Organization, 2011.
Decision-making process
No publications were identified that directly address the specific questions. The 
Guideline Development Group agreed on the following recommendations based 
on the WHO fact sheet, their medical and scientific knowledge and experience 
from best practice. 
Recommendations
Accept
 Household contacts of individuals with syphilis 
Defer
 Current sexual contacts of individuals with syphilis 
 Former sexual contacts of individuals with syphilis: defer for 12 months since 
last sexual contact
 Individuals with gonorrhoea: defer for 12 months following completion of 
treatment and assess for high-risk behaviour
 Current sexual contacts of individuals with gonorrhoea
 Former sexual contacts of individuals with gonorrhoea: defer for 12 months 
since last sexual contact
Defer permanently
 Individuals who have ever had a diagnosis of syphilis
7.5.3 Brucellosis
Question
What should be the criteria for acceptance or deferral of prospective blood donors 
with a diagnosis of brucellosis?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Prevent transmission of brucellosis 
to recipients of blood transfusion 
 Avoid unnecessary deferrals of 
suitable blood donors
 Provide a safe and sufficient blood 
supply
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Key search and MeSH words
Brucella melitensis, brucellosis, blood transfusion, blood donor, blood donation 
donor selection, suitab-, eligib-, defer, accept, zoono-
Search strategy: PUBMED
#16Search (#12) AND#3 Limits: Humans, English, published in the last 10 years18:20:39 0
#15Search (#9) AND#12 Limits: Humans, English, published in the last 10 years18:19:01 2
#14Search (#12) AND#6 Limits: Humans, English, published in the last 10 years18:13:50 0
#13Search (#12) AND#5 Limits: Humans, English, published in the last 10 years18:12:59 0
#12Search (#4) AND zoono* Limits: Humans, English, published in the last 10 
years18:09:50 227
#11Search (blood donor deferral OR donor suitability OR donor eligibility ) AND#4 Limits: 
Humans, English, published in the last 10 years17:53:21 0
#10Search (#2) AND#4 Limits: Humans, English, published in the last 10 years17:48:56 1
#9Search (#1) AND#4 Limits: Humans, English, published in the last 10 years17:47:11 13
#8Search (#6) AND#4 Limits: Humans, English, published in the last 10 years17:45:43 0
#7Search (#5) AND#4 Limits: Humans, English, published in the last 10 years17:43:32 1
#6Search (#1) AND#3 Limits: Humans, English, published in the last 10 years17:41:39 353
#5Search (#1) AND#2 Limits: Humans, English, published in the last 10 years17:41:12 2725
#4Search Brucella melitensis OR brucellosis Limits: Humans, English, published in the 
last 10 years17:38:49 1262
#3Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years17:37:42 5019
#2Search donor safety OR donor suitability OR donor risk OR donor well-being OR donor 
defer* OR donor eligibl* OR donor selection OR donor accept* Limits: Humans, English, 
published in the last 10 years17:34:07 16351
#1Search blood donor* OR blood donat* OR donating blood OR blood transfusion Limits: 
Humans, English, published in the last 10 years17:33:34 28965
Number of citations screened 242
Number of papers that address the study question 0
Decision-making process 
The Guideline Development Group agreed on the following recommendation based 
on their medical and scientific knowledge and experience from best practice.
Recommendation
Defer permanently
 Individuals who have ever had a diagnosis of brucellosis 
7.5.4 Yersinia infection
Question
What should be the criteria for acceptance or deferral of prospective blood donors 
with symptoms suggestive of Yersinia enterocolitica, salmonella, campylobacter, 
streptococcus or staphylococcus infection?
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Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Prevent transmission of Y. 
enterocolitica, salmonella, 
campylobacter, streptococcus or 
staphylococcus to recipients of blood 
transfusion 
 Avoid unnecessary deferrals of 
suitable blood donors
 Provide a safe and sufficient blood 
supply
Yersinia enterocolitica
Key search and MeSH words
Y. enterocolitica , Yersinia enterocolitica, enteritis, abdominal symptoms, diarrhoea
red cell transfusion, blood transfusion, blood donor, blood donation, donor 
selection, suitab-, eligib-, defer, accept
Search strategy: PUBMED
#23Search (#9) AND#20 Limits: Humans, English, published in the last 10 years20:47:47 9
#22Search (#20) AND#11 Limits: Humans, English, published in the last 10 years20:46:17 0
#21Search (#20) AND#12 Limits: Humans, English, published in the last 10 years20:45:27 0
#20Search (#14) AND#19 Limits: Humans, English, published in the last 10 years20:44:11 10
#19Search transfusion-transmissible OR transfusion-associated Limits: Humans, English, 
published in the last 10 years20:42:46 404
#18Search (#17) AND#11 Limits: Humans, English, published in the last 10 years20:24:32 8
#17Search (#9) AND#14 Limits: Humans, English, published in the last 10 years20:23:03 
862
#16Search (#13) AND#14 Limits: Humans, English, published in the last 10 years20:21:59 8
#15Search (#12) AND#14 Limits: Humans, English, published in the last 10 years20:20:25 17
#14Search Y. enterocolitica OR Yersinia enterocolitica OR enteritis OR abdominal symptoms 
OR diarrhoea Limits: Humans, English, published in the last 10 years20:18:27 80639
#13Search (#9) AND#11 Limits: Humans, English, published in the last 10 years20:17:15 
354
#12Search (#9) AND#10 Limits: Humans, English, published in the last 10 years20:16:48 
2741
#11Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years20:16:14 5020
#10Search donor safety OR donor suitability OR donor risk OR donor well-being OR donor 
defer* OR donor eligibility OR donor selection OR donor accept* Limits: Humans, English, 
published in the last 10 years20:15:24 16405
#9Search blood donor* OR blood donat* OR donating blood OR blood transfusion OR red 
cell transfusion Limits: Humans, English, published in the last 10 years20:13:37 29117
Number of citations screened 242
Relevant papers selected 1
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Key reference
1 Leclercq A et al. Fatal Yersinia enterocolitica biotype 4 serovar O:3 sepsis after red 
blood cell transfusion. Transfusion, 2005, 45(5):814–818.
Decision-making process
The Guideline Development Group agreed on the following recommendations 
based on the above study, their medical and scientific knowledge and experience 
from best practice.
Recommendation
Defer
 Individuals with recent abdominal symptoms, particularly diarrhoea, suggestive 
of Y. enterocolitica infection: defer for 28 days following full recovery
7.5.5 Salmonella, campylobacter, streptococcus and 
staphylococcus
Key search and MeSH words
salmonella, campylobacter, streptococcus, staphylococcus, blood transfusion, 
blood donor, blood donation
donor selection, suitab-, eligib-, defer, accept, post-transfusion sepsis, abdominal 
pain, diarrhoea
Search strategy: PUBMED
#12Search ((#1) AND#7) AND#6 Limits: Humans, English, published in the last 10 
years19:00:50 13
#11Search (#5) AND#6 Limits: Humans, English, published in the last 10 years18:55:30 1
#10Search ((#4) AND#6) AND#3 Limits: Humans, English, published in the last 10 
years18:52:51 1
#8Search ((#4) AND#6) AND#7 Limits: Humans, English, published in the last 10 
years18:51:29 1
#7Search post-transfusion sepsis OR abdominal pain OR diarrhoea Limits: Humans, 
English, published in the last 10 years18:49:31 35266
#6Search Salmonella OR campylobacter OR streptococcus OR staphylococcus Limits: 
Humans, English, published in the last 10 years18:47:42 40540
#5Search (#1) AND#3 Limits: Humans, English, published in the last 10 years18:46:44 353
#4Search (#1) AND#2 Limits: Humans, English, published in the last 10 years18:46:20 2725
#3Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years18:45:53 5019
#2Search donor safety OR donor suitability OR donor risk OR donor well-being OR donor 
defer* OR donor eligibl* OR donor selection OR donor accept* Limits: Humans, English, 
published in the last 10 years18:45:21 16351
#1Search blood donor* OR blood donat* OR donating blood OR blood transfusion Limits: 
Humans, English, published in the last 10 years18:44:42 28965
Number of citations screened  59
Number of papers that address the study question 0
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Decision-making process
The Guideline Development Group agreed on the following recommendations based 
on their medical and scientific knowledge and experience from best practice.
Recommendations
Defer
 Individuals with:
— Symptoms suggestive of recent infection with salmonella, campylobacter 
or streptococcus: defer for 28 days following full recovery
— Other evidence of potential infection with staphylococcus: e.g. recent 
superficial but significant wounds: defer for 14 days following full wound 
healing
7.5.6 Tuberculosis
Question
What should be the criteria for acceptance or deferral of prospective blood donors 
with a diagnosis or symptoms suggestive of tuberculosis?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Prevent transmission of tuberculosis 
to recipients of blood transfusion 
 Avoid unnecessary deferrals of 
suitable blood donors
 Provision of a safe and sufficient 
blood supply
Key search and MeSH words
tuberculosis, TB, mycobacteria, blood transfusion, blood donor, blood donation 
donor selection, suitab-, eligib-, defer, accept
Search strategy: PUBMED
#15Search (#1) AND#12 Limits: Humans, English, published in the last 10 years19:52:56 88
#16Search (#15) AND#3 Limits: Humans, English, published in the last 10 years19:51:13 0
#14Search (#4) AND#12 Limits: Humans, English, published in the last 10 years19:48:44 10
#13Search (#2) AND#12 Limits: Humans, English, published in the last 10 years19:46:47 51
#12Search (transfusion-transmission OR transfusion-transmitted OR transfusion 
associated) AND Tuberculosis OR TB OR mycobacterium tuberculosis Limits: Humans, 
English, published in the last 10 years19:44:26 17296
#11Search ((#1) AND donor deferral) AND#6 Limits: Humans, English, published in the 
last 10 years19:40:08 0
#10Search ((blood transfusion) AND#2) AND#6 Limits: Humans, English, published in 
the last 10 years19:33:34 2
#9Search ((blood transfusion) AND#6) AND#3 Limits: Humans, English, published in the 
last 10 years19:31:15 0
#8Search (#5) AND#6 Limits: Humans, English, published in the last 10 years19:29:56 0
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#7Search (#4) AND#6 Limits: Humans, English, published in the last 10 years19:27:33 14
#6Search Tuberculosis OR TB OR mycobacterium tuberculosis OR mycobacteria Limits: 
Humans, English, published in the last 10 years19:25:44 32786
#5Search (#1) AND#3 Limits: Humans, English, published in the last 10 years19:23:54 353
#4Search (#1) AND#2 Limits: Humans, English, published in the last 10 years19:23:30 
2725
#3Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years19:23:03 5019
#2Search donor safety OR donor suitability OR donor risk OR donor well-being OR donor 
defer* OR donor eligibl* OR donor selection OR donor accept* Limits: Humans, English, 
published in the last 10 years19:22:25 16351
#1Search blood donor* OR blood donat* OR donating blood OR blood transfusion Limits: 
Humans, English, published in the last 10 years19:21:50 28965
Number of citations screened  114
Number of papers that address the study question 0
Decision-making process
The Guideline Development Group agreed on the following recommendations based 
on their medical and scientific knowledge and experience from best practice.
Recommendations
Defer
 Individuals with tuberculosis: defer for 2 years following confirmation of cure
 Contacts of individuals with tuberculosis: defer household contacts and other 
close contacts until screened and confirmed clear of infection
7.6 RICKETTSIAL INFECTIONS
Question
What should be the criteria for acceptance or deferral of prospective blood 
donors with a diagnosis or symptoms suggestive of rickettsial infection, such 
as Q fever and Rocky Mountain spotted fever?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Prevent transmission of rickettsial 
infection to recipients of blood 
transfusion 
 Avoid unnecessary deferrals of 
suitable blood donors
 Provide safe and sufficient blood 
supply
Key search and MeSH words
rickettsiae, Q fever, Rocky Mountain spotted fever, blood transfusion, blood donor, 
blood donation 
donor selection, suitab-, eligib-, defer, accept
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Search strategy: PUBMED
#22Search (#20) AND#3 14:48:20 29
#21Search (#20) AND#14 14:36:36 24
#20Search (#4) AND#18 14:32:24 373
#19Search (#5) AND#18 14:27:43 35
#18Search Rickettsia OR Q fever OR Rocky Mountain Spotted Fever14:24:59 857550
#17Search (#16) AND#3 14:23:35 6
#16Search (Rickettsia) AND#14 14:21:57 201
#15Search (#14) AND#6 14:19:46 0
#14Search transfusion-transmission or transfusion-associated14:19:20 1296
#13Search (#5) AND#614:17:25 0
#12Search ((blood transfusion OR blood donor OR blood donation ) AND#6) AND#3 
Limits: Humans, English, published in the last 10 years14:14:26 0
#11Search (#4) AND#6 Limits: Humans, English, published in the last 10 years14:12:43 2
#9Search (#2) AND#6 Limits: Humans, English, published in the last 10 years14:11:51 4
#7Search (#1) AND#6 Limits: Humans, English, published in the last 10 years14:10:25 13
#6Search Rickettsiae OR Q fever OR Rocky Mountain Spotted Fever Limits: Humans, 
English, published in the last 10 years14:09:05 925
#5Search (#1) AND#3 Limits: Humans, English, published in the last 10 years14:07:29 353
#4Search (#1) AND#2 Limits: Humans, English, published in the last 10 years14:07:04 
2726#3Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years14:06:40 5019
#2Search donor safety OR donor suitability OR donor risk OR donor well-being OR donor 
defer* OR donor eligibl* OR donor selection OR donor accept* Limits: Humans, English, 
published in the last 10 years14:06:00 16353
#1Search blood donor* OR blood donat* OR donating blood OR blood transfusion Limits: 
Humans, English, published in the last 10 years14:05:07 28968
Number of citations screened  314
Relevant paper(s) selected 1
Key reference
1 ECDC Technical Report. Risk assessment on Q fever. Stockholm, European Centre for 
Disease Prevention and Control, 2010. 
Decision-making process
The Guideline Development Group agreed on the following recommendations 
based on this published article, their medical and scientific knowledge and 
experience from best practice.
Recommendation
Defer 
 Individuals with:
— Rickettsial infection: defer for 6 months following completion of treatment 
or cessation of symptoms 
— Acute Q fever: defer for 2 years following completion of treatment and 
full recovery, whichever is the longer
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Defer permanently
 Individuals with chronic Q fever 
7.7 PRION DISEASES
7.7.1 Creutzfeldt-Jakob disease 
7.7.2 Variant Creutzfeldt-Jakob disease 
Question
What should be the criteria for the acceptance or deferral of prospective blood 
donors with symptoms suggestive of Creutzfeldt-Jakob disease, a family history 
of CJD or variant Creutzfeldt-Jakob disease?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Prevent transmission of CJD to 
recipients of blood transfusion 
 Avoid unnecessary deferrals of 
suitable blood donors
 Provide a safe and sufficient blood 
supply
Key search and MeSH words
Creutzfeldt-Jakob disease, CJD, transmissible spongiform encephalopathy, sporadic, 
genetic familial, iatrogenic, variant, vCJD, blood transfusion, blood donor, blood 
donation, transfusion-transmission, pituitary-derived human growth hormone, 
human gonadotrophin, dura mater grafts, corneal transplants
donor selection, suitab-, eligib-, defer, accept, BSE
Search strategy: PUBMED
#16Search ((#2) AND#15) AND#6 Limits: Humans, English, published in the last 10 
years18:52:45 8
#15Search pituitary-derived human growth hormone OR human gonadotrophin OR dura 
mater grafts OR corneal transplants Limits: Humans, English, published in the last 10 
years18:48:09 15642
#14Search (#5) AND#12 Limits: Humans, English, published in the last 10 years18:37:01 6
#13Search (#4) AND#12 Limits: Humans, English, published in the last 10 years18:35:34 8
#12Search (#6) AND#9 Limits: Humans, English, published in the last 10 years18:33:45 22
#11Search (#5) AND#6 Limits: Humans, English, published in the last 10 years18:32:09 13
#10Search (#4) AND#6 Limits: Humans, English, published in the last 10 years18:30:39 
110
#9Search transfusion-transmission Limits: Humans, English, published in the last 10 
years18:28:29 81
#6Search Creutzfeldt-Jakob disease OR CJD OR transmissible spongiform encephalopathy 
OR sporadic CJD OR genetic CJD OR familial CJD OR iatrogenic CJD OR variant OR vCJD 
Limits: Humans, English, published in the last 10 years18:27:35 38546
#5Search (#1) AND#3 Limits: Humans, English, published in the last 10 years18:24:28 353
#4Search (#1) AND#2 Limits: Humans, English, published in the last 10 years18:24:06 
2729
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#3Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years18:23:38 5020
#2Search donor safety OR donor suitability OR donor risk OR donor well-being OR donor 
defer* OR donor eligibl* OR donor selection OR donor accept* Limits: Humans, English, 
published in the last 10 years18:23:03 16363
#1Search blood donor* OR blood donat* OR donating blood OR blood transfusion Limits: 
Humans, English, published in the last 10 years18:22:00 28987
Number of citations screened  167
Number of papers that address the study question 7
Key references
1 Wilson K, Code C, Ricketts MN. Risk of acquiring Creutzfeldt-Jakob disease from blood 
transfusions: systematic review of case-control studies. British Medical Journal, 2000, 
321(7252):17–19. 
2 FDA Guidance for Industry. Preventive measures to reduce the possible transmission 
of CJD and vCJD by blood and blood products. Rockville, MD, US Food and Drug 
Administration. 
3 Variant Creutzfeldt-Jakob disease: current data. National Creutzfeldt-Jakob Surveillance 
Unit, United Kingdom. 
4 Ludlam C, Turner M. Managing the risk of transmission of variant Creutzfeldt-Jakob 
disease by blood products. British Journal of Haematology, 2005, 132:13–24.
5 Wilson K, Ricketts M. Transfusion transmission of vCJD: a crisis avoided? Lancet, 
2004, 384:477–479. 
6 Peden A, Ritchie D, Ironside J. Risks of transmission of variant Creutzfeldt-Jakob 
disease by blood transfusion. Folia Neuropathologica, 2005, 43(4):271–278.
7 Editorial team. Fourth case of transfusion-associated vCJD infection in the United 
Kingdom. Eurosurveillance, 2007, 12(3):3117.
Decision-making process
The Guideline Development Group agreed on the following recommendations based 
on published literature, their medical and scientific knowledge and experience 
from best practice.
Recommendations
 Countries should conduct a risk assessment and risk-benefit analysis taking 
into account national and international data on the epidemiology of vCJD 
in order to implement appropriate risk-mitigating measures to prevent the 
transmission of vCJD through blood transfusion
 The decision to defer blood donors with a history of travel or residence for 
defined cumulative exposure periods in specified countries or areas, as a 
measure to reduce the risk of transmitting vCJD by blood transfusion, should 
be based on the findings of the risk assessment and risk-benefit analysis 
and the impact on the blood supply
Defer permanently
 Individuals with sporadic or familial CJD 
 First-degree relatives of individuals with sporadic or familial CJD 
 Individuals with vCJD 
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 Individuals who have received a transfusion or any other human-derived 
therapeutic products since 1980 in a country in which the risk of vCJD has 
been identified 
 Individuals with a history of treatment with pituitary-derived human growth hormone, 
human gonadotrophin, dura mater graft, corneal transplant or neurosurgery
7.9 HIGH-RISK BEHAVIOURS
7.9.1 High-risk sexual behaviours
Question
Should individuals engaging in high-risk sexual behaviour, specifically men who 
have had sex with men (MSM), be permanently deferred from blood donation? 
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Avoid unnecessary deferral of 
suitable blood donors 
 Minimize risk of transfusion-
transmitted infections in recipients 
of blood transfusion
Key search and MeSH words
MSM OR (men who have sex with men) OR (men having sex with men) OR 
(homosexual males) OR gay OR gays OR bisexual OR (male-male sex)
(blood donor) OR (blood donors) OR (blood donation) OR (blood donations) OR 
(donating blood)
Search strategy: PUBMED
#34 Search ((“(blood donor)”[Title/Abstract] OR “(blood donors)”[Title/Abstract] OR 
“(donations)”[Title/Abstract] OR “(blood donations)”[Title/Abstract] OR “(donating 
blood)”[Title/Abstract]) AND (“1995”[Publication Date] : “2009”[Publication Date])) AND 
(#8) Limits: Humans, English 14:23:21 4
#8 Search#6 AND#7 Limits: Humans, English 15:33:07 287
#6 Search (“MSM”[Title/Abstract] OR “(men who have sex with men)”[Title/Abstract] OR 
“(men having sex with men)”[Title/Abstract] OR “(homosexual males)”[Title/Abstract] OR 
“gay”[Title/Abstract] OR “gays”[Title/Abstract] OR “bisexual”[Title/Abstract] OR “(male-
male sex)”[Title/Abstract]) AND (“1995”[Publication Date] : “2009”[Publication Date]) 
Limits: Humans, English 11:10:57 5455 
#1 Search MSM Limits: Humans, English 10:45:15 1615
Number of citations screened 675
Number of papers reviewed 26
Number of papers that address the study question  10, of which 7 were  
discussions of evidence
Papers selected for full evaluation 3
Ten papers were found that directly address the study question. Three are risk/
benefit studies using mathematical modelling; seven are discussions of available 
evidence, two of which are by the same author.
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Key references
1 Soldan K, Sinka K. Evaluation of the de-selection of men who have had sex with men 
from blood donation in England. Vox Sanguinis, 2003, 84:265–273.
2 Germain M, Remis RS, Delage G. The risks and benefits of accepting men who have 
had sex with men as blood donors. Transfusion, 2003, 43:25–33.
3 Anderson SA et al. Quantitative estimate of the risks and benefits of possible alternative 
donor deferral strategies for men who have had sex with men. Transfusion, 2009, 
49:1103–1114.
Summary of evidence
Two reviews in 2003 (Soldan, Germain) estimated the number of HIV positive 
donations that would enter the blood supply if the permanent deferral of MSM 
donors were relaxed to 12 months (Soldan, Germain) or removed altogether 
(Soldan). Soldan estimated that the deferral of MSM for 12 months since 
last sexual contact, or complete removal of this selection criterion, would be 
expected to increase the risk of HIV-infectious donations entering the blood 
supply by approximately 60% (from 0.45 to 0.75 per year) and 500% (to 2.5 
per year) respectively, with an increase in non-infectious donations of less than 
2%. Germain concluded that acceptance of MSM 12 months after last sexual 
contact would potentially result in one HIV-contaminated unit for every 136 000 
additional donations, equating to an overall increase in HIV risk of 8% against 
an increase in donations of 1.3%.
In 2009, Anderson et al used quantitative probabilistic models to assess changes 
in the residual risk of transfusion-transmitted HIV and HBV in the initial year of 
two hypothetical policy scenarios: allowing donations from donors abstaining from 
MSM behaviour for at least five years (MSM5) or at least one year (MSM1), taking 
into account blood testing and quarantine release errors. The authors predicted 
annual increases in units of HIV-infected blood of 0.5% and 3.0% respectively, 
conditional on sensitive donation screening methods and reliable process control. 
They concluded that more accurate inputs were required (percentage of MSM in 
the population, percentage of MSM abstaining from MSM activity for one or five 
years, prevalence of HIV in these groups, rate of self-deferral, rates of quarantine 
release errors for HIV infected units) before making more precise predictions.
Quality of evidence (see GRADE table below)
Criteria for the assessment of mathematical modelling are not available; however, 
all authors acknowledge the limitations of accuracy of these studies because of 
the need to estimate some inputs. Moreover, the studies use epidemiological 
data from the developed world and the risk estimates are applicable only to 
the blood transfusion services in which they were carried out. It should also 
be acknowledged that HIV testing technology has improved since these studies 
were published; hence, the estimates of increased risk of shortening the deferral 
period may be overestimated (in particular the study by Soldan in 2003 which 
relates to HIV antibody testing). Despite differences in methodology, the studies 
are consistent inasmuch as all authors acknowledge that, even in a highly 
regulated blood transfusion service, a change to a policy of lifetime deferral for 
MSM would result in an increased risk, variably estimated and possibly very 
small indeed, of HIV-infected units entering the blood supply.
222
S
u
m
m
ar
y 
o
f 
ev
id
e
nc
e
A
ut
ho
r
Ye
ar
P
op
ul
at
io
n 
st
ud
ie
d
1
2
 m
on
th
s 
M
S
M
 d
ef
er
ra
l
5
 y
ea
rs
 M
S
M
 d
ef
er
ra
l
N
o 
M
S
M
 d
ef
er
ra
l
R
is
k
B
en
efi
t
R
is
k
B
en
efi
t
R
is
k
B
en
efi
t
G
er
m
ai
n
2
0
0
3
C
an
ad
a
8
%
 i
nc
re
as
ed
 
ris
k
1
.3
%
 i
nc
re
as
ed
 
do
na
tio
ns
S
ol
da
n
2
0
0
3
U
K
6
0
%
 i
nc
re
as
ed
 
ris
k
5
0
0
%
 i
nc
re
as
ed
 
ris
k
<
2
%
 i
nc
re
as
e 
in
 
do
no
rs
An
de
rs
on
2
0
0
9
U
S
A
3
%
 i
nc
re
as
ed
 
ris
k 
in
 fi
rs
t 
ye
ar
0
.8
8
%
 m
ea
n 
an
nu
al
 i
nc
re
as
e 
in
 d
on
or
s
0
.5
%
 i
nc
re
as
ed
 
ris
k 
in
 fi
rs
t 
ye
ar
0
.1
7
%
 m
ea
n 
an
nu
al
 i
nc
re
as
e 
in
 d
on
or
s
C
ri
ti
ca
l 
ev
al
u
at
io
n 
o
f 
st
u
di
e
s 
(G
R
A
D
E
 t
ab
le
)
A
ut
ho
r
S
tu
dy
 
de
si
gn
Li
m
it
at
io
ns
C
on
si
st
en
cy
D
ir
ec
tn
es
s 
(a
pp
lic
ab
ili
ty
)
P
re
ci
si
on
o
th
er
 
co
ns
id
er
at
io
ns
Q
ua
lit
y
G
er
m
ai
n
M
at
he
m
at
ic
al
 
m
od
el
S
om
e 
as
su
m
pt
io
ns
 
ba
se
d 
on
 e
st
im
at
es
; 
“w
or
st
-c
as
e 
sc
en
ar
io
s”
 
us
ed
N
/A

 B
as
ed
 o
n 
ep
id
em
io
lo
gy
 o
f 
H
IV
 in
 C
an
ad
a 
an
d 
U
S
A;
 c
la
im
s 
“r
ep
re
se
nt
at
iv
e 
of
 m
os
t 
in
du
st
ria
liz
ed
 c
ou
nt
rie
s”

 A
pp
lic
ab
le
 t
o 
B
TS
 u
si
ng
 a
 h
ig
h 
de
gr
ee
 o
f 
pr
oc
es
s 
co
nt
ro
l, 
se
ns
iti
ve
 H
IV
 a
nt
ib
od
y 
te
st
in
g 
pl
us
 m
in
ip
oo
l N
AT
N
/A
N
o 
cr
ite
ria
 e
xi
st
 
fo
r 
ev
al
ua
tio
n 
of
 m
at
he
m
at
ic
al
 
m
od
el
s
H
ig
h
S
ol
da
n 
M
at
he
m
at
ic
al
 
m
od
el
U
se
s 
as
su
m
pt
io
ns
 
ba
se
d 
on
 e
st
im
at
es
 
w
ith
 w
id
e 
ra
ng
es
 o
f 
pr
ob
ab
ili
ty
N
/A

 B
as
ed
 o
n 
ep
id
em
io
lo
gy
 o
f 
H
IV
 in
 U
K

 A
pp
lic
ab
le
 t
o 
B
TS
 u
si
ng
 a
 h
ig
h 
de
gr
ee
 o
f 
pr
oc
es
s 
co
nt
ro
l a
nd
 s
en
si
tiv
e 
H
IV
 a
nt
ib
od
y 
te
st
in
g 
(n
ow
 s
up
er
se
de
d)
N
/A
N
o 
cr
ite
ria
 e
xi
st
 
fo
r 
ev
al
ua
tio
n 
of
 m
at
he
m
at
ic
al
 
m
od
el
s
H
ig
h
An
de
rs
on
 
et
 a
l
Q
ua
nt
ita
tiv
e 
pr
ob
ab
ili
st
ic
 
m
od
el
Ac
cu
ra
cy
 o
f 
in
pu
ts
 
im
pr
ov
ed
 f
ro
m
 p
re
vi
ou
s 
st
ud
ie
s 
bu
t 
st
ill
 s
om
e 
as
su
m
pt
io
ns
 b
as
ed
 o
n 
es
tim
at
es
N
/A

 B
as
ed
 o
n 
ep
id
em
io
lo
gy
 o
f 
H
IV
 in
 U
S
A

 A
pp
lic
ab
le
 t
o 
B
TS
 u
si
ng
 a
 h
ig
h 
de
gr
ee
 o
f 
pr
oc
es
s 
co
nt
ro
l a
nd
 H
IV
 a
nt
ib
od
y 
an
d 
N
AT
 
te
st
in
g 
N
/A
N
o 
cr
ite
ria
 e
xi
st
 
fo
r 
ev
al
ua
tio
n 
of
 m
at
he
m
at
ic
al
 
m
od
el
s
H
ig
h
223
Discussion papers
1 Leiss W, Tyshenko M, Krewski D. Men having sex with men donor deferral risk 
assessment: an analysis using risk management principles. Transfusion Medicine 
Reviews, 2008, January, 22(1):35–57.
2 Vamvakas EC. Scientific background on the risk engendered by reducing the lifetime 
blood donation deferral period for men who have sex with men. Transfusion Medicine 
Reviews, 2009, 23 (2):85–102.
3 Vamvakas, EC. Why are all men who have had sex with men even once since 1977 
indefinitely deferred from donating blood? Editorial. Transfusion, 2009: 49:1037–1042.
4 Galarneau C. Blood donation, deferral and discrimination: FDA donor deferral policy 
for men who have sex with men. American Journal of Bioethics, 2010, 10(2):29–39.
5 Wainberg MA et al. Reconsidering the lifetime deferral of blood donation by men who 
have sex with men. Canadian Medical Association Journal, 2010, 182(12):1321–1324.
6 Alonso M et al. Preventing transfusion-transmitted HIV infection in Latin America and 
the Caribbean: issues associated with blood donor interviews and sex between men. 
Journal of Acquired Immune Deficiency Syndromes, 2009, 51:Supp 1:S67–72.
In 2008, Leiss discussed the evidence of Germain and Soldan and concluded 
that the increase in risk resulting from the removal of deferral of MSM or a 
change to a one-year deferral period would be ethically unacceptable. However, 
he considered that a continued policy of permanent deferral was difficult to justify 
on scientific grounds, in the absence of evidence of increased risk resulting from 
a deferral period of five years since last sexual activity.
Two papers by Vamvakas challenge the inconsistency and lack of scientific 
justification for a lifetime deferral for MSM against a 12-month deferral for females 
following a high-risk heterosexual contact. He acknowledges that a change in 
MSM deferral would result in a small increase in the risk of HIV transmission, but 
observes that this would be less than other currently accepted risks: e.g. from 
pooled whole-blood derived platelets. He argues for a 5-year deferral period for 
both MSM and high-risk heterosexual contacts as being appropriate to protect 
recipients of transfusion from HIV and also from sexually-transmitted novel agents. 
Galarneau criticises the US Food and Drug Administration’s permanent deferral of 
MSM on the grounds that it is discriminatory and based on inadequate supporting 
evidence. Similar arguments are put forward by Wainberg et al who nevertheless 
acknowledge that in Canada, as in most developed countries, MSM account for 
the largest sub-population (51.3% in 2008) of HIV-infected people. They conclude 
that, in Canada, any potential negative consequences of a change in deferral 
policy would be offset by benefits. Alonso et al review the safety of blood related 
to HIV infection in Latin America and the Caribbean and draw attention to the 
importance of the pre-donation interview in determining sexual behaviour. 
Additional background paper
1 Seed CR et al. No evidence of a significantly increased risk of transfusion-transmitted 
human immunodeficiency virus infection in Australia subsequent to implementing a 
12-month deferral for men who have had sex with men. Transfusion, 2010, 50:2722–
2730. 
Decision-making process
The Guideline Development Group concluded that permanent deferral of MSM as 
blood donors should continue to be recommended by WHO as the safest option, 
based on the principle of risk reduction to “as low as reasonably achievable” 
(ALARA). This policy should be critically and frequently reviewed by blood transfusion 
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services in the light of changes in disease epidemiology, residual risk of HIV 
transmission, sensitivity of HIV screening assays and ongoing research.
Recommendations
Defer
 Current sexual contacts of individuals whose sexual behaviours put them at 
high risk of transfusion-transmissible infections 
 Former sexual contacts of individuals whose sexual behaviour put them at 
high risk of transfusion-transmissible infections: defer until 12 months since 
last sexual contact
Defer permanently
 Individuals whose sexual behaviour put them at high risk of transfusion-
transmissible infections 
7.9.2 Injecting drug use
Question
Should individuals with a history of injecting recreational drug use be permanently 
deferred from blood donation? 
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Avoid unnecessary deferral of 
suitable blood donors 
 Minimize risk of transfusion-
transmitted infections in recipients 
of blood
Key search and MeSH words
(blood donor) OR (blood donors) OR (blood donation) OR (blood donations) OR 
(donating blood)
(recreational drug) OR (injecting drug) OR IDU OR (injecting drug user) OR (injected 
drugs) OR (intravenous drug user)
(steroid injection) OR (anabolic steroids) OR (anabolic-androgenic steroids) OR 
AS OR (fitness-enhancing substances) OR (anabolic agents)
Search strategy: PUBMED
#29 Search ((“(steroid injection)”[Title/Abstract] OR “(anabolic steroids)”[Title/Abstract]) 
AND (“HIV”[Title/Abstract] OR “(human immunodeficiency virus)”[Title/Abstract] OR 
“HBV”[Title/Abstract] OR “(hepatitis B virus)”[Title/Abstract] OR “HCV”[Title/Abstract] OR 
“(hepatitis C virus)”[Title/Abstract])) AND (“1995”[Publication Date] : “2009”[Publication 
Date]) Limits: Humans, English 10:14:23 52
#28 Search ((“(Blood donor)”[Title/Abstract] OR “(Blood donors)”[Title/Abstract] OR 
“(blood donation)”[Title/Abstract] OR “(blood donations)”[Title/Abstract] OR “(donating 
blood) “[Title/Abstract]) AND (“1995”[Publication Date] : “2009”[Publication Date])) AND 
((steroid injection) OR (anabolic steroids) AND sport) Limits: Humans, English 09:26:02 0
#27 Search (steroid injection) OR (anabolic steroids) AND sport 09:23:25 1296 
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#8 Search ((“(Blood donor) Or (Blood donors)”[Title/Abstract] OR “(blood donation)”[Title/
Abstract] OR “( blood donations)”[Title/Abstract] OR “(donating blood)”[Title/Abstract]) 
AND (“Recreational drug”[Title/Abstract] OR “(injecting drug)”[Title/Abstract] OR 
“IDU”[Title/Abstract] OR “(injecting drug user)”[Title/Abstract] OR “(injected drugs)”[Title/
Abstract] OR “(intravenous drug user)”[Title/Abstract])) AND (“1995”[Publication Date] : 
“2009”[Publication Date]) 09:14:29 21
30 Nov 09 Pubmed: MeSH search for “recreational drugs”
MeSH entry terms for “Recreational drugs”
drugs, street
recreational drugs
drugs, recreational
illicit drugs
drugs, illicit
drugs of abuse
abuse drugs
crack cocaine
Search strategy: PUBMED
#9 Search ((“blood donors”[Text Word] OR “blood donation”[Text Word] OR “donating 
blood”[Text Word]) AND (“steroid injection”[Text Word] OR “anabolic steroids”[Text Word] 
OR “anabolic-androgenic steroids”[Text Word] OR “AS”[Text Word] OR “fitness-enhancing 
substances”[Text Word] OR “anabolic agents”[Text Word])) AND (“1995”[Entrez Date] : 
“2009”[Entrez Date]) Limits: Humans, English 17:28:06 1
#8 Search ((“blood donors”[Title/Abstract] OR “blood donation”[Title/Abstract] OR “donating 
blood”[Title/Abstract]) AND (“steroid injection”[Title/Abstract] OR “anabolic steroids”[Title/
Abstract] OR “anabolic-androgenic steroids”[Title/Abstract] OR “AS”[Title/Abstract] OR 
“fitness-enhancing substances”[Title/Abstract] OR “anabolic agents”[Title/Abstract])) 
AND (“1995”[Entrez Date] : “2009”[Entrez Date]) Limits: Humans, English 17:23:58 0
#7 Search ((“blood donors”[Text Word] OR “blood donation or donating blood”[Text 
Word]) AND (“street drugs”[Text Word] OR “recreational drugs”[Text Word] OR “illicit 
drugs”[Text Word] OR “drugs of abuse”[Text Word] OR “abuse drugs”[Text Word] OR 
“crack cocaine”[Text Word])) AND (“1995”[Entrez Date] : “2009”[Entrez Date]) Limits: 
Humans, English 17:10:14 2
#3 Search (#1) AND#2 Limits: Humans, English 16:51:02 2 
#2 Search (“street drugs”[Title/Abstract] OR “recreational drugs”[Title/Abstract] OR 
“illicit drugs”[Title/Abstract] OR “drugs of abuse”[Title/Abstract] OR “abuse drugs”[Title/
Abstract] OR “crack cocaine”[Title/Abstract]) AND (“1995”[Entrez Date] : “2009”[Entrez 
Date]) Limits: Humans, English 16:50:31 3688 
#1 Search (“blood donors”[Title/Abstract] OR “blood donation”[Title/Abstract] OR “donating 
blood”[Title/Abstract]) AND (“1995”[Entrez Date] : “2009”[Entrez Date]) Limits: Humans, 
English 16:48:54 6733
Note on study selection process
Papers were selected for inclusion only if they provided evidence relevant to 
consideration of a change to the common policy of the permanent deferral of 
individuals who have ever injected recreational drugs, including steroids. Papers 
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relating to the risks of blood-borne infections in regular injecting drug users (IDUs) 
were therefore not included. Papers were also excluded if the study population 
was IDU males who were also MSM.
Number of citations screened: 304
Number of papers selected for full text review 14
Papers selected for evaluation 4
Key references
1 Crampin AC et al. The risk of infection with HIV and hepatitis B in individuals who inject 
steroids in England and Wales. Epidemiology and Infection, 1998, 121(2):381–386.
2 Aitken C, Delalande C, Stanton K. Pumping iron, risking infection? Exposure to hepatitis 
C, hepatitis B and HIV among anabolic-androgenic steroid injectors in Victoria, Australia. 
Drug and Alcohol Dependence, 2002, 65(3):303–308.
3 Musto JA et al. Estimating the risk of blood donation associated with HIV risk 
behaviours. Transfusion Medicine, 2008, 18:49–54.
4 Salmon AM et al. High HIV testing and low HIV prevalence among injecting drug 
users attending the Sydney Medically Supervised Injecting Centre. Australian and New 
Zealand Journal of Public Health, 2009, 33(3):280–283.
Summary of evidence (see table below)
There were no studies that investigated the prevalence of transfusion-transmissible 
infection in previous IDUs (more than 12 months previously). Only one paper 
(Musto et al) looked at HIV risk in infrequent drug users (once a year), but did 
not specify the type of drugs used. Using a mathematical model, they estimated 
that a single episode of injecting drug use is associated with very low risk of 
window-period HIV transmission, and concluded that it may seem appropriate 
to consider reducing the HIV-risk associated exclusion period to less than 12 
months for injecting drug users. However, they emphasized that IDU is also a 
major risk factor for other blood-borne viruses, particularly HCV, the prevalence 
of which in IDU in Australia is 54%. Even taking into account the reduction in 
window-period HCV transmission by implementation of NAT testing, the authors 
did not recommend a change of policy.
Two papers (Cramplin et al, Aitken et al) considered the risks of blood-borne 
virus infection in users of injected anabolic steroids, with somewhat differing 
conclusions. Cramplin et al found a low incidence of needle and syringe sharing 
and a significantly lower prevalence of markers for HBV and HIV among 149 
users of anabolic steroids compared to heroin and amphetamine injectors, and 
considered that they should be regarded as a distinct group in terms of lifestyle 
and injecting practice. Aitken also found HCV exposure at lower prevalence among 
63 injectors of illicit anabolic steroids compared to other drug injectors, but found 
that those exposed to HCV reported other risk behaviours, and concluded that 
steroid injectors should not be neglected in blood-borne virus prevention efforts.
The study by Salmon investigated the effect of medical supervision on the 
prevalence of HIV among IDUs, finding an overall prevalence of 2%, independently 
associated with MSM behaviour and psychostimulant use. 
These studies suggests that infrequent use of injected drugs, use of steroids 
alone and medical supervision may reduce the prevalence of blood-borne infections 
among IDUs, but is insufficient to justify consideration of a change to the policy 
of permanent deferral for blood donation.
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Quality of evidence (see GRADE table below)
The included studies are applicable only to populations, healthcare systems 
and blood transfusion services in developed countries. The quality of evidence 
of the observational studies of Crampin and Aitken is limited by the extremely 
small size of the study populations.
There are no criteria for the assessment of mathematical models; the authors 
acknowledge the limitations of accuracy because of the need to estimate some 
inputs.
Summary of evidence 
Author Year Population Summary
Crampin 1998 UK Data from National Unlinked Anonymous HIV 
Prevalence Monitoring Survey on 149 participants 
who had injected anabolic steroids in the 
previous month. A low incidence of needle and 
syringe sharing was reported. 2.0% had anti-HBc, 
none had anti-HIV. Prevalence of infection was 
significantly lower than in heroin injectors (18%) 
or amphetamine injectors (12%). Steroid users 
are a distinct group in terms of lifestyle and 
injecting practice.
Aitken 2002 Australia 63 current injectors of illicit anabolic steroids. 
9.5% found to have anti-HCV, 12% anti-HBc, none 
anti-HIV. HCV exposure at much lower prevalence 
than normally found among other drug injectors. 
Factors other than steroid injecting were 
associated with exposure. Those exposed to 
HCV reported many steroid-related and other risk 
behaviours which could spread the virus. Steroid 
injectors should not be neglected in blood-borne 
virus prevention efforts.
Musto 2008 Australia Model developed to estimate probability of blood 
donation during window period for HIV infection 
in 5 scenarios including people injecting drugs 
once per year. Single episodes of injecting drug 
use are associated with very low risk of window-
period HIV transmission (0.002/10 000). 
Salmon 2009 Australia Measured the self-reported prevalence of HIV, 
history of HIV testing and associated risk factors 
of 9 778 injecting drug users (IDUs) attending 
the Sydney Medically Supervised Injecting Centre 
(MSIC). Overall prevalence was 2%, independently 
associated with MSM and psychostimulant use.
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Critical evaluation of studies (GRADE table)
Author Study design Limitations Consistency Directness 
(applicability)
Precision other 
conside-
rations
Quality 
of 
evidence
Crampin Observational 
study
Very small 
study group
N/A Relates to 
current IDUs 
in developed 
country 
N/A Other 
factors (e.g. 
MSM) not 
considered
Low
Aitken Observational 
study
Very small 
study group
N/A Relates to 
current IDUs 
in developed 
country
N/A Low
Decision-making process
The Guideline Development Group considered that there was insufficient evidence 
for change to the current widely implemented recommendation of permanent 
deferral for individuals with a history of injecting recreational drug use.
Recommendations
Defer
 Current sexual contacts of injecting drug users 
 Former sexual contacts of injecting drug users: defer for 12 months since 
last sexual contact 
Defer permanently 
 Individuals with a history of injecting drug use 
7.9.5 Cosmetic treatments and rituals
Question
What should be the deferral period for prospective blood donors who have 
undergone procedures involving penetration of the skin, including body piercing, 
tattooing, scarification, injections with collagen or botulinum toxoid (botox), 
electrolysis and semi-permanent make-up?
Population Intervention outcome
Prospective blood 
donors
Acceptance or 
deferral for blood 
donation
 Avoid unnecessary deferral of 
suitable blood donors 
 Minimize risk of transfusion-
transmitted infections in recipients 
of blood transfusion
Key search and MeSH words
body piercing, skin piercing, tattoo, tattooing, scarification, cosmetic treatment, 
cosmetic procedures, collagen injection, botulinum toxoid (botox), electrolysis , 
permanent make-up
blood transfusion, blood donor, blood donation, donor selection, suitab*, eligib*, 
defer, accept, sexual partner, sexual contact
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Search strategy: PUBMED
#15Search (#13) AND#5 Limits: Humans, English, published in the last 10 years14:44:11 0
#14Search (#13) AND#4 Limits: Humans, English, published in the last 10 years14:43:23 1
#13Search (#6) AND#11 Limits: Humans, English, published in the last 10 years14:41:30 45
#11Search sexual partner OR sexual contact Limits: Humans, English, published in the 
last 10 years14:39:35 10600
#10Search ((blood donation) AND#6) AND#3 Limits: Humans, English, published in the 
last 10 years14:20:11 1
#9Search ((blood donation) AND#6) AND#2 Limits: Humans, English, published in the 
last 10 years14:18:13 26
#8Search (#5) AND#6 Limits: Humans, English, published in the last 10 years14:10:56 0
#7Search (#4) AND#6 Limits: Humans, English, published in the last 10 years14:10:20 25
#6Search body piercing OR skin piercing OR tattoo OR tattooing OR scarification OR 
cosmetic treatment OR cosmetic procedures OR collagen injection OR botulinum toxoid 
OR botox OR electrolysis OR permanent make-up Limits: Humans, English, published in 
the last 10 years14:07:35 18358
#5Search (#1) AND#3 Limits: Humans, English, published in the last 10 years14:05:24 353
#4Search (#1) AND#2 Limits: Humans, English, published in the last 10 years14:05:03 
2739 
#3Search recipient risk OR recipient safety OR recipient well-being Limits: Humans, 
English, published in the last 10 years14:04:18 5021
#2Search donor safety OR donor suitability OR donor risk OR donor well-being OR donor 
defer* OR donor eligibility OR donor selection OR donor accept* Limits: Humans, English, 
published in the last 10 years14:03:24 16409 
#1Search blood donor* OR blood donat* OR donating blood OR blood transfusion Limits: 
Humans, English, published in the last 10 years14:02:29 28992
Number of citations screened 98
Relevant papers selected 9
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9 Nishioka Sde A, Gyorkos TW. Tattoos as risk factors for transfusion-transmitted 
diseases. International Journal of Infectious Diseases, 2001, 5(1):27–34.
Decision-making process
The papers selected confirmed that the procedures in question carry a risk of 
transfusion-transmissible infection but provided no recommendations regarding 
deferral. The Guideline Development Group therefore agreed on the following 
recommendation. 
Recommendation
Defer
 Individuals who have had acupuncture, piercing, tattoos, scarification or any 
other invasive cosmetic procedures: defer for 12 months following the last 
procedure 
978 92 4 154851 9
